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Abstract 
Most drugs come with unwanted, and perhaps harmful, side-effects. Depending on 
the size of the treatment benefit such harms may be tolerable. In acute stroke, 
treatment with aspirin and treatment with alteplase have both proven to be effective 
in reducing the odds of death or dependency in follow-up. However, in both cases, 
treated patients are subject to a greater risk of haemorrhage – a serious side-effect 
which could result in early death or greater dependency. Current treatment licenses 
are restricted so as to avoid treating those with certain traits or risk factors associated 
with bleeding. It is plausible however that a weighted combination of all these 
factors would achieve better discrimination than an informal assessment of each 
individual risk factor. This has the potential to help target treatment to those most 
likely to benefit and avoid treating those at greater risk from harm. This thesis will 
therefore: (i) explore how predictions of harm and benefit are currently made; (ii) 
seek to make improvements by adopting more rigorous methodological approaches 
in model development; and (iii) investigate how the predicted risk of harm and 
treatment benefit could be used to strike an optimal balance. 
Statistical prediction is not an exact science. Before clinical utility can be established 
it is essential that the performance of any prediction method be assessed at the point 
of application. A prediction method must attain certain desirable properties to be of 
any use, namely: good discrimination – which quantifies how well the prediction 
method can separate events from non-events; and good calibration – which measures 
how close the obtained predicted risks match the observed. A comparison of informal 
predictions made by clinicians and formal predictions made by clinical prediction 
models is presented using a prospective observational study of stroke patients seen at 
a single centre hospital in Edinburgh. These results suggest that both prediction 
methods achieve similar discrimination. A stratified framework based on predicted 
risks obtained from clinical prediction models is considered using data from large 
randomised trials. First, with three of the largest aspirin trials it is shown that there is 
no evidence to suggest that the benefit of aspirin on reducing six month death or 
dependency varies with the predicted risk of benefit or with the predicted risk of 
harm. Second, using data from the third International Stroke Trial (IST3) a similar 
 
  iv 
question is posed of the effect of alteplase and the predicted risk of symptomatic 
intracranial haemorrhage. It was found that this relationship corresponded strongly 
with the relationship associated with stratifying patients according to their predicted 
risk of death or dependency in the absence of treatment: those at the highest 
predicted risk from either event stand to experience the largest absolute benefit from 
alteplase with no indication of harm amongst those at lower predicted risk. It is 
concluded that prediction models for harmful side-effects based on simple clinical 
variables measured at baseline in randomised trials appear to offer little use in 
targeting treatments. Better separation between harmful events like bleeding and 
overall poor outcomes is required. This may be possible through the identification of 
novel (bio)markers unique to haemorrhage post treatment. 
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Chapter 1: Background and Introduction 
Background and summary 
How are the results from individual trials used to make treatment decisions for 
individual patients? How applicable is the average treatment effect to those at a very 
low or a very high risk of ‘bad outcome’? Such questions are of utmost importance to 
both the clinician and the patient – especially when harmful side-effects are 
associated with treatment. This chapter outlines the argument that the targeted 
treatment of patients based on the balance of predicted harms and benefits could 
yield overall improvements in patient recovery. The stratified treatment of stroke 
patients is investigated. 
1.1 Introduction 
The evidence-based medicine paradigm states that the best treatment decisions are 
made by a doctor on the behalf of his or her patients with the support of objective 
scientific evidence (Guyatt et al., 1992). This evidence will typically come from two 
or more randomised controlled trials each suitably designed to assess the efficacy of 
the experimental treatment (Senn, 2007). The body of available trial data for a given 
indication may be summarised through systematic review and meta-analysis 
providing a single source of information used to guide the application of any licensed 
treatments at the clinic level. However, the clinician is faced with a dilemma: how 
applicable is the evidence in the case of the individual patient? The clinician may 
wonder whether the individual patient is well represented by the trial-patients and 
might reflect on the inclusion and exclusion criteria as well as any presented 
demographic data to assess whether their patient is, in some sense, interchangeable. 
This is often referred to as the external validity of a trial. Indeed a treatment that 
works on average could result from treatment benefit amongst a small proportion of 




or even a harmful treatment effect, amongst the vast majority of low risk patients 
(i.e., those with a low risk control event rate) (Kent and Hayward, 2007a). A primary 
trial publication presents the main findings but will frequently include a plethora of 
subgroup analyses thus acknowledging the underlying heterogeneity in the patient 
population. Pocock et al. summarised the various statistical concerns associated with 
this approach citing inadequate statistical power and uncontrolled type I error rates 
(Pocock et al., 2002). 
If there is the suggestion that a given treatment works for some patients but not for 
others then how should investigation proceed? The pooling of aggregate results from 
subgroup analysis across trials is possible, but is dependent upon the availability of 
the relevant data (Thompson and Higgins, 2005). The sharing of the original patient 
level data enables better use of existing data resources (e.g., defining events, 
handling missing data, adjusting for variables etc. all in a unified manner). This has 
the potential to yield more reliable results thanks to the level of consistency that can 
be achieved (Riley et al., 2010). Since 2000 there has been a substantial rise in the 
number of Individual Patient Data Meta-Analyses (IPD-MAs) with Riley et al. 
noting an average of around 49 publications per year from 2005 onwards – this 
suggests some positive movement since Andrew Vickers commentary on his 
personal struggles in obtaining IPD (Riley et al., 2010, Vickers, 2006). It is rarely the 
case that individual sub-group analyses will achieve a sufficient degree of 
discrimination which can uniquely characterise patients with regards to either 
treatment benefit or harm. Multivariable regression techniques which combine 
multiple risk factors predictive of outcome have greater statistical power, beyond that 
of the standard subgroup tests (Hayward et al., 2006). This is a far superior and more 
efficient way of exploring whether treatment effect varies with patient heterogeneity 
(either in prognosis or risk from harmful side-effects) (Kent et al., 2010, van der 
Leeuw et al., 2014, Pocock et al., 2014) 
With access to individual patient data the opportunity to explore specific secondary 
questions relating to harmful treatment side-effects with greater statistical power is 
therefore possible. An article by Whiteley et al. is an excellent example of this 




clinically plausible interaction between the predicted risk of haemorrhage (harm), the 
predicted risk of thrombosis (benefit) and treatment with heparin across five 
individual trial datasets. Stroke is a heterogeneous condition with very few available 
drug treatments. Greater benefit may be possible by better targeting those existing 
treatments to those most likely to benefit. This thesis aims to explore this question in 
detail reflecting on available trial datasets. 
1.2 Stroke epidemiology 
Stroke is the disruption of blood flow to the brain caused by a either a blockage 
(ischaemic stroke) or a rupturing of a blood vessel (haemorrhagic stroke). This 
disruption starves the brain of oxygen and is typically expressed by visible functional 
disability, e.g., limpness, slurred speech etc. Stroke is a leading cause of disability. It 
is currently ranked as the fourth most common cause of death and, despite a reported 
decrease in its incidence across developed countries, the absolute number of strokes 
continues to rise as a result of an ever aging population (Go et al., 2014). The most 
commonly used definition of stroke was provided by the World Health Organization 
(WHO) in 1976 (Hatano, 1976). They defined a stroke as the: 
“…rapidly developing clinical signs of focal (at times global) 
disturbance of cerebral function, lasting more than 24 h or 
leading to death with no apparent cause other than that of 
vascular origin.” 
The mechanisms through which cerebral blood flow is disrupted can be uniquely 
characterised as being either: ischaemic or haemorrhagic in origin. The advent of 
brain imaging has enabled the reliable distinguishing of the two (Donnan et al., 
2008). The majority of strokes that occur are ischaemic and make up 80-85% of all 
strokes (Rathore et al., 2002). Ischaemic strokes are caused by an obstruction in a 
blood vessel which results in the under-perfusion of brain tissue. This obstruction can 
arise via: (i) embolism (either arterial or cardiac in origin); (ii) decreased perfusion 
(from stenosis – a narrowing of the arteries); or (iii) thrombosis (blood clotting 
formed in the heart or the blood vessels) (Mohr et al., 1997). Haemorrhagic strokes 
make up the remaining 15-20% of strokes and can be further categorised as being 




Historically suspected stroke cases which resolve within 24 hours from symptom 
onset are termed Transient Ischaemic Attacks (TIA) (Albers et al., 2002). More 
recently this categorisation of the duration of symptoms has come into question and a 
tissue-based definition has been advocated (Sacco et al., 2013). This incorporates the 
presence or absence of evidence of infarction via brain imaging, indicating that 
strokes can indeed occur within a 24 hour period. Brain ischaemia may be best 
viewed then as a continuum with both duration and the extent of infarction having 
serious implications for patient recovery (Easton et al., 2009). 
Stroke places a considerable burden on health care. A study comparing the total 
health care expenditure on stroke at an international level suggested that the cost of 
stroke across eight countries constituted approximately 3% of spending (Evers et al., 
2004). The societal cost of stroke in the UK has been estimated as being around £8.9 
billion per year whilst in the US the cost has been estimated as $20.6 billion per year 
(Saka et al., 2009, Go et al., 2014). 
1.2.1 Stroke outcomes 
1.2.1.1 Functional outcome following a stroke 
There are a number of ways to measure functional ability following a stroke. Each 
approach places a patient on some ordinal scale of severity or dependency providing 
a qualitative assessment of disability after stroke. These scales are multi-faceted 
incorporating a spectrum of possible stroke related deficits e.g.: mobility; 
consciousness; and responsiveness. A single score for a given patient is determined 
via patient interview by a trained professional (e.g., a stroke nurse or physician) at an 
appropriate time point. 
The National Institutes of Health Stroke Scale (NIHSS) summarises 15 unique 
elements of impairment scoring patients on a scale that ranges from 0 to 42 in unit 
increments of worsening severity (Lyden et al., 1999). When measured at baseline it 
indicates the severity of the initial stroke which is useful for establishing the likely 
prognosis. When recorded later in follow-up it can be used as a primary outcome in 
trials. The Scandinavian Stroke Scale (SSS) summarises nine unique elements of 




meaning that lower SSS scores are associated with more severe strokes 
(Scandinavian Stroke Study Group, 1985). As is the case with the NIHSS, the SSS 
can be utilised as a measure of severity for the initial stroke and for describing 
longer-term functional outcome. The NIHSS and the SSS largely measure the same 
attributes and have a particularly strong correlation. A conversion model has been 
previously described enabling the translation of the NIHSS to the SSS and vice versa 
(Gray et al., 2009). The Barthel Index (BI) measures ten activities of daily living 
covering aspects regarding ability to carry out personal tasks (for example, toilet use, 
grooming etc.) as well as mobility (Mahoney and Barthel, 1965). The BI measure 
ranges from 0 to 100 and is used as a measure of functional outcome following 
stroke – lower scores indicate more dependency. The modified Rankin Scale (mRS) 
is a seven level ordinal score of disability ranging from 0 (fully recovered) to 6 
(dead) in unit increments of increasing dependency (van Swieten et al., 1988). A 
review by Quinn et al. found that the mRS was the most commonly used primary 
endpoint in randomised stroke trials (Quinn et al., 2009). Another scale, with the 
same number of levels as the mRS where each of the corresponding levels has a 
qualitatively similar definition to the mRS, is the Oxford Handicap Scale (OHS) 
(Bamford et al., 1989). The OHS was developed for application in a community 
setting with an emphasis on reporting patient handicap resulting from a stroke (New 
and Buchbinder, 2006). For the most part the mRS and the OHS are interchangeable. 
Goldie et al. identified strong correlations amongst the most commonly used stroke 
outcome scales (i.e., NIHSS, mRS, SSS, and BI) to an extent which was much higher 
than was previously reported (Goldie et al., 2014) 
1.2.1.2 Associated complications in recovery 
After a stroke, patients are at greater risk from various intermediate events and 
complications (Langhorne et al., 2000). Pneumonia due to aspiration is common 
amongst stroke patients (Armstrong and Mosher, 2011). In one study conducted at a 
hospital in Glasgow, Scotland the rate of pneumonia after stroke was around 20% 
(Sellars et al., 2007). Post-stroke depression also occurs at a high rate, with about a 
third of all stroke sufferers experiencing depression (Hackett et al., 2005). Stroke 




around 25% suffering a recurrence by five years (Mohan et al., 2011, Go et al., 
2014). A systematic review of 39 separate studies suggests that the risk of 
myocardial infarction can range from 0.5% to 5.7% (Touzé et al., 2005). A Canadian 
multicentre stroke registry suggested a 1% risk of pulmonary embolism after stroke 
(Pongmoragot et al., 2013). 
This list is not exhaustive but serves to illustrate the volume of ‘bad-outcomes’ that 
can result from a stroke. Early complications in the aftermath of a stroke are 
associated with additional increased risk of mortality and poor functional recovery 
beyond that of those risk factors recorded at baseline (Grube et al., 2013). 
1.2.2 Risk factors 
There are a number of known prognostic risk factors for the primary occurrence of 
stroke as well as recurrent events (Sacco et al., 1997, Warlow et al., 2003, Go et al., 
2014). A prognostic risk factor is a measure which is associated with the occurrence 
of some clinical outcome or endpoint. Risk factors can be modifiable or fixed. Both 
are important in understanding patient prognosis but those modifiable risk factors are 
generally regarded as being of particular interest for targeted intervention (Riley et 
al., 2013). 
1.2.2.1 First ever stroke 
Fixed risk factors for ischaemic stroke are unchangeable either because they are 
intrinsic to the patient (e.g., gender or race) or inevitable (e.g., increasing age). 
Potentially modifiable risk factors include: hypertension (high blood pressure); atrial 
fibrillation; TIAs; myocardial infarction; carotid artery disease; cigarette smoking; 
diabetes mellitus; and obesity (Go et al., 2014). Controlling these risk factors through 
public education (e.g., helping smokers quit) or treatment intervention (e.g., treating 
hypertension) is of upmost importance. This can yield considerable health gains for 
the individual patient as well as offering economic gains for an often overly stretched 
health care budget (Donnan et al., 2008, Bornstein et al., 2006, Shah and Cole, 
2010). Risk factors for SAH include: a history of hypertension, smoking and 




include: increasing age, hypertension, male gender and excessive alcohol 
consumption (Ariesen et al., 2003). 
1.2.2.2 Recurrent stroke 
Stroke recurrence is common amongst first-time stroke patients but rates recorded 
within the control arms of stroke prevention trials have reduced over time from 9% 
in 1970 to 5% in 2000 (Go et al., 2014). Mohan et al. used multivariable regression 
techniques to identify risk factors associated with recurrence over a 10 year follow-
up period within a South London Stroke Register. They found that the presence of 
atrial fibrillation, myocardial infarction, and hypertension were all associated with 
recurrent stroke (Mohan et al., 2009). In a similar study Hillen et al. found that both 
atrial fibrillation and diabetes mellitus were associated with recurrence in follow up 
(Hillen et al., 2003).  
In general, overall patient recovery following a first time stroke depends upon 
various characteristics associated with aging (i.e., additional co-morbidities, for 
example, heart diseases and dementia) as well as the impact of the initial stroke (i.e., 
high NIHSS scores) (Appelros et al., 2003). 
1.2.3 Treating acute ischaemic stroke patients 
The aim of treatment as early as possible after the onset of an acute ischaemic stroke 
is to restore normal blood flow to the affected area of the brain and therefore 
minimise the amount of damage caused. There are two effective medications: 
aspirin; and recombinant tissue plasminogen activator (rtPA). 
1.2.3.1 Aspirin 
Aspirin is an antiplatelet drug which, if given within 48 hours from acute ischaemic 
stroke onset, reduces the risk of death or dependency by 1% (Sandercock et al., 
2008). Platelets are responsible for the formation of blood clots: antiplatelet 
treatments inhibit this process and counteract the formation of new clots. Although 
aspirin is associated with only a small absolute reduction in death or dependency, its 
effect is still important. It is cheap, easy to administer and applicable to a large 




concern but rarely occurs with an increased risk of about 2 for every 1000 patients 
treated (Chen et al., 2000). Risk of bleeding is still an important consideration though 
and is one of the main contraindications to starting treatment (e.g., a previous 
gastrointestinal bleed or high blood pressure). 
1.2.3.2 Recombinant tissue plasminogen activator 
Thrombolysis with rtPA is effective in the treatment of vascular conditions like 
myocardial infarction and in recent years has emerged as an effective treatment for 
acute ischaemic stroke (The GUSTO investigators, 1993, White and Van de Werf, 
1998, Wardlaw et al., 2012a). Treatment with rtPA within 3 hours of acute ischaemic 
stroke onset increased patients chance of a good recovery by six months (mRS≤2) by 
approximately 4% (Wardlaw et al., 2012a). Instead of preventing further clotting, 
rtPA works by dissolving the original clot thus restoring normal blood flow (Yaghi et 
al., 2014). Time to treatment with rtPA after acute ischaemic stroke onset is of vital 
importance as there is empirical evidence to suggest that the benefit of rtPA 
decreases over a four and a half hour window from onset (Lees et al., 2010). Patients 
treated with rtPA are at risk from suffering symptomatic intracranial haemorrhage 
(SICH) which frequently lead to premature death (Wardlaw et al., 2012a). Various 
definitions have been adopted in the identification of SICH post rtPA through 
randomised trials and observational registries. An SICH as defined according to the 
National Institute of Neurological Diseases and Stroke (NINDS) trial attributes any 
deterioration of the patient’s condition as measured by the NIHSS within 36 hours of 
thrombolysis plus the development of an intracerebral haemorrhage (ICH) verified 
by brain imaging (i.e., CT or MRI) (The National Institute of Neurological Disorders 
and Stroke rt-PA Stroke Study Group, 1995). The European Cooperative Acute 
Stroke Study (ECASS) II defined an SICH as any type of visible bleed during post-
treatment brain imaging as associated with clinical deterioration or a neurological 
deterioration of four or more NIHSS points within seven days of starting 
thrombolysis (Hacke et al., 1998). Finally, the SITS-Monitoring Study (SITS-
MOST) defined SICH as a local or remote type 2 parenchymal haemorrhage 
identified on CT taken between 22 and 36 hours from the administration of 




baseline or the lowest score after baseline recorded up until seven days or leading to 
death (Wahlgren et al., 2007). 
1.3 Stratified Medicine 
Stratified medicine is the targeted treatment of groups of individuals who test 
positive for some measureable trait (e.g., a biomarker or a combination of multiple 
characteristics via statistical modelling) who experience a differential treatment 
effect. Hingorani et al. distinguish aspects pertaining to stratified treatment decisions 
on an absolute risk scale (i.e., assuming a constant relative treatment effect) or on a 
relative risk scale where the relative effect of treatment necessarily differs (Hingorani 
et al., 2013). 
In the absolute risk case, if the overall relative treatment effect is constant over 
patient prognosis then those with the poorest prognosis stand to gain the largest 
absolute risk reduction in contrast to those with a good prognosis (Rothwell, 2007a). 
In statistical terms this corresponds to the assumption that that there is no interaction 
between predicted prognosis and the effect of treatment on outcome. If this holds 
true then it makes sense to interpret the gain in treatment benefit with respect to the 
risk of treatment harm as illustrated in Figure 1-1 (Glasziou and Irwig, 1995). This 
would then suggest that a ‘breakpoint’ for net benefit conditional on baseline risk 
exists. It is important to understand the risk of harm and establish the threshold at 
which benefit from treatment exceeds harm. Note that a constant rate of harm is 
assumed in Figure 1-1 though there is no reason why this could not also depend on 
the baseline risk and also have a positive slope (van der Leeuw et al., 2014). 
A non-constant relative treatment effect invalidates the simple risk-benefit model. 
This would then correspond to a stratified approach with the relative treatment effect 
differing according to one or more identifiable subgroups of a patient population. 
Any assessments of interaction should though be based upon biological grounds in 
advance to testing. Validation and replication of biological interactions are a central 
































Figure 1-1 Basic risk-benefit decision model concept 
1.3.1 Biomarkers 
The WHO define a biomarker as (Strimbu and Tavel, 2010): 
“…any substance, structure, or process that can be measured 
in the body or its products and influence or predict the 
incidence of outcome or disease.” 
In this sense any patient measure associated with an outcome of interest is a 
‘biomarker’, though more often than not so called laboratory-measured biomarkers 
are of primary research interest. An example of such a biomarker is the predictive 
Human Epidermal growth factor Receptor 2(HER-2) marker for breast cancer 
patients (Hudis, 2007). Studies have shown that those who test positive for the HER-
2 marker may be treated with trastuzumab (a monoclonal antibody) whilst those that 
test negative may not. A recent systematic review of the use of biomarkers within 
drug licenses issued by the European Medicines Agency (EMA) suggested that the 
frequency of their use in practice did not entirely match with the research efforts and 




prescription slip has not been as productive as hoped (Malottki et al., 2014). 
However, these licenses were predominantly for HIV and cancer treatments and 
focused more on efficacy than toxicity. Few biomarkers though make it into clinical 
practice. Of those published biomarkers in cancer under 1% have any clinical utility 
(Kern, 2012). 
1.3.2 Prediction models 
When multiple risk factors are associated with patient prognosis, e.g., recurrent 
stroke or poor functional outcome after acute stroke, it is sensible to consider the 
impact of all clinically important variables at once thus creating a detailed picture of 
an individual’s risk profile (Kent et al., 2010). A clinical prediction model formally 
combines multiple variables for the prediction of some clinical endpoint in a given 
population of patients (Steyerberg, 2009, Steyerberg et al., 2013). Each variable is 
weighted by an estimated coefficient which reflects the importance of a unit increase 
or decrease of that variable upon the risk/chance of outcome. When multiple risk 
factors are predictive of treatment response then a risk-stratified approach may be 
possible. An excellent illustration of this is found in the study by Farooq et al. who 
demonstrated that treatment decisions for patients with complex coronary artery 
disease can be guided by unique prediction models (Farooq et al., 2013). The authors 
extended an existing prediction model (the SYNTAX score), which original 
comprised of just anatomical features, by including clinical variables. The SYNTAX 
II model provides predicted risks for patients four year mortality if treated with 
percutaneous coronary intervention (PCI) and separately the risk when treated with 
coronary artery bypass graft surgery (CABG). Patients and doctors may then make 
judicious decisions as to which treatment yields the largest potential benefit. 
The statistical methodology required is neither new nor challenging – indeed sensible 
statistical tests of the additivity assumption are well established as are the proper 
approaches to model development (Harrell, 2001). Despite this, efficient quantitative 
methods are rarely utilised in practice even though they have the potential to improve 




The methodological aspects central to the development and assessment of clinical 
prediction models will be discussed in Chapter 2. 
1.3.3 The targeted treatment of stroke patients 
Acute ischaemic stroke is a heterogeneous condition with very few effective 
treatments. Those few available treatments come with benefits and harms. The one-
at-a-time subgroup approach is not an efficient way of exploring the underlying 
heterogeneity of risk of harm or chance of benefit. A multivariable risk prediction 
approach has the potential to yield substantial gains in overall clinical benefit (Kent 
et al., 2010). For instance, not everyone is eligible for rtPA though a risk stratified 
approach could help elucidate whether clinicians are under– or over-treating their 
patients based on perceived risk factors from SICH. Additionally, a risk stratified 
approach could help yield greater benefits from treatment with aspirin where rtPA is 
not an option. 
An approach based on risk prediction is reliant upon models achieving a sufficient 
level of discrimination so as to ensure the accurate targeting of treatments. Using 
trial datasets this approach will be explored in this thesis is to explore the possible 
risk stratified treatment of stroke patients weighting by the predicted risk of harm and 





1.4 Thesis outline 
The methods used in the development and evaluation of a clinical prediction model 
are introduced and discussed in Chapter 2. This chapter covers various aspects of 
methodology which recur throughout the course of this thesis and may therefore be 
used by the reader for reference. A systematic review of clinical prediction models 
for the prediction of recurrent ischaemic stroke or myocardial infarction following an 
ischaemic stroke is presented in Chapter 3. Those identified models are then 
evaluated in a new prospective single centre hospital cohort of stroke patients in 
Chapter 4. Their relative performance is compared to that of the treating clinicians’ 
who each made informal predictions of vascular endpoints for their patients. In 
Chapter 5 a similar question is explored, evaluating a number of existing prediction 
models for the prediction of poor functional outcome. These models are chosen from 
a previously conducted systematic review and again tested within the same dataset 
used in Chapter 4 (Veerbeek et al., 2011). These data also contain clinicians’ 
informal predictions of functional outcome allowing a further comparison of 
informal versus formal methods of prediction. 
Various trial datasets are re-analysed as part of this thesis with the results presented 
in Chapters 6 through to 9. Chapter 6 is an IPD-MA of three acute ischaemic stroke 
trials of aspirin. Here a balance between predicted risk of treatment harm and 
treatment benefit favouring good functional outcome is sought. Chapter 7 presents an 
analysis of a recent rtPA trial to investigate whether the effect of rtPA on the 
reduction of six month death or dependency varies with predicted risk of treatment 
harm. Using the same dataset Chapter 8 investigates the possible long-term impact of 
rtPA on mortality and explores whether this depends upon patients prognosis or 
delay to treatment. Finally, in Chapter 9 data from a large stroke trial archive are 
used to investigate whether the separate impact from early thrombotic and early 





Chapter 2: The development and evaluation of a 
clinical prediction model 
Background and summary 
Methods for the development of clinical prediction models and the metrics used to 
assess their performance are discussed. These concepts are illustrated using worked 
examples based on stroke trial datasets. 
2.1 Introduction 
Medical data collected through routine observation or direct experimentation is 
opaque and uninterpretable without statistical examination. Underlying patterns and 
relationships can be explored by first positing some plausible association between an 
outcome and one or more additional measurements. The existence of an underlying 
rule or model involves the combination of a number of associations each describing 
the conditional relationship between outcome and predictors. The aim of this chapter 
is to discuss and illustrate various methodological aspects of model development and 
model evaluation. The methods introduced here will be used throughout this thesis. 
2.2 What is a clinical prediction model? 
A statistical model is a description of some phenomenon of interest investigated 
through experimentation and numerical observation (Dawid and Senn, 2011). Cox 
highlighted two broad types of statistical model: first the substantive model, the form 
of which stems from some scientific or biological justification; and second the 
empirical model, a ‘black-box’ approach commonly adopted in regression modelling 
where data are used to estimate effects (Cox, 1990). There are two general 
motivations for modelling data. Firstly, they can provide an explanation of the 
underlying mechanisms perhaps with some adjustment for potential confounders. 
Secondly, assuming that the model is generalisable, they can be used to make 




where quantitative data have been collected. For example, consider the Framingham 
Risk Score (FRS) derived from a population of men and women free of Coronary 
Heart Disease (CHD) who were prospectively followed up for 12 years for the 
prediction of 10 year CHD risk. The FRS is based on six variables: age, total 
cholesterol, smoking status, high-density lipoprotein cholesterol and systolic blood 
pressure (Wilson et al., 1998). The most up-to-date version of the FRS has been 
adapted to predict Cardiovascular Disease (CVD). The FRS plays an important role 
in the prescription of statins used in the primary prevention of CVD, where statins 
are recommended to those with a predicted risk of 20% or greater of developing 
CVD (National Institute for Health and Care Excellence (NICE), 2006). 
A Clinical Prediction Model (CPM) is therefore a combination of appropriately 
weighted clinical risk factors associated with a clinical outcome of interest. The 
proposed fit may be used to either explain the underlying associations or else to 
predict patient risk. The focus throughout this thesis is predominantly on the latter 
function. 
2.3 Simplicity versus complexity 
One way of quantifying the complexity of a proposed statistical model is by 
considering the number of included parameters. Statisticians denote this as the 
‘degrees of freedom’ which are the number of required parameter estimates for each 
outcome-predictor association, i.e., for continuous variables and dummy variables (as 
only contrasts are identifiable). The degrees of freedom summarise all included 
effects, i.e., main effects, interactions and any non-linear transformations. Strictly 
speaking, formal and informal tests used to screen variables for inclusion or 
exclusion should also incur additional expenditure of the degrees of freedom, 
however, this is rarely acknowledged in practice. A useful analogy is to view this as 
a financial transaction: the degrees of freedom act as currency; the data denote the 
available balance; and the goodness-of-fit is the service provided. With access to all 
of this information the wisdom of the investment can be assessed. In general, the 
model which strikes the most economical balance between the degrees of freedom 




bankruptcy it is necessary to consider whether the data permit the proposed model. In 
practice the data will frequently impose some (often major) limitations on the 
development of a model. 
Model complexity should be tuned to meet the intended study purpose. It has been 
suggested that the level of detail that a complex model provides is better suited when 
explanation is the goal, for example in effect estimation or hypothesis testing (Núñez 
et al., 2011). Investigators can include multiple confounders in an attempt to extract 
some of the noise and heterogeneity from the system. In the case of continuous 
outcome data this produces a more precise estimate, whilst in the case of a binary 
outcome a more subject specific effect estimate is obtained (Robinson and Jewell, 
1991). The resulting effect estimate may be more informative and the hypothesis test 
more reliable. Model overfitting is an important consideration and the sample data 
details the degree of plausible complexity. In the case of prediction, generalisability 
of the model fit is the primary motivation (Steyerberg, 2009). The predicted risks 
estimated on the development population must be generalisable to a different 
population to serve some purpose. This generalisability becomes more plausible 
when the proposed fit conditions less on the observed data and thus avoids 
capitalising on certain data-specific-quirks. This is one reason why a simple or 
parsimonious model is often preferred. Simple models which require little 
manipulation from the user, with only a few easy to measure input variables, will 
have superior face validity making it more likely that the proposed model is adopted 
(Moons et al., 2012b). 
Throughout this thesis simplicity will frequently be preferred over complexity. 
2.4 Model development 
The focus of this chapter is on the methods used in the development and evaluation 
of a clinical prediction model. The methods introduced here are used throughout this 





2.4.1 The general framework 
The development of a clinical prediction model should follow a sensible procedure 
or protocol defined from the outset (Collins, 2011). First, a relevant question of 
clinical importance must be asked, for example: what is the six month risk of death 
or dependency following an acute ischaemic stroke? To answer such a question, 
reliable high quality data must be used, e.g., patients recruited consecutively, who are 
prospectively followed-up recording all events of a priori interest over a fixed period 
of time. A Randomised Clinical Trial (RCT) of acute ischaemic stroke patients 
comparing some active treatment to a control will fit most of these desirable criteria, 
although may suffer from poor generalisability especially if the trial followed strict 
exclusion and inclusion criteria. If existing data sources are not available or 
inadequate then new data should be collected for the purpose of model development. 
When selecting which risk factors to include it is important to consider whether there 
is a body of existing knowledge available, this should be systematically reviewed so 
that clinically important risk factors – regardless of their statistical significance – can 
be included (Moons et al., 2012b). 
It then follows that the performance of the proposed model is scrutinised within some 
external dataset, for example within a similar randomised trial run in a different 
country (Moons et al., 2012a). Issues relating to the selection of risk factors and 
evaluation will be discussed later in this chapter. 
2.4.2 The logistic regression model 
In this section some common approaches to analysing categorical data are discussed: 
in particular binary and ordinal outcome data. 
2.4.2.1 Binary outcomes 
Often statistical analysis will be carried out on outcome data, Y, which are strictly 
binary in nature. Frequently the end point of interest will be the presence or absence 
of some event, for example, the patient is alive or dead. Associations between the 
outcome and other measured patient characteristics can be estimated using logistic 




variable, Y, is dependent upon a set of observed covariates (or predictors), Xj, ( j = 1, 















α . (2.1) 
The probability of a response is given by πi = P(Yi = 1| α, β; Xi) and similarly the 
probability of a non-response by 1 – πi. The probability for the ith observation 
depends directly on a vector of p independent covariates, Xi = [X1, X2, …, Xp], with 
the unknown parameters β = [β1, β2 ,… , βp] and intercept α. 
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There is no explicit solution for the partial derivatives of this function, it is therefore 
necessary to use numerical approximation (e.g., Newton-Raphson) to compute each 
of the p + 1 possible derivatives of the log-likelihood. 
The logistic function described by equation (2.1) restricts all predictions to the range 
0 ≤ πi ≤ 1 giving a sigmoidal shape between π and βTX, although a simple 
transformation enables a linear interpretation (see Figure 2-1). Under the logit 
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Here, a unit increase in the Xij (where j = 1, 2, … p and i = 1, 2, …, N) risk factor is 
interpreted as an increase (+βj) or decrease (-βj) in the log odds of response holding 




effect can be interpreted on the odds scale with the relevant odds ratio (OR) where 
the OR describes the increase (OR>1) or decrease (OR<1) in the odds of some 
outcome, π / (1 – π), relative to some risk factor. 
The logistic regression is the most common method for analysing binary data. One 
less commonly encountered method is the probit model, Φ-1(π), where Φ is the 
cumulative probability function for the standard Normal. Historically the probit 
model has roots in dose response modelling (Dobson, 1991). This method will not be 

















































Figure 2-1 Example of the logistic function for a binary logistic regression showing the association between: (i) the linear predictor and the logistic function, 




2.4.2.2 Ordinal outcomes 
Many medical conditions record patient disability at a fixed time point on an ordinal 
outcome scale. Such outcomes are commonly encountered in stroke and in head 
trauma studies. An ordinal outcome specifies a finite number of category levels 
(where k > 2) with the assumption that one level will qualitatively describe where a 
given patient belongs along the scale. In stroke these unique levels have a natural 
ordering specifying increasingly more severe levels of disability. It is common to see 
the modified Rankin Scale (mRS) used to score stroke patient disability. The mRS is 
a seven-point scale, ranging from fully recovered (a mRS of 0) to dead (a mRS of 6) 
in single unit increments. Investigators will often dichotomise the mRS enabling a 
binary interpretation, e.g., 0-2 versus 3-6, corresponding to ‘alive and independent’ 
and ‘dead or dependent’ respectively (Weisscher et al., 2008). 
A more efficient use of the recorded information would be to analyse the entire range 
of the ordered response capitalising on the inherent ordinal structure. The 
proportional odds logistic regression (POLR) model achieves this by assuming that 
individual covariate effects are common across each of the k – 1 categorisations of 
the ordered outcome (McCullagh, 1980). Here the cut-point which splits the ordinal 
outcome into favourable versus unfavourable is moved across the ordinal scale 
creating all potential dichotomous splits. This invokes the proportional odds 
assumption which, if true, states that no matter how the outcome is dichotomised a 

















αα L . (2.3) 
Here the regression parameters are assumed to be the same and constant for each of 
the k intercepts (k = 1, … , K). 
Again, a linear interpretation is obtained through the logit transformation with 
equation (2.2). By exponentiating the regression coefficients in the POLR model the 




common across all potential cut-points of the ordered outcome. This is highlighted in 
Figure 2-2 which illustrates another interpretation of the proportional odds 
assumption as ‘parallelism’, that is for all response categorisations the corresponding 
predictors are parallel on the log odds scale. 
The proportionality assumption can be assessed both formally and informally, 
although formal tests suffer from extreme anticonservatism (Harrell, 2001). Informal 
visual assessments of the residuals can be far more informative, e.g., examining plots 
of score residuals: 
 )ˆ)(( ikiipip PkYIXU −≥=  
(2.4) 
Here ikP̂ is the predicted probability of the outcome Yi ≥ k for the ith individual, 
estimated using equation (2.3). I (Yi ≥ k) is an indicator variable for the event 
predicted and Xip is the ith observation for the pth predictor. The resulting ‘forest-plot’ 
of mean scores, pU ⋅  with associated 95% CIs against the corresponding levels of Y 
can be inspected to determine how plausible the PO assumption is (Harrell et al., 
1998).  
This is illustrated in Figure 2-3 where any deviation away from the desirable flat 
relationship indicates a violation of the proportional odds assumption. However, 
others have shown that the model is fairly robust against such departures (McHugh et 
al., 2010). 
Separate methods for the analysis of ordinal outcomes exist. The multinomial logistic 
regression model and the partial proportional odds logistic regression model are 
distinguished by the number of effect estimates obtained. This is reasonable when 
there is a clear violation of the proportional odds assumption such that multiple 
effects are associated with the possible categorisations of the ordinal outcome as a 
posed to just a single effect (Biesheuvel et al., 2008, Harrell, 2001). The drawback is 
a shift away from a simple interpretation toward a more complex and fragmented 


























































Figure 2-2 Example of the logistic function for a POLR showing the association between: (i) the βTX component of the linear predictor and the logistic 










































2.4.3 Selecting risk factors 
Investigators are often faced with a multitude of potential predictors to include in 
their model(s). There are two schools of thoughts which may be used exclusively or 
perhaps in combination. The first argument is that investigators should only consider 
those predictors which appear in a pre-specified list of clinically important 
predictors, for example, those variables highlighted through a systematic review as 
known risk factors for poor functional outcome after stroke. The second approach is 
an automatic selection procedure whereby the most important relationships expressed 
by the data are chosen. Each approach places a premium on different forms of 
information: existing prior information; and newly obtained information (i.e., sample 
data). These are discussed below in reverse order. 
2.4.3.1 Automatic variable selection 
Stepwise variable selection follows an algorithm which iteratively selects variables 
until the best combination of predictors is reached. The goal is to produce an optimal 
fit which maximises some pre-defined stopping rule, e.g., the χ2 test statistic with 
entry or removal at a P-value < α or else an improvement in the Akaikes Information 
Criterion (AIC). The algorithm can be set to choose predictors using: forward 
selection building from the intercept, i.e., the null model; backward selection, which 
starts with the full model and simplifies it by removing those ‘unimportant’ 
variables; or both forward and backward selection which involves both including and 
removing covariates in such a way that all combinations are considered. The main 
attraction to stepwise selection is that it is simple to implement and provides a quick 
and easy answer to the question: which predictors should I include in my model? 
However, provided that there is pre-existing information this is a pseudo-scientific 
approach. Several drawbacks make this method problematic (Steyerberg et al., 
1999). Harrell summarised a number of these, citing: (i) biased small SEs; (ii) 
coefficients that are too large due to a selection process that favours the inclusion of 
effect sizes that are over-estimated; and (iii) the removal of intellectual input, which 





2.4.3.2 Pre-specified variable selection 
By using a priori clinical knowledge the problems that arise with data-dependent 
selection methods are avoided. One drawback is the requirement for the relevant 
background information to already exist. Under these circumstances automatic 
variable selection with a less stringent stopping rule (e.g., P-value < 0.10 or 0.20) 
may be used. 
The generalisability of an estimated model can be assessed by considering the ratio 
of the number of events to the number of parameters to estimate. A simulation study 
suggested that a minimum of 10 events per parameter/variable (EPV) should be 
available as anything below this could result in overfitting and biased effect 
estimates (Peduzzi et al., 1996). For instance, consider a sample of 1000 acute 
ischaemic stroke patients with 10 years’ worth of follow-up available by which point 
100 of the patients suffer a recurrent stroke. Therefore in this example with 100 
events, a minimum of 10 parameters can be reliably estimated. This is not a strict 
mathematical rule though and subsequent studies have suggested that this rule may 
even be relaxed to as low as 5 EPV (Vittinghoff and McCulloch, 2007). 
In this thesis pre-specified risk factors and the 10EPV rule will be used throughout. 
2.4.4 Model assumptions 
Here three assumptions which apply to most regression models are considered (i.e., 
linear regression, Cox proportional hazards and logistic regression) (Harrell et al., 
1988). First that the sample of patients studied is a random sample from the 
population of interest on which generalisable inferences can be made. Second, the 
functional relationship between predictor and response is a particular shape (e.g., 
linear, cubic, etc.). Finally, the predictors are additive, i.e., no interactions exist. 
2.4.4.1 Random sample 
Any statistical inferences drawn from a simple random sample of data from some 
well-defined population are unbiased and therefore generalisable to the population 
under study. The RCT is the ‘gold-standard’ for evaluating treatment efficacy which 




various exclusion and inclusion criteria this sample may bear little resemblance to 
the target population meaning that those recruited comprise of a highly selected 
subset of the target population (Senn, 2007). Despite this drawback datasets from 
RCTs offer some of the most robust and reliable data upon which to develop a model 
thanks to the prospective record of predictor variables as well as the ascertainment of 
adjudicated patient outcomes (Steyerberg, 2009). The validity of the prediction 
model is best assessed through model evaluation studies which are also informative 
about how generalisable the prediction model is. Design issues with model 
evaluation studies and the associated performance metrics will be discussed later on 
in this chapter. 
2.4.4.2 Assessing linearity 
The models presented in equations (2.1) and (2.3) implicitly assume linearity on the 
log odds scale. Irrespective of the scale, there is little reason why a continuous 
covariate, X, should have a linear relationship with g (Y), other than when strong 
prior knowledge is available – where g (·) is some function of the outcome, e.g., the 
logit transformation. Non-linearity can be explored in a number of different ways. 
Cubic splines involve fitting cubic polynomial functions across designated intervals 
of a continuous covariate, X. These intervals are defined by the number and 
placements of joins, or knots, which span the range of X. 
Consider placing three knots at A, B and C across X. With three cut-points four 














p βββββ  (2.5) 
Where uu =+)( if 0>u and equals 0 if 0≤u . Note that accepting non-linearity here 
would imply rejecting the null hypothesis, H0: β2 = β3 =…= β6 = 0. 
In general, with k knots, there are k + 3 degrees of freedom used, excluding the 
intercept. By forcing the first and second derivatives of the function to be equal at the 




One unfortunate property is instability in the tales of the distribution. The Restricted 
Cubic Spline (RCS) is advocated by Harrell, which, by forcing linearity in the tails, 
produce more stable predictions (Harrell, 2001). In addition, a saving is made in the 
number of parameters to estimate (reduced to k – 1, excluding the intercept), 
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The number of knots, not their location, is central to the quality of the fit, which is 
typically based upon percentiles of the distribution of the covariate (Stone, 1986). 
In this thesis simpler transformations will be sought in place of the RCS fit provided 
that the improvement in fit is similar (e.g., a log transformation, or a quadratic 
expansion etc.). For example, in Figure 2-4 the quadratic fit is strikingly similar to 
the RCS fit with four knots, with a similar improvement (a model χ2 of 12.85 
compared to 12.82). The RCS can therefore be used as a powerful test for non-
linearity. Although in this case a simpler fit is made by using a quadratic 
transformation which saves on a degree of freedom. The impact here is quantified by 
the size of the χ2, this will be discussed in detail later in the chapter. 
It is contradictory to advocate the use of hypothesis testing to select the functional 
form of a predictor whilst simultaneously oppose their use in variable selection. 
However, an elegant rebuttal to this is articulated by the following quote from Frank 
E. Harrell, Jr (Harrell, 2001): 
“Carefully fitting an improper model is better than badly 






























Linear SBP with 1 df, χ2 0.22 and Squared SBP with 2 df, χ2 12.85

























Linear SBP with 1 df, χ2 0.22 and RCS SBP with 3 df, χ2 12.82
 




2.4.4.3 Assessing additivity 
In equation (2.1) each term has one associated regression parameter. An interaction 
occurs when the presence of one predictor modifies that of another. The simplest 
example of this is for a continuous predictor X1 and a binary predictor X2, regressed 
upon Y. The function g (·) here represents some property, e.g., E(Y | X), of the 
distribution of Y | X, 
 .),|( 2132211021 XXXXXXYg ββββ +++=   
When X2 = 1, the categorical variable is present; the consequent impact on the slope 
of X1 is given as, 
 .)()()1,|( 1312021 XXXYg ββββ +++==   
Evidence of an interaction between X1 and X2 therefore suggests that a different slope 
applies for X1 dependent upon X2. This is illustrated in the figure below (Figure 2-5). 
The additivity assumption will be assessed in this thesis by investigating the 
associated improvement in model fit when allowing two-way interactions (Harrell et 
al., 1996). 
2.4.5 Model comparison 
A formal method for selecting the best model fit (e.g., between a non-linear 
transformation and linear) is required. Given the observed data, the maximised 
likelihood (ML) is informative of the overall quality of the fit. Directly comparing 
the ML from two competing fits on the same data seems an appealing way to rank 
competing models. However, where a smaller model is contained within a larger 
model (i.e., nested), the model that fits more parameters will always have a larger 
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2.4.5.1 Penalised likelihood 
Instead of using the ML directly, a penalty for the number of parameters fitted can be 
applied to account for the complexity of the fit relative to the improvement in ML 
(Christie et al., 2011). 
 ),(ˆ npfll −=∗   
Here l̂ denotes the maximised log likelihood and f (p, n) some penalty function based 
on the number of parameters modelled, p, and the size of the sample, n. One 
approach is to use Akaikes Information Criterion (AIC), which applies a penalty for 
the number of parameters only. 
 plAIC 2ˆ2 +−=  (2.7) 
A reduction in AIC units indicates an improvement in the model fit. Another 
formulation of the AIC commonly encountered is the adjusted χ2 which is given by 
the model χ2 – 2p, with p as specified before. Under this form an increase in AIC 
indicates an improved fit. A useful feature of the AIC is that there is no need for 
models to be nested provided they are fit using the same data. 
Example From Figure 2-4 and using equation (2.7) the AIC for the simple linear fit of 
SBP (using 1df) to the log odds of death or dependency was 5383.7 and for the 
quadratic 5373.1 (using 2 df), an improvement in fit which translates as a reduction 
of 10.6 AIC units. 
2.4.5.2 The likelihood ratio-test 
A significance test can be used to compare two nested models where the null 
hypothesis is that the additional parameters have no additional value to the quality of 
the fit (Dobson, 1991). 
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Example The log likelihood for the linear fit in Figure 2-4 was -2689.9 and -2683.5 
for the quadratic fit. This gives a LR of 12.8 with a P-value of 0.0004, supporting the 
quadratic fit over the linear fit when compared to a 2 )12( −χ  where 84.3
2
95.0,12 =−χ . 
2.5 Model evaluation 
The most important aspect of prediction is the performance of the model evaluated in 
new or existing data (Collins and Le Manach, 2013). This process is typically 
referred to as model validation; however the point will be made here that this is in 
fact a misnomer. The purpose is to evaluate the performance of the model; the notion 
of validation is somewhat pre-specified and confirmatory. In this thesis model 
evaluation will be used. Model evaluation is therefore informative of how well a 
given model meets its intended purpose, for example: how well does a clinical 
prediction model predict the risk of a recurrent stroke? There are two approaches 
denoted as internal evaluation and external evaluation (Altman et al., 2009). 
Internal evaluation involves the partial or complete re-use of the original model 
development data. The most commonly adopted methods used to internally evaluate 
model performance are outlined (Steyerberg, 2009). The first and most appealingly 
simple is the apparent evaluation. Here model performance is assessed within the 
original data used in development. However, the model should be expected to 
perform well in these data due to overfitting; the resulting performance metrics are 
optimistically large. The only justification for assessing apparent evaluation is as a 
‘sanity-check’ during the model development process to illustrate that the proposed 
fit holds some prognostic ability. Secondly, a split-sample evaluation may be used. 
This requires the investigator to employ a random split (e.g., a 50:50 split) of their 
obtained data which is then used to fulfil both the requirement of model development 
and of model evaluation. The issue with this approach is that the model is fitted only 
within a sub-section of the obtained data with a consequent impact upon the 
precision of the obtained estimates. This can lead to unstable effect estimates and 
additionally imprecise metrics of performance. The use of a random-split ensures 
that the data will represent a simple random-sample of the data with each side of the 




somewhat optimistic. The third method is cross-validation, which is similar to the 
split-sample approach only here the sample data are partitioned in such a way that a 
subsection of the dataset is left out of model development (e.g., one tenth) for the 
purpose of assessing performance. This is called a K-fold cross-validation process as 
it is repeated till each of the Kth subsections is used. One of the drawbacks of this 
approach is that it does not reflect all aspects of model uncertainty when variable 
selection methods are used suggesting more stability in variable selection than would 
be anticipated in practice. The final approach is bootstrap evaluation. Bootstrap 
evaluation is regarded as the most robust method for internally assessing model 
performance by correcting for optimism. Here the entire dataset is used in model 
development thus avoiding the small sample size problem associated with the split-
sample approach. Model evaluation is undertaken in a series of samples drawn with-
replacement from the original data of the same size as the original sample. For each 
draw the difference between metrics, i.e., apparent minus bootstrap replicate, is 
evaluated over all replications and used to estimate the optimism in the apparent 
performance. An average estimate of this optimism can then be subtracted from the 
original estimate providing an estimate of performance that is said to have been 
corrected for optimism. 
Internal evaluation methods attempt to account for the fact that assessing model 
performance directly on the same data as used in development ultimately results in 
predictions that are over-fit to the data. It is not possible to assess the generalisability 
of the proposed model fit using internal evaluation and for this reason performance is 
best assessed on external data. External evaluation involves measuring model 
performance on a different set of patients recruited under different 
exclusion/inclusion criteria to that used in development, or perhaps within a different 
clinical setting (e.g., primary or secondary care). It is therefore important to 
understand how the development cohort compares to the evaluation cohort to fully 
judge the generalisability. 
Regardless of whether the data source used is ‘internal’ or ‘external’ the metrics 




2.5.1 Overall model performance 
Overall performance may be best measured by the amount of variance explained by 
the model, i.e., the R-squared (R2). Although synonymous with linear regression, an 
analogue for binary outcomes exists in the form of Nagelkerke’s R2 logarithmic 













=  (2.8) 
Where n is the number of patients, L0 is the likelihood for the model with no 
predictors (the null model) and L1 is the model with predictors. This measure is 
scaled to range from 0 to 100%. 
More generally, overall performance can be split into two constituent components: 
(i) discrimination; and (ii) calibration (Steyerberg et al., 2010). 
2.5.2 Model discrimination 
Discrimination summarises how well a model separates those with an event from 
those without. The concordance statistic or c-statistic is a rank order measure and is 
one way of measuring how well a given prediction model or risk score separates 
patients. For a given pair of patients, one with the event of interest and one without, 
the c-statistic is interpreted as the probability that a greater predicted risk (or higher 
risk score) is given to the patient with the event than the patient without. For a 
dichotomous outcome this corresponds to the area under the receiver operating 
characteristic curve (AUROCC). The Receiver Operating Characteristic (ROC) curve 
is a plot which maps sensitivity to one minus specificity for each potential cut-off of 
the score or predicted probability (see example Figure 2-6). The sensitivity of a test 
is the conditional probability of a positive result (i.e., a score or predicted probability 
above some fixed threshold) amongst events and the specificity of a test is the 
conditional probability of a negative result (i.e., below some fixed threshold) 
amongst non-events. The AUROCC can therefore be interpreted as the probability 
that a higher score or predicted probability is given to a patient with the event of 




Let N1 represent the number of patients with an event and N2 represent the number 
without and 
21 ,1,1
ˆ and ˆ nn pp  the respective individual predicted probabilities. The c-
















































ppψ   
A non-parametric test for comparing two ROC curves was proposed by DeLong et 
al. which accounts for the correlation between the two vectors of predictions made 
by two separate models on the same data. A P-value can be obtained by comparing 
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Figure 2-6 Example of a Receiver Operating Characteristic (ROC) Curve for two logistic 
regression models predicting six month death or disability. Model 1 (AUROCC = 0.66) contains 
a number of important predictors whilst Model 2 (AUROCC = 0.71) contains the same 





2.5.3 Model calibration 
Calibration summarises how well the observed events match the predicted events. 
For example, if a model predicts the risk of recurrent stroke as 5%, then 5 out of 100 
such patients should experience the event. The best representation of this is to plot 
grouped predicted risks along the x-axis (e.g., deciles of risk) against the observed 
fraction of events within each group on the y-axis (see example Figure 2-7). This 
contrasts the mean predicted risk to the mean observed frequency and is therefore a 
graphical display of the Hosmer-Lemeshow test of goodness of fit – a formal test 
which contrasts observed event rates to the expected event rates (Lemeshow and 
Hosmer, 1982). By estimating the slope and the intercept a better understanding of 
the bias in prediction can be obtained. A perfectly calibrated model has a slope of 
one and an intercept of zero. The slope indicates the degree of bias resulting from the 
model being: (i) over fit in development; and (ii) real differences in predictors. The 
intercept indicates differences in the prevalence of the outcome and the consequent 
systematic over (< 0) or under (> 0) prediction of risk. Estimates for these are 
outlined below. 
2.5.3.1 Calibration-in-the-large 
Calibration-in-the-large is the difference between the mean predicted risk and the 
mean of the new outcomes (i.e., in new data). For a non-linear model like a binary 
logistic regression, this difference must be evaluated on the log odds scale. However, 
the mean difference is not the same as the difference in the means. Therefore, when 
modelling this relationship some adjustment must be made for the corresponding 
intercept term (i.e., new predictions) achieved through an offset which enables a 
literal interpretation of the predicted risks (Steyerberg, 2009). The included offset 
term forces the coefficient for the linear predictor to equal one (Crowson et al., 
2013). 
2.5.3.2 Calibration slope 
The calibration slope is calculated by fitting the linear predictor obtained through the 
application of an existing model to a new dataset in a logistic regression. Note that 
for both of these measures (slope and intercept) the corresponding standard errors 






























Figure 2-7 Example of a calibration plot. Each triangle denotes the observed frequency by 
grouped decile of predicted risk. Wilson 95%CI are provided about these estimates (Wilson, 
1927).The distributions of predicted risk split by outcome are provided at the bottom of the plot. 
This is indicative of discrimination: the more distinct the two distributions are from one another 





2.5.4 The Net Reclassification Improvement 
The AUROCC is difficult to interpret. Additionally, it has been highlighted that it is 
an insensitive measure for quantifying the added benefit of a new risk factor (Cook, 
2007). Nancy Cook demonstrated this by considering a number of known predictors 
for the 10 year risk of CVD in healthy women, the same predictors in fact used in the 
established Framingham Risk Score. Interestingly, when low-density lipoprotein 
cholesterol (LDL-C) was included in a Cox model already containing age the c-
statistic showed little incremental improvement moving from 0.70 to 0.71. This is 
despite the fact that LDL-C is known to be statistically significant and has a 
moderate effect size on the risk of 10 year CVD. Cook concluded that it is far more 
important to quantify the shift in predicted risks than to rely upon the c-statistic when 
assessing a new predictive marker. This paper prompted a bid to place a value on 
such a shift resulting in the Net Reclassification Improvement (NRI). The NRI uses 
reclassification tables to quantify the proportionate movement in events and non-
events attributed to the inclusion of the new risk factor (Pencina et al., 2008). 
Consider two models: M0, a base model and M1, a model with all the predictors in M0 
but with one additional risk factor (e.g., a new biomarker or imaging variable). Two 
vectors of predicted probabilities, PM0 and PM1, can be calculated on the same data. 
By categorising patients into groups of risk, separate cross classifications of events 
and non-events can be produced (as seen in Table 2-1). This is formalised below, 
closely following the exposition given by Pencina et al., 
 )0|()0|()1|()1|( =−=+=−== YupPYdownPYdownPYupPNRI  (2.10) 
where Y = 1 signifies an event, and Y = 0 a non-event. Each of the conditional 
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An estimate for the NRI is then obtained using each of these components. 
 )ˆˆ()ˆˆ( 0,0,1,1, ==== −−−= YdownYupYdownYup ppppnri  (2.11) 
The NRI is the sum of four conditional probabilities and is therefore bound within the 
















)( 0,0,1,1,  (2.12) 
This is used to give an asymptotic test of the null hypothesis that the NRI is equal to 
zero. Assuming independence between events and non-events, the associated z-
statistic is given as the ratio of nri and its standard error. 
Example Two arbitrarily defined categories are used to categorise the predicted risks 
obtained from two logistic regressions for the risk of poor outcome at low and high 
risk defined as ≤50% and >50% respectively. A re-classification table is provided in 
Table 2-1. Using equation (2.11) and equation (2.12) the NRI and standard error were 
estimated as 0.0701 and 0.0275 respectively. Under the assumption of asymptotic 
normality the 95% CI for the NRI estimate was 0.0162 to 0.1240, and the associated 




Table 2-1 Example of reclassification for the predicted probabilities with and without patients 
conscious state on admission amongst events and non-events in MAST-I 
Model without consciousness  Model with consciousness 
Frequency (Row %)  ≤ 50% > 50 % Total, % 
Participants who experience an event 
≤ 50%  35 (54) 30 (46) 65 (16) 
> 50 %  18 (5) 313 (95) 331 (84) 
Total, %  53 (13) 343 (87) 396 
     
Participants who do not experience an event 
≤ 50%  72 (91) 7 (9) 79 (35) 
> 50 %  16 (11) 131 (89) 147 (65) 
Total, %  88 (39) 138 (61) 226 
Note: dark grey shaded area indicates movement in the correct direction whilst light shaded area 




A myriad of publications and citations arose in the wake of the Pencina et al. article 
with the NRI rapidly adopted amongst medical journals and fiercely critiqued within 
statistical journals (Vickers and Pepe, 2014). A recent review from Kerr et al. 
summarised the difficulties with the NRI drawing particular attention to its many 
misinterpretations and weaknesses (Kerr et al., 2014). The main drawbacks are 
provided here. First, the NRI is commonly quoted as a percentage; however (as 
mentioned above), the NRI combines four conditional probabilities and is therefore 
bound within the range [-2 to 2]. Second, combining the component reclassification 
measures (i.e., events and non-events) is of little benefit and in actual fact limits the 
interpretation considerably. Explicitly stating these unique values alongside their 
precision and reclassification tables is far more informative. Third, for three or more 
categories the NRI gives equal weight to all movement, despite the fact that a shift 
from high risk to medium risk may have a comparably smaller impact in the decision 
making process than a move from high to low risk. Finally, determining how the 
obtained predicted risks should be categorised in the absence of any pre-specified 
groups by necessity will be arbitrary. 
Indeed, Pencina et al. have extended their NRI to a category-free, or so called 
continuous NRI (Pencina et al., 2011). However, Kerr et al. also highlight a number 
of issues with this measure, including: (i) uninformative new markers yielding 
beneficial NRIs; (ii) small and clinically irrelevant changes in the predicted risk have 
an equal contribution in the calculation; and (iii) its interpretation is undefined. 
Importantly, Kerr et al. conclude that the NRI indices should not be used in the 
context of hypothesis testing especially when far superior tests already exist for this 





2.6 Missing data 
Missing data arise frequently in practice. Appropriate actions must be taken when 
handling such data – these actions should be explicitly outlined and justified. 
2.6.1 The mechanisms of missingness 
In essence missing data represent gaps in the available data: entries that were lost or 
else never recorded during recruitment to the study. Missing data act through three 
distinct mechanisms (Steyerberg, 2009). First, data may be missing by accident, e.g., 
an accident in the lab which resulted in a set of blood samples being destroyed 
(Missing Completely At Random – MCAR), in which case missingness is 
independent from the data observed. Second, for a given variable entries may be 
missing as a direct result of other measured variables (Missing At Random – MAR) 
in which case a dependency exists between the probability of missingness and some 
or all of the observed covariates. Finally, data can go missing for some hidden reason 
(Missing Not At Random – MNAR), i.e., the probability of a missing value is 
dependent upon a measure which was never recorded or may even depend on the 
missing values themselves. 
2.6.2 Handling missingness 
There are various methods for handling missing data. The most commonly 
encountered method is the complete case analysis. Here subjects with missing 
observations are removed from the dataset and hence removed from the formal 
analysis. Should an investigator decide to report both univariate and multivariable 
results then it becomes important that explicit references be made to which sample-
size each analysis corresponds to (Harrell, 2001). The complete case approach incurs 
a reduction in the sample size and implicitly assumes that any missing values are 
MCAR. A consequence of this is a reduction in the statistical power, and, where the 
MCAR assumption fails, the production of biased effect estimates (Vergouwe et al., 
2010). Imputation methods are used as a way of sensibly ‘filling in the gaps’ so that 
all measurements on all subjects contribute to the analysis. This is typically internal 
and will be based on some or all of the measured characteristics and their inter-




continuous variables is to replace any missing entries with the mean of that variable, 
whilst for categorical variables missing entries are replaced with the most frequently 
observed level. The main drawback of this approach is that it ignores additional 
information regarding the correlation structure between the measured variables. A 
more sophisticated approach utilises this information by regressing the variable with 
missingness upon the additional observed characteristics producing a statistical 
model specified for the explicit prediction of missing entries. This method requires 
that the missing entries have arisen at least in part through the MAR mechanism. A 
single draw is then made generating one complete dataset which is then analysed. 
However, this does not truly reflect the uncertainty that is present in the imputation 
process since on a second draw a slightly different dataset is obtained which once 
analysed will yield slightly different results. This issue is mitigated by generating 
multiple sets of imputed data each of which is then analysed and combined using 
Rubin’s rules (Rubin, 1996). 
2.6.3 The imputation model 
Provided that the missing data are indeed MAR (at least in part) then the imputation 
model will act as the link between those values that are missing and those that have 
been observed. The form taken in prediction is dependent upon the type of variable 
to be imputed, for example a binary variable would imply that a logistic regression 
be used, whilst a continuous variable suggests a normal linear model. The variables 
to be included are of three kinds: (i) those variables of interest to the analysis proper, 
e.g., the covariates to be included in a clinical prediction model; (ii) those variables 
that are of importance in the prediction of missingness, and regarded as auxiliary; 
and (iii) the outcome. Including the outcome in the imputation model is often thought 
to be somewhat self-fulfilling, however, if omitted, then covariate values are imputed 
as if not related to the outcome which can lead to biased results (Moons et al., 2006).  
The imputation model takes the kth variable of the K available variables and uses the 
remaining k-1 variables to predict those missing entries in k. This process is repeated 
for each of the K variables with missing entries. It is generally the case that in 




of missingness within k. This is handled by using a chained equations approach 
(Azur et al., 2011). First some value must be used to create some pseudo complete 
data; a first use point is defined, e.g., a single imputation using the mean. This is a 
temporary imputation though which will allow an imputation model to be devised for 
each variable. Each prediction model is then used to impute the originally missing 
values thus replacing the first use mean values used at the beginning with a predicted 
imputation. This process is repeated for a pre-specified number of iterations until 
stability is achieved. This then provides the first of the m complete datasets. A 
further complication arises when handling missing outcomes in imputation. Provided 
that MAR holds for the missing outcomes, there is a small gain in efficiency to be 
made by including cases with missing outcomes in the prediction of missing 
covariate information (Little, 1992). However, the log likelihood for cases with 
imputed outcome values is equal to zero, so retaining imputed outcomes equates to 
adding noise to estimates (Von Hippel, 2007). 
2.6.4  Rubin’s rules 
Having obtained m datasets and m associated analyses, pooled estimates are 
generated using Rubin’s rules (Rubin, 1996). Consider some parameter, Q, and its 
corresponding variance, U, across m multiple sets two vectors are obtained: 
]ˆ,...,ˆ[ˆ 1 mQQ=Q  and ]ˆ,...,ˆ[ˆ 1 mUU=U , where )ˆ(ˆ ii QVarU = . Rubin suggested a 
method for combining multiple estimates and calculating an associated standard error 
for the pooled estimate. These steps are summarised as follows: 












































Dawid and Senn elegantly describe the philosophical issues that relate to the practice 
of constructing models from data (Dawid and Senn, 2011). They begin by noting that 
by their very nature models are abstract. They highlight the importance of refraining 
from ‘reification’, that to treat the model as if it truly exists is erroneous. A model 
will not, nor should it be expected to, exactly fit reality. By directly comparing 
models a better description of reality may be reached, though there are those levels of 
uncertainty that will always persist: (i) stochastic uncertainty, an intrinsic part of a 
probability model; (ii) statistical uncertainty relating to the limitations of knowledge 
given the availability of data; (iii) model uncertainty regarding the limits of 
knowledge about how the world works; (iv) philosophical uncertainty relating to the 
two schools of thought in statistics (i.e., frequentist or Bayesian); and finally (v) the 
unknown unknowns. 
The following quote from Box and Draper is often used to summarise the issues 
associated with the modelling of data (Box and Draper, 1987): 
“Essentially, all models are wrong, but some are useful.” 
Indeed, prediction models can be incredibly useful when used in the correct context 
and setting. More recently, Thaddeus Tarpey in his presentation to the Joint 
Statistical Meetings in 2009 emphasised that models are not wrong, but that treating 
them as the truth is (i.e., the same reification fallacy noted by Dawid and Senn). He 
offered a more positive way of framing the Box and Draper quote (Gelman, 2012): 




Chapter 3: Predicting recurrent stroke and MI 
after stroke 
Background and summary 
This chapter presents a systematic review of the development of clinical prediction 
models for recurrent events in acute ischaemic stroke. A meta-analysis of model 
evaluation studies is followed in order to describe model performance. It is found 
that those currently available models appear to discriminate only modestly between 
patients with and without recurrent events: this may be explained at least in part by 
design weaknesses. 
3.1 Introduction 
Recovery after stroke can be complicated by recurrent events, e.g., stroke, 
myocardial infarction, and gastro-intestinal bleeding. The risk of recurrence is 
around 9% two years following the initial stroke (Azarpazhooh et al., 2008, Burn et 
al., 1994). Suppose a deterministic rule existed whereby it was a priori possible to 
say whether a given patient would or would not experience a complication. It 
logically follows that such a rule could influence the course of therapy. Whilst a 
perfectly discriminating rule (i.e., with an AUROCC of 1) is seldom available, a 
multivariable combination of measurements taken from patients on admission can 
often yield a sensible estimate of the underlying risk which can be of some value 
(Hayward et al., 2006). 
Multivariable clinical prediction models have the potential to better inform both 
doctor and patient about patient prognosis by providing an absolute estimate of 
individual patient risk. The clinical utility of the model depends on a number of 
factors; including its perceived discriminative ability. For instance, a model 
developed to predict the risk of recurrent ischaemic stroke or MI for recent ischaemic 




patients: some of whom will have a low predicted risk; and some at a high predicted 
risk. Provided that those with events in follow-up are given higher predicted risks 
than those free from events in follow-up then the prediction model may be useful in 
practice. It is well understood that better knowledge on patient prognosis has the 
potential to influence many facets of health care (Hemingway et al., 2013). In 
particular, informing a patient of his or hers predicted prognosis can play an 
important role in making treatment decisions (Moons et al., 2012b). This 
personalised approach to medicine places informed decisions in the hands of the 
patient and can be especially useful when emphasising those modifiable risk factors. 
However, models for recurrent events after stroke are currently not in widespread 
use. It is not clear why this is the case. Systematic reviews of clinical prediction 
models in other conditions (e.g., type II diabetes, cancer, traumatic brain injury) have 
identified a common set of flaws which, but to name a few, include: the use of poor 
methods; the inappropriate handling of missing data and the arbitrary categorisation 
of continuous variables (Collins et al., 2011, Mallett et al., 2010, Altman, 2009, Perel 
et al., 2006). 
This chapter presents a systematic review of those existing models for the prediction 
of recurrent stroke or MI after stroke. There are two broad aims: (i) to explore the 
quality of the cohorts and statistical methodology used in model development; and 
(ii) to summarise any evidence of their external performance. 
3.2 Methods 
An analysis protocol was developed (Thompson, Murray and Whiteley) and 
circulated amongst the convenors of the Cochrane Prognosis Methods Group 
(http://prognosismethods.cochrane.org/welcome) for comment. This protocol was 
made available online prior to conducting the electronic search: 
http://www.dcn.ed.ac.uk/dcn/documents/profile_protocols/whiteley_p2.pdf. 
Medline and EMBASE databases were searched from 1980 to the 19th of April 2013 
with an electronic search strategy using a search term for ‘stroke’ and synonyms for 
‘clinical prediction models’ (see Appendix A Table 3-4). Additional checks for any 




Scholar’ (http://scholar.google.com/) for citations of relevant articles. This review 
adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) checklist (see http://www.prisma-statement.org). 
3.2.1 Inclusion criteria 
Eligible articles developed and/or evaluated a multivariable clinical prediction model 
for the risk of recurrent ischaemic stroke, myocardial infarction or all vaso-occlusive 
arterial events in cohorts of adult patients with ischaemic stroke (or mixed ischaemic 
stroke and TIA). Articles had to provide their model in sufficient detail such that 
predictions could be made for new patients. An inception date of 1980 was used to 
account for the introduction and routine use of CT scans in clinical practice. Risk 
factor studies presenting a univariable model were excluded. Any studies using 
cohorts that included haemorrhagic stroke patients at baseline or any haemorrhagic 
events in follow-up were excluded. No language restrictions were made. 
3.2.2 Data extraction  
One author screened all titles and abstracts identified by the electronic search against 
the inclusion criteria prior to full text assessment (Thompson). Two authors 
(Thompson and Whiteley) extracted data independently with a detailed data 
extraction form that was developed and piloted by three of the authors (Thompson, 
Murray, and Whiteley). Discrepancies were resolved by discussion. 
No recommended tool for appraising the quality of prediction models currently 
exists. Quality items were therefore adapted from similar systematic reviews to 
ensure that all qualitative assessments made in this review were in-keeping with 
previous such studies (Counsell and Dennis, 2001, Hayden et al., 2006, Mallett et al., 
2010, Mushkudiani et al., 2008, Collins et al., 2011, Kwakkel et al., 1996, Laupacis 
et al., 1997). These items are discussed in detail below. 
Two types of articles were distinguished: (i) development studies reporting the 
construction of a prediction model, and (ii) evaluation studies (also known as 




3.2.3 Qualitative assessment of development studies 
The quality of a development study may be best assessed through its: (i) reporting; 
and (ii) methods. It is evident that the first aspect overlaps the second since a poorly 
reported study could detract from, or obscure, the methods used. It is argued that 
authors must be transparent and meet a high standard of reporting thus enabling 
consumers of the research to weigh up the value that the prediction model offers in 
influencing clinical practice. In principle, the process should be reported in enough 
detail that the model development could be independently reproduced, put simply: 
the same rigor expected in the reporting of RCTs should be adopted in model 
development studies (Groves and Godlee, 2012). 
3.2.3.1 Internal validity 
The sample of data used in model development is integral to the quality and 
generalisability of the proposed fit. The data should be viewed as the foundations of 
the model: if these foundations are weak or inappropriate for answering the research 
question then any inferences will very likely be subject to various biases. 
Prospectively collected data are typically of greater quality than retrospectively 
collected data and are therefore preferred in model development (Moons et al., 
2009). 
Loss to follow up is common. Authors should state the number of patients lost along 
with any explanations for these losses. An arbitrary proportion often thought 
adequate for analysis is anything between 80 to 95% complete follow-up (Fewtrell et 
al., 2008). The completeness of follow-up, which takes into account the duration of 
follow-up can be an informative way of reporting follow-up in survival data (Clark et 
al., 2002). 
Predictor variables, outcomes, and the time window across which they apply should 
be explicitly defined and reported. Predictions obtained using ill-defined variables 
can be difficult to generalise and in some instances may even be invalid. 
An exhaustive summary of the extent of missing data and how such data were 




favour of Multiple Imputation (MI) methods (Rubin, 1996, Vergouwe et al., 2010). 
As a general rule of thumb it has been suggested that imputation should be 
considered where the proportion of missingness exceeds 5% of the data. The impact 
of bias caused by proportions beneath this level may be negligible though still 
warrant investigation (Harrell, 2001, Schafer, 1999). 
3.2.3.2 Statistical validity 
Authors should avoid using data dependent predictor selection methods (e.g., 
stepwise selection) where possible (Sun et al., 1996, Steyerberg et al., 1999). As 
discussed in Chapter 2, these methods have various shortcomings which make them 
only suitable when there is a lack in background clinical knowledge. Clinical 
knowledge should always be used to inform the selection of risk factors. These risk 
factors should be retained within the final prediction model irrespective of their 
statistical significance (i.e., forced inclusion). 
Continuous variables should be kept continuous and modelled as such. Arbitrary 
categorisations are often adopted without justification and should be avoided. 
Dichotomisation is both statistically and clinically inefficient (Altman and Royston, 
2006). It equates to a needless reduction in statistical power as well as treating 
patients close to the respective cut-points as if entirely different. Such steps in risk 
are of course biologically implausible. The figure below illustrates the problems 
associated with categorising continuous variables by contrasting a simple continuous 
linear fit to a binary categorical fit (Figure 3-1). The relationship between the 
predictor variable X (e.g., patient age) and the binary outcome Y (e.g., death) on the 
log odds scale is assumed linear. A patients risk from the outcome therefore depends 
upon their value for X. Alternatively, the categorical fit assumes a constant risk for 
all of those where X<70 and a single step increase for those where X≥70. Altman 
and Royston stressed that if cut-points are used then they should be based on clinical 
reasoning, blinded to the observed data and ideally defined across more than two 
levels (Altman and Royston, 2006). Optimal cut-points based on P-values should 


































Figure 3-1 Example plot demonstrating the relationship between a continuous predictor, X, and 
the log odds of outcome for: (i) linear X; and (ii) X dichotomised at 70. 
The sample size available for model development (hereafter referred to as the 
derivation sample) must be reported along with a sufficient description of the 
baseline characteristics, missing data and the exclusion of any subgroups. The 
number of patients experiencing an event in follow-up (hereafter referred to as the 
effective sample size) should be stated explicitly. This has great importance in 
evaluating how over-fit the model may be relative to the selection of covariates 
considered. Peduzzi et al. demonstrated through simulation that a minimum of 10 to 
15 events per fitted parameter should be used as a guide for sensible parameter 
estimation: anything below this risked considerable biases in parameter estimates 
(Peduzzi et al., 1996). This rule of thumb can be used as an upper limit for the 
number of predictors that can be introduced to a model. Note that the effective 
sample size for a binary outcome is the smaller of the two numbers in the ratio of 




clinical prediction model should ideally be based on pre-existing clinical knowledge. 
Data dependent predictor selection, e.g., stepwise selection or univariate screening 
against some pre-specified significance level (e.g., P-value < 0.05) have many 
limitations, one of which is that they lead to an overfitting of the model by 
capitalising on data specific quirks and idiosyncrasies (Harrell, 2001). Michael 
Babyak gives an excellent overview of the points discussed above regarding over-fit 
models, describing a strategy on how to minimise the risks of overfitting through 
cautious expenditure of the degrees of freedom and shrinkage methods to correct 
over-fit regression coefficients (Babyak, 2004). 
3.2.3.3 Evaluation of the model 
The performance of a prediction model is best assessed within a new cohort of 
patients. Authors frequently state the performance of their model for the same data 
used for development (training data). This is equivalent to a student sitting last year’s 
paper as this year’s exam: the student training on past papers will perform well but 
may be thrown by a set of unseen questions. External validation in new data (test 
data) offers the most rigorous assessment of model performance and generalisability. 
A description of the baseline characteristics in the validation cohort should be 
reported to enable a comparison of the validation cohort to the development cohort 
suggesting how well the model may perform and ultimately summarising how the 
model may be generalisable (e.g., amongst older/younger patients etc.). Model 
performance must be assessed quantitatively via discrimination (e.g., the Area Under 
the Receiver Operating Characteristic Curve (AUROCC)) and calibration metrics 
(e.g., Hosmer-Lemeshow test or calibration plots) (Steyerberg et al., 2010). Although 
external validation in new data is preferred, so called internal validation techniques 
(e.g., bootstrap re-sampling or k-fold cross-validation) can also be applied. These 
methods re-use the development data to some degree, adjusting the apparent 
performance (that observed in the training data) for optimism. Internal validation, 
however, is only as useful as the quality of the data used in model development, for 
example, no adjustments can be made to correct for centre specific attributes when 




It is noted that the phrase ‘model validation’ is somewhat self-fulfilling. This 
unfortunate terminology persists in the literature but will be referred to as ‘model 
evaluation’ throughout this thesis. 
3.2.4 A brief overview of methods in meta-analysis  
In this section an overview of meta-analysis is provided covering the basic concepts 
regarding: the pooling of information; and the assessment of heterogeneity. 
Often a number of studies assessing the efficacy of a given treatment with similar 
trial protocols will have been conducted. It would be convenient to summarise this 
information as a single ‘pooled measure’. Meta-analysis is the branch of statistics 
concerned with the quantitative synthesis of such information where the goal is to 
provide a single, sensible, pooled measure of treatment effect (Deeks et al., 2008). 
There are two commonly adopted frequentist approaches in meta-analyses 
(Borenstein et al., 2010). A fixed effect meta-analysis assumes that each study 
measures the same true and fixed effect; therefore any observed variation is due to 
random error. Alternatively, a random effects meta-analysis says that estimates will 
vary from study to study due to random error and also due to true variation in the 
effect size assuming that the individual study estimates, θi, come from some 
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Here, Q is the heterogeneity statistic describing the sum of squared differences of the 




squared distribution and can be used to provide a test of heterogeneity with k – 1 
degrees of freedom). The weights, wi, denote the ith inverse variance weight 
associated to each of the k studies: imprecise estimates (i.e., large SE) are given less 
weight whilst precise estimates (i.e., small SE) are given more weight. To account 
for the degree of variability due to real study differences in the pooled estimate, 
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1)(θ , (3.3) 
which can be used to produce a 95% CI, )(21 DLDL SEz θθ α−± . 
When reporting the summary estimate from a random effects meta-analysis the 
associated prediction interval (PI) should also be provided (Higgins et al., 2009). The 
95% PI is interpreted as a plausible range within which an unknown estimate will be 
expected to lie in 95% of future samples (Riley et al., 2011). 
 22
21;2 )(ˆ DLkDL SEt θτθ α +± −−  
(3.4) 
Where 2/1;2 α−−kt  is the 100(1 – α/2)% from a t-distribution with k – 2 degrees of 
freedom. 
3.2.4.1 The meta-analysis of AUROCC values 
Area Under the Receiver Operating Characteristic Curve (AUROOC) obtained from 
evaluation studies were meta-analysed in a similar way to that adopted by Meads et 




using inverse variance weights was discussed above. Frequently though the standard 
error (SE) of the AUROCC estimate will not be provided, instead, only the 95% CI 
will have been reported. An estimate for the SE can be obtained by rearranging the 
approximate confidence interval: )(21 AUROCCSEzAUROCC α−± . With a 





ab .  
In almost all situations the CI reported is a 95% CI and therefore the critical value for 
z is 1.96 giving a denominator of 3.92. A loss of accuracy can be expected as CIs for 
AUROCC estimates are typically only reported to two decimal places. 
Individual evaluation studies will yield different model performance metrics as 
according to differences by chance and differences attributable to study design, i.e., 
patient populations, selection etc. It is for this reason that a random effect meta-
analysis model will be used to summarise model performance. If three or more 
studies assessed the same model’s performance within separate patient populations, 
then a random-effects meta-analysis was undertaken (DerSimonian and Laird, 1986, 
Viechtbauer, 2010). All measures of model performance were extracted along with 
any associated measures of uncertainty (e.g., 95% confidence intervals (CI) or 
standard error). Publication bias was assessed using funnel plots.  
3.3 Results 
A total of 12,456 articles were screened by title and abstract (Figure 3-2), thirteen of 
which were eligible for review. A further ten were identified from reference list 
checks and forward citation searches in Google Scholar. This comprised twelve 
development studies (Table 3-1) developing a total of 31 models (a median of 2 per 
study, interquartile range (IQR) 1 to 3) and eleven evaluation studies evaluating the 
performance of four models (Table 3-2). One relevant study written in a language 
other than English was included which was translated by Miss Cristina Matthews of 
the Centre for Population Health Sciences, University of Edinburgh (Alvarez-Sabin 




6,985 articles identified through
electronic search (Medline)
11,074 articles identified through
electronic search (EMBASE)
12,456 articles after duplicates were removed
12,384 excluded on abstract
72 full-text art icles assessed
for eligibility
59 of full-text articles
Reasons for exclusion:
Risk factor study (25)
Endpoint not appropriate (7)
Primary aim not model development (11)
Other (16)
13 articles eligible for review
23 articles eligible for review
10 articles included after 
reference check and forward citation 
 




Table 3-1 Characteristics of 12 development studies presenting prognostic models for recurrent vascular events after ischaemic stroke 
Author 
(model) Year Study design n/N Baseline event Outcome 
Time of 
outcome 
Ay et al 
(RRE90) 
2010 Retrospective single centre 60/1458 IS < 72 hours IS ≤90 days 
Dhamoon et al 2007 Prospective population cohort 102/655 IS MI; or vascular death 5 years 
Diener et al 
(ESRS) 
2005 Prospective RCT NA/6431 
1 week ≤ IS ≤6 
months 
Stroke recurrence 1 year 
Kamouchi et al 
(FSRJ) 
2012 
Prospective multicentre and 
retrospective registry 
175/3067 IS ≤ 7 days IS 1 year 
Kernan et al 
(SPI-I) 
1991 Retrospective single centre 38/142 TIA or minor stroke Stroke or death 2 years 
Kernan et al 
(SPI-II) 
2000 Prospective RCT 90/525 
TIA or minor stroke 
<90days 
Stroke or death 2 years 
Pezzini et al 2009 Prospective multicentre 73/511 
First ever IS aged 18 
to 45 
Ischaemic recurrence: 
fatal/nonfatal MI, IS, or TIA 
4 years 
Putaala et al 2010 Prospective single centre 72/807 
First ever IS aged 15 
to 49 
Fatal/nonfatal IS; or fatal/nonfatal 




2013 Prospective cohort 23/197 IS Cardiovascular events 1 year 
Sumi et al 2012 Prospective registry 133/3290 IS IS; or Cardiovascular events 1 year 
Suzuki et al 2012 Prospective multicentre NA/3324 
2 week ≤ IS ≤6 
months 
IS NA 
van Wijk et al 
(LiLAC) 
2005 
Prospective RCT with 
retrospective follow-up 
NA/2362 TIA or minor stroke Long-term vascular events 10 years 




3.3.1 Qualitative assessment of development studies 
3.3.1.1 Cohort characteristics 
Studies which collect data prospectively have a lower risk of information and 
selection biases for both baseline data and outcome events occurring during follow-
up. Most studies used prospectively collected data, though 4/12 did not (Ay et al., 
2010, Kernan et al., 1991, van Wijk et al., 2005, Kamouchi et al., 2012) one of which 
(van Wijk et al., 2005) used prospective trial data but included retrospective events 
obtained beyond the trial’s original follow-up period. Few, 4/12, development studies 
recruited patients consecutively from routine practice (Ay et al., 2010, Pezzini et al., 
2009, Putaala et al., 2010, Kamouchi et al., 2012). Loss of patients to follow-up often 
occurs when studies last for long time periods. Most, 9/12, (Ay et al., 2010, 
Dhamoon et al., 2007, Kernan et al., 1991, Putaala et al., 2010, Sumi et al., 2012, 
Suzuki et al., 2012, van Wijk et al., 2005, Stahrenberg et al., 2013, Kamouchi et al., 
2012) development studies reported loss to follow up; and where it could be 
calculated, 7/8, (Dhamoon et al., 2007, Kernan et al., 1991, Putaala et al., 2010, Sumi 
et al., 2012, Suzuki et al., 2012, van Wijk et al., 2005, Weimar et al., 2009, 
Stahrenberg et al., 2013, Kamouchi et al., 2012) rates of loss were small (less than 
5%). 
The most frequent variables included in multivariable clinical prediction models 
were: age, history of TIA or stroke, history of hypertension, and diabetes (Appendix 
B Table 3-5). Five articles (Dhamoon et al., 2007, Kernan et al., 1991, Pezzini et al., 
2009, Stahrenberg et al., 2013, Kamouchi et al., 2012) defined all predictors, three 
(Ay et al., 2010, Putaala et al., 2010, Sumi et al., 2012) defined only some, and four 
(Diener et al., 2005, Kernan et al., 2000, Suzuki et al., 2012, van Wijk et al., 2005) 
did not define any. Most articles defined outcome adequately, though three failed to 
define the outcome and/or the duration of follow-up (Diener et al., 2005, Kernan et 
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Figure 3-3 Aspects of model development 
Missing baseline data occur frequently when collecting information from patients. A 
complete case analysis using only those patients with complete baseline data risks 
selection bias and loss of information. Five of the development studies (Kernan et al., 
1991, Kernan et al., 2000, Pezzini et al., 2009, Suzuki et al., 2012, van Wijk et al., 
2005) reported missing data; four (Kernan et al., 1991, Pezzini et al., 2009, Suzuki et 
al., 2012, van Wijk et al., 2005) of which stated the impact a complete case analysis 




3.3.1.2 Statistical methods 
Most investigators collect more potential predictors than will be included in their 
final model. Data dependent methods (e.g., univariate selection or stepwise selection) 
are often used to select a few ‘important variables’ from those available to develop a 
prediction model. This can lead to over-fitted models that perform over-
optimistically in their development datasets which may be impossible to replicate in 
external evaluation (Steyerberg, 2009). Most of the studies used data dependent 
variable selection methods: stepwise selection (2/12) (Kernan et al., 1991, Putaala et 
al., 2010); univariate significance tests (4/12) (Ay et al., 2010, Dhamoon et al., 2007, 
Pezzini et al., 2009, Kamouchi et al., 2012); and further reduction of univariate 
selection by inspection of multivariable significance (2/12) (Suzuki et al., 2012, van 
Wijk et al., 2005). Three modifications of pre-existing prediction models were 
identified with new predictors chosen by clinical justification (Kernan et al., 2000, 
Sumi et al., 2012, Stahrenberg et al., 2013). One study gave no description of how 
variables were selected (Diener et al., 2005). 
Models were derived using Cox proportional hazard regression (9/12) (Ay et al., 
2010, Dhamoon et al., 2007, Kernan et al., 1991, Kernan et al., 2000, Pezzini et al., 
2009, Putaala et al., 2010, Suzuki et al., 2012, van Wijk et al., 2005, Stahrenberg et 
al., 2013) or multivariable binary logistic regression (3/12) (Diener et al., 2005, Sumi 
et al., 2012, Kamouchi et al., 2012). Most studies presented their models as point 
scores (7/12) by rounding regression coefficients (Ay et al., 2010, Diener et al., 2005, 
Kernan et al., 1991, Kernan et al., 2000, Sumi et al., 2012, Pezzini et al., 2009, 
Kamouchi et al., 2012). The categorisation of a continuous predictor results in the 
loss of information. The majority of studies categorised continuous predictors (8/12) 
(Ay et al., 2010, Dhamoon et al., 2007, Diener et al., 2005, Kernan et al., 1991, 
Kernan et al., 2000, Pezzini et al., 2009, Sumi et al., 2012, Kamouchi et al., 2012), 
only one of which gave some clinical justification for the cut-points chosen (Sumi et 
al., 2012). The remaining four studies used a mixture of categorised and continuous 
variables (Putaala et al., 2010, Suzuki et al., 2012, van Wijk et al., 2005, Stahrenberg 




Internal evaluation methods use the model development data to provide optimism-
corrected estimates of model performance. Few authors internally assessed their 
models performance (3/12) using cross-validation methods (Ay et al., 2010, 
Kamouchi et al., 2012, Sumi et al., 2012). 
A common rule of thumb used in prediction model literature is the ‘ten events per 
tested variable’ (10 EPV) rule. The median total sample size across the twelve 
development studies was 1132 (IQR 522 to 3123). Where reported (9/12) the median 
number of events was 73 (IQR 60 to 102). Only one of the five studies where the 
EPV could be calculated had more than the minimum recommended EPV of 10 
events per parameter (Sumi et al., 2012). 
3.3.2 Meta-analysis of evaluation studies 
3.3.2.1 Study characteristics 
The ESSEN Stroke Risk Score (ESRS) (Diener et al., 2005), the Stroke Prognosis 
Instrument II (SPI-II) (Kernan et al., 2000), the Recurrence Risk Estimator at 90 days 
(RRE-90) (Ay et al., 2010) and the Life Long After Cerebral ischemia (LiLAC) (van 
Wijk et al., 2005) were externally evaluated in eleven different studies. Four 
additional evaluations were identified amongst the model development studies (Ay et 
al., 2010, Kernan et al., 2000, Sumi et al., 2012, Stahrenberg et al., 2013) giving 
fifteen evaluation cohorts: five evaluations of the ESRS (Alvarez-Sabin et al., 2008, 
Fitzek et al., 2011, Sumi et al., 2012, Weimar et al., 2009, Weimar et al., 2008); three 
of the SPI-II (Kernan et al., 2000, Navi et al., 2011, Wijnhoud et al., 2010); five 
head-to-head comparisons of the ESRS and the SPI-II (Ay et al., 2010, Chandratheva 
et al., 2011, Meng et al., 2011, Weimar et al., 2010, Weimar et al., 2012, Stahrenberg 
et al., 2013); one head-to-head comparison of the ESRS and the RRE-90 (Maier et 
al., 2013); and one comparing the ESRS, the SPI-II and the LiLAC models (Weimar 
et al., 2010) (Table 3-2). 
The median sample size in the 15 evaluation cohorts was 1286 (IQR 619 to 5004). 
Various combinations of events and follow-up periods were used yielding 49 specific 
AUROCC values for extraction (Appendix BC Table 3-6). Where the effective 





Table 3-2 Characteristics of 15 evaluation studies assessing the performance of prediction models for recurrent vascular events after ischaemic stroke 
Study Model(s) Study design Baseline event Outcome(s) Country Follow-up 
Alvarez-Sabin 
(2008) 
ESRS Prospective multicentre IS IS/new vascular events Spain 6 months 





Prospective multicentre TIA or Stroke IS UK 90 days 
Fittzek (2011) ESRS Prospective single centre TIA or acute IS IS Germany 13.4 (5.9) months1 




Prospective single centre IS IS/CV death Germany 8 (6 to 11) days2 
Meng (2011) ESRS/SPI-II Multicentre registry TIA or IS IS & any vascular event China 1 year 






IS CV events/ total mortality Germany 1 year 







IS/stroke & CV death Germany 1 year 
Weimar (2008) ESRS Prospective multicentre TIA or acute IS IS/stroke & CV death Germany 17.5 (0.88) months1 
Weimar (2009) ESRS Prospective registry TIA or IS IS, MI, and CV death NA 1 year 
Weimar (2012) ESRS/SPI-II Prospective multicentre IS IS, MI, and CV death Germany 1 year 
Wijnhound 
(2010) 
SPI-II Prospective single centre TIA or minor IS 
IS, MI & vascular death / fatal 
or nonfatal IS 
Netherlands 2 years 




3.3.2.2 Statistical performance 
A meta-analysis of the AUROCC values observed in evaluation studies of the ESRS 
and the SPI-II models are presented in Figure 3-4. The median sample size in eleven 
pooled studies for the ESRS was 1727 (IQR 700 to 3292) and for the SPI-II was 
1372 (IQR 572 to 6486). Where the effective sample size could be determined the 
median size was 78 (IQR 52 to 124) and 96 (IQR 51 to 964) respectively. 
The pooled AUROCC values for the ESRS was 0.60 (95% CI 0.59 to 0.62) and for 
the SPI-II was 0.62 (95% CI 0.60 to 0.64) (Figure 3-4). Six head to head 
comparisons of the ESRS and the SPI-II were identified. Four of these (Stahrenberg 
et al., 2013, Meng et al., 2011, Weimar et al., 2010, Weimar et al., 2012) (the other 
two (Ay et al., 2010, Chandratheva et al., 2011) used much shorter follow-up 
periods) were pooled to calculate the AUROCC estimates: 0.61 (95% CI 0.58 to 
0.64) with 95% PI (0.29 to 0.93) and 0.62 (95% CI 0.59 to 0.66) with 95% PI (0.23 
to 0.99) respectively for the ESRS and the SPI-II scores. One evaluation study for the 
RRE-90 score estimated an AUROCC of 0.72 (95% CI 0.64 to 0.80) (Maier et al., 
2013) and another of the LiLAC score estimated an AUROCC of 0.65 (95% CI 0.61 
to 0.70) (Weimar et al., 2010). Two evaluations of the ABCD2 score (Johnston et al., 
2007) were identified (Chandratheva et al., 2011, Maier et al., 2013). Although the 
ABCD2 score did not meet the inclusion criteria of this systematic review these 
evaluations suggests generalisability to a broader range of patients suffering 
ischaemic strokes for the prediction of recurrent stroke (Figure 3-4). Only one study 
assessed the calibration of the SPI-II score which found it to be good but only after 
re-calibration (Wijnhoud et al., 2010). There was no evidence for small study (i.e., 
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Figure 3-4 Meta-analysis of the AUROCC values for the ESRS and the SPI-II (Note: percentage 




3.3.2.3 Sensitivity analyses 
Some evaluation studies deviated from the original derivation outcome definitions 
and follow-up times. However, often multiple AUROCC values were provided (see 
Appendix B Table 3-6). A series of sensitivity analyses for the ESRS and the SPI-II 
are provided in the table below (Table 3-3) meta-analysing those AUROCC values 
reported for specific outcome definitions. Small differences in the AUROCC values 
were identified, but note that after the first row in this table the AUROCC values are 
no longer comparable between the two models since they relate to different 
endpoints. 
 
Table 3-3 Sensitivity analyses for meta-analysis of AUROCCs for ESRS and SPI-II 
Sensitivity analyses No. studies AUROCC 95% CI 95% PI 
All studies   
ESRS 10 0.60 0.59 to 0.62 0.57 to 0.63 
SPI-II  9 0.62 0.60 to 0.64 0.56 to 0.67 
Outcome as per development    
ESRS 8 0.59 0.57 to 0.61 0.28 to 0.91 
SPI-II 7 0.62 0.61 to 0.64 0.39 to 0.86 
Follow-up time as per development   
ESRS 5 0.61 0.59 to 0.62 0.43 to 0.78 
SPI-II 1 0.68 0.61 to 0.75 NA 
Follow-up and outcome as per development   
ESRS 4 0.60 0.57 to 0.63 0.24 to 0.95 






There were four externally evaluated clinical prediction models for the prediction of 
recurrent stroke and myocardial infarction after stroke (the ESRS, the SPI-II, the 
RRE-90 and LiLAC) each having modest but similar discrimination (AUROCC 0.60 
to 0.72). 
Design weaknesses may explain the modest performance observed in external 
evaluation: the categorisation of continuous variables may have caused a loss in 
predictive power; data-dependent variable selection may have led to models over-fit 
to the data; and the cohorts were generally too small for reliable model development, 
in fact only one study achieved more than the recommended minimum of 10 EPV. 
The cohorts used to develop the models had weaknesses that are frequent in 
epidemiological studies: there were missing baseline data; whether the recruited 
patients were representative of those seen in routine clinical practice was uncertain; 
some data were collected retrospectively; and most cohorts did not record all 
potentially predictive variables. Despite the differences in the derivation of the 
ESRS, the SPI-II and the LiLAC, they all discriminated similarly (and modestly) 
between patients with and without recurrent stroke (Weimar et al., 2010). The ESRS 
and the SPI-II have four predictors in common (age, history of TIA or stroke, 
diabetes, and blood pressure). Three head to head comparisons demonstrated a 
relative difference in AUROCC which did not exceed 2% (Meng et al., 2011, 
Weimar et al., 2010, Weimar et al., 2012). 
It is not known whether the discrimination of any prediction model for recurrent 
stroke is better or worse than a clinicians’ informal prediction, therefore their utility 
in clinical practice remains unclear. Despite direct comparisons between formal and 
informal predictions perhaps providing the most robust argument for or against the 
use of statistical prediction model, they remain rare. For instance, there are many 
prediction rules for poor outcome or disability after stroke (Veerbeek et al., 2011) but 
few have been tested against clinicians’ informal predictions (Counsell et al., 2004). 




informal clinicians’ predictions of recurrent vascular events in an observational 
cohort. 
3.4.1 Implications for research 
This review identified a number of areas which could, if adopted, potentially 
improve the discrimination of future clinical prediction models for recurrent stroke or 
myocardial infarction: (i) using all the available information from a cohort by 
avoiding the categorisation of continuous predictors, and using multiple imputation 
of missing data where a complete case analysis would exclude a significant 
proportion of the cohort; (ii) reporting regression coefficients (i.e., prior to any 
transformation) to allow more accurate evaluation of models in independent cohorts. 
Point score models are probably obsolete as more precise predictions can easily be 
obtained using applications accessed via mobile computers at the bedside. There are 
too many proposed models in clinical practice to remember them all, and it is only 
sensible that they should be available electronically; and finally, (iii) measuring 
whether newly identified predictors, (e.g. blood markers or imaging techniques) add 
to the accurate classification of patients over more easily measured variables, for 
example using the net reclassification improvement (NRI) (Pencina et al., 2008, 
Stahrenberg et al., 2013). 
A number of methodological decisions in model development may lead to clinical 
prediction models that make less accurate predictions (Bouwmeester et al., 2012). It 
is for this reason that an agreed set of guidelines in model development and reporting 
in healthcare would be helpful to developers and users of clinical prediction models 
alike (Collins, 2011). 
The impact of a clinical prediction model on clinical practice should ultimately be 
assessed through a randomised trial where the use of a prediction model forms part 
of the intervention. A well designed impact study should incorporate an assessment 
of patient outcome as well as cost-effectiveness (Moons et al., 2012a). This 
systematic review suggests moderate discrimination of recurrent stroke and MI when 




calibrated for a given population, and assessed using an impact study thus 
quantifying the overall worth of the model. 
3.4.2 Limitations of the study 
Assessing the quality of studies of predictive models is difficult, and there is no 
widely agreed set of guidelines. This is likely to become an increasing problem as 
such studies are frequent, and very likely will begin to influence practice. 
No scoring tool was used to rank the development studies. However, it is debatable 
whether such a tool should be used in assessing model quality. For instance it may be 
the case that despite methodological flaws in development the model performs well 
in practice. Indeed, given the quality observed through this systematic review, by 
assigning poor scores to quality of model development has the potential to cause an 
excess of ‘non-starters’. In addition it is not clear how each item should be weighted: 
intuitively a score of ‘1’ should have the same impact across the full range of quality 
items, however, it is not clear that this would strictly be the case. Finally, model 
performance assessed through external evaluation in new data is by far the more 
robust way to rate the quality of the model. 
The electronic search was overly sensitive and returned a small number of relevant 
articles. Additional searches of the ‘grey’ literature were not performed, although this 
would not likely have resulted in many more articles. This is an unfortunate artefact 
of poor indexing, as no Medical Subject Heading (MESH) terms for clinical 
prediction model papers currently exist. Extensive use of forward citation searching 





3.5 Appendix A: electronic search strategy 
Table 3-4 Electronic search term implemented in Medline and EMBASE 
Medline 
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain 
ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid stenosis/ 
or cerebrovascular accident/ or exp brain infarction/ or exp hypoxia-ischemia, brain/ 
or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/  
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior 
circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw.  
4. 1 or 2 or 3 
5. ((risk or predictive or prediction or statistical or cox or logistic or survival or 
multivariate or multivariable or hazard$) and (prediction or model$ or equation or 
rule or calculator)).tw. 
6. cox proportional hazard model$.ab. or cox proportional hazard model$.ti. or cox 
proportional-hazard$.ab. or cox proportional-hazard$.ti.  
7. 5 or 6 
8. 7 and 4 
9. Child/ or ethnic groups/ or *Depression/ or economics/ or *caregivers/  
10. 8 not 9 
11. (Bibliography or Editorial or Letter or News).pt. 
12. 10 not 11 
13. limit 12 to 1980-current 









1. cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar 
insufficiency/ or wallenberg syndrome/ or exp brain infarction/ or exp brain 
ischemia/ or exp occlusive cerebrovascular disease/ or cerbrovascular disease/ or exp 
carotid artery diseases/  
 
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior 
circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw. 
4. 1 or 2 or 3 
5. ((risk or predictive or prediction or statistical or cox or logistic or survival or 
multivariate or multivariable or hazard$) and (prediction or model$ or equation or 
rule or calculator)).tw. 
6. cox proportional hazard model$.ab. or cox proportional hazard model$.ti. or cox 
proportional-hazard$.ab. or cox proportional-hazard$.ti.  
7. 5 or 6 
8. 7 and 4 
9. Child/ or ethnic group/ or depression/ or health economics/ or caregiver/ 
10. 8 not 9 
11. (Bibliography or Editorial or Letter or News).pt. 
12. 10 not 11 
13. limit 12 to 1980-current 





3.6 Appendix B: Extra tables and figures 
Table 3-5 illustrates the variables used in each of the 12 model development studies. 
Some presented multiple models per publication making for a total of 28 models 
which could be extracted. 
Figure 3-5 shows graphical assessment of publication bias using contour-enhanced 
funnel plots. 
Table 3-6 lists the various additional AUROCC values that could be extracted from 





































































































































Model per publication  1 2 1 2 1 1 2 1 1 1 2 3 1 2 3 4 1 2 3 1 2 1 1 2 3 4 5 6 
Demographics                              
Age 9   • • • • • • •    • • • •    • • • • • • • • • 
Gender 4             • • • •    • • • • • • • • • 
Social Factors                              
Smoking 4     • • •       • • •    • •        
Past medical history                              
TIA/stroke 7 • •   • • •  •     •  •    • • •       
Stroke in family 1          •  •                 
CAD 2   • •     •                    
PAD 3     •         • • •    • •        
CHF/Heart failure 3   • •     •    • •  •             
CHD 3        •      • • •             
MI 5    • •         •  •    • •  • • •    
Diabetes 8     • • • • •    • • •     • • • • • • • • • 
Chronic kidney disease 1      • •                      
                              
                              
                              




































































































































Past medical history cont.                             
Other cardiovascular 
disease (not MI/AF) 
3     • • •             • •        
Peripheral vascular 
surgery 
1                       • •     
Intermittent 
claudication 
1                       • • • • • • 
Details of stroke                              
Stroke not TIA 3        • •               • •  • • 
Lacunar subtype 1    •                         
Nonlacunar subtype 1      • •                      
Embolic subtype 1    •                         
Subtype (not SAO) 1                    • •        
Admission CCS 2 • •           • • • •             
Migraine with aura 1          •  •                 
Amaurosis Fugax 1                        •     
Risk score: ESRS 1                 •            
Risk score: SPI-II 1                  •           
NIHSS 1                   •          
                              




































































































































General examination cont.                             
Waist circumference/ 
Obesity 
3              •  •    • • •       
Hypertension or BP 9     • • • • • •  •  • • •    • • • • • • •   
Hyperlipidemia 1                      •       
AF 3   • •  •        •  •             
mRS 1                      •       
Paresis 1                           • • 
Dysarthia 1                        • •  • • 
Dyslipidemia 1              •  •             
Vertigo 1                        • •    
CT/MRI/ECG                              
Multiple infarcts of 
different ages 
1 •                            
Simultaneous infarcts in 
different circulations 
1 •                            
White matter lesions 1                         •   • 
Any infarct 1                         •   • 
                              
                              




































































































































CT/MRI/ECG cont.                              
Q wave on ECG 1                         •    
Negative T wave 1                         •    
ST-depression 1                         •   • 
Genetic 
factors/biomarkers 
                             
FVG1691A 1           • •                 
TT677 MTHFR 1           • •                 
PTG20210A 1           • •                 













































0.40 0.50 0.60 0.70 0.80
0.1 > p > 0.05
0.05 > p > 0.01
p < 0.01
Studies







































0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80
0.1 > p > 0.05








Table 3-6 Discrimination metrics for externally evaluated models (n = number of events, N = total sample size, CV = cardiovascular, IS = ischaemic stroke) 
Study AUROCC (95%CI) n/N Outcome Additional AUROCC with 95% CI 
ESRS     
Ay (2010) 0.59 (0.53 to 0.66) NA IS - 
Chandretheva 
(2011) 
0.50 (0.42 to 0.59) 49/520 IS 0.49 (0.35 to 0.62), for 7 day events 
Fitzek (2011) 0.59 NA 76/723 IS - 
Weimar (2010) 0.65 (0.60 to 0.69) 135/1897 IS or CV death 0.62 (0.57 to 0.67) for IS 
Weimar (2008) 0.61 (0.54 to 0.69) 60/700 IS or CV death 0.56 95%CI. NA for IS 
Weimar (2009) 0.60 (0.58 to 0.62) NA/15605 
Nonfatal IS/MI or CV 
death 
0.56 (0.53 to 0.58) for IS 
Weimar (2012) 0.59 (0.56 to 0.63) NA/846 
Nonfatal IS/MI or CV 
death 
0.62 (0.59 to 0.65) fatal/non-fatal IS 
Maier (2013) 0.59 (0.50 to 0.68) 95/1727 IS 0.50 (0.42 to 0.58), for 7 day events 
Meng (2011) 0.60 (0.59 to 0.61) NA/11384 
Nonfatal IS/MI or CV 
death 
0.59 (0.58 to 0.60) for IS, for baseline IS only: 0.60 (0.59 to 




0.695 (0.567 to 
0.822) 
23/197 IS or CV death 0.744 (0.575 to 0.912), for all-cause mortality 
Sumi (2012) 
0.613 (0.564 to 
0.661) 
133/3292 IS/MI or CV death 0.604 (0.554 to 0.654) for IS 
SPI-II     
Ay (2010) 0.56 (0.49 to 0.64) NA IS - 
Chandretheva 
(2011) 
0.48 (0.39 to 0.60) 49/514 IS 0.50 (0.37 to 0.64), for 7 day events 
Kernan (2000)  0.63 (0.62 to 0.65) 1241/9220 IS or death - 
Navi (2011) 0.62 (0.61 to 0.64) 1422/5575 IS or death 0.55 (0.51 to 0.59) stroke; 0.64 (0.62 to 0.66) death 
     




Table 3-6 Continued from previous page 
     
Study AUROCC (95%CI) n/N Outcome Additional AUROCC with 95% CI 
SPI-II continued     
Weimar (2010) 0.66 (0.61 to 0.70) 135/1897 IS or CV death 0.65 (0.60 to 0.70) for IS 
Weimar (2012) 0.60 (0.57 to 0.64) NA/846 
Nonfatal IS/MI or CV 
death 
0.56 (0.53 to 0.60) fatal/non-fatal IS 
Wijnhound (2010) 0.68 (0.61 to 0.75) 57/592 IS/MI or CV death 0.64 (0.56 to 0.72) fatal/non-fatal IS 
Meng (2011) 0.60 (0.58 to 0.61) NA/11384 
Nonfatal IS/MI or CV 
death 
0.59 (0.58 to 0.61) for IS, for baseline IS only: 0.61 (0.59 to 




0.699 (0.587 to 
0.810) 
23/197 IS or CV death 0.708 (0.549 to 0.867), for all-cause mortality 
ABCD2     
Chandretheva 
(2011) 
0.62 (0.54 to 0.70) 49/520 IS 0.64 (0.53 to 0.74), for 7 day events 
Maier (2013) 0.60 (0.52 to 0.69) 95/1727 IS 0.60 (0.53 to 0.67), for 7 day events 
LiLAC     
Weimar (2010) 0.65 (0.61 to 0.70) 135/1897 IS or CV death 0.64 (0.59 to 0.69) for stroke 
RRE-90 A/B     
Maier (2013) 0.72 (0.56 to 0.88) 95/1727 IS 0.58 (0.46 to 0.70), for 7 day events 




Chapter 4: Predictions of recurrent stroke and 
MI after ischaemic stroke 
Background and summary 
This chapter presents an assessment of models for the prediction of recurrent stroke 
or MI after stroke identified via a systematic review of the available literature 
between 1980 till 19th of April 2013 in a new prospective cohort of stroke patients. A 
unique record of clinicians’ informal predictions raised the opportunity to compare 
formal and informal predictions. It is concluded that neither method out performs the 
other and that discrimination of events from non-events is poor. 
4.1 Introduction 
The occurrence of a recurrent stroke or an MI during a patient’s recovery following 
an initial ischaemic stroke could have important implications for both the state of 
independent living the patient can expect to return to as well as their chance of long 
term survival. If it were possible to reliably determine the absolute risk of a recurrent 
vascular event then the treating clinicians could use this to implement a suitable 
preventative strategy or else direct certain admissions to specialised stroke centres. 
To make the best use of medical resources it is therefore as important to identify 
those at low risk as it is to identify those at high risk: such evidence could inform 
important aspects across recovery (Lemmens et al., 2013). There are two ways that 
recurrence free survival may be predicted: (i) using clinicians’ predictions, i.e., a gut 
feeling based on clinical experience; or (ii) using some clinical prediction model, 
combining a number of prognostic risk factors whose importance is suitably 
weighted within a single equation. Each method will draw from a similar pool of 
available information, but may use it in different ways. In the previous chapter it was 
seen that a number of clinical prediction models already exist. The conclusion was 




common amongst available models developed for other diseases persist 
(Bouwmeester et al., 2012). Whilst model development is important, provided that 
the model performs well in practice, it is of little concern how well the derivation 
was undertaken (Collins and Le Manach, 2013). This is not to devalue the 
importance of using robust and methodologically sound model development 
techniques as in the absence of external evaluation; a close inspection of model 
development is by far the best way of judging which model to back. The 
performance of a clinical prediction model is best assessed though in a new 
prospective cohort of patients by investigators with no vested interest in how the 
results turn out (Collins et al., 2014). This chapter has two aims: (i) to test the 
performance of existing clinical prediction models in a new cohort of first time 
stroke patients; and (ii) to assess whether there are any important differences 
between those predictions made by clinicians and those made by statistical models. 
4.2 Materials and Methods 
The previous chapter covered many important aspects of model development asking 
general qualitative questions of all those models identified. In what follows a more 
detailed description is provided for each of the models whose performance could be 
evaluated in the data made available for analysis in this chapter. A summary of the 
available data will be given following which a discussion as to how it compares to 
the derivation data from which each model came. 
4.2.1 Predicting recurrent vascular events 
Five of the twelve identified clinical prediction models could be assessed in the 
Edinburgh Stroke Study. All were derived as Cox Proportional Hazard models 
(PHMs) except for the ESRS which was derived using binary logistic regression. 
Most (3 out of 5) were presented as a point score. 
4.2.1.1 The ESSEN Stroke Risk Score (ESRS) 
The ESSEN Stroke Risk Score (ESRS) was developed using prospectively collected 
trial data from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events 
(CAPRIE) trial (Diener et al., 2005). Interestingly, whilst this model has had 




4.2.1.2 The second Stroke Prognosis Instrument (SPI-II) 
The second Stroke Prognosis Instrument (SPI-II) was developed by Kernan et al. and 
was offered as an improvement on the original SPI-I, which, the authors suggest, 
may have been based on too small a sample (142 patients with 38 events) (Kernan et 
al., 1991, Kernan et al., 2000). The authors explored the inclusion of new predictors 
based on existing literature which Kernan et al. tested in the Women’s Estrogen for 
Stroke Trial (WEST). These new variables were fit as a multivariable Cox PHMs 
where only those variables that achieved a P-value less than or equal to 0.1 were 
included. The estimated regression coefficients were rounded to produce a point 
score. The authors quote identifiable risk groups (i.e., low, medium and high) and 
provided the Kaplan-Meier estimates of stroke or death within each of these strata. 
4.2.1.3 The 90 day Recurrence Risk Estimator (RRE-90) 
Ay et al. developed the 90 day Recurrence Risk Estimator (RRE-90) to predict 
ischaemic stroke patient’s risk of recurrent stroke by 90 days with a recurrence 
defined as a visible area of new infarction through imaging (Ay et al., 2010). The 
patients included in the study were obtained retrospectively between 2003 and 2006 
from a single center in the US. They developed their model in a sample of 1458 
patients of which 60 suffered a recurrent stroke. Two models were published: Model 
A, a clinical-based model; and Model B, Clinical-and imaging-based model. A 
process of univariable significance was used to establish which of the important 
predictors should make it into a Cox PHM with the obtained regression coefficients 
rounded to produce a simple point score. Model A included history of TIA or stroke 
and patient’s Admission CCS (Causative Classification of Stroke System) subtype. 
Model B included: multiple infarcts of different ages; simultaneous infarcts in 
different circulations; multiple acute infarcts; isolated cortical infarcts; history of 
TIA or stroke; and admission CCS subtype. The authors provided the Kaplan-Meier 
estimated risk from the derivation data split into five distinct score strata. In this 
chapter only Model A will be evaluated due to an unavailability of patient baseline 




4.2.1.4 Putaala’s model 
Putaala et al. investigated the risk of recurrent vascular events in a young cohort of 
807 stroke patients aged from 15 to 49 (Putaala et al., 2010). They cited the need for 
a better understanding of the etiological differences in the risk of recurrence within a 
younger population of stroke patients as the primary motivation for introducing a 
new model. They developed four separate prediction models using two distinct 
outcomes: nonfatal/fatal ischaemic stroke, and a composite outcome of any arterial 
event. They incorporated covariates using two strategies: individual clinical risk 
factors and stroke etiology; or a simple count of clinical risk factors, as well as age, 
gender and stroke etiology. A backward stepwise selection process was used to 
choose the most important risk predictors. 
4.2.1.5 Dhamoon’s model 
Dhamoon et al. developed a model for myocardial infarction or vascular death after a 
first time ischaemic stroke using a prospective population cohort (Dhamoon et al., 
2007). They studied a sample of 655 patients of which 102 suffered the event of 
interest by 5 years. Cox PHMs were used to explore univariable and multivariable 
associations amongst historical and physiological risk factors as well as patients’ 
stroke etiological subtype. Those covariates identified as significant at the 
univariable level with a P-value <0.1 made it into a multivariable fit at which point 
further selection was undertaken using a stepwise algorithm. The authors published 
two models: one included age, CAD, CHF and AF; and another included age, MI, 
CAD without MI, CHF, AF and stroke subtype. In this chapter only the first of these 
will be evaluated due to an unavailability of patient baseline data in the ESS. 
4.2.1.6 Clinicians’ predictions in the Edinburgh Stroke Study 
Informal predictions of recurrent events in the Edinburgh Stroke Study were made on 
patients seen at outpatient clinics only. These were made as an absolute percentage 
quantifying the perceived risk of the event. It was possible to obtain some 
information regarding thirteen of the clinicians making predictions for 542 (94%) of 
the patients. Eight were neurologists (62%) and five were stroke physicians (38%); 
seven were in training (54%) and six were fully trained (46%). The median number 




Table 4-1 Overview of the five clinical prediction models 
Model ESRS (2005) SPI-II (2000) RRE-90 (2010) Putaala (2010) Dhamoon (2007) 
Source 
population 
Prospective RCT Prospective RCT Retrospective single 
center 
Prospective single center Prospective population 
cohort 
Outcome Recurrent stroke Stroke or death Recurrent stroke Fatal or nonfatal 
ischaemic stroke 
MI or vascular death 
Time window 1 year 2 years 90 days 5 years 5 years 
No. predictors 8 7 2 6 4 
Predictors      
Demographics Age Age  Age Age 
    Gender  
Clinical 
characteristics 
 Stroke not TIA    
Risk factors Prior TIA Prior stroke Prior stroke or TIA Prior TIA History of Atrial 
Fibrillation 
 Arterial hypertension Severe hypertension  Heart failure History of coronary heart 
failure 




 Diabetes Mellitus History of coronary artery 
disease 
 Diabetes Mellitus Diabetes Mellitus    




   
 Peripheral Artery Disease     
 Smoking     
Stroke etiology   Admission CCS 
subtype 
TOAST classification  




4.2.2 The Edinburgh Stroke Study (ESS) 
The Edinburgh Stroke Study (ESS) was a prospective observational study of stroke 
patients admitted to the Western General Hospital in Edinburgh between April 2002 
and May 2005. Patients were followed for a minimum of one year. Details on the 
study’s design have been published elsewhere (Jackson et al., 2009). In brief, 
clinicians were asked to use gut-feeling to estimate the absolute risk of a recurrent 
stroke or a vascular event – that is, stroke, MI or vascular death – within one year of 
the initial stroke amongst those seen as outpatients (N=671). The definition of 
recurrent stroke required a period of neurological stability of at least 24 hours 
between the initial stroke and the recurrent stroke whilst simultaneously excluding 
any other potential causes of neurological deterioration. Myocardial infarction in 
follow-up was defined either through autopsy or else through evidence of at least two 
of the following signs: symptoms of myocardial ischemia, e.g., chest pain; enzyme 
changes associated with MI, e.g., elevated troponin levels; and ECG changes 
suggesting new ischemia. Probable MI was defined as any abrupt deaths with no 
alternative explanation. There were few missing baseline data (see Table 4-2) 
therefore complete case data are used throughout this chapter. 
4.2.3 Cohort Comparability 
Important differences may exist between the development and evaluation 
populations. Baseline data were extracted from each of the five prediction models as 
far as was possible, including variables not used in the final proposed models. No 
baseline data could be extracted for the ESRS due to poor reporting of its 
development. Variables included in the final models are highlighted in Table 4-2 in 
bold. ESS did not classify stroke according to the Causative Classification of Stroke 
System (CCS); although a record of classification as per the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) algorithm could be manipulated to a form that 
closely resembled the CCS. Considerable differences are noted when comparing the 
prevalence of the observed patient characteristics in ESS to those patient 
characteristics obtained for each of the five prediction model cohorts (see Table 4-2). 
The development population used by Putaala et al. was younger by design and it may 





Table 4-2 Baseline characteristics of the five prediction model cohorts and the evaluation cohort. Note ‘*’ denotes the mean, else the median is presented 
Variable ESS cohort Missing  ESRS SPI-II RRE-90 (Model A) Putaala Dhamoon 
         
Total patients in study 1257 -  - 525 1458 807 655 
Outpatients  53% (671) -  - - - - - 
Outcomes         
Recurrent stroke (<90 days) 4% (52) -  - - 60 - - 
Recurrent stroke (within one year) 8% (102) -  - 90 - - - 
Myocardial infarction (within one year) 2% (28) -  - - - - 102 
Any vascular event (within one year) 22% (274) -  - - - - - 
Baseline characteristics         
Age (median, mean) 74, 72*   - - 72 (no event), 74 (event) 42* 70* 
< 65 years 26% (321) -  - 27% (141) - - - 
65 – 75 years 46% (577) -  - - - - - 
> 75 years 29% (359) -  - - - - - 
> 70 years 61% (770) -  - 57% (301) - - - 
Male 51% (644) -  - 0% (0) 54% (783) 63% (508) 45% (292) 
History of hypertension  54% (683) 1  - 71% (373) - 39% (314) 70% (454) 
History of diabetes mellitus 13% (158) -  - 31% (165) 24% (349) 7% (54) 45% (295) 
Previous Myocardial Infarction 28% (350) -  - 24% (124) - 4% (31) 16% (106) 
Heart Failure 6% (80) 3  - 6% (29) - 5% (29) 14% (90) 
Current or prior atrial fibrillation 22% (271) 2  - 16% (83) 30% (431) 4% (30) 11% (72) 
Peripheral Artery Disease 8% (96) 5  - - - 2% (17) 22% (141) 
Current or Ex-Smoker < 12 months 66% (820) 22  - - 21% (310) 47% (377) 54% (349) 
Prior TIA or ischaemic stroke  31% (391) 3  - 34% (178) 8% (110) - - 
Admission CCS subtype         
Large Artery Atherosclerosis 8% (104) -  - - 23% (338) 8% (68) - 
Cardio-aortic embolism 14% (171) -  - - 25% (358) 19% (151) - 
Small Artery occlusion 21% (258) -  - - 11% (153) 14% (112) - 
Other Causes 8% (105) -  - - 6% (83) 26% (209) - 




4.3 Outcomes in follow-up for ESS 
After a follow-up period of one year 8% of patients (102/1257) had suffered a 
recurrent stroke whilst 22% (274/1257) had suffered the broader any vascular event. 
Note that each of the identified prediction models was developed to predict patient 
outcomes with somewhat different definitions (Table 4-1). However, the previous 
chapter illustrated that it is commonplace for investigators to test the generalisability 
of a given prediction model. Indeed from a practical perspective it is of interest to 
assess whether prediction models may be generalised beyond those patients seen in 
the initial development cohort. For this reason, each of the clinical prediction models 
described in Table 4-1 will be evaluated in the ESS using the following outcome 
definitions: (i) recurrent stroke within one year; (ii) any vascular event within one 
year; and, as far as is possible (iii) the original development outcome. 
4.3.1 Discrimination: formal versus informal 
Clinicians’ informal prediction of recurrent stroke and any vascular events was 
available for those seen as outpatients (N=671) in the ESS. All comparisons between 
informal and formal prediction are therefore made within this subset. The median 
time from stroke onset to assessment for outpatients was 19 days (IQR 12 to 28). 
Formal tests using the method described by DeLong et al. are provided comparing 
the ROC curves obtained from each clinical prediction model to that of the clinicians 
(Figure 4-1 and Table 4-3) under the null hypothesis of no true difference in 
AUROCC (DeLong et al., 1988). Contrasting informal clinicians’ predictions 
(clinical gestalt) with formal clinical prediction models suggests that when 
discriminating between those who do suffer an event (either recurrent stroke or any 
vascular event) from those who do not, both methods of prediction perform poorly 
yet similarly (all DeLong tests P-value>0.05). When testing these clinical prediction 
models in all patients (Figure 4-2 and Table 4-3), each of the models demonstrated 
an improvement in AUROCC discriminating any vascular event compared to the 
recurrent stroke outcome. Using the outcome definitions as originally defined in 
model derivation generally resulted in the highest discrimination, except for the 
ESRS which performed best when discriminating between those with and those 




Table 4-3 Discriminative performance of informal clinicians’ predictions (clinical gestalt) and clinical prediction models in the Edinburgh Stroke Study 
 Recurrent stroke  Any vascular event  Original development outcome 
Prediction Method n/N AUROCC 95% CI P-value*  n/N AUROCC 95% CI P-value*  n/N AUROCC 95% CI 
ESS outpatients only            
Clinical gestalt 40/575 0.53 0.44 to 0.63 -  63/574 0.56 0.48 to 0.64 -  - - - 
ESRS (2005) 50/664 0.56 0.48 to 0.64 0.8409  80/664 0.57 0.50 to 0.63 0.8751  - - - 
SPI-II (2000) 50/669 0.58 0.49 to 0.66 0.9664  80/669 0.59 0.52 to 0.66 0.5385  - - - 
RRE-90 (2010) 50/671 0.61 0.52 to 0.69 0.4404  80/671 0.59 0.53 to 0.66 0.7266  - - - 
Dhamoon (2007) 50/668 0.60 0.52 to 0.68 0.5043  80/668 0.61 0.54 to 0.67 0.2005  - - - 
Putaala (2010) 50/669 0.48 0.39 to 0.57 0.4995  80/669 0.56 0.49 to 0.63 0.9422  - - - 
ESS outpatients and inpatients            
ESRS (2005) 101/1224 0.54 0.49 to 0.60 -  256/1224 0.62 0.59 to 0.66 -  101/1224 0.54 0.49 to 0.60 
SPI-II (2000) 102/1253 0.53 0.48 to 0.59 -  274/1253 0.63 0.59 to 0.67 -  274/1253 0.63 0.59 to 0.67 
RRE-90 (2010) 102/1254 0.58 0.52 to 0.64 -  273/1254 0.59 0.56 to 0.63 -  52/1254 0.59 0.51 to 0.67 
Dhamoon (2007) 102/1253 0.57 0.51 to 0.63 -  274/1253 0.68 0.64 to 0.71 -  205/1253 0.73 0.69 to 0.76 
Putaala (2010) 102/1247 0.50 0.44 to 0.55 -  269/1247 0.65 0.61 to 0.68 -  269/1247 0.65 0.61 to 0.68 









































B: ROC Curves for any vascular event
 
Figure 4-1 Receiver Operating Characteristic (ROC) curves contrasting discrimination as 


















































Figure 4-2 Receiver Operating Characteristic (ROC) curves contrasting discrimination as 
achieved by various formal clinical prediction models: (A) recurrent stroke; (B) any vascular 





4.3.2 Discrimination: updated meta-analysis 
A meta-analysis of AUROCC values obtained through the systematic review of 
model evaluation studies was presented in the previous chapter for two models: the 
Essen Stroke Risk Score (ESRS) and the Stroke Prognosis Instrument (SPI-II). Table 
4-4 below summarises the updated pooled estimates obtained after a random effects 
meta-analysis when including the AUROCC estimates obtained from the Edinburgh 
Stroke Study. The AUROCC values pooled in Chapter 3 were those estimated for the 
discrimination of any vascular event, therefore the corresponding estimates in the 
ESS were used to update the previous estimates (Table 4-3). The prediction intervals 
based on ten and nine previous model evaluation studies respectively were accurate 
in capturing a future estimate of AUROCC for the ESRS and SPI-II. 
No qualitative or indeed practical quantitative improvement in the pooled estimate 
was detected after updating the previous meta-analysis. 
 
Table 4-4 Updated meta-analysis of ESRS and SPI-II discrimination 
Analysis ESRS SPI-II 
Original Meta-analysis   
Number of studies 10 9 
AUROCC with 95% CI 0.60 (0.59 to 0.62) 0.62 (0.60 to 0.64) 
95% PI 0.57 to 0.63 0.57 to 0.67 
Q-statistic, P-value* 12.95, 0.1649 26.34, 0.0009 
Updated with ESS data   
AUROCC with 95% CI 0.60 (0.59 to 0.62) 0.62 (0.60 to 0.64) 
95% PI 0.57 to 0.63 0.57 to 0.67 
Q-statistic, P-value* 14.42, 0.1548 26.88, 0.0015 




4.3.3 Calibration: formal versus informal 
Frequently the final model presented in publication is in the form of a point score 
making no or little reference to the absolute risk observed in the derivation data. In 
general, baseline risk is the constant term in any regression model with all predictor 
variables set equal to zero – this is the intercept in the case of a logistic regression or 
some estimate for the baseline hazard in the case of the Proportional Hazards model. 
A point score involves some rounding of the estimated regression coefficients, 
perhaps after being scaled by some constant. Risk categories may then be presented 
(e.g., low, medium and high), which was the case for the SPI-II and the RRE-90 
models thus providing some information about the absolute risk associated with the 
original derivation data. This information was utilised to generate calibration plots 
(plotting predicted risk against observed risk in new data) and associated calibration 
slopes and calibration intercepts in the ESS – though the small number of category 
levels will have an impact on the accuracy with which the calibration slope and 
intercept can be estimated which are transformed on to the logit scale and fit as 
continuous (see Table 4-5 and Figure 4-3). Contrasting the calibration of informal 
and formal prediction in the ESS data, neither prediction method performs 
particularly well with considerable systematic biases and slopes less than one. 
Information about absolute predicted risk could not be obtained for the three 
remaining models and were therefore not assessed. 
Table 4-5 Calibration of clinical gestalt and clinical prediction models in the ESS (note, all 
quoted intervals are 95% CIs) 
Outcome Clinical gestalt SPI-II RRE-90 
Recurrent stroke 
n/N 40/575 50/669 50/671 
Intercept 0.97 (0.64 to 1.29) -1.13 (-1.43 to -0.84) 0.24 (-0.07 to 0.55) 
Slope 0.18 (-0.39 to 0.76) 0.25 (-0.20 to 0.69) 0.39 (0.13 to 0.66) 
Any vascular event 
n/N 63/574 80/669 80/671 
Intercept 1.49 (1.23 to 1.76) -0.59 (-0.83 to -0.35) 0.85 (0.59 to 1.10) 
Slope 0.39 (-0.08 to 0.86) 0.37 (0.01 to 0.72) 0.32 (0.10 to 0.54) 
Original development outcome 
n/N - 274/1253 52/1254 
Intercept - 0.07 (-0.07 to 0.21) -0.62 (-0.91 to -0.33) 







































































































































































Figure 4-3 Calibration plots for informal and formal prediction of recurrent stroke and any 





It is well recognised that for a clinical prediction model to successfully enter into 
clinical practice it must have a clear and intended application ultimately resulting in 
better patient care and improve the chance of patient recovery (Moons et al., 2012a, 
Altman et al., 2009, König et al., 2007). Evidence of good performance (i.e., high 
discrimination and accurate calibration) must be demonstrated in a number of 
external cohorts to convince clinicians (the intended consumers of the research) that 
the model has the potential to be useful in prognostication. Model performance in the 
ESS cohort was similar to that seen in previous model evaluation studies (see Table 
4-4 and Chapter 3). There appears to be a sufficient body of evidence to conclude 
that the ESRS and the SPI-II achieve modest discrimination between those with and 
those without vascular events in follow up amongst those cohorts already assessed. 
One aspect that typically receives less attention is that of comparing predictions 
made by statistical models to the clear alternative, expert predictions from 
experienced clinicians. The comparison of prediction models for vascular events to 
informal clinicians’ predictions presented in this chapter appears to be one of the few 
studies in this area. Of those patients observed as part of the Edinburgh Stroke Study 
only those seen as outpatients had clinicians’ predictions. Prediction models 
performed similarly to clinicians’ predictions in this subset but the separation of 
events from non-events using the same models appeared to be better when applied to 
inpatients and outpatients combined (Table 4-3) or alternatively when used on 
inpatients only (see Table 4-6 below). The median time from stroke onset to 
assessment for inpatients was 2 days (IQR 1 to 4). It must be understood though that 
the patient seen at an outpatient clinic differs from the patient admitted to hospital. 
The incidence of recurrent stroke in the ESS for instance was 9% and 7% for 
inpatients and outpatients respectively; similarly, the incidence of any vascular event 
was 33% and 12%, suggesting differing case-mix. It was not possible from these data 
to say how well clinicians performed at discriminating between events for those 






Table 4-6 Discriminative performance of clinical prediction models in the 586 inpatients. Note all intervals are 95% CIs 
 Recurrent stroke  Any vascular event  Original development outcome 
Model n/N AUROCC  n/N AUROCC  n/N AUROCC 
ESRS (2005) 51/560 0.51 (0.44 to 0.59)  176/560 0.62 (0.57 to 0.67)  51/560 0.51 (0.44 to 0.59) 
SPI-II (2000) 52/584 0.47 (0.40 to 0.54)  194/584 0.61 (0.57 to 0.66)  194/584 0.61 (0.57 to 0.66) 
RRE-90 (2010) 52/583 0.53 (0.45 to 0.62)  193/583 0.53 (0.49 to 0.58)  32/583 0.56 (0.46 to 0.66) 
Dhamoon (2007) 52/585 0.53 (0.45 to 0.62)  194/585 0.67 (0.62 to 0.72)  167/585 0.71 (0.66 to 0.75) 





It is important to place these findings in a broader context. Historically it has been 
shown that predictions made by statistical models are more accurate than those made 
by experts irrespective of the medical speciality (Grove et al., 2000). With regards to 
prediction in stroke other researchers have compared formal and informal prediction 
methods. For example, there are numerous prediction rules for poor outcome or 
disability after stroke, however Counsell et al. demonstrated that the sensitivity and 
specificity achieved by clinical prediction models was comparable to that achieved 
by clinicians (Veerbeek et al., 2011, Counsell et al., 2004). Studies of other clinical 
conditions have demonstrated better discrimination achieved via statistical prediction 
contrast with predictions made by an experienced clinician. For example, Dehing-
Oberije et al. showed that the occurrence of radiation-induced dysphasia in patients 
with lung cancer could be better identified by a statistical model than clinicians’ 
predictions (Dehing-Oberije et al., 2010). 
The role of a clinical prediction model is not to replace the treating clinician but 
rather to act as an extra tool in the clinician’s tool kit: it can help inform patient 
prognosis by offering an objective estimate of the absolute risk (Moons et al., 2012b, 
Kattan and Gerds, 2011). It is important to acknowledge that a clinical prediction 
model operates on a finite number of variates. There are many plausible scenarios 
under which nonsense predictions can be generated if applied ignorant to an 
important piece of extra information – information not formally incorporated within 
the statistical model. This has become known as Paul E. Meehl’s broken leg scenario 
which should serve as an essential reminder that there is no replacement for intuition 
and interpretation (Salzinger, 2005). Provided that the obtained predictions are 
suitable at the point of application though, accurate clinical prediction models could 
play an important role within a range of clinical settings, for example: automating 
certain clinical processes; educating more junior doctors; as well as generating 
enriched patient recruitment to a clinical trial. 
Finally, before applying a model in practice it is important to investigate whether the 
model fits the proposed setting. It should be recognised that calibration is a joint 
property of both model and data. A model may be said to be well calibrated for 




property of that model (Vickers and Cronin, 2010). Indeed, predictions of the same 
outcome from different models can often have poor agreement due to differing case 
mix and baseline risk, in which case appropriate updating must be implemented 
(Steyerberg et al., 2005, Steyerberg, 2009). Calibration of the SPI-II and the RRE-90 
were partly explored in the ESS, although a limited availability of development 




Chapter 5: Predictions of functional outcome 
after ischaemic stroke 
Background and summary 
Prediction of functional outcome can be achieved formally through clinical 
prediction models or informally using expert clinical experience. This chapter 
compares each method for the prediction of functional outcome in a single 
observational cohort of stroke patients. It is found that clinical predictions models 
are at least as good as informal doctor’s predictions at discriminating between good 
and bad functional outcome after ischaemic stroke. 
5.1 Introduction 
Recent ischaemic stroke patients, their families and their doctors would like an 
accurate prediction of patient recovery (i.e., a poor or good functional outcome). 
Such a prediction is typically made informally at the bedside by a doctor using his or 
her clinical experience and expertise. Not every patient will want to know the same 
amount of prognostic information (Back and Arnold, 2006). Nevertheless, 
predictions (formal or informal) are required and will influence how the patient is 
treated. 
It is not clear whether formal statistical models do better or worse than doctors at 
predicting outcomes for stroke patients. In Chapter 4 the prediction of recurrent 
stroke and vascular events was explored comparing formal and informal methods. 
Both were fairly poor at discriminating outcomes though neither method 
outperformed the other. A similar evaluation is presented in the current chapter with 
the focus on the prediction of death or disability. 
It has been previously shown that when contrast with algorithms or objective 




Grove et al., 2000). The first proper review of this topic came from the American 
psychologist Paul E. Meehl whose seminal text “Clinical versus statistical 
prediction”, published now over half a century ago, highlighted that in many unique 
settings predictions made by clinical psychologists were frequently outperformed by 
quite simple statistical models (Meehl, 1954). Meehl speculated that the reason for 
such disparity stemmed from a tendency for experts to overcomplicate scenarios: 
something which a simple objective statistical formula avoids. 
The accuracy of predictions made by experts in the clinic depends upon the condition 
under consideration. For example, a study of doctors predicting the survival of 
terminally ill patients systematically gave overly optimistic survival times (Christakis 
and Lamont, 2000). A study comparing the subjective predictions of nurses and 
doctors of mortality in patients seen at an intensive therapy unit discriminated 
between those dead and alive better than the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) – a score of disease severity of those seen in intensive 
care units (Marks et al., 1991). In the context of stroke, Counsell et al. demonstrated 
that similar levels of sensitivity and specificity were found when contrasting 
predictions of functional outcomes made by clinicians and by statistical models 
(Counsell et al., 2004). An important dimension to take into consideration is the 
environment in which the predictions are made and whether this can be considered as 
regular and consistent. Simply put: do repeat scenarios arise from which the experts 
can learn? 
Expert intuition is strongly related to the breadth of experiences and identifiable 
scenarios likely to be encountered. As analogy, consider the experienced chess player 
who benefits from the familiarity of moves learned through thousands of previous 
games. In the same way the expert will base his or her prediction on his or her 
previous experience. Kahneman and Klein dubbed this the validity of the 
environment which, if considered high, will reflect the extent to which learning 
through experience can benefit prediction (Kahneman and Klein, 2009). 
The aims of this chapter are to: (i) determine whether or not the predictions of 




worse than the predictions made by statistical models; and (ii) to explore what 
attributes (patient or clinician) make an informal prediction more or less accurate. 
5.2 Materials 
5.2.1 The Edinburgh Stroke Study (ESS) 
The Edinburgh Stroke Study (ESS) was introduced previously in Chapter 4. In brief, 
it was a prospective observational study of recent stroke or TIA patients recruited 
consecutively from the outpatient, inpatient and emergency departments of the 
Western General Hospital, Edinburgh, UK between April 2002 and May 2005 
(www.dcn.ed.ac.uk/ess/protocol) (Jackson et al., 2008). The Edinburgh Stroke Study 
had four main objectives: (i) to investigate how risk factors differ across the subtypes 
of ischaemic stroke (Jackson et al., 2010); (ii) to explore how recurrent events differ 
across ischaemic stroke subtypes (Jackson et al., 2009); (iii) to assess what role novel 
genetic risk factors or biomarkers have in the process of prediction (Whiteley et al., 
2009); and (iv) to assess the current methods of predicting death or dependency and 
recurrent vascular events. 
5.2.1.1 Defining types of doctor 
Doctors with varying levels of experience in stroke medicine were asked to predict 
the six month Oxford Handicap Scale (OHS) for their patients at presentation using 
their clinical experience. Clinical experience was classified broadly into seniority 
(i.e., fully trained in neurology or stroke medicine versus in training) and speciality 
(i.e., geriatrics/internal medicine versus neurology). This was achieved 
retrospectively with reference to the initials recorded on each clinical report form for 
those patients with a doctors’ prediction. Colleagues of the doctors at the Western 
General Hospital in Edinburgh were able to identify who each of the initials 
belonged to.  
5.2.1.2 Outcome definition 
Functional outcome was measured using the Oxford Handicap Scale (OHS) six 
months from the initial stroke onset. The OHS is an ordinal outcome summarising 
patient disability and death across seven unique levels. Levels 1 through to 5 denote 




undertaking everyday tasks. A score of 6 is reserved for mortality and a score of 0 for 
fully recovered. In this chapter poor functional outcome at six months was defined as 
an OHS of 3 or more. All analyses were restricted to those patients with definite or 
probable ischaemic stroke. This was defined as a focal deficit of cerebral origin 
lasting for at least 24 hours, where brain imaging showed either positive evidence of 
cerebral infarction, or was normal or equivocal and the clinical syndrome was most 
in keeping with stroke. This definition excluded patients with haemorrhagic strokes 
because such patients likely differ in recovery to those with ischaemic stroke. 
Functional outcome was measured independently (i.e., not by the original clinician 
seen on admission) with the OHS at six months using a validated postal 
questionnaire. Non-responders were sent a repeat questionnaire. Patients were 
flagged for death with the General Register Office for Scotland, which provided 
information on the date, place and cause of death. 
5.2.1.3 Baseline variable definitions 
Doctors recorded baseline clinical variables using a standardised pro-forma. This 
included basic patient demographic variables (e.g., patient age, smoking status etc.) 
as well as more novel blood biomarkers (Whiteley et al., 2009). For the purpose of 
this chapter only those simple characteristics considered by the pre-existing models 
(Table 5-1) will be explored. 
5.2.2 Pre-existing models 
Five multivariable binary logistic regression models were identified (Table 5-1) 
(Appelros et al., 2003, Counsell et al., 2002, Lee et al., 2009, Reid et al., 2010, 
Weimar et al., 2004) from a previously published systematic review of models for 
the risk of poor functional outcome after stroke (Veerbeek et al., 2011). The linear 
predictor was calculated for each of these models using the associated regression 
coefficients reported by each author and in one case used the natural logarithm of the 
odds ratios to two decimal places (Appelros et al., 2003). Some models predicted 
poor functional outcome whilst others predicted good functional outcome. Since the 





5.2.2.1 Counsell et al. 
The Six Simple Variables (SSV) model (Counsell et al., 2002) was developed on 530 
stroke patients seen within 30 days of stroke onset as part of the Oxfordshire 
Community Stroke Project (OCSP) between 1981 and 1986 (Bamford et al., 1990). 
Patients were defined as independent at six months if they achieved an OHS of less 
than three. Predictor selection was pragmatic: the authors included risk factors based 
on clinical importance and availability in clinical practice. The model included six 
easily obtained patient characteristics which summarised independence prior to the 
stroke and the impact of the stroke itself on patient ability at baseline. In the same 
publication the authors evaluated the performance of their model using an external 
dataset. Discrimination was good (AUROCCs ≥ 0.80) irrespective of: (i) time from 
stroke onset; (ii) type of stroke and (iii) history of previous stroke. There was a 
difference though when restricting to those patients seen as outpatients (0.65) 
compared to those seen as inpatients (0.83). Subsequent model evaluations have been 
undertaken suggesting good discrimination with the SSV model (AUROCCs ≥ 0.75) 
(Teale et al., 2012). Additionally, the SSV appears to have a degree of geographical 
generalisability with strong discrimination (AUROCC ≥ 0.90) amongst stroke 
patients in an observational study from China (Li et al., 2012). 
5.2.2.2 Reid et al. 
A model for independence (OHS<3) at six months (Reid et al., 2010) was developed 
using 538 stroke patients seen as part of the Stroke Outcomes Study (SOS) in Canada 
between 2001 and 2002. The purpose was to produce a model that outperformed the 
SSV by including CT scan information. Additivity and linearity assumptions were 
assessed. The final model fit used a stroke severity score which was derived from the 
EC/IC bypass study (The EC/IC Bypass Study group, 1985). This is rarely used in 
practice, and for the purpose of this chapter the NIHSS score was used in its place. 
The implications of this are discussed later. 
5.2.2.3 Appelros et al. 
Apperlos et al. aimed to investigate the risk factors associated with death, disability 
and recurrent stroke each within one year of first time stroke patients followed as 




assessed 377 stroke patients who had suffered a first time stroke within the period 
1999 to 2000 with one year of follow-up. Various characteristics (i.e., demographic, 
medical history and stroke severity) were recorded for each patient at baseline. 
Patient age and stroke severity (NIHSS) were kept continuous. The authors used 
univariate tests to screen 13 risk factors excluding any variables not significant at the 
5% level from entry into a multivariable fit. Binary logistic regression was used to 
model multivariable associations on the dichotomised outcome mRS≥3 at one year 
which included: patient age, stroke severity and history of heart failure. No intercept 
was reported precluding the assessment of calibration in external data sets. 
Additionally only the odds ratios could be obtained, although these could be 
transformed with the natural log to obtain the regression coefficients, there is an 
inevitable loss of precision. 
5.2.2.4 Weimar et al. 
Weimar et al. developed two prediction models for the separate prediction of 
incomplete recovery (defined as a Barthel index <95) or death after stroke and 
mortality (Weimar et al., 2004). They used 7238 patients with ischaemic stroke 
symptoms from a German stroke data bank between 1998 and 1999. This data source 
spanned a total of seven separate centres. They identified sixteen potentially 
important predictors by systematic review. This covered demographic aspects, 
patient medical history and the severity of the initial indexing stroke (e.g., NIHSS 
and other deficits). Any deviations from linearity for the continuous variables were 
assessed using fractional polynomials, although no improvement was made on the 
standard linear fits. They implemented both a forward and backward stepwise 
selection process excluding variables with a P-value > 0.001 and retaining those with 
a P-value ≤ 0.005. The authors evaluated the performance of their models in a 
separate dataset demonstrating that the model explained an important amount of 
variability in the data with an R2 of 44%. Subsequent evaluation studies have 
demonstrated that this model achieves good discrimination of those with and those 
without the outcome of interest (AUROCC of 0.81) (König et al., 2008). The authors 
suggested that their models have potential use in the design of randomised trials and 




purpose in the IST-3 trial to explore the effect of rtPA whilst adjusting for the 
predicted risk of the primary outcome based on the Weimar et al. model (The IST-3 
collaborative group, 2012b). 
5.2.2.5 Lee et al. 
In their study of Taiwanese stroke patients, Lee et al. aimed to explore the 
underlying differences in risk profiles of those dead or dependent at six months (Lee 
et al., 2009). They recorded demographic, neurologic severity and lab based 
measurements in 533 first-ever ischaemic stroke patients recruited prospectively at a 
single hospital in Taiwan between October 2004 and November 2006. They 
developed a multivariable logistic regression using forward stepwise selection with 
the inclusion criterion P-value set to < 0.05. 
5.2.3 Sensitivity Analyses 
Clinical prediction models for risk of good functional outcome (OHS<3) perform 
differently when evaluated amongst patients seen in different settings (Counsell et 
al., 2002). Therefore all analyses were repeated within patients admitted to hospital 
and those seen at outpatient clinics. An alternative dichotomy of the Oxford 
Handicap Scale (OHS ≥ 2) was also explored as this often influences the results in 







Table 5-1 Formal statistical prediction models for functional outcome. 
Variables Lee et al. (2009) Appelros et al. (2003) Weimar et al. (2004) Counsell et al. (2002) Reid et al. (2010) 
Intercept   − 5.782 + 12.340 + 2.401 
Age  + 0.077 + 0.049 − 0.051 − 0.049 
Pre-stroke 
independence 
   − 2.744 + 3.497 
Living alone    + 0.661  
Arm power    − 2.106 + 1.402 
Able to walk    − 1.311  
Normal GCS verbal    − 2.160  
NIHSS (stroke severity 
score) 
+ 0.362 + 0.285 + 0.272  − 0.549 
Heart failure  + 1.099    
History of diabetes − 2.296     
Total cholesterol − 0.029     
      
Outcome mRS>2 at six months mRS≥3 at one year BI<95 or dead OHS≤2 at six months OHS≤2 at six months 
Source population Taiwanese hospital 
cohort 
Community based 
cohort of first ever 
strokes in Sweden 
Stroke data bank of 
the German Stroke 
Foundation 
OCSP community 
based incidence study  
Consecutive patients 
enrolled in the Stroke 
Outcome Study 
Additional comments No intercept was 




from the natural log of 
odds ratios reported 
to two decimal places 
 The SSV model scores 
1 for presence and 2 
for absence of risk 
factor 
Stroke severity 
measured using a 
score adapted from 
the EC/IC bypass study 
ABBREVIATIONS: modified Rankin Scale (mRS); the Oxford Handicap Scale (OHS); National Institutes of Health Stroke Scale (NIHSS); 
Glasgow Comma Scale (GCS); Barthel Index (BI); Six Simple Variables model (SSV); Extracranial/Intracranial (EC/IC) and the Oxford 




5.3 Methods - measuring predictive accuracy 
Functional outcome was recorded on a commonly used ordinal scale of death or 
disability, the Oxford Handicap Scale (OHS) at six months. Measuring the accuracy 
of formal or informal predictions can be approached in two ways: either (i) specify 
some dichotomous split; or else (ii) retain the ordinal structure. In this section each 
approach will be discussed, covering some methodological details before drawing 
some conclusion as to what impact this has on the interpretation in the context of the 
analyses. 
5.3.1 Assessing accuracy on a dichotomous outcome 
The informally predicted OHS and six month observed OHS scores were 
dichotomised into favourable (OHS<3) and unfavourable (OHS≥3) responses. A two 
by two cross classification of the form seen in Table 5-2 is produced. Two commonly 
encountered measures are the conditional probabilities: sensitivity and specificity 
which quantify the accuracy of a test (Zhou et al., 2008a). From Table 5-2 sensitivity 
describes the probability of correctly predicting an outcome given that the outcome 
occurs in follow up (P (Pred = 1 | Obs = 1) = s1 /n1) whereas specificity describes the 
probability of predicting absence of outcome given that the outcome is indeed absent 
in follow up (P (Pred = 0 | Obs = 0) = r0 /n0). 
 
Table 5-2 Standard two by two cross-classification table 
 Observed outcome (Obs)  
Predicted outcome (Pred) 
OHS<3 
(Obs = 0) 
OHS≥3 
(Obs = 1) 
Row total 
OHS<3 (Pred= 0) r0 r1 m0 
OHS≥3 (Pred = 1) s0 s1 m1 





For each binomial proportion, p, an associated 95% confidence interval can be 
produced. An asymptotic interval is commonly adopted which appeals to the normal 
approximation of the binomial distribution. However, as ]1,0[∈p  such intervals can 
easily give illogical results with confidence intervals that exceed these bounds, 
especially when the estimated proportions are close to one or zero (Newcombe, 
1998). In this chapter Zhou-Li confidence intervals (ZL CIs) have been used to 
provide confidence intervals for doctors’ sensitivity and specificity (Zhou et al., 
2008b). The ZL confidence interval has good coverage in circumstances where p is 
close to one or zero. 
For each clinical prediction model (Table 5-1) the thresholds of predicted probability 
of poor functional outcome (OHS≥3) that had: (i) the same specificity; and (ii) the 
same sensitivity as the doctor’s predictions were calculated. The model sensitivity 
was therefore calculated at the threshold of doctors’ specificity and similarly the 
model specificity at the threshold of doctors’ sensitivity. Informally, this equates to 
simply reading the sensitivity/specificity for fixed specificity/sensitivity off of the 
ROC curve as is illustrated in Figure 5-1. Each threshold was formally obtained 
using the R-package pROC which calculates the sensitivity and specificity obtained 
for all possible cut-points of the linear predictor (Robin et al., 2011). 
This approach is used to address the question: given the accuracy of a doctor at 
successfully predicting OHS≥3 or ruling out OHS≥3 in favour of OHS<3 how does a 
clinical prediction model compare? A comparison between informal and formal 
predictions can then be made in a similar way as that seen in Counsell et al. 





















Figure 5-1 Example Receiver Operating Characteristic (ROC) curve with associated 95% 




5.3.2 Assessing accuracy on an ordinal outcome 
5.3.2.1 Weighted kappa statistic 
Cohen’s kappa (κ) statistic is a commonly used measure of agreement between raters 
made on the same subjects (Graham and Jackson, 1993). It is calculated from the 
proportion of pairs which agree and the proportion of pairs that would be expected to 
agree by chance. By deducting the latter from the former the measure is said to be 








=κ  (5.1) 
A further specification is to adopt a weighting scheme awarding partial credit for 
near agreement (Cohen, 1968) the so called weighted kappa (κw). 
Here pobs and pexp are the observed and expected weighted proportions respectively 






















Where, nij and wij denote the observed frequency and weight for the ijth cell 
respectively. Note that bullet notation has been adopted here to indicate the marginal 
sums of nij over the respective index (i.e., i or j) subsequently replaced by a bullet 
point. A broad range of different weighting schemes can be applied but the most 










jiwij . (5.2) 
Where r is the number of categories and i and j are the respective row and column 
ranks. Squared weights have an appealing asymptotic relationship with the Intra 




Limitations of the weighted kappa statistic have been previously cited. Graham and 
Jackson argued that the weighted kappa statistic is in fact not a measure of agreement 
but a measure of association (Graham and Jackson, 1993). They illustrated this using 
a hypothetical example in which one rater systematically disagrees with the other for 
most levels of some ordinal measure by one level yet this still yields a large weighted 
kappa statistic. Such behavior is undesirable for a measure of agreement. 
Additionally, it is highlighted that a single measure cannot possibly summarise all 
the information regarding agreement and disagreement. The quasi-association 
modelling approach outlined by Agresti may be more informative (Agresti, 2002). 
Despite these drawbacks, the weighted kappa is used in this chapter largely for its 
simplicity. It has an intuitive interpretation that is easily understood. It can be viewed 
as playing a similar role as the sensitivity and specificity measures in the binary case. 
Aspects that could possibly explain disagreement are explored and are discussed 
below. 
5.3.2.2 The ordinal c-index (ORC) 
Discrimination on an ordinal outcome should take the added complexity of the scale 
into account. The ordinal c-index (ORC) is a set-based measure which summarises 
the closeness of the predicted ordering to the observed (Van Calster et al., 2012). For 
example, take the OHS, which describes disability and death on a seven level ordinal 
scale. Suppose a complete set is observed, i.e., seven patients taking on each of the 
possible seven levels of OHS. A given model would ideally rank this set of seven 
patients in the correct order of severity, the so called ‘target ordering’ (i.e., the 
patient with outcome O0 should have a lower predicted risk or score than the patient 
with outcome O1 who should also have a lower predicted risk or score than the 
patient with outcome O2 and so on up to O6). The closeness of the predicted ordering 
to the target ordering is indicative of the degree of discrimination. The number of 
steps, S, required to put a set of predicted risks into the correct order can be made for 











where k denotes the number of category levels. When tied risks occur (i.e., the 
predicted risk for one patient in a set is equal to that of another), 0.5 is added to S for 
each pairwise tie. The ORC can then be interpreted as the average proportionate 

























This measure also has a simpler pairs-based interpretation as the unweighted average 
of the pairwise AUROCCs. Bootstrap methods are used to calculate the 95% CI (Van 
Calster et al., 2012). 
For each model, the linear predictor was fitted as the only predictor in a proportional 
odds logistic regression (POLR) for observed six month OHS. The resulting linear 
predictor was used to explore ordinal discrimination. To enable identifiable 
parameter estimates and no empty cells, the ordinal outcome was interpreted as a five 





5.4 Methods – doctors’ characteristics 
Each doctor gave an informal prediction of six month OHS across the full ordered 
range (i.e., 0 to 6) for their own patients on initial assessment. Once the actual six 
month patient outcomes were observed the following classification was used as 
illustrated in the matrix below: (i) correct – when the predicted matched the 
observed, i.e., on the diagonal; (ii) optimistic – when the predicted rank was less than 
the observed, i.e., upper triangle; and (iii) pessimistic – when the predicted rank was 
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There is no implicit ordering for these three classification types as there may be 
unknown harmful effects from the treatments administered or withheld based on 
these informal predictions. Multinomial logistic regression was used to explore 
whether: type of doctor; patient characteristics; or hospital setting were jointly 





5.4.1 Multinomial logistic regression 
Multinomial (or polytomous) logistic regression can be applied when an outcome has 
more than two discrete responses with no implicit ordering (Biesheuvel et al., 2008). 
In the general case, let outcome Y take on any value k with k = 1, 2, …, m, m + 1. 
One level is set as a reference category, e.g., m + 1, on which all other levels are 









































, for k = 1, 2, …, m.  
The scenario described in the matrix above has three unordered outcome levels 
(optimistic, correct and pessimistic) implying two sub-models. Two sets of measures 
of association each of length p (for p unspecified predictors) can be interpreted 
relative to the reference category. The reference category was chosen as correct 
classification, i.e., were doctors gave a predicted OHS score which matched that 
observed in follow-up. It therefore follows that there are two generalised logits 


































)(log .  
By simultaneously modelling the probability of the potential classifications, it is 
possible to explore the associations demonstrated in this observational cohort of 






A total of 931 patients were analysed. The flow diagram (Figure 5-2) summarises 
which patients in the Edinburgh Stroke Study were analysed. Of 1257 patients, 1051 
had record of doctor’s predictions of which 931 had complete follow-up by six 
months. Record of baseline measurements taken from patients on entry to the study 
were largely complete (Table 5-3) with low rates of missing data on those variables 
used by the pre-existing prediction models for functional outcome (Table 5-1). 
These data are limited by consent bias. Of those that were eligible, 88% consented 
for their data to be part of a repository for further research, the main barrier to which 
was obtaining informed consent (Jackson et al., 2008). Despite this, characteristics 
were similar between those consenting and non-consenting patients. 
To reduce the risk of bias from complete cases analyses, missing baseline data were 
imputed generating 20 datasets (Vergouwe et al., 2010). All of the measures listed in 
Table 5-3 were adopted in the imputation model. Whilst this included six month 
OHS all patients with missing outcome entries were removed from each imputed 
dataset since retaining imputed outcomes only adds random noise to the pooled 
results (Von Hippel, 2007).  
On average those with missing six month outcomes or missing doctor’s predictions 
were younger (median 73 years versus 74 years, P-value = 0.0130) and had less 
severe strokes (median NIHSS of 1 versus 2, P-value = 0.0193) (see Table 5-5 in 





First Ischaemic Stroke (n = 1257)
- outpatients (n = 671)
- inpatients (n = 586)
Lost to six month follow-up (n = 120)
Doctor's predictions available (n = 1051)
- outpatients (n = 540)
- inpatients (n = 511)
Patients available for analysis (n = 931)
- outpatients (n = 489)
- inpatients (n = 442)
 




Table 5-3 Characteristics of 931 ischaemic stroke patients observed in the ESS 
Variable Data (N = 931) Number (%) missing 
Doctor’s clinical experience   
Fully trained vs. in training, n (%) 499 (54) 107 (11) 
Stroke specialist vs. neurologist, n (%) 550 (59) 107 (11) 
Baseline characteristics   
Age, years, median (IQR) 74 (66 to 81) - 
Male, n (%) 474 (51) - 
History of hypertension, n (%) 520 (56) 1 (<1) 
History of diabetes mellitus, n (%) 119 (13) - 
Pre-stroke independence, n (%) 867 (93) 2 (<1) 
Lived alone prior to stroke, n (%) 361 (39) - 
Arm power, n (%) 799 (86) 1 (<1) 
Able to walk, n (%) 672 (72) 2 (<1) 
Normal GCS verbal, n (%) 810 (87) 5 (<1) 
NIHSS (median, IQR) 2 (0 to 5) 35 (4) 
Heart failure, n (%) 55 (6) 2 (<1) 
Total cholesterol, mmol/l, median (IQR) 5 (4 to 6) 73 (8) 
Systolic BP, mmHg, median (IQR) 146 (130 to 160) 2 (<1) 
Seen at outpatients, n (%) 489 (53) - 
Six month OHS score, n (%)   
0 (Fully recovered) 168 (18) - 
1 252 (27) - 
2 183 (20) - 
3 126 (14) - 
4 49 (5) - 
5 55 (6) - 
6 (Dead) 98 (11) - 
ABBREVIATIONS: Oxford Handicap Scale (OHS); National Institutes of Health Stroke 





5.5.1 Model performance in ESS 
The models described in Table 5-1 were applied to the Edinburgh Stroke Study data 
to assess their performance in an external dataset. Two aspects of model performance 
were assessed: discrimination and calibration. Discrimination was measured using 
the area under the receiver operating characteristic curve (AUROCC) and calibration 
was measured by calculating the associated slope and intercept estimates from the 
calibration plot. 
5.5.1.1 Discrimination 
Statistical models discriminated patients with poor outcome (OHS≥3) from those 
with good outcome (OHS<3) after stroke moderately well with AUROCC values 
ranging from 0.76 to 0.84 depending on which model was used (Table 5-4). The 
model developed by Reid et al. achieved the largest AUROCC, although there was 
considerable overlap between the 95% CIs of the other models (Reid et al., 2010). 
The model developed by Lee et al. achieved the lowest AUROCC (Lee et al., 2009). 
Whilst there were large quantitative differences noted during the sensitivity analyses 
this was met with only small qualitative differences. There were no important 
changes in the ordering of the models by AUROCC either with a poor outcome 
defined as OHS≥2 or OHS≥3 or when restricting to those seen in hospital or those 
seen at the outpatients (see section 5.7 Appendix A, Table 5-6 and Table 5-7). The 
largest AUROCCs were obtained when analysing all patients with poor functional 
outcome defined as an OHS≥3. 
5.5.1.2 Calibration 
Calibration was poor amongst those models that could be assessed (Table 5-4). Each 
systematically overestimated the risk of poor outcome except for the SSV which 
underestimated the risk. All models had calibration slopes less than one. This occurs 
when the effect estimates are on average smaller (i.e., from overfitting in 
development or because of true differences between the two development and 
evaluation cohorts) resulting in extreme risk estimates made for the ESS patients. 
The Weimar et al. model had a calibration slope of almost 1; it is likely that this 
model would only require slight updating to improve its calibration-in-the-large 




No improvement in calibration was found when limiting the analysis to hospital 
inpatients and outpatients (see section 5.7 Appendix B, Table 5-6 and Table 5-7). 
5.5.2 Assessing accuracy on a dichotomous outcome 
Eighteen doctors made clinical predictions: ten neurologists (56%) and eight stroke 
physicians (44%). Ten were in training (56%) and eight were fully trained (44%). 
Doctors correctly predicted level of disability or death in 310 patients (33%). A 
doctor’s informal prediction of poor functional outcome (OHS≥3) six months after 
stroke had a sensitivity of 0.44 (95% 0.39 to 0.49) and a specificity of 0.96 (95% 
0.94 to 0.97). The performance of clinical prediction models was similar: at the 
specificity of a doctor, the sensitivity of risk prediction rules to predict poor 
functional outcome ranged from 0.38 to 0.45; at the sensitivity of a doctor specificity 
of risk prediction rules ranged from 0.94 to 0.96 (Table 5-4). 
There were no important differences in these results when restricting to inpatients 
and outpatients exclusively nor when defining six month outcome as OHS≥2 and 
restricting to inpatients. However, there was an indication that doctors were more 
accurate at identifying outpatients with OHS≥2 at six months compared to models 
(see section 5.7 Appendix A, Table 5-8). 
5.5.3 Assessing accuracy on an ordinal outcome 
Doctors predictions of OHS at six months had moderate agreement with the observed 
six month OHS for inpatients (weighted κ of 0.53 with 95% CI 0.42 to 0.63 on 442 
patients) but had poor agreement for outpatients (0.30 with 95% CI 0.21 to 0.39 on 
489 patients). Doctors tended toward optimistic prediction with 61% (95% CI 55% to 
68%) of inpatients and 45% (95% CI 38% to 51%) of outpatients given a lower 
predicted OHS than observed at six months. 
Smoothed non-parametric plots of the distribution of the linear predictor illustrate the 
discrimination achieved by a model since in general: the greater the spread; the 
greater the discrimination. The kernel density plots are provided in Figure 5-3 and 
show the spread of predictions made by each CPM compared to the predictions made 




irrespective of the method of prediction suggesting little difference in discriminative 
ability between formal and informal methods. 
Ordinal discrimination by doctors was moderate (ORC of 0.74 with 95% CI 0.72 to 
0.76) and comparable to that obtained by statistical prediction, where the probability 
of correctly separating a pair of patients from two randomly selected levels of the 
OHS (defined on categories: 0, 1, 2, 3, and ≥4) could be as low as 0.69 and as high as 
0.75 (Table 5-4). Similar results applied when restricting to inpatients alone and 
lower discrimination when restricting to outpatients (see section 5.7 Appendix A, 
Table 5-9). 
Clinical prediction models therefore did no better than doctors’ informal prediction 






Table 5-4 Comparison of prediction methods (Note that all intervals are 95% CIs) 
 Discrimination  Calibration  Accuracy 
Method  AUROCC1 ORC2  Intercept1 Slope1  Sensitivity3 Specificity3 
Doctors - 0.74 (0.72 to 0.76)  - -  0.44 (0.39 to 0.49) 0.96 (0.94 to 0.97) 
Clinical Prediction Model       
Reid 0.84 (0.81 to 0.87) 0.75 (0.73 to 0.77)  1.09 (0.98 to 1.19) 0.46 (0.43 to 0.50)  0.45 (0.34 to 0.52) 0.96 (0.93 to 0.98) 
Weimar 0.82 (0.79 to 0.85) 0.73 (0.71 to 0.76)  0.57 (0.49 to 0.65) 0.98 (0.90 to 1.06)  0.43 (0.35 to 0.51) 0.96 (0.92 to 0.98) 
SSV 0.81 (0.78 to 0.84) 0.72 (0.70 to 0.74)  -0.30 (-0.39 to 0.21) 0.71 (0.66 to 0.76)  0.43 (0.36 to 0.51) 0.95 (0.93 to 0.98) 
Appelros 0.82 (0.79 to 0.85) 0.73 (0.71 to 0.75)  - -  0.42 (0.35 to 0.50) 0.95 (0.93 to 0.97) 
Lee 0.76 (0.72 to 0.79) 0.69 (0.66 to 0.71)  - -  0.38 (0.32 to 0.45) 0.94 (0.91 to 0.96) 
1 Values pooled across 20 imputed datasets for missing data 
2 Single imputed set, with 95% confidence intervals calculated on 1000 bootstrap replicates 










Informal versus Reid et al model














Informal versus Weimar et al model














Informal versus Apperlos et al model














Informal versus Lee et al model














Informal versus SSV model















5.5.4 Doctors’ characteristics 
In total there were 18 doctors initials identified each of whom predicted the outcome 
for a number of patients. The number of predictions (i.e., patients seen) per doctor 
varied from 2 to 204 with a median of 30 and interquartile range 16 to 48 (Figure 
5-4). 
Classification was not influenced by doctor (i.e., level of training or specialty) or 
patient characteristics (i.e., neurological impairment, age or additional risk factors) 
(Figure 5-5). However, patients seen as outpatients were more likely to have had a 
correct prediction than an optimistic prediction of their eventual disability than those 
seen as inpatients (OR of 0.59 with 95% CI 0.38 to 0.92). This analysis was 
restricted to those patients for whom doctors’ characteristics could be obtained (i.e., 
the 824 patients in Figure 5-4, of which: 282 (34%) where correctly classified; 418 
(51%) optimistically classified; and 124 (15%) pessimistically classified). The 
inclusion of clinician characteristics in the model was not significant (χ2 of 8.9 on 6 
df, with a P-value = 0.1819) suggesting that no further information on classification 

















































Odds Ratios and 95% CIs
Multivariable Multinomial Logistic Regression
0 1 2 3 4 5 6
Geriatrics/internal medicine specialist*fully trained
Geriatrics/internal medicine specialist vs neurologist
Fully trained vs in training








































1.10 [ 0.55 , 2.19 ]
0.93 [ 0.56 , 1.55 ]
0.61 [ 0.34 , 1.08 ]
1.15 [ 0.53 , 2.49 ]
1.14 [ 0.69 , 1.88 ]
1.02 [ 0.89 , 1.16 ]
0.97 [ 0.93 , 1.02 ]
0.70 [ 0.34 , 1.43 ]
1.20 [ 0.86 , 1.66 ]
1.22 [ 0.57 , 2.58 ]
0.65 [ 0.37 , 1.16 ]
1.50 [ 0.78 , 2.90 ]
1.01 [ 1.00 , 1.02 ]
0.59 [ 0.38 , 0.92 ]
0.88 [ 0.34 , 2.30 ]
0.91 [ 0.43 , 1.96 ]
1.19 [ 0.55 , 2.61 ]
0.82 [ 0.27 , 2.50 ]
1.16 [ 0.59 , 2.26 ]
1.02 [ 0.85 , 1.23 ]
0.99 [ 0.93 , 1.06 ]
0.56 [ 0.23 , 1.38 ]
0.87 [ 0.55 , 1.38 ]
0.78 [ 0.28 , 2.14 ]
0.73 [ 0.32 , 1.66 ]
1.96 [ 0.73 , 5.23 ]
1.01 [ 0.99 , 1.03 ]































Figure 5-5 Multivariable multinomial logistic regression classified on a single imputed set. Solid points (i) denote the classifications ‘optimistic vs. correct’ 





The accuracy of predictions made by doctors and those made by formal models were 
found to be similar in this single centre prospective observational study. Doctors had 
good specificity, but poor sensitivity at identifying those with a poor functional 
outcome after ischaemic stroke, however prediction models, with the corresponding 
sensitivity or specificity fixed at that of a clinician, achieved a similar level of 
accuracy. 
Neither doctor characteristics nor patient characteristics made a great deal of 
difference to the accuracy of informal prediction; however predictions were more 
likely to be correct in outpatients. This is likely due to the delay in time of onset to 
assessment (median of 18 days with IQR 12 to 28) by which point most patients 
suffering minor strokes would have recovered making their observed disability at 
outpatients a good surrogate for their likely disability by six month. Outpatients can 
therefore be regarded as closer to their end-state in contrast to inpatients. The 
association between an early indication of recovery and longer term outcome has 
been noted elsewhere and was utilised in the third International Stroke Trial (IST-3) 
to impute missing six month functional outcome entries using measurements 
recorded at seven days within a simple algorithm (The IST-3 collaborative group, 
2012b, The IST-3 collaborative group, 2012a). 
More recently developed clinical prediction models, such as the ASTRAL score, the 
iScore and the BOAS score, could not be assessed using these data as not all of the 
baseline predictors were available in the ESS (Ntaios et al., 2012, Saposnik et al., 
2011, Muscari et al., 2011). These models either required different measures of 
deficits caused by the stroke (e.g., the use of the Canadian Neurological Scale) or 
else a record of various other co-morbidities (e.g., cancer or renal dialysis). For the 
most part these characteristics were well represented by those models assessed in this 
chapter (Table 5-1). The level of performance demonstrated by these untested 
models is similar to those that were tested in this chapter (Ntaios et al., 2012, 
Muscari et al., 2011, Papavasileiou et al., 2013, Zhang et al., 2013). It is unlikely that 




making the findings in this chapter broadly generalisable to any closely related 
models. 
Some of the prediction models tested in this chapter were developed to predict 
distinct outcomes or used predictors with different definitions. Specifically, the 
model developed by Reid et al. included a stroke severity score which – though 
useful – is rarely used in practice (The EC/IC Bypass Study group, 1985). The 
NIHSS was used in its place where it was found that regardless of any qualitative 
differences between these two measures the Reid model performed well. This is 
likely due to a strong correlation between the stroke severity score and the NIHSS 
(Goldie et al., 2014). This is therefore supportive of a good degree of generalisability 
in the discriminatory ability of these models. Updating would likely be required to 
improve upon calibration (Collins and Le Manach, 2013). 
Similar studies have suggested conflicting findings. A simulation study demonstrated 
that doctors predictions were worse than model-based predictions, albeit based on 
scenario-based, rather than clinical predictions (Saposnik et al., 2013a). However, the 
findings made in this chapter support those made in a previous study which 
demonstrated that doctors predictions of poor functional outcome were similar to the 
six simple variables model (Counsell et al., 2004). Additionally, patients’ functional 
outcome was examined in this chapter whilst maintaining its true ordinal structure 
which has not been investigated in such detail before. 
The inclusion of more complex variables such as the NIHSS and stroke subtype may 
seem intuitive, though they add to the difficulty of using these models, which may 
limit their use by non-specialists, non-doctors, and doctors early in their training. In 
any case, the main distinction between the SSV model and the Reid et al. model is 
the use of a stroke severity measure (note that the NIHSS was used in this chapter). 
The performance of these models was largely the same in the ESS, with the 
suggestion that the Reid et al. model holds the edge on the SSV in predicting poor 





5.7 Appendix A: Extra tables 
5.7.1 Loss to follow-up and missing doctor’s predictions 
A number of patients were either missing an OHS score at six months or missing a 
doctor’s prediction. Such patients were excluded from all analyses. The associations 
at a univariate level are shown in Table 5-5. 
5.7.2 Sensitivity analyses 
Table 5-6, Table 5-7 Table 5-8 and Table 5-9 summarise the relevant analyses 
presented above in the Results section within subsets and differently defined patients 






Table 5-5 Prevalence of risk factors at baseline in those included in analysis vs. those with either missing informal prediction or missing observed outcome at 
six month follow-up. Data presented as number and percentage (%) unless otherwise stated. 
 Patients available for analysis (n = 931)  Missing outcome or prediction (n = 326)  
Measurements taken on entry  No. (%) No. Missing  No. (%) No. Missing P-value 
Variables used in formal prediction models       
Age (years) (median, IQR) 74 (66 to 81) -  73 (61 to 81) - 0.0130 
Pre-stroke independence 867 (93) 2  298 (91) 3 0.5167 
Lived alone prior to stroke 361 (39) -  120 (37) 2 0.5794 
Arm power 799 (86) 1  276 (85) 2 0.7468 
Able to walk 672 (72) 2  240 (74) 4 0.4445 
Normal GCS verbal 810 (87) 5  279 (86) 3 0.6121 
NIHSS (median, IQR) 2 (0 to 5) 35  1 (0 to 3) 42 0.0193 
Heart failure 55 (6) 2  25 (8) 1 0.2619 
History of diabetes 119 (13) -  39 (12) - 0.7012 
Total cholesterol (mmol/l) (median, IQR) 5 (4 to 6) 73  5 (4 to 6) 46 0.3635 
Additional variables       
Systolic BP (mmHg) (median, IQR) 146 (130 to 160) 2  148 (130 to 164) 5 0.9778 
Gender, Male 474 (51) -  170 (52) - 0.7012 
History of hypertension 520 (56) 1  163 (50) - 0.0653 
Atrial fibrillation  66 (20) 2  205 (22) - 0.4918 
Able to talk 844 (91) 1  295 (90) 2 0.8734 
       
       





Table 5-5 Continued from previous page 
 
 Patients available for analysis (n = 931)  Missing outcome or prediction (n = 326)  
Measurements taken on entry  No. (%) No. Missing  No. (%) No. Missing P-value 
Additional variables (continued)       
Stroke syndrome       
TACS 97 (11)   32 (10)  - 
LACS 250 (28)   73 (24)  - 
PACS 412 (47)   149 (49)  - 
POCS 122 (14)   53 (17)  - 
Missing - 50  - 19 0.2853 
Seen at outpatients 489 (53) -  182 (56) - 0.3036 






Table 5-6 Model performance split by whether patients were seen in hospital or in outpatients. Poor functional outcome defined as OHS≥3 
   Calibration  Discrimination 
Patients Median R2 (%, IQR) AIC Intercept (95%CI) Slope (95%CI)  AUROCC (95%CI) 
Inpatients       
Reid 34.7 (34.4 to 34.9) 204 0.84 (0.69 to 0.98) 0.35 (0.31 to 0.39)  0.82 (0.78 to 0.86) 
Weimar 36.5 (36.1 to 36.8) 196 0.77 (0.65 to 0.88) 0.79 (0.70 to 0.89)  0.82 (0.78 to 0.86) 
SSV 37.6 (37.3 to 37.7) 199 -0.11 (-0.24 to 0.02) 0.61 (0.55 to 0.68)  0.82 (0.78 to 0.86) 
Apperlos* 37.6 (37.4 to 37.8) 197 - -  0.81 (0.77 to 0.85) 
Lee* 24.6 (24.3 to 24.7) 130 - -  0.75 (0.70 to 0.79) 
Outpatients       
Reid 12.0 (11.7 to 12.1) 66 1.33 (1.19 to 1.46) 0.68 (0.58 to 0.79)  0.71 (0.65 to 0.78) 
Weimar 8.8 (8.6 to 9.2) 56 0.36 (0.24 to 0.48) 1.04 (0.82 to 1.26)  0.67 (0.60 to 0.73) 
SSV 8.6 (8.6 to 8.6) 62 -0.48 (-0.61 to -0.35) 0.54 (0.43 to 0.66)  0.64 (0.57 to 0.71) 
Apperlos* 7.0 (6.8 to 7.3) 53 - -  0.66 (0.59 to 0.73) 
Lee* 0.0 (0.0 to 0.1) 24 - -  0.57 (0.50 to 0.65) 
       
       





Table 5-6 Continued from previous page 
   Calibration  Discrimination 
Patients Median R2 (%, IQR) AIC Intercept (95%CI) Slope (95%CI)  AUROCC (95%CI) 
All patients       
Reid 41.8 (41.6 to 42.0) 334 1.09 (0.98 to 1.19) 0.46 (0.43 to 0.50)  0.84 (0.81 to 0.87) 
Weimar 40.0 (39.9 to 40.2) 317 0.57 (0.49 to 0.65) 0.98 (0.90 to 1.06)  0.82 (0.79 to 0.85) 
SSV 39.2 (39.0 to 39.5) 319 -0.30 (-0.39 to -0.21) 0.71 (0.66 to 0.76)  0.81 (0.78 to 0.84) 
Apperlos* 39.6 (39.5 to 39.8) 313 - -  0.82 (0.79 to 0.85) 
Lee* 27.9 (27.7 to 28.0) 207 - -  0.76 (0.72 to 0.79) 
Note: Based on a single imputation; with bootstrap 95% CIs fixed at clinicians informal sensitivity/specificity. Also, *no calibration 






Table 5-7 Model performance split by whether patients were seen in hospital or in outpatients. Poor functional outcome defined as OHS≥2 
   Calibration  Discrimination 
Patients Median R2 (%, IQR) AIC Intercept (95%CI) Slope (95%CI)  AUROCC (95%CI) 
Inpatients       
Reid 22.0 (21.5 to 22.3) 129 2.50 (2.36 to 2.64) 0.28 (0.24 to 0.33)  0.77 (0.72 to 0.82) 
Weimar 21.5 (20.9 to 21.7) 117 1.96 (1.83 to 2.08) 0.61 (0.52 to 0.71)  0.77 (0.72 to 0.82) 
SSV 24.0 (23.8 to 24.3) 133 1.34 (1.21 to 1.48) 0.53 (0.46 to 0.59)  0.78 (0.73 to 0.82) 
Apperlos* 22.9 (22.5 to 23.1) 116 - -  0.77 (0.72 to 0.82) 
Lee* 13.0 (12.8 to 13.3) 69 - -  0.70 (0.65 to 0.75) 
Outpatients       
Reid 9.9 (9.6 to 10.2) 56 2.69 (2.59 to 2.79) 0.60 (0.50 to 0.70)  0.66 (0.61 to 0.71) 
Weimar 6.9 (6.6 to 7.0) 45 1.52 (1.43 to 1.62) 0.73 (0.57 to 0.90)  0.63 (0.58 to 0.68) 
SSV 7.8 (7.8 to 7.8) 47 0.80 (0.70 to 0.90) 0.52 (0.41 to 0.63)  0.62 (0.56 to 0.67) 
Apperlos* 4.9 (4.7 to 4.9) 42 - -  0.62 (0.57 to 0.67) 
Lee* 0.11 (0.10 to 0.15) 21 - -  0.57 (0.51 to 0.62) 
       
       





Table 5-7 Continued from previous page 
   Calibration  Discrimination 
Patients Median R2 (%, IQR) AIC Intercept (95%CI) Slope (95%CI)  AUROCC (95%CI) 
All patients       
Reid 29.5 (29.3 to 30.0) 227 2.62 (2.54 to 2.70) 0.44 (0.40 to 0.48)  0.78 (0.75 to 0.81) 
Weimar 27.1 (26.9 to 27.2) 207 1.68 (1.61 to 1.76) 0.82 (0.74 to 0.90)  0.77 (0.74 to 0.80) 
SSV 26.7 (26.5 to 27.1) 221 0.99 (0.92 to 1.07) 0.64 (0.58 to 0.69)  0.75 (0.72 to 0.78) 
Apperlos* 26.5 (26.4 to 26.6) 202 - -  0.76 (0.73 to 0.79) 
Lee* 17.3 (17.2 to 17.4) 125 - -  0.71 (0.67 to 0.74) 
Note: Based on a single imputation; with bootstrap 95% CIs fixed at clinicians informal sensitivity/specificity. Also, *no calibration 





Table 5-8 Sensitivity and specificity for formal and informal prediction methods split by where the patient was seen for two common dichotomies of OHS 
 OHS≥2  OHS≥3 
Patients Sensitivity (95%CI) Specificity (95%CI)  Sensitivity (95%CI) Specificity (95%CI) 
Inpatients      
Reid 0.60 (0.50 to 0.73) 0.73 (0.64 to 0.83)  0.51 (0.39 to 0.60) 0.89 (0.82 to 0.94) 
Weimar 0.60 (0.49 to 0.74) 0.74 (0.64 to 0.82)  0.51 (0.42 to 0.61) 0.89 (0.82 to 0.94) 
SSV 0.62 (0.51 to 0.71) 0.72 (0.60 to 0.82)  0.52 (0.42 to 0.63) 0.90 (0.84 to 0.95) 
Apperlos 0.61 (0.53 to 0.75) 0.74 (0.65 to 0.83)  0.52 (0.41 to 0.61) 0.89 (0.82 to 0.94) 
Lee 0.54 (0.45 to 0.65) 0.60 (0.47 to 0.72)  0.47 (0.37 to 0.54) 0.84 (0.76 to 0.91) 
Doctor’s predictions 0.69 (0.64 to 0.74) 0.79 (0.70 to 0.85)  0.55 (0.49 to 0.62) 0.91 (0.87 to 0.95) 
Outpatients      
Reid 0.28 (0.20 to 0.34) 0.86 (0.80 to 0.90)  0.16 (0.10 to 0.30) 0.99 (0.97 to 1.00) 
Weimar 0.21 (0.13 to 0.29) 0.80 (0.75 to 0.86)  0.10 (0.02 to 0.20) 0.98 (0.95 to 1.00) 
SSV 0.24 (0.17 to 0.30) 0.79 (0.71 to 0.85)  0.15 (0.05 to 0.27) 0.98 (0.97 to 1.00) 
Apperlos 0.19 (0.11 to 0.30) 0.81 (0.72 to 0.87)  0.09 (0.01 to 0.17) 0.98 (0.94 to 0.99) 
Lee 0.18 (0.11 to 0.28) 0.80 (0.68 to 0.87)  0.07 (0.01 to 0.15) 0.97 (0.93 to 0.99) 
Doctor’s predictions 0.38 (0.31 to 0.45) 0.92 (0.88 to 0.94)  0.09 (0.04 to 0.16) 0.98 (0.96 to 0.99) 





Table 5-8 Continued from previous page 
 OHS≥2  OHS≥3 
Patients Sensitivity (95%CI) Specificity (95%CI)  Sensitivity (95%CI) Specificity (95%CI) 
All patients      
Reid 0.56 (0.49 to 0.63) 0.87 (0.83 to 0.90)  0.45 (0.34 to 0.52) 0.96 (0.93 to 0.98) 
Weimar 0.54 (0.47 to 0.60) 0.85 (0.79 to 0.90)  0.43 (0.35 to 0.51) 0.96 (0.92 to 0.98) 
SSV 0.52 (0.46 to 0.58) 0.80 (0.74 to 0.89)  0.43 (0.36 to 0.51) 0.95 (0.93 to 0.98) 
Apperlos 0.52 (0.44 to 0.58) 0.83 (0.78 to 0.88)  0.42 (0.35 to 0.50) 0.95 (0.93 to 0.97) 
Lee 0.47 (0.41 to 0.53) 0.78 (0.72 to 0.84)  0.38 (0.32 to 0.45) 0.94 (0.91 to 0.96) 
Doctor’s predictions 0.58 (0.53 to 0.62) 0.88 (0.85 to 0.91)  0.44 (0.39 to 0.49) 0.96 (0.94 to 0.97) 







Table 5-9 Performance of formal and informal prediction of the ordinal OHS (defined on five levels: 0, 1, 2, 3 and ≥4) 
 Inpatients (N = 442)  Outpatients (N = 489) 
Method of prediction AIC ORC (95%CI)  AIC ORC (95%CI) 
Doctor’s predictions 191 0.72 (0.69 to 0.77)  79 0.65 (0.61 to 0.69) 
Formal: statistical model      
Reid et al 182 0.71 (0.68 to 0.75)  54 0.65 (0.61 to 0.70) 
Apperlos et al 192 0.72 (0.68 to 0.76)  16 0.61 (0.57 to 0.66) 
Weimar et al 185 0.71 (0.68 to 0.75)  21 0.62 (0.58 to 0.66) 
SSV 190 0.72 (0.68 to 0.75)  26 0.60 (0.55 to 0.65) 
Lee et al 122 0.66 (0.62 to 0.71)  -2 0.57 (0.51 to 0.62) 




Chapter 6: Benefits and harms from aspirin in 
acute ischaemic stroke 
Background and summary 
Patients at a high predicted risk of further thrombosis or a low predicted risk of 
haemorrhage may experience greater benefit from aspirin. Additionally, absolute 
benefit from treatment may increase with baseline prognosis risk. This chapter 
explores these questions using individual patient data from three randomised trials 
of aspirin in acute stroke. There was no evidence to support targeting aspirin to 
acute ischaemic stroke patients with a high predicted risk of thrombosis or a low 
predicted risk of haemorrhage. 
6.1 Introduction 
Aspirin has been established as an effective and beneficial treatment for patients with 
acute stroke (Sandercock et al., 2008). Aspirin is an antiplatelet drug which reduces 
the chance of clot formation and subsequent thrombotic events (e.g., ischaemic 
stroke or myocardial infarction) (Paikin and Eikelboom, 2012, Antithrombotic-
Trialists’-Collaboration, 2002). The Cochrane review of antiplatelet therapy in acute 
ischaemic stroke showed that aspirin was of overall benefit with 13 more patients 
alive and independent for every 1000 treated, i.e., an absolute risk reduction in poor 
functional outcome of just over 1% (Sandercock et al., 2008). An unfortunate side-
effect of aspirin is that it increases patient risk of suffering intra-cranial or extra-
cranial haemorrhage. One understanding of the net benefit of aspirin is that the 
reduction in thrombotic events out-weighs the harmful increase in haemorrhage 
(Bednar and Gross, 1999). 
For any given trial baseline prognostic risk in the absence of treatment will vary from 
patient to patient. Kent and Hayward note that this risk typically has a strong positive 




events in follow-up (Kent and Hayward, 2007b). For a constant relative risk 
reduction, those at a low baseline outcome risk often do not stand to gain as much 
benefit from treatment as those at a high risk. Absolute treatment benefit therefore 
necessarily varies with baseline risk. This has been called the ‘heterogeneity of 
treatment effect’ (HTE) (Kent et al., 2010). In the absence of treatment related harm 
the problem may be entirely framed as one of the cost-effectiveness of treatment. 
However, when treatment comes with a harmful side effect (e.g., haemorrhage); then 
it may be the case that the size of any potential benefit for those at low baseline 
outcome risk may be far less than the cost with respect to harm. The benefit harm 
balance may therefore tip in favour of harm more frequently amongst those least 
likely to benefit from treatment. 
Often trials will investigate HTE using a plethora of subgroup analyses. Hayward et 
al demonstrated that subgroup analyses are frequently underpowered and that by 
stratifying by predicted risk based on multivariable prediction models it was possible 
to regain some of this lost power (Hayward et al., 2006). Recently Kent et al. 
proposed a formalised framework to explore HTE using prediction models (Kent et 
al., 2010). This type of approach has gained momentum with, for example, the HTE 
for various interventions in cardiovascular disease explored using existing 
randomised trial data and risk scores (Dorresteijn et al., 2011a, Dorresteijn et al., 
2011b, van der Leeuw et al., 2014). With the associated harms and benefits of aspirin 
in acute stroke there is scope to explore treatment effect by predicted risk (see 
Chapter 1 for more discussion). The predicted risk of treatment related harm and 
benefit was not considered in the Cochrane review of aspirin (Sandercock et al., 
2008). It is hypothesised that treating those with the greatest expected benefit (high 
risk of thrombosis) or those with the lowest expected harm (low risk of haemorrhage) 
may further reduce the risk of poor functional outcome following stroke. 
The aims of this chapter are therefore twofold: (i) to develop and evaluate new 
clinical prediction models from large RCT data for the separate prediction of 
haemorrhagic, thrombotic, and poor functional outcome events; and (ii) to use these 
models to suggest a stratified approach for treating patients with aspirin based on 




6.2 Meta-analysis and Individual Patient Data (IPD) 
Three distinct types of meta-analysis can be identified (Senn, 2000). Using Senn’s 
terminology: type A distinguishes those analyses for which the individual patient 
data have been made available, each recording the same outcome measure; type B 
meta-analyses are perhaps the most commonly encountered of the three using 
summary statistics obtained from publication, again with each trial using the same 
outcome measure; and finally type C which describes a ‘unit-free’ approach. This 
was first proposed by Glass (Glass, 1976) for summarising trials measuring efficacy 
of treatment on different outcomes. The latter of these approaches is irrelevant so far 
as any of the analyses undertaken throughout this thesis and will not be discussed 
any further. 
International collaboration has seen the sharing of entire datasets allowing for the 
type A method to be used more frequently. This approach is more commonly known 
as Individual Patient Data Meta-Analysis (IPDMA) which enables a level of 
continuity that a traditional type B meta-analysis may be incapable of achieving 
(Debray et al., 2013). For instance, pooling measures adjusted for important (and 
recorded) prognostic covariates is entirely reliant on the original authors publishing 
these results. With IPD though detailed risk prediction analyses (i.e., model 
development and model evaluation) can be carried out. This can be especially useful 
when the outcome event rate is low; this pooling of data may give researchers the 
statistical power needed to reliably estimate the model parameters (Ahmed et al., 
2014). In summary, individual patient data sources can be appropriately combined 
and used to answer important questions that smaller studies cannot achieve in 
isolation. 
The latest Cochrane review of antiplatelet therapy for acute ischemic stroke was used 
to identify trials of aspirin versus placebo or control in acute ischemic stroke 
(Sandercock et al., 2008). It was not possible to obtain the individual patient data for 
two small trials one of which was unpublished (Pince, 1981, Rödén-Jüllig et al., 




of the largest randomised trials of aspirin versus control (inactive or active) in acute 
ischaemic stroke (summary provided in Table 6-1). 
6.2.1 The first International Stroke Trial (IST-1) 
The first International Stroke Trial (IST-1) was a large, randomised, factorial 
designed, open control trial of up to 14 days of aspirin and two doses of heparin 
started within 48 hours of acute stroke onset (IST Collaborative Group, 1997). 
Patients were followed up for a maximum of six months. The primary outcomes 
were: (i) death from any cause within 14 days of randomisation and (ii) death or 
dependency at six months. A minimisation algorithm was used to ensure balance 
between the treatment arms for a number of “…recorded prognostic features…” 
although it is not clear from the original publication what exactly these were. The 
IST-1 had a 2x3 factorial design randomising patients to receive either: (i) 
300mg/day of aspirin and 12,500 IU bd heparin per day (medium-dose); (ii) 
300mg/day of aspirin and 5000 IU bd heparin per day (low-dose); (iii) 300mg/day of 
aspirin and no heparin; (iv) no aspirin and 12,500 IU bd heparin per day; (v) no 
aspirin and 5000 IU bd heparin per day; and (vi) no aspirin and no heparin. The 
factorial design was adopted to investigate whether any important interactions 
occurred between aspirin and heparin (low or medium dose). Patients were recruited 
from January 1991 till May 1996 from 36 countries and 467 hospitals. A total of 
19435 patients were randomised to receive one of the six combinations listed above. 
Follow-up was good with 19285 (99.2%) of those randomised with observed 
outcomes by six months (a total of 150 lost, ranging from 0.9 to 0.6% across the six 
treatment regimens). No significant differences were identified in early deaths (≤14 
days) amongst those randomised to receive either heparin (low and medium doses 
pooled) or no heparin or amongst those randomised to receive either aspirin or no 
aspirin (P-values ≥ 0.05). Similarly there was no difference in those dead or 
dependent at six months between treatment arms, although, after adjustment for 
baseline stroke severity a beneficial reduction of 14 per 1000 treated (P-value = 0.03) 
was identified. The trialists found that no treatment interaction existed between 




6.2.2 The Chinese Acute Stroke Trial (CAST) 
The Chinese Acute Stroke Trial (CAST) was a large, randomised, placebo controlled 
trial of up to 28 days of aspirin started within 48 hours of acute stroke onset (Zheng-
Ming, 1997). Patients were followed up for a maximum of 28 days. The primary 
outcomes were: (i) death from any cause within 28 days; and (ii) death or 
dependence at discharge. The CAST recruited patients from November 1993 till 
March 1997 from 413 Chinese hospitals. A total of 21106 patients were randomised 
to receive either 160mg/day aspirin or an inactive placebo. Follow-up was good with 
20655 (97.9%) of those randomised with available discharge forms by 28 days (a 
total of 451 lost, with 2.1% in the aspirin arm and 2.4% in placebo). A significant 
treatment effect was identified amongst those dead by 28 days, with around 6 fewer 
deaths per 1000 treated with aspirin (P-value = 0.03). Of those dead or dependent at 
discharge there were around 11 per 1000 fewer (P-value = 0.08). 
6.2.3 Multicentre Acute Stroke Trial – Italy (MAST-I) 
The Multicentre Acute Stroke Trial – Italy (MAST-I) was a small, randomised, 
factorial designed trial of streptokinase or aspirin (Multicentre Acute Stroke Trial - 
Italy, 1995). The primary outcome was death or severe disability six months from 
randomisation. The purpose of the trial was to assess whether there was any benefit 
from aspirin and/or streptokinase in reducing the incidence of death or severe 
disability. The MAST-I had a 2x2 factorial design randomising patients to receive 
either: (i) a one hour intravenous infusion of 1.5 MU streptokinase; (ii) 300mg/day of 
buffered aspirin for ten days; (iii) both active treatments; or (iv) neither. Four interim 
analyses were planned after the recruitment of 100, 300, 500 and 600 patients. The 
MAST-I recruited 622 patients between May 1991 and February 1995 out of a 
planned total of 1500 patients. No patients were lost to follow-up. The trial was 
interrupted in January 1995 due to an excess number of early deaths amongst those 
randomised to receive streptokinase. A significant excess of deaths by 10 days was 
identified amongst those randomised to receive either of the streptokinase regimens. 
By six months a non-significant reduction in those dead or severely disabled was 
suggested for both those randomised to receive streptokinase (OR 0.9 with 95% CI 




Table 6-1 Characteristics of included aspirin trials 
Design Features IST-1 CAST MAST-I 
Number of 
patients 
19435 21106 622 
Aspirin dose, mg 300 160 300 
Duration, days 14 28 10 
Non-aspirin 
treatment arm(s) 
Low dose/ medium 
dose/ or avoid 
heparin 
Placebo Streptokinase or 
avoid streptokinase 
Randomisation 2x3 factorial 1:1 2x2 factorial 
Time from onset, 
hours 
0 to 48 0 to 48 0 to 6 
Follow up for early 
events 
14 days 28 days 10 days 
Follow up for 
death or 
dependence 





6.2.4 Patient characteristics across trials 
A total of 39166 patients with acute ischemic stroke from the three trials were 
suitable for this analysis. Patients with definite or probable (i.e., unknown pathology) 
ischaemic stroke at baseline were retained. 
6.2.4.1 Baseline covariate data 
Most baseline characteristics were used as originally defined or were modified so as 
to induce a degree of communality across the three trials. MAST-I recorded the 
presence of a weakness in the ‘arm or leg’ as a single binary variable, this variable 
was therefore defined within both IST-1 and CAST and adopted throughout all 
analyses. Age was parameterised per increasing intervals of ten years and systolic 
blood pressure per increasing intervals of ten millimetres of mercury (mmHg). The 
remaining variables were used as originally measured: presence of dysphasia, 
hemianopia, visuospatial disorder, brainstem or cerebellar deficits, a history of atrial 
fibrillation, delay from stroke to randomisation, and evidence of infarct on CT. In 
order to assess the modest but beneficial effect of aspirin both the IST-1 and CAST 
trials were designed pragmatically. Pragmatic trials help to evaluate the applicability 
of primary findings in a broader context and ultimately have a greater influence on 
health services and policy making (Treweek and Zwarenstein, 2009). However, the 
pragmatism employed in the running of these trials meant that few baseline 
measurements were taken thus placing a necessary limit on the amount of variable 
selection possible in this secondary-analysis of the data. 
Patients in CAST were on average younger (median age of 64); had a lower SBP 
(median of 154mmHg) and were more often male (63%) in contrast with those 
recruited to IST-1 and MAST (similar median age (73 and 71 respectively), equal 
SBP (160mmHg) and an equal proportion who were male (54%), see Table 6-3). 
Stroke deficits were largely comparable between the three trials with the exception of 
hemianopia and visuospatial deficit which occurred less often and dysphasia which 




6.2.4.2 Early and late outcomes 
Two early composite events were defined: a thrombotic event (any Deep Venous 
Thrombosis (DVT); Pulmonary Embolism (PE); ischaemic stroke; and Myocardial 
Infarction (MI)) and a haemorrhagic event (any significant intracranial haemorrhage; 
major extra-cranial haemorrhage; and haemorrhagic transformation). IST-1 reported 
these events at 14 days. In a sensitivity analysis those with DVTs were excluded (see 
section 6.6). Early events in CAST were restricted up to and including 14 days whilst 
MAST-I recorded early events at 10 days. Differences in incidence were noted across 
trials with: 6.1% of patients suffering a thrombotic event and 1.4% a haemorrhagic 
event in IST-1; 1.9% and 1.0% in CAST; and 1.6% and 5.8% in MAST-I. A 
particularly high rate of haemorrhage in MAST-I can be attributed to an excess risk 
amongst those treated with streptokinase: this was the reason for the early 
termination of MAST-I (Multicentre Acute Stroke Trial - Italy, 1995). Allowances 
for these differences were made through recalibrated predicted risks which will be 
discussed in detail later (see section 6.4.1). 
Each trial used slightly different ordinal scales to record functional outcome by end 
of follow-up. The IST-1 recorded functional outcome at six months. This ordered 
scale ranged from 1 to 4, describing patients as: dead; dependent; not recovered; and 
recovered. The original publication for CAST claims a record of functional outcome 
on the modified Rankin Scale (mRS), although on inspection of the available IPD a 
measure similar to that used in  IST-1 seems to have been recorded at 28 days 
describing patients as: dead; partly dependent; severely disabled; recovered, but 
independent; and fully recovered. Finally, MAST-I assessed patients using a more 
conventional ordinal scale by six months: the modified Rankin Score (mRS). It was 
possible to define a ‘common ordinal outcome’ across the three trials. As IST-1 
offered the most restricted number of levels the ordinal outcomes for CAST and 
MAST-I were constrained and categorised in order to fit within the constructs of the 
four levelled IST-1 outcome scale. Therefore an assumption that patients so defined 
are comparable across trials is made. This common ordinal outcome is summarised 
below (Table 6-2). Poor functional outcome was defined as those dead or dependent, 




patients in IST-1 (62%) and MAST-I (64%) had a poor functional outcome by six 
months compared to just under a third of those in CAST (31%) by 28 days (Table 
6-4). 
 
Table 6-2 Defined common ordinal outcome 
 Ordinal category level (1 to 4) 
Trial 1 2 3 4 
IST-1 Dead Dependent Not recovered Recovered 






MAST-I mRS = 6 mRS = 3 to 5 mRS = 2 mRS = 0 to 1 





Table 6-3 Baseline characteristics for the three aspirin trials. For continuous measurements the median and inter-quartile range is quoted; for categorical 
measurements the frequency and % is provided. 
Variable IST-1 (N = 18372) Missing CAST (N = 20172) Missing MAST-I (N = 622) Missing 
Age (per year) 73 (65-80) - 64 (57-70) 66 (<1) 71 (62-78) - 
Gender, male 9855 (54) - 12759 (63) - 335 (54) - 
Time from onset, hours 20 (9-29)  24 (12-37) 25 (<1) 4 (3-5) - 
Prior antiplatelet 729 (4) 13 (<1) 1590 (8) 534 (3) - - 
Stroke syndrome  52 (<1) - - - - 
Total anterior 4395 (24) - - - - - 
Partial anterior 7395 (40) - - - - - 
Lacunar circulation 4428 (24) - - - - - 
Posterior circulation 2103 (11) - - - - - 
Systolic Blood Pressure (mmHg) 160 (140-180) - 154 (140-180) 19 (<1) 160 (140-170) 3 (<1) 
Presence of Deficits       
Face 13392 (73) 231 (1) 14999 (74) 484 (2) - - 
Arm/hand 15781 (86) 114 (1) 17958 (89) 161 (1) - - 
Leg/foot 13899 (76) 238 (1) 17872 (89) 168 (1) - - 
Either arm/leg 15920 (87) 258 (1) 18505 (92) 222 (1) 527 (85) - 
Dysphasia 8041 (44) 554 (3) 10792 (53) 322 (2) 265 (43) - 
Hemianopia 2924 (16) 3712 (20) 915 (5) 1986 (10) 71 (11) - 
Visuospatial 2992 (16) 3255 (18) 722 (4) 1997 (10) 82 (13) - 
Brainstem/cerebellar signs 2018 (11) 1479 (8) 1350 (7) 1135 (6) 16 (3) - 
Other 1143 (6) 1165 (6) 1370 (7) 1645 (8) - - 
Conscious at randomisation 14117 (77) - 17588 (87) 24 (<1) 568 (91) - 
Atrial Fibrillation (AF) 3034 (17) 947 (5) 1350 (7) 90 (<1) 150 (24) - 





Table 6-4 Early and long term outcome events in aspirin trials. 
 IST-1 (N = 18372) CAST (N = 20172) MAST-I (N = 622) Total (N = 39166) 
 No. % No. % No. % No. % 
Early outcomes, 14 days or less         
Deep venous thrombosis (DVT) 21 0.11 - - - - 21 0.05 
Pulmonary embolism (PE) 122 0.66 19 0.09 - - 141 0.36 
Ischaemic stroke/ cerebral infarction 632 3.44 319 1.58 5 0.80 956 2.44 
Myocardial infarction (MI) 357 1.94 49 0.24 5 0.80 411 1.05 
All thrombotic events 1118 6.09 380 1.88 10 1.62 1508 3.85 
Significant intracranial haemorrhage  119 0.65 75 0.37 32 5.14 226 0.58 
Major extra-cranial haemorrhage 150 0.82 90 0.45 8 1.29 248 0.63 
Haemorrhagic transformation 49 0.27 50 0.25 - - 99 0.25 
All haemorrhagic events 265 1.44 204 1.01 36 5.79 505 1.29 
         
Long term outcome, six months or less         
Common functional score (1-4)         
(1) Recovered 3142 17.10 7415 36.76 167 26.85 10724 27.38 
(2) Not recovered 3680 20.03 6498 32.21 59 9.49 10237 26.14 
(3) Dependent 7460 41.61 5445 26.99 209 33.60 13114 33.48 
(4) Dead 3953 22.52 765 3.79 187 30.06 4905 12.52 
Dead or dependent 11413 62.12 6210 30.79 396 63.67 18019 46.01 
Missing 137 0.75 49 0.24 - - 186 0.01 




6.2.4.3 Missing data within each of the trials 
Baseline characteristics for the three datasets are summarised in Table 6-3 alongside 
the proportion and frequency of missing data. The MAST-I data were entirely 
complete for these measures with the exception of systolic blood pressure with three 
missing readings. Atrial fibrillation was not recorded for any patient during the initial 
pilot recruitment phase of IST-1 (January 1991 to February 1993). These 
observations can therefore be assumed to be Missing At Random (MAR). The IST-1 
had 12291 (67%) patients with completely observed data, 2825 (15%) with one 
missing value and 1699 (9%) with two. Fewer had multiple missing values with one 
patient having a maximum of ten missing values. The CAST data had a total of 
15657 (78%) patients with completely observed data, 2406 (12%) with one missing 
and 910 (5%) with two. As with the IST-1 data, fewer had multiple missing values 
with one patient having a maximum of eleven missing values. 
Joint missingness was explored using cluster plots (Figure 6-1 and Figure 6-2) for the 
IST-1 and CAST trial datasets (NB such a plot could not be produced for MAST-I 
since there were no jointly missing values). In both the IST-1 and the CAST data, the 
majority of jointly missing values were associated amongst the stroke deficits.  
Imputation was undertaken for each of the datasets. The adopted imputation model 
included each of the variables listed in the cluster plots (Figure 6-1 and Figure 6-2). 
Indicator variables for missingness amongst each variable can be created to explore 
the extent to which missingness can be explained by the observed values. For IST-1 
this ranged from as low as 3% to as high as 90% and for CAST as low as 3% to as 
high as 82%. Missingness may be at least partly Missing At Random (MAR) and 
therefore a multiple imputation approach could reduce the risk of bias. Missing data 
were imputed multiple times generating twenty complete datasets per trial.  
It is noted that 186 (0.01%) of the 39166 patients have missing long term outcomes. 
Imputing missing outcomes contributes random noise to the results (Von Hippel, 
2007); however, given how few had missing outcomes, the expected impact of this 




































































































































































































































































































































































































































































































6.2.5 Pooled aggregate results from aspirin trials  
The IST-1 and CAST trials were run concurrently. The intention was that both 
analyses would be pooled to show the effect of aspirin within a much larger sample 
of ischaemic stroke patients than had ever been studied before (Chen et al., 2000). 
Following the Chen et al paper in 2000, a Cochrane analysis was conducted in 2008 
using all three trials (CAST, IST-1 and MAST) (Sandercock et al., 2008). The figure 
below describes how the three datasets were combined with respect to: (i) the 
Cochrane analysis (dotted lines); and (ii) the analyses undertaken in this chapter 
(solid lines). 
 
Figure 6-3 Flow-diagram of included aspirin trial IPD. Solid lines indicate how the datasets are 
handled in this chapter whilst dotted lines indicate the original Cochrane analysis. Note ‘*’ the 
obtained patient data for CAST did not match publication 
The Cochrane review considered all patients in IST-1 treated with aspirin since there 
was no indication that heparin and aspirin interacted with one another to produce a 
difference in outcome, harm or benefit. In the case of MAST-I there was an 
interaction between treatments. It was noted above that the trial was stopped early 
due to an excess number of early deaths (see section 6.2.3). Sandercock et al. 




A: Cochrane meta-analysis 
Study
Fixed effect model











































B: Analysis using obtained IPD 
Study
Fixed effect model











































Figure 6-4 Meta-analysis of three RCTs assessing aspirin versus control: (A) as per Cochrane 
review data; and (B) using available IPD for the analysis in this chapter (note 137 and 49 
patients missing in IST-1 and CAST respectively) 
 
This analysis is reproduced in Figure 6-4 (A) above and contrast with the data used 
specifically in this chapter Figure 6-4 (B). For this chapter only confirmed ischaemic 
or unknown strokes at baseline are included and MAST-I is used in its entirety. The 
addition of those on streptokinase resulted in a slightly smaller effect from aspirin 
although in neither setting was this shown to be significantly different from no effect. 




6.3 Developing and evaluating new models  
Models for the prediction of recurrent stroke or myocardial infarction were identified 
in Chapter 3. None of which, however, could be applied to the IST-1, CAST or 
MAST-I datasets since the required baseline predictors of these models were not all 
recorded by these trials. Therefore, new models had to be developed. In order to both 
develop and evaluate new clinical prediction models a non-random split of the IST-1 
trial data was used. This was done by country of recruitment and constitutes a 
geographical evaluation of performance (Toll et al., 2008). A simple random-split 
ensures similarly distributed characteristics in each sample and is overly optimistic. 
Patients recruited to UK and Italian hospitals made up the training set and were used 
for model development whilst the remaining 34 countries formed the test set and 
were used for model evaluation. Development was undertaken in the training set. 
6.3.1 Predicting 14 day thrombosis and haemorrhage 
Two multivariable binary logistic regression (LR) models for the separate prediction 
of: 14 day thrombosis on control; and 14 day haemorrhage on aspirin were 
developed. Linearity and additivity assumptions were assessed using restricted cubic 
splines and two-way interactions respectively. A single imputed dataset was 
generated using the imputation model previously discussed. The model development 
subset (i.e., the training set) was specified within this single imputation and the 
model assumptions were explored. Clinical plausibility was given prominence over 
statistical significance. A high level of improvement had to be demonstrated before 
the added complexity of either an interaction or a non-linear association would be 
included in the final models. To meet inclusion an increase of 10 or more Akaike’s 
Information Criterion (AIC) units on the Chi-squared scale was set (Steyerberg, 
2009). The changes in AIC units are presented in Table 6-5. There were no 
substantial improvements in either of the early event models when including non-
linear effects nor when considering the inclusion of interaction terms. Increasing age 
and the presence of a visible infarct were the only statistically significant prognostic 
factors; both suggested an increase in the log-odds of thrombosis (Table 6-6). For 
most of the predictors the association was in the same direction across each of the 




Table 6-5 Testing model assumptions for early event models in a single imputed dataset. 
Test performed Age (years) SBP (mmHg) OTT (hours) 
    
Fourteen day thrombosis model    
Additivity    
Gender -1.84 (0.6934) -1.81 (0.6664) 0.86 (0.0908) 
Visible infarct on CT -1.28 (0.3968) -0.09 (0.1668) -2.00 (0.9607) 
Atrial fibrillation -1.21 (0.3753) -1.94 (0.8106) -2.00 (0.9842) 
Conscious (Drowsy/Coma vs. Alert) -0.38 (0.2033) -0.25 (0.1862) -1.95 (0.8211) 
Motor deficit -1.73 (0.6044) -1.99 (0.9042) -2.00 (0.9672) 
Presence of dysphasia -1.28 (0.3957) 0.48 (0.1154) -1.94 (0.8106) 
Presence of hemianopia -0.68 (0.2505) 0.85 (0.0911) -1.35 (0.4211) 
Presence of visuospatial disorder -0.36 (0.2006) -2.00 (0.9992) -1.19 (0.3694) 
Presence of brainstem/ cerebellar deficit 1.41 (0.0647) -1.96 (0.8423) -1.82 (0.6746) 
Linearity    
Restricted cubic spline    
Three knots 1.41 (0.0648) 0.15 (0.1426) -1.95 (0.8258) 
Four knots -0.38 (0.1633) 2.37 (0.0413) -3.95 (0.9766) 
Five knots -2.36 (0.3031) 0.87 (0.0763) -1.06 (0.1761) 
Square term 1.38 (0.0662) 0.89 (0.0891) -1.99 (0.9251) 
    
Fourteen day haemorrhage model    
Additivity    
Gender -1.50 (0.4805) -0.66 (0.2466) -1.18 (0.3651) 
Visible infarct on CT -1.77 (0.6315) -1.29 (0.4005) -1.97 (0.8565) 
Atrial fibrillation -0.88 (0.2890) -1.97 (0.8634) -1.91 (0.7613) 
Conscious (Drowsy/Coma vs. Alert) -0.01 (0.1588) -1.63 (0.5404) -1.97 (0.8682) 
Motor deficit 0.45 (0.1177) -2.00 (0.9525) -2.00 (0.9819) 
Presence of dysphasia -1.39 (0.4344) -1.99 (0.9296) -2.00 (0.9742) 
Presence of hemianopia -1.97 (0.8733) 1.41 (0.0648) -1.93 (0.7882) 
Presence of visuospatial disorder -1.99 (0.9065) 0.99 (0.0839) -1.86 (0.7036) 
Presence of brainstem/ cerebellar deficit 1.57 (0.0589) -1.44 (0.4531) -2.00 (0.9685) 
Linearity    
Restricted cubic spline    
Three knots -0.48 (0.2171) -1.84 (0.6901) -1.75 (0.6164) 
Four knots -2.26 (0.4185) -3.52 (0.7849) -0.47 (0.1715) 
Five knots -2.72 (0.3507) -5.06 (0.8162) -1.57 (0.2185) 
Square term 0.40 (0.1213) -1.91 (0.7618) -1.49 (0.4770) 
NOTE: The difference in AIC units contrasting a complex fit to a simple fit is provided alongside the P-





Table 6-6 Multivariable prediction models for 14 day events in the development split with imputed IST-1 data (over 20 imputed sets) 
 Thrombotic model (291/4504)  Haemorrhagic model (74/4511) 
Variable Coefficient (SE) OR (95% CI) P-value  Coefficient (SE) OR (95% CI) P-value 
Intercept -4.339 (0.659) - <0.0001  -5.8526 (1.286) - <0.0001 
Age (per decade) 0.193 (0.064) 1.21 (1.07 to 1.38) 0.0027  0.215 (0.125) 1.24 (0.97 to 1.58) 0.0860 
SBP (per 10 mmHg) -0.024 (0.023) 0.98 (0.93 to 1.02) 0.3040  -0.015 (0.045) 0.98 (0.90 to 1.08) 0.7362 
Delay from randomisation (hours) -0.009 (0.005) 0.99 (0.98 to 1.00) 0.0641  -0.005 (0.010) 1.00 (0.98 to 1.01) 0.6422 
Sex (Male) 0.201 (0.127) 1.22 (0.95 to 1.57) 0.1125  0.379 (0.246) 1.46 (0.90 to 2.37) 0.1239 
Visible infarct on CT 0.419 (0.135) 1.52 (1.17 to 1.98) 0.0019  0.110 (0.271) 1.12 (0.66 to 1.90) 0.6841 
Conscious (Drowsy/Coma vs. Alert) -0.028 (0.162) 0.97 (0.71 to 1.34) 0.8639  0.001 (0.315) 1.00 (0.54 to 1.86) 0.9986 
Atrial fibrillation 0.168 (0.153) 1.18 (0.88 to 1.60) 0.2743  0.216 (0.314) 1.24 (0.67 to 2.30) 0.4924 
At least one or more of arm/leg deficits 0.431 (0.226) 1.54 (0.99 to 2.39) 0.0561  0.309 (0.450) 1.36 (0.56 to 3.28) 0.4937 
Presence of dysphasia 0.026 (0.131) 1.03 (0.79 to 1.33) 0.8441  -0.361 (0.255) 0.70 (0.42 to 1.15) 0.1567 
Presence of hemianopia 0.159 (0.187) 1.17 (0.81 to 1.69) 0.3949  0.334 (0.366) 1.40 (0.68 to 2.86) 0.3607 
Presence of visuospatial disorder 0.103 (0.188) 1.11 (0.77 to 1.60) 0.5831  0.036 (0.351) 1.04 (0.52 to 2.06) 0.9193 




6.3.2 Evaluating the performance of the early event models 
The two multivariable logistic regression models developed for the prediction of 14 
day thrombosis and 14 day haemorrhage (Table 6-6) were internally evaluated using 
the test set (i.e., non UK/Italian recruited hospital patients). Model performance was 
assessed using: (i) Nagelkerke’s R2, an overall measure of model performance; (ii) 
the AUROCC to quantify model discrimination where perfect discrimination has an 
AUROCC of 1 and no discrimination an AUROCC of 0.5; and (iii) calibration, split 
into the calibration intercept and slope, which should ideally be as close to 0 and 1 
respectively as possible. These measures were calculated on the twenty imputed test 
sets and combined using Rubin’s rules (Table 6-7). Discrimination between those 
patients with and without thrombosis by 14 days (AUROCC of 0.56) and those with 
and without haemorrhage by 14 days (AUROCC of 0.57) was poor. Calibration was 
moderate, although for both outcomes there was the suggestion that the outcome-
predictor associations in development were optimistically large (slope<1) as well as a 
slight systematic component indicating a consistent under prediction of risk from 
early events (intercept>0). 
Table 6-7 Performance of multivariable prediction models for 14 day events in the evaluation 
split with imputed test data. Note 95%CI provided unless otherwise stated 
Performance Measure Thrombosis (337/4685) Haemorrhage (87/4672) 
Median % R2 (IQR) 0.58 (0.55 to 0.59) 0.57 (0.39 to 0.67) 
AUROCC 0.56 (0.53 to 0.59) 0.57 (0.52 to 0.64) 
Calibration   
Intercept 0.14 (0.09 to 0.20) 0.20 (0.09 to 0.31) 
Slope 0.46 (0.33 to 0.60) 0.52 (0.26 to 0.78) 




6.3.3 Predicting six month death or dependency 
The same methodological approach used for the development of prediction models 
for early events was used to develop a model to predict six month death or 
dependency on control. Two non-linear effects were identified as important for age 
and systolic blood pressure. This departure from linearity was identified first by 
fitting restricted cubic splines were it was observed that a substantial improvement in 
model fit could be made through this flexible fit (Table 6-8). However it was also 
noted that the same improvement could be made by fitting a simple quadratic 
function (Figure 6-5). 
The presence of arm/leg weakness, dysphasia, hemianopia, visuospatial disorder and 
unconscious or drowsy at randomisation were associated with a statistically 




Table 6-8 Testing model assumptions for six month death or dependency model in a single 
imputed dataset. 
Test performed Age (years) Systolic BP (mmHg) OTT (hours) 
Additivity     
Gender 1.95 (0.8261) -1.74 (0.6082) -1.23 (0.3793) 
Visible infarct on CT -1.97 (0.8711) -2.00 (0.9903) 7.20 (0.0024) 
Atrial fibrillation 5.30 (0.0069) -1.53 (0.4923) -1.78 (0.6382) 
Conscious (Drowsy/Coma vs. Alert) 1.06 (0.0802) -1.41 (0.4429) -1.96 (0.8323) 
Motor deficit -1.89 (0.7364) -0.83 (0.2794) -2.00 (0.9570) 
Presence of dysphasia -0.49 (0.2193) -1.95 (0.8294) -1.69 (0.5780) 
Presence of hemianopia 3.52 (0.0188) 1.93 (0.0475) -1.34 (0.4151) 
Presence of visuospatial disorder -0.77 (0.2680) -2.00 (0.9633) -1.58 (0.5151) 
Presence of brainstem/ cerebellar deficit -1.92 (0.7717) -0.66 (0.2464) -1.53 (0.4937) 
Linearity    
Restricted cubic spline    
Three knots 41.18 (<0.0001) 10.47 (0.0004) 0.85 (0.0916) 
Four knots 42.07 (<0.0001) 8.61 (0.0018) -0.80 (0.2018) 
Five knots 43.10 (<0.0001) 6.63 (0.0055) 0.10 (0.1069) 
Square term 40.35 (<0.0001) 10.63 (0.0004) 1.50 (0.0615) 
NOTE: The difference in AIC units contrasting a complex fit to a simple fit is provided 
alongside the P-value for the associated LR test. Positive AIC on the chi-squared scale 


















Linear fit, χ2 329.34 and Quadratic fit, χ2 371.34






















Linear fit, χ2 0.22 and Quadratic fit, χ2 12.93









Figure 6-5 Transformations of patient age (per decade) and systolic blood pressure (per 10mmHg) in univariable analysis comparing a simple linear fit to a 




Table 6-9 Multivariable prediction models for six month death or dependency in the 
development split with imputed IST-1 data (over 20 imputed sets) 
 Development split (3225/4504) 
Variable Coefficient (SE) OR (95% CI) P-value 
Intercept 3.098 (1.384)  0.0252 
Age (per 10 years)    
Age -0.801 (0.293) 0.44 (0.25 to 0.79) 0.0063 
Age2 0.095 (0.022) 1.10 (1.05 to 1.15) <0.0001 
SBP (per 10 mmHg)    
SBP -0.359 (0.136) 0.69 (0.53 to 0.91) 0.0083 
SBP2 0.011 (0.004) 1.01 (1.00 to 1.02) 0.0058 
Delay from randomisation (hours) 0.004 (0.003) 1.00 (1.00 to 1.01) 0.2001 
Sex (Male) -0.329 (0.078) 0.72 (0.62 to 0.84) <0.0001 
Visible infarct on CT 0.051 (0.088) 1.05 (0.89 to 1.25) 0.5638 
Conscious (Drowsy/Coma vs. Alert) 1.495 (0.147) 4.48 (3.36 to 5.98) <0.0001 
Presence of atrial fibrillation 0.109 (0.113) 1.11 (0.89 to 1.38) 0.3342 
At least one or more of arm/leg deficits 0.937 (0.109) 2.58 (2.08 to 3.19) <0.0001 
Presence of dysphasia 0.365 (0.080) 1.44 (1.24 to 1.69) <0.0001 
Presence of hemianopia 0.732 (0.132) 2.06 (1.59 to 2.67) <0.0001 
Presence of visuospatial disorder 0.618 (0.130) 1.83 (1.41 to 2.38) <0.0001 





6.3.4 Evaluating the performance of the death or dependency 
model 
The six month death or dependency model discriminated well between those with 
poor functional outcome (dead or dependent) and those without (Table 6-10) within 
the test dataset, the CAST and the MAST-I data (AUROCC values ranging from 
0.77 to 0.71). Calibration was moderate and reflected some key differences between 
incidence of outcome and trial design. The observed calibration slope in internal 
evaluation and in the CAST evaluation (<1) suggests optimistically large predictor-
outcome associations in model development indicative of overfitting, whilst the 
negative intercepts points toward an over estimation in the predicted risks. This can 
be explained by a shorter follow-up period in CAST (28 days compared to 6 months 
in IST-1) and a greater incidence of death or dependence amongst the UK and Italian 
recruitment centres compared to the test dataset (72% versus 55%). The similar 
incidence rate in MAST-I would suggest good calibration-in-the large which indeed 
was near equal to zero. The slope suggests smaller predictor-outcome associations 
The model had similar discrimination and calibration in the CAST (AUROCC 0.71, 
slope 0.92 and intercept -1.31) and MAST-I trials (AUROCC 0.76, slope 1.39 and 
intercept 0.02). The calibration slope in MAST-I reflects the earlier follow-up (28 
days) when contrast to IST-1 and MAST-I. 
Table 6-10 Performance of six month death or dependence model in test set and CAST and 
MAST-I (over 20 imputed sets) 
 Data set 
Performance Measure Test data: 2587/4685 CAST: 3164/10080 MAST: 203/313 
% R2 (IQR) 28.58 (28.46 28.82) 17.14 (17.09 to 17.22) 24.93 (24.90 to 24.98) 
AUROCC 0.77 (0.76 to 0.78) 0.71 (0.70 to 0.72) 0.76 (0.70 to 0.81) 
Calibration    
Intercept -0.75 (-0.78 to -0.71) -1.31 (-1.34 to -1.29) 0.02 (-0.10 to 0.14) 
Slope 0.90 (0.87 to 0.93) 0.92 (0.89 to 0.94) 1.39 (1.19 to 1.59) 




6.4 Heterogeneity in treatment effect 
In this section, the predicted risk of early and late events is calculated for each 
patient in each of the three trials. Differences in incidence will be corrected using a 
simple updating procedure. Differences in the effect of aspirin on poor functional 
outcome will be explored on both the absolute and the relative scale. A single 
imputed set for missing values for each trial were used for practicality and 
interpretability; although a more rigorous approach would use each of the imputed 
datasets and pool the results. 
6.4.1 Recalibration and updating of prediction models 
Model calibration describes how accurately a given model estimates risk. Ideally 
predictions should closely match that which is observed. The three binary logistic 
regression models developed using the IST-1 dataset should, in principle, be suitable 
for use in new patients similar to those in the UK and Italian recruitment hospitals of 
the development set, i.e., similar baseline characteristics and outcome rates. In such 
instances these models should produce accurate predicted risks and may be described 
as well calibrated. However, it is evident from Table 6-4 that, for example, the 
incidence of thrombotic events differ from trial to trial (6.1%, 1.9% and 1.6% in IST-
1, CAST and MAST-I respectively). Some adjustment must therefore be made to 
enable sensible predictions for each patient within each trial. If not, all patients will 
have predicted risk estimates that match those seen in the development data which 
are known to not be representative of the other two trials. A simple re-calibration of 
the three binary logistic regressions intercepts was carried out adjusting for the 
differences in incidence between the development data and the new data (Janssen et 
al., 2009). This form of adjustment relates only to the estimated risk and does not 
affect the ordering of the patients. Thus, discrimination, a rank based measure, is 
unaffected. A correction factor is calculated from the incidence of the outcome in the 





















This correction factor (cf) can be interpreted as the log odds ratio of incidence and 
estimated risk. Adding this cf to the original model constitutes as updating the old 
model to the new local setting (Table 6-11). 
 
Table 6-11 Models recalibrated for IST-1, CAST and MAST-I. Note intervals provided are 
95%CIs 
Measure Thrombosis Haemorrhage Dead/dependent 
IST-1    
Correction factor (cf) 0.078 0.102 -0.313 
events/Total 628/9189 161/9183 5812/9189 
Calibration intercept 0.00 (-0.08 to 0.08) 0.00 (-0.15 to 0.16) -0.08 (-0.13 to -0.04) 
Calibration slope 0.68 (0.47 to 0.89) 0.71 (0.32 to 1.09) 0.94 (0.89 to 0.99) 
CAST    
Correction factor (cf) -1.105 -0.032 -1.135 
events/Total 206/10080 123/10092 3164/10080 
Calibration intercept -0.01 (-0.14 to 0.13) 0.00 (-0.18 to 0.18) -0.18 (-0.23 to -0.14) 
Calibration slope 0.81 (0.41 to 1.21) 0.42 (-0.08 to 0.92) 0.92 (0.87 to 0.97) 
MAST-I    
Correction factor (cf) -1.695 1.446 0.047 
events/Total 4/313 22/309 203/313 
Calibration intercept -0.01 (-0.99 to 0.98) 0.01 (-0.43 to 0.44) 0.02 (-0.27 to 0.22) 
Calibration slope 0.37 (-2.73 to 3.47) -0.88 (-2.08 to 0.33) 1.39 (1.00 to 1.79) 




6.4.2 Predicted risk of early events across the three trials 
Each patient’s risk from an early event was predicted using the two logistic 
regression models updated for each trial using the adjustment method given by 
equation (6.1). Figure 6-6 given below adequately captures all elements of this 
problem. For each trial patients predicted risk of haemorrhage and thrombosis were 
plotted. Due to the size of the IST-1 and CAST trials a simple random sample of 600 
patients (drawn from each of the trial totals) was used so as to aid visual 
interpretation. The plots that appear in the left hand column are of those patients on 
aspirin and the right hand column of those on control. The x and y-axes have 
different scales for each trial, reflecting the differences in early event rates. For 
example, in CAST the rate of thrombotic events was much lower than that seen in 
IST-1 explaining why the data scatter lies closer to the line of equality (dashed 
diagonal line) whereas for MAST-I there was a greater incidence of haemorrhage, 
thus the scatter falls below the line of equality. The grey vertical and horizontal lines 
highlight quarters of predicted haemorrhagic and thrombotic risk respectively. These 
were defined using the IST-1 trial with cut-points made at the 25th, the 50th and the 
75th percentiles. This categorisation was then applied in turn to each of the trials thus 
defining sixteen distinct strata of predicted risk. The sixteen strata were not filled 
equally by each of the trials, for instance, in MAST-I all patients fell within the strata 
comprising the upper haemorrhagic quarter and lower thrombotic quarter. Patients 
were plotted as dark grey if dead or dependent by the end of follow-up. The 
difference in follow-up was therefore captured in the CAST plots as incidence of 
death or dependency was about half of that seen in IST-1 and MAST-I. This figure is 
of vital importance. It enables a visual representation of the problem in its entirety. 
The distribution of those dead or dependent across predicted risk is largely the same 
in each trial and each arm. Trials contribute evidence differently according to their 
predicted risks of early events, populating the sixteen strata to varying degrees. A 
correlation between predicted risk of thrombosis and haemorrhage can be seen in 
each of the plots highlighting that the identification of thrombotic events from 
haemorrhagic events is poor. Finally, there are no identifiable patterns of death or 
dependence across the sixteen defined risk strata nor are there any such patterns 





















































































































































Figure 6-6 Predicted risk of thrombosis vs. predicted risk of haemorrhage. Horizontal and 
vertical grey lines indicate quarters of risk. Grey points indicate patient dead or dependent and 




6.4.2.1 Meta-analysis of treatment effect within predicted risk strata 
The meta-analysis approach used pools together all of the information displayed in 
Figure 6-6. The absolute risk reduction of poor functional outcome within each of the 
sixteen risk groups for each trial was estimated. Brown and Prescott state that it is 
inadvisable to model random effects when the number of centres (trials) is anything 
less than five (Brown and Prescott, 2006). Each estimate was then pooled across the 
three trials using a fixed effects Mantel-Haenszel meta-analysis. Out of all sixteen of 
these risk strata there was only one occasion (see MAST-I scatter plots in Figure 6-6) 
where all three studies provided an observed ARR. It is again emphasised that for 
some of the risk strata estimates of absolute risk reduction in poor functional 
outcome were obtained from the IST-1 data only (Figure 6-7). 
Inspection of the 16 groups (Figure 6-7 above) suggests that there is no evidence that 
those with a high haemorrhagic risk and a low thrombotic risk experience any overall 
harm from treatment with aspirin, i.e., an excess of death or dependency on aspirin, 
nor was there evidence that those with a low haemorrhagic risk and high thrombotic 
risk benefited any more than the overall estimate of a reduction in absolute risk of 
poor functional outcome by 1%. In no risk group of haemorrhage or thrombotic 
events was the absolute reduction in poor functional outcome at final follow up 
statistically different from the overall estimate of 1%. Only one out of the sixteen 
pooled strata specific ARR estimates was based on IST-1, CAST and MAST-I data. 
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Haemorrhagic Thrombotic n/N ARR [95% C.I.]No. Studies
Quarters of Predicted Risk:
Overall 3 18126/39166  1.0 [ 0.1 , 1.9 ]
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6.4.2.2 Relative effect of aspirin by predicted risk of early events 
Predicted probabilities of patient risk from 14 day thrombosis and 14 day 
haemorrhage were calculated for all 39166 patients. These were fitted as continuous 
predictors within a binary logistic regression for the outcome ‘death or dependency’ 
at last follow-up and also within a proportional odds logistic regression modelling 
the full ordinal outcome scale of death or disability (defined in Table 6-2). For each 
of these models the predicted risks were introduced on the original predicted log 
odds scale. To enable a sensible biological interpretation of the interaction between 
risk of early events and treatment with aspirin, each of the predicted early outcome 
terms were centred on their respective means (Schielzeth, 2010). The table below 
describes the contribution of each covariate to the full model fit. An adjustment was 
made for trial which made the largest contribution to the model fit (binary and 
ordinal). This is likely due to the differences in follow-up between CAST and IST-1 
Table 6-4. Whilst the predicted risk of thrombosis and haemorrhage provided sizable 
contributions to each of the respective model fits, there was no evidence to support 
an interaction between these covariates and aspirin so far as separate two way 
interactions or three way interactions. 
For the binary LR fit aspirin appeared to reduce the odds of poor outcome although it 
was not statistically significant (OR 0.96 95% CI 0.92 to 1.01). The more sensitive 
proportional odds LR did demonstrate a statistically significant shift in the ordinal 
scale favouring better functional outcomes (OR 0.95 95% CI 0.91 to 0.99). 
Note that the exclusion of those patients randomised to streptokinase or high dose 






Table 6-12 Wald statistics for a binary LR (dead or dependent) and a proportional odds LR 
(across the ordinal functional outcome) modelling predicted risks from early events 
 Binary LR  Proportional Odds LR 
Factor χ2 d.f. P-value  χ2 d.f. P-value 
Predicted haemorrhagic risk (XH) 33.10 4 <0.0001  63.95 4 <0.0001 
All interactions 11.30 3 0.0102  52.44 3 <0.0001 
Predicted thrombotic risk (XT) 1436.09 4 <0.0001  1910.44 4 <0.0001 
All interactions 13.47 3 0.0037  54.68 3 <0.0001 
Aspirin 8.86 4 0.0647  13.37 4 0.0096 
All interactions 3.66 3 0.3006  4.42 3 0.2198 
Trial 3948.78 2 <0.0001  4826.65 2 <0.0001 
Interactions        
XH:XT 10.98 2 0.0041  50.92 2 <0.0001 
XH:Aspirin 1.27 2 0.5303  2.30 2 0.3159 
XT:Aspirin 3.35 2 0.1875  4.41 2 0.1102 
XH:XT:Aspirin 0.93 1 0.3356  0.86 1 0.3530 
Total Interaction 13.83 4 0.0079  54.68 4 <0.0001 





6.4.3 Absolute benefit or harm of aspirin across strata of 
predicted poor outcome 
Benefit from treatment can vary according to patients’ baseline outcome risk in the 
absence of treatment (Califf et al., 1997, Dorresteijn et al., 2011a, Dorresteijn et al., 
2011b). With a constant relative treatment effect it is expected that the absolute 
reduction it the risk of six month death or dependency varies with patient prognosis. 
To explore this using the aspirin trial datasets patients were grouped into deciles of 
increasing predicted risk of poor functional outcome as estimated by the model 
developed for six month death or dependency in section 6.3.3. For each trial the same 
simple updating procedure (equation (6.1)) was applied (Table 6-11) adjusting for 
the observed differences in incidence of death or dependency across the three trials. 
The benefit of recalibration is illustrated by comparing the updated calibration 
metrics in Table 6-11 with the original metrics presented in Table 6-10. After 
updating the calibration intercepts for IST-1 and CAST were no longer negative. 
This is because the mean predicted risk is set equal to the incidence observed in the 
new data. No difference was observed for MAST-I (correction factor of 0.047) likely 
reflecting the similarity between the development data (UK and Italian centres) and MAST-I 
(an Italian study). 
The IST-1 data was used to define the groups of predicted risk strata. For this 
analysis the predicted risk of death or dependency was categorised into deciles 
creating ten equal sized groups. The same grouping was then applied to the 
recalibrated predicted risks for CAST and MAST-I. Figure 6-8 plots the predicted 
risk of death or dependency if all patients were on control against the observed 
absolute risk difference. Each tenth was pooled using fixed effects meta-analysis. 
There was no suggestion that patients with higher predicted risk of poor functional 
outcome experienced any greater or lesser benefit from aspirin than the overall 
estimate of 1% (Figure 6-8). The theoretical relationship based on the relative effect 
of aspirin (OR of 0.94) and the predicted risk on control appears in the plot as a 
dashed black line with a positive slope. Note, a global test of additivity suggested 
that a single OR was reasonable (P-value = 0.8232). This theoretical relationship 




of poor outcome in the absence of treatment as predicted at baseline assuming a 
constant relative effect. Fitting a line through the deciles it is possible to test whether 
the theoretical relationship differs from this observed relationship. The fitted line has 
a slope of 0.01 (95% CI -0.04 to 0.06) were the assumption that the slope is equal to 
zero was not rejected (P-value = 0.6897). The theoretical relationship has a constant 
slope of 0.0566; an F-test was used to test whether the observed slope was 
significantly different from this. The P-value was 0.1655, so that the null hypothesis 
of no difference from the theoretical slope is supported by the data. Again, the 
exclusion of those patients randomised to streptokinase or high dose heparin made no 
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Figure 6-8 Meta-analysis of predicted risk of poor outcome (in tenths) across all three trials 





6.4.4 Relative effect of aspirin by predicted risk of death or 
dependency 
Logistic regression models were used to model functional outcome as both a binary 
outcome as well as an ordinal outcome. The predictors used were: the logit of the 
predicted risk from death or dependence; aspirin and an adjustment for trial. Note 
that as before, the predicted risk of death or dependency (introduced in the raw linear 
predictor format not as a probability, centred on its mean) was allowed to interact 
with aspirin. The importance of trial was considerably less when compared with what 
was observed in the early events model (Table 6-12) were the Wald statistic for trial 
was about three times that of the contribution of predicted thrombotic risk. In Table 
6-13 it can be seen that aspirin was significant (P-value = 0.0319 for binary LR and 
P-value = 0.0020 for POLR) and in neither case did the predicted risk of death or 
dependence interact with treatment. The effect of aspirin was estimated by both 
models as an OR of 0.95 (95% CI 0.92 to 1.00) and a common OR of 0.94 (95%CI 
0.90 to 0.97) for the binary LR and the POLR respectively. 
 
Table 6-13 Wald statistics for a binary LR (dead or dependent) and a proportional odds LR 
(across the ordinal functional outcome) modelling predicted risks from death or dependence 
 Binary LR  Proportional Odds LR 
Factor χ2 d.f. P-value  χ2 d.f. P-value 
Predicted death/dependence 5119.62 2 <0.0001  7841.61 2 <0.0001 
All interactions 0.11 1 0.7368  0.84 1 0.3588 
Aspirin 6.89 2 0.0319  12.44 2 0.0020 
All interactions 0.11 1 0.7368  0.84 1 0.3588 
Trial 4380.70 2 <0.0001  5715.43 2 <0.0001 
Predicted death/dependence: 
aspirin 
0.11 1 0.7368  0.84 1 0.3588 






In this chapter a stratified approach toward the treatment of acute ischaemic stroke 
patients with aspirin was explored. No differential treatment effects were identified 
amongst patients either when grouped by quarters of predicted risk from early events 
(thrombosis and haemorrhage) or when grouped by deciles of predicted baseline 
outcome risk (i.e., six month death or dependency). 
Only three trial datasets were used for this analysis, however, these three trials 
contribute the majority of the evidence of aspirin efficacy for acute stroke 
(Sandercock et al., 2008). The logistical efforts made in obtaining the patient data for 
the purpose of this chapter were not nearly as great as that which may be anticipated 
by other larger studies where the obtainment of many datasets from many trials is 
pursued. For instance an IPDMA investigating the prognostic risk factors of foot 
ulceration amongst those with diabetes allowed: three to six months for background 
and research; 12 months for data checking; and another three to six months for 
analysis and publication (Crawford et al., 2013). Similarly, summarising the findings 
from the International Mission for Prognosis and Analysis of Clinical Trials in TBI 
(IMPACT) consortium, Mass et al highlighted the merging of multiple datasets into 
one standardised stacked dataset as one of the main struggles (Maas et al., 2013). No 
doubt spurred on by a degree of exasperation in this lengthy process, some have even 
called for the creation of a central repository within which all datasets collected and 
collated for IPDMA projects could be stored; thus enabling easier access to the 
resources created by the hard work of others (Tudur Smith et al., 2014). Therefore it 
is well understood that obtaining individual datasets from each of the contributing 
studies is frequently time consuming and potentially costly. Cost-effectiveness 
should be discussed in larger IPDMA studies summarising whether the added effort 
and time required, beyond that of a standard meta-analysis based on aggregate data, 
is justified. Some comments are made regarding the IPD analysis of the aspirin trial 
data versus the standard meta-analysis based on aggregate results. 
First, it is noted that the same conclusion about the efficacy of aspirin was reached 




understand this consider the three most popular methods for a fixed effects meta-
analysis: Peto’s OR method; the Mantel-Haenszel method; and maximum likelihood 
estimation using logistic regression (Deeks et al., 2008). These different approaches 
will yield very similar results, for example, using each method on the data provided 
in Figure 6-4 part B the following estimates are obtained: 0.9483, 0.9484 and 0.9484 
respectively. The logistic regression approach can be understood as fitting a dummy 
variable for treatment (associated coefficient β1) and two dummy variables to adjust 
for trial (β2 and β3): 
02301210),|( TrialTrialAspirinTrialAspirinYG ββββ +++=  Model 1 
It is now obvious that the model fit in Table 6-12 is merely an extension of this 
simple model (Model 1) with the inclusion of: the predicted risk of haemorrhage; the 
predicted risk of thrombosis; their separate interaction with treatment; their joint 



















 Model 2 
Interactions between aspirin and predicted risk did not improve the model fit (χ2 of 
3.66, see Table 6-12) providing insufficient evidence to reject the null hypothesis 
that δ1 = δ2 = δ4 = 0. The model was, however, considerably improved by the 
inclusion of predicted risk from early events (Model 2 Likelihood ratio χ2 of 6359.13 
versus Model 1 Likelihood ratio χ2 of 3950.86). This had little impact on the estimate 
for the effect of aspirin (OR of 0.9613). It is evident then that it should in fact be 
anticipated that were there is no evidence of an interaction the IPDMA should at 
least reach the same conclusion as the aggregate result. This replication is therefore 
reassuring. 
Second, these findings may be mistakenly interpreted as a ‘failed result’. However, 
this would be a rather pessimistic conclusion to draw. Rothwell points out that even 




this may indicate that the treatment is more generalisable than previously anticipated 
(Rothwell, 2007b). Such findings can therefore be used to dissuade the 
undertreatment of certain patient groups otherwise thought at a greater risk of harm. 
Based only on the aggregate data it would not have been possible to have commented 




6.6 Appendix A: Sensitivity analyses 
It may be the case that by including those patients on heparin and streptokinase in 
IST-1 and MAST-I respectively could cause a dilution of the effect of aspirin. All of 
the analyses undertaken in this chapter were therefore repeated excluding those 
randomised to receive either low dose or medium dose heparin or streptokinase. 
The impact this had on the size of the trial data sizes was to reduce IST-1 from 18372 
to 9197 and MAST-I from 622 to 309. Note CAST contributes the same number of 
patients as before. The total size of the three trials together is then 29678 patients 
meaning that there is a 24% reduction in the sample size contrast with the sample 
used throughout this chapter. What follows is a table summarising these findings 
(Table 6-14) and the resulting output (Table 6-15, Table 6-16, Figure 6-9 and Figure 
6-10). 
Excluding these patients made no qualitative change to the findings compared to 
those made on all data. Accuracy was likely lost due to models being fit on fewer 
events. 
The composite early outcomes as defined in this chapter are heterogeneous. For 
instance the mechanism of deep venous thrombosis may differ from MI. Aspirin may 
have a differential effect on the reduction of the risk of occlusive arterial events and 
occlusive venous events. A sensitivity analysis is presented in Table 6-17 excluding 
venous events from the model presented in Table 6-6. This restriction made no 





Table 6-14 Summary of results from repeating all analyses in patients treated with aspirin or 
control only. 
Analysis Summary 
Models development The main impact this has is on the size of the data available 
for model development. This will have a impact on the 
estimation of parameters due to the small number of 
events 
I. Thrombotic model; effect sizes largely in the same 
direction, except for dysphasia which was negatively 
associated although not significantly. Delay from 
randomisation was also no longer significant. No 
new significant associations detected. 
II. Haemorrhagic model; effect sizes largely in the 
same direction, except for visuospatial disorder 
which was negatively associated although not 
significantly. Age was also no longer significant. No 
new significant associations detected. 
III. Death or dependence; effect sizes all in the same 
direction. Presence of brainstem/ cerebellar deficit 
now significant. 
Model performance Model performance was as poor, and with even fewer 
events the reliability of the estimated metrics is debatable. 
16ths of predicted 
risk 
Lower risk of haemorrhage noted. With less haemorrhagic 
events occurring in the MAST-I aspirin only subset the trial 
data contribute to more than one strata. No change in the 
conclusion though (see Figure 6-9) 
Baseline outcome risk Visual assessment of Figure 6-10 suggests that the best fit 
line through the deciles matches the theoretical slope 






Table 6-15 Sensitivity analysis: Multivariable prediction models for early events and late events with imputed IST-1 development data (over 20 imputed sets) 
 Thrombosis (153/2266)  Haemorrhage(18/2239)  Dead/dependent (1608/2266) 
Variable Coef (SE) P-value  Coef (SE) P-value  Coef (SE) P-value 
Intercept -5.119 (0.944) <0.0001  -4.650 (2.540) 0.0671  2.920 (1.870) 0.1184 
Age (per 10 years)         
Age 0.261 (0.092) 0.0046  -0.030 (0.239) 0.9004  -0.758 (0.380) 0.0459 
Age2 - -  - -  0.092 (0.029) 0.0014 
SBP (per 10 mmHg)         
SBP -0.023 (0.032) 0.4779  -0.055 (0.093) 0.5522  -0.341 (0.192) 0.0762 
SBP2 - -  - -  0.011 (0.006) 0.0699 
Delay from randomisation (hours) 0.001 (0.007) 0.8770  -0.016 (0.020) 0.4092  0.003 (0.004) 0.4445 
Sex (Male) 0.179 (0.176) 0.3090  0.723 (0.525) 0.1683  -0.346 (0.110) 0.0017 
Visible infarct on CT 0.278 (0.188) 0.1382  0.789 (0.515) 0.1252  0.097 (0.124) 0.4315 
Conscious (Drowsy/Coma vs. Alert) -0.105 (0.230) 0.6468  0.134 (0.625) 0.8304  1.559 (0.228) <0.0001 
Presence of atrial fibrillation 0.304 (0.206) 0.1408  0.560 (0.602) 0.3520  0.091 (0.162) 0.5764 
At least one or more of arm/leg deficits 0.570 (0.337) 0.0906  0.792 (1.070) 0.4591  0.854 (0.159) <0.0001 
Presence of dysphasia -0.014 (0.182) 0.9395  -0.983 (0.558) 0.0784  0.486 (0.113) <0.0001 
Presence of hemianopia 0.307 (0.264) 0.2447  0.401 (0.665) 0.5463  0.903 (0.205) <0.0001 
Presence of visuospatial disorder 0.054 (0.255) 0.8316  -0.311 (0.673) 0.6443  0.631 (0.190) 0.0009 




Table 6-16 Sensitivity analysis: model performance in IST-1 evaluation split. Measures pooled 









AUROCC 0.59 (0.55 to 0.63) 0.51 (0.39 to 0.64) 0.77 (0.75 to 0.79) 
Calibration    
Intercept 0.34 (0.26 to 0.41) -0.09 (-0.32 to 0.14) -0.75 (-0.78 to -0.71) 




Table 6-17 Sensitivity analysis: Multivariable prediction model for 14 day thrombotic events 
excluding DVTs (260/4504) 
Variable Coefficient (SE) OR (95% CI) P-value 
Intercept -4.529 (0.697) - <0.0001 
Age (per decade) 0.231 (0.069) 1.26 (1.10 to 1.44) 0.0008 
SBP (per 10 mmHg) -0.030 (0.025) 0.97 (0.92 to 1.02) 0.2191 
Delay from randomisation 
(hours) 
-0.009 (0.005) 0.99 (0.98 to 1.00) 0.0976 
Sex (Male) 0.244 (0.134) 1.28 (0.98 to 1.66) 0.0673 
Visible infarct on CT 0.373 (0.143) 1.45 (1.10 to 1.92) 0.0089 
Conscious (Drowsy/Coma 
vs. Alert) 
-0.031 (0.170) 0.97 (0.70 to 1.35) 0.8539 
Atrial fibrillation 0.127 (0.161) 1.14 (0.83 to 1.56) 0.4293 
At least one or more of 
arm/leg deficits 
0.303 (0.227) 1.35 (0.87 to 2.11) 0.1831 
Presence of dysphasia 0.104 (0.139) 1.11 (0.85 to 1.46) 0.4545 
Presence of hemianopia 0.043 (0.200) 1.04 (0.71 to 1.54) 0.8318 
Presence of visuospatial 
disorder 
0.106 (0.188) 1.11 (0.77 to 1.61) 0.5726 
Presence of brainstem/ 
cerebellar deficit 
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Haemorrhagic Thrombotic n/N ARR [95% C.I.]No. Studies
Quarters of Predicted Risk:
Overall 3 12188/29678  1.0 [ 0.1 , 1.9 ]
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Figure 6-10 Sensitivity analysis: meta-analysis of predicted risk of poor outcome (in tenths) across all three trials pooled using fixed-effects meta-analysis. 




Chapter 7: Benefits and harms from iv-rtPA in 
acute ischaemic stroke 
Background and summary 
It is unclear whether those at highest risk of symptomatic intracranial haemorrhage 
or poor functional outcome after acute ischaemic stroke benefit from treatment with 
intravenous rtPA. Using the IST-3 data, there was no evidence to suggest that those 
at a high predicted risk of intracranial haemorrhage or poor functional outcome 
should avoid rtPA. 
7.1 Introduction 
Thrombolytic treatments are a class of drugs used to dissolve blood clots and restore 
normal blood flow. Tissue plasminogen activator (tPA) is a naturally occurring 
thrombolytic which catalyses the conversion of inactive plasminogen into active 
plasmin, an enzyme responsible for clot breakdown (Collen and Lijnen, 2009). 
Recombinant tPA is a manufactured form of tPA (also known as rtPA or alteplase) 
and is one of the few known effective treatments for acute ischaemic stroke (Adams 
et al., 2007, Wardlaw et al., 2013). 
Between 1995 and 2012 the efficacy of rtPA was assessed across 12 separate trials 
randomising a total of 7012 acute ischaemic stroke patients to receive rtPA or a 
comparator (Wardlaw et al., 2012a). Two of these studies concluded that rtPA 
significantly reduced the odds of a poor outcome over that of control (National 
Institute of Neurological Disorders and Stroke, NINDS trial and the second 
European-Australasian Acute Stroke Study, ECASS-III) (The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, Hacke et al., 
2008). A meta-analysis conducted by Wardlaw et al. showed that rtPA was 
associated with a significant increase in the odds of a favourable outcome with 




Exactly who benefits has been an area of ongoing research (The Stroke 
Thrombolysis Trialists' Collaborative Group, 2013, Sandercock et al., 2011). One of 
the harmful side-effects of treatment with rtPA is an increase in the odds of 
Symptomatic Intracranial Haemorrhage (SICH) with an OR of 3.72 (95%CI 2.98 to 
4.64). A bleed into the brain is a catastrophic event which ultimately results in severe 
disability or death. Physicians are justifiably cautious when prescribing rtPA; this is 
reflected in the licence for its use. The current European licence for rtPA restricts its 
use to patients with: SBP <185mmHg; blood glucose ≤400mg/dl (22mmol/l); 
patients with small cerebral infarction; and moderate stroke severity (an NIHSS >4, 
but NIHSS <25) (The European Stroke Organisation Executive Committee, 2008). A 
key issue is the impact that delay from stroke onset to the administration of treatment 
has on the expected benefit. Evidence has suggested that an interaction exists 
between rtPA and the onset time to treatment (OTT) which favours the earliest 
administration of treatment to those eligible patients so as to ensure the largest 
beneficial effect from treatment (Lees et al., 2010). The current window of OTT for 
the North American licence is restricted to three hours from onset, whilst in Europe a 
maximum of four and a half hours is permitted. 
It is possible that those at high risk from SICH post rtPA or low risk from poor 
functional outcome may be harmed by treatment. A formalised strategy based on 
predictions is therefore a reasonable strategy to explore (Kent et al., 2010). Indeed 
prediction made by clinical prediction models may do better than the informal 
judgements made by clinicians. In this chapter, the use of clinical prediction models 
for SICH post rtPA will be reviewed using data from the third International Stroke 
Trial (IST-3): the largest trial of rtPA in acute ischaemic stroke patients. A 
framework for treating patients with rtPA will be explored based on their predicted 
risk of post rtPA SICH or poor functional outcome. The aims of this chapter are 
threefold: (i) to evaluate the performance of existing models; (ii) to develop a new 
model in IST-3 adopting a more rigorous statistical methodology; and (iii) to 
investigation whether those at high predicted risk of SICH or low risk of poor 




7.2 Data and definitions 
7.2.1 The third International Stroke Trial (IST-3) 
The third International Stroke Trial (IST-3) was a pragmatic, international, 
multicentre, randomised-controlled, open-treatment trial of intravenous rtPA in acute 
ischaemic stroke (The IST-3 collaborative group, 2012a). The active treatment was 
given at a dose of 0.9 mg/kg with 10% administered as a single dose with the 
remaining amount given over a one hour period. All patients had planned follow-up 
of six months – though some contributing countries had a longer follow-up period of 
18 months as part of a pre-planned secondary objective assessing the long term 
impact of rtPA (The IST-3 collaborative group, 2013). 
The IST-3 trial was designed to assess the benefits and harms of rtPA within a wider 
patient population than had been previously tested for thrombolysis treatment; this 
meant that the majority of those recruited to IST-3 did not meet the license criteria 
for treatment with rtPA (Sandercock et al., 2011). No upper age limit was set and a 
wider window of onset time to treatment was allowed of up to six hours. The primary 
outcome was the proportion of those alive and independent at six months as 
measured on the Oxford Handicap Scale (OHS). This was defined both as a 
dichotomy with an OHS≥3 as a poor outcome as well as on the original ordinal scale 
(The IST-3 collaborative group, 2012b). Minimisation was used to randomise those 
recruited. This is a dynamic method of randomisation which ensures balance 
between two treatment arms with respect to pre-specified patient characteristics 
(Senn, 2007). The minimisation algorithm had an allocation probability of 0.8 and 
balanced on: region; age; sex; NIHSS; treatment with antiplatelet in previous 48 
hours; and stroke clinical syndromes. Patients were recruited from May 2000 till July 
2011 from 12 countries and 156 centres. A total of 3035 patients were randomised to 
receive recombinant tissue plasminogen activator (rtPA) plus standard care or 
standard care alone. Patients were enrolled into the trial using the uncertainty 
principle meaning that both the treating physician and the patient (or a proxy) felt 
that the benefit of rtPA was promising but unproven. Patients were eligible provided 
that: they had symptoms and signs of clinically definite acute stroke; that the onset 




within 6 hours of the index stroke; and that an intracranial haemorrhage or mimic 
stroke (e.g., cerebral tumor) could be reliably excluded using a scan (e.g., on CT or 
MRI). Complete six-month follow-up was achieved. There was no significant 
difference in the effect of treatment on the binary categorisation of the OHS (with a 
P-value of 0.181) though there was a significant shift which favored treatment with 
rtPA over standard therapy alone (with a P-value of 0.001). 
The reporting of the IST-3 was completely transparent with the study protocol 
(Sandercock et al., 2011) and the statistical analysis plan (The IST-3 collaborative 
group, 2012b) published prior to any analysis. 
7.2.2 Defining patient characteristics and outcomes  
Baseline data were collected either through a voice-activated telephone line, or else 
using a secure website system. Biologically implausible values were flagged up as 
and when they arose. Specific attention was given to the way in which brain scans 
were carried out. This is discussed later in this chapter. Symptomatic Intracranial 
Haemorrhage (SICH) by seven days was defined in the IST-3 protocol as:  
“… clear evidence of significant intracranial haemorrhage on 
the post-randomisation scan (or autopsy if not re-scanned and 
death occurs after 7 days). Significant haemorrhage is present 
on any post-randomisation scan if the expert reader gives any 
response to Question 22 other than a blank value or 'Petechial 
haemorrhage' (i.e. significant HTI, parenchymal haematoma, 
etc) AND a response to Question 23 of ‘yes’, indicating that 
haemorrhage is a major component of the IST-3 lesion (or is 
remote from the lesion and likely to have contributed 
significantly to the burden of brain damage). This event 
includes clinical events described as a recurrent stroke within 
7 days, in which the recurrent stroke was confirmed to be due 
to an intracranial haemorrhage.” 
Functional outcome was recorded at six months for each patient using the Oxford 
Handicap Scale (OHS): a measure grading patients on an ordinal disability scale. The 
OHS ranges from 0 (recovered) in unit intervals to 6 (dead). The binary classification 




7.2.3 Sensitivity Analyses 
It was noted in the introduction that the size of the effect of rtPA is strongly related 
to the delay from stroke onset to receipt of treatment (Lees et al., 2010). The patients 
recruited as part of IST-3 could be randomised as late as six hours from stroke onset. 
All the analyses conducted in this chapter were therefore repeated amongst those 
receiving rtPA within four and a half hours as well as those treated after four and a 
half hours. Additionally, there are various definitions for haemorrhage. One 
alternative definition of haemorrhage was explored: parenchymal haemorrhage. 
Finally, a per-protocol analysis was conducted, restricting analysis to just those that 
adhered to the protocol specified by IST-3. 
7.3 Predicting post rtPA events 
A number of pre-existing models are now introduced. An extensive evaluation of 
their performance in the IST-3 dataset follows in section 7.3.4. 
7.3.1 Selection of pre-existing models 
A literature search was conducted from inception to 25th January 2013 (Dr 
Whiteley) for studies which had developed multivariable clinical prediction models 
for the prediction of intracranial haemorrhage or poor functional outcome in acute 
ischemic stroke patients treated with rtPA. Models were eligible if developed within 
a cohort of acute ischemic stroke patients, all of whom had been treated with rtPA, 
and reported a prediction model either as a score, or a model with constant and 
weighting for each of the covariates. Studies were identified using: an electronic 
search strategy; reference lists of relevant studies; forward searches from relevant 
studies with Google Scholar; and from personal files. The literature search identified 
797 publications of which 11 studies were relevant, reporting the development of 12 
models, nine of which could be applied using the IST-3 dataset (see Table 7-1 for an 
account of the variables included in each).  
All were derived as multivariable binary logistic regression models except for the 
HAT and the SPAN-100 scores which were derived using existing knowledge with 




7.3.2 Models for SICH 
7.3.2.1 The HAT score 
The Haemorrhage after Thrombolysis (HAT) score was developed by systematically 
reviewing risk factor studies (Lou et al., 2008). The authors used a selection criterion 
requiring that at least two studies supported the importance of a clinical risk factor 
associated with SICH post rtPA. Points where assigned based on the strength of the 
odds ratios reported. The authors evaluated their model in the NINDS trials group 
which suggested good discriminative ability with AUROCC values ranging from 
0.68 to 0.75 depending on how haemorrhage was defined. A recent study supported 
this finding with 0.70, 0.69 and 0.73 with SICH as defined by the National Institute 
of Neurological Disorders and Stroke (NINDS), the second European-Australasian 
Acute Stroke Study (ECASS II) and the Safe Implementation of Thrombolysis in 
Stroke-Monitoring Study (SITS-MOST) respectively (Sung et al., 2013). Strbian et 
al found a moderate level of discrimination in their data using the same definitions of 
SICH: 0.65, 0.65 and 0.64, whilst an evaluation by Cucchiara et al suggested a more 
conservative AUROCC of 0.59 (Cucchiara et al., 2011, Strbian et al., 2014). 
7.3.2.2 The SEDAN score 
The Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis (SEDAN) 
score was developed on 974 ischaemic stroke patients treated with rtPA within four 
and a half hours of stroke onset (Strbian et al., 2012a). Patients were recruited 
consecutively at several centers in Helsinki, Finland. Univariate screening (P-value 
<0.1) followed by backward stepwise selection (P-value <0.1) was used for predictor 
selection. The final score included five clinical risk factors. The authors presented an 
external evaluation which suggested good discrimination (AUROCC of 0.77) though 
a separate evaluation indicated a more moderate level of discrimination with an 
AUROCC of 0.60 where SICH was defined by SITS-MOST and 0.66 for ECASS-II 
(Mazya et al., 2013). Another study supported a higher level of discrimination that 
was little affected by the definition of SICH with AUROCC values of 0.69, 0.70 and 
0.69 with SICH as defined in NINDS, ECASS II and SITS-MOST respectively 




7.3.2.3 The SITS score 
The Safe Implementation of Treatments in Stroke (SITS) SICH risk score was 
developed within a large multinational registry of centers treating ischaemic stroke 
patients with thrombolysis (Mazya et al., 2012). A random 50:50 split meant that half 
were used in model development (15814) and the rest to evaluate model performance 
(15813). The score included nine statistically significant risk factors after a process 
of univariate screening (P-value ≤0.10) and screening for significance in a 
multivariable model fit (P-value <0.05). Discrimination was good with an AUROCC 
of 0.70. Sung et al. suggested that the SITS score achieved moderate discrimination 
with AUROCC values of 0.62, 0.61 ad 0.68 with SICH defined respectively 
according to NINDS, ECASS II and SITS-MOST (Sung et al., 2013). Strbian et al. 
found similar levels with AUROCC values of 0.61, 0.64 and 0.67 using the same 
definitions for SICH (Strbian et al., 2014). 
7.3.2.4 The GRASPS score 
The Glucose Race Age Sex Pressure Stroke Severity (GRASPS) score used data 
from the: Get with the Guidelines–Stroke (GWTG-Stroke) register (Menon et al., 
2012). The authors used 10242 patients and implemented a 70:30 split, developing 
the model on the majority of the data and using the remaining proportion for internal 
evaluation. Sung et al tested the discriminative ability of the GRASPS score in their 
prospectively collected hospital data and found AUROCC values of 0.62, 0.61 and 
0.63 when SICH was defined as according to NINDS, ECASS-II and SITS-MOST 
respectively whilst Strbian et al found an AUROCC of 0.67 irrespective of the way 
SICH was defined (Strbian et al., 2014, Sung et al., 2013). 
7.3.2.5 The SPAN-100 score 
The Stroke Prognostication using Age and NIH Stroke Scale (SPAN) index 
combined two common determinants of stroke prognosis as a rationale for predicting 
ICH and favorable outcome (mRS≤1) after treatment with thrombolysis (Saposnik et 
al., 2013b). The authors found that amongst those given rtPA, ICH rates for SPAN + 
ve patients were higher than those SPAN –ve patients (42% vs. 12%). Subsequent 
external evaluations of the SPAN-100 index have been disappointing with Sung et al 




NINDS, ECASS-II and SITS-MOST respectively with similar findings made by 
Strbian et al with AUROCCs of 0.55, 0.56 and 0.56 (Sung et al., 2013, Strbian et al., 
2014). 
7.3.3 Models for poor functional outcome 
7.3.3.1 The Stroke-TPI score 
The Stroke Thrombolytic Predictive Instrument (TPI) used randomised clinical trial 
data from five trials investigating the use of rtPA within six hours of stroke onset 
(Kent et al., 2006). The authors developed models for the prediction of mRS≤1 and 
mRS≥5. Predictor selection was carefully considered with the authors 
acknowledging the risk of overfitting and the inclusion of variables difficult to record 
in practice. A core set of important risk factors where used. Discriminative 
performance in an independent dataset was good (AUROCC of 0.77) as was 
calibration. An external evaluation by McMeekin et al. demonstrated the same level 
of discrimination (McMeekin et al., 2012). 
7.3.3.2 The DRAGON score 
The (hyper)Dense middle cerebral artery sign or early infarct signs on admission CT 
head scan, prestroke modified Rankin Scale score >1, Age, Glucose level on 
admission, OTT, and NIHSS (DRAGON) score was developed and evaluated on 
1319 consecutive rtPA treated acute ischaemic stroke patients seen at hospital in 
Helsinki, Finland (Strbian et al., 2012b). Variables were selected a priori and 
retained regardless of statistical significance. However, an additional 15 risk factors 
were not included since no statistical association was identified. Performance in 
external evaluation (333 patients) was good with an AUROCC of 0.80 (95% CI 0.74 
to 0.86). A subsequent study supported this discriminative performance (Strbian et 
al., 2013). 
7.3.3.3 The THRIVE score 
The Totaled Health Risks in Vascular Events (THRIVE) score was developed using 
data from two multicenter trial, the Mechanical Embolus Removal in Cerebral 




model was developed, although it was not clear how the authors chose risk factors 
for inclusion. 
7.3.3.4 A NIHSS/age model 
Kӧnig et al. developed a model within the Virtual International Stroke Trial Archive 
(VISTA) data base (König et al., 2008, Weimar et al., 2002). This model was used to 
explore subgroup effects in the IST-3 trial. It was developed to predict Barthel Index 






Table 7-1 Models for the prediction of post rtPA SICH and poor functional outcome. 
 Post rtPA SICH  Post rtPA poor outcome 
Variables HAT SEDAN SITS GRASPS SPAN-100  Stroke-TPI DRAGON THRIVE Kӧnig et al 
NIHSS • • • • •  • • • • 
Glucose • • • •   • • •  
Age  • • • •  • • • • 
Visible infarct on CT • •     • •   
Hyperdense artery on CT  •      •   
Systolic blood pressure   • •       
Prior hypertension   •      •  
Use of antiplatelets   •        
Weight   •        
Delay to rtPA   •     •   
Sex    •       
Ethnicity    •       




7.3.4 Model performance in IST-3 
All assessments of model performance were undertaken within those treated with 
rtPA in the IST-3 dataset. No imputation of missing data was undertaken. Similar 
risk factors were included in each of the models irrespective of the outcome they 
were developed to predict. It was anticipated that discriminatory ability would be 
similar whether using a model original derived to predict SICH to predict poor 
outcome and vice versa. Note that the AUROCC measure is a rank based measure 
and therefore unaffected by differences in baseline risk (i.e., contrasting the 
incidence of SICH post rtPA to poor functional outcome). 
7.3.4.1 Cohort comparability 
Patient baseline information was extracted from each of the development cohorts 
where possible from the original published articles (see Table 7-2, Table 7-3 and 
Table 7-4). Additional baseline information recorded but not included in the final 
model was also extracted in a bid to understand differences between the development 
cohorts and the IST-3 cohort. No baseline information could be extracted for the 
THRIVE model or the Kӧnig model (Flint et al., 2010, König et al., 2008). 
On average those recruited to IST-3 were older than most of those included in the 
development cohorts with a typically longer onset time to treatment, except for 
Stroke-TPI patients who had similar onset times to treatment. Stroke severity as 
measured using the NIHS score was broadly comparable, bar one exception, 
indicating that those in the SPAN-100 evaluation cohort suffered more severe strokes 
on average. Also, where reported, IST-3 tended to have a larger proportion of 






Table 7-2 Baseline characteristics of derivation cohorts for post rtPA SICH models (SEDAN and GRASPS) and one evaluation cohort (HAT) contrast with 
the IST-3 cohort. Rows in italics highlight variables not included in the final model. 
Risk factors Summary IST-3 HAT  Summary IST-3 SEDAN  Summary IST-3 GRASPS 
NIHS Score <15 (%) 64 52  Median (IQR) 11 (12) 10 (9)  <5 (%) 20 18 
 15-20 (%) 19 31  -  -  6-10 (%) 28 28 
 ≥20 (%) 17 17  -  -  11-15 (%) 20 21 
 - - -  - - -  16-20 (%) 18 18 
 - - -  - - -  >20 (%) 14 15 
Glucose level (mg/dl) >200 or DM (%) 6 3  Median (IQR) 7 (2) 7 (2)  <100 (%) 17 16 
 - - -  - - -  100-149 (%) 56 60 
 - - -  - - -  ≥150 (%) 18 23 
 - - -  - - -  Missing 9 - 
Age Mean (SD) 78 (12) 71 (17)  Median (IQR) 81 (14) 70 (17)  ≤60 (%) 10 27 
 - - -  - - -  61-70 (%) 12 20 
 - - -  - - -  71-80 (%) 23 25 
 - - -  - - -  >80 (%) 54 28 
CT appearance of infarct None (%) 61 77  Present (%) 41 34  - - - 
 <1/3MCA (%) 24 20  - - -  - - - 
 ≥1/3MCA (%) 15 3  - - -  - - - 
CT Hyper dense artery  - - -  Present (%) 25 19  - - - 





Table 7-2 Continued from previous page 
Risk factors Summary IST-3 HAT  Summary IST-3 SEDAN  Summary IST-3 GRASPS 
Systolic BP (mmHg) - - -  Median (IQR) 156 (31) 156 (31)  <120 (%) 6 8 
 - - -  - - -  120-149 (%) 33 33 
 - - -  - - -  150-179 (%) 44 39 
 - - -  - - -  ≥180 (%) 17 20 
Prior hypertension - - -  Present (%) 64 59  - - - 
Delay to rtPA (mins) - - -  Median (IQR)- 231 (117) 120 (68)  - - - 
Sex - - -  - - -  Male (%) 48 51 
Ethnicity - - -  - - -  Asian (%) NA 2 
ABBREVIATIONS: DM - Diabetes Mellitus; IQR - Interquartile Range; SD - Standard Deviation; NIHS - National Institutes of Health Stroke; CT - Computerised 





Table 7-3 Baseline characteristics of an evaluation cohort for the SPAN-100 model and the derivation cohort for the SITS model contrast with the IST-3 
cohort. Rows in italics highlight variables not included in the final model. Note that for these two models reported characteristics are split by defined strata, 
thus IST-3 has been summarised accordingly. 
 Summary  IST-3  SPAN-100  Summary  IST-3  SITS 






positive   SICH No SICH SICH No SICH 
NIHS Score Mean (SD) 9 (5) 20 (5) 14 (7) 24 (4)  Median (IQR) 15 (11) 11 (11) 14 (10) 12 (10) 
Glucose level (mg/dl) Mean (SD) 130 (46) 133 (39) 150 (79) 137 (43)  Median (IQR) 126 (54) 126 (36) 127 (56) 118 (39) 
Age Mean (SD) 74 (12) 87 (5) 65 (11) 81 (5)  Median (IQR) 81 (12) 81 (14) 74 (12) 69 (16) 
Visible infarct on CT Present (%) 38 50 29 52  Present (%) 54 40 37 22 
Systolic BP (mmHg) Mean (SD) 156 (24) 155 (24) 158 (28) 157 (25)  Median (IQR) 160 (31) 155 (31) 160 (25) 150 (30) 
Prior hypertension Present (%) 64 66 65 80  Present (%) 62 65 78 63 
Use of antiplatelets Aspirin (%) 44 53 34 40  Aspirin (%) 66 46 50 31 
 Heparin (%) 1 2 2 2  Clopidogrel (%) 5 5 5 4 
Weight (kg) Mean (SD) 74 (15) 66 (12) 78 (19) 71 (15)  Median (IQR) 70 (15) 70 (18) 79 (20) 75 (18) 
Delay to rtPA (mins) Mean (SD) 242 (71) 201 (70) 50 (65) 49 (33)  Median (IQR) 222 (110) 231 (117) 150 (56) 145 (53) 
ABBREVIATIONS: IQR - Interquartile Range; SD - Standard Deviation; NIHS - National Institutes of Health Stroke; CT - Computerised Tomography; BP - Blood Pressure; 





Table 7-4 Baseline characteristics of the derivation cohort for the Stroke-TPI model and the DRAGON score contrast with the IST-3 cohort. Rows in italics 
highlight variables not included in the final model. 
Risk factors Summary IST-3 Stroke-TPI  Summary IST-3 DRAGON  
NIHS Score Median (IQR) 11 (12) 12 (9)  Median (IQR) 11 (12) 9 (9)  
Glucose level Median (IQR) mmol/l 7 (2) 7 (3)  Median (IQR) 7 (2) 7 (2)  
Age Mean (SD) 78 (12) 66 (11)  Median (IQR) 81 (14) 69 (17)  
CT appearance of infarct - - -  Present (%) 41 31  
CT Hyper dense artery - - -  Present (%) 25 18  
Total ASPECTS Median (IQR) 12 (2) NA  - - -  
Systolic BP (mmHg) Mean (SD) 156 (24) 153 (20)  Median (IQR) 156 (31) 156 (31)  
Prior hypertension Present (%) 64 59  Present (%) 64 60  
mRS score >1, prestroke - - -  Present (%) 23 6  
Delay to rtPA (mins) Mean (SD) 231 (73) 235 (135)  Median (IQR) 231 (117) 118 (70)  
Sex Male (%) 48 55  Male (%) 48 55  
ABBREVIATIONS: IQR - Interquartile Range; SD - Standard Deviation; NIHS - National Institutes of Health Stroke; CT - Computerised Tomography; BP - Blood Pressure; 





Ideally the predicted risk of post rtPA SICH or poor functional outcome would equal 
that which is actually observed. Calibration graphs and estimates for the slope and 
intercept of the calibration line were used to explore how well each score predicted 
patient risk in IST-3. No re-calibration was undertaken for the analysis presented in 
Table 7-5, Figure 7-1 and Figure 7-2, meaning that the point of reference for each 
score was the risk originally observed in development or else a previous evaluation 
(as mentioned above in the case of HAT and SPAN-100). 
As pointed out in Chapter 4, models presented as risk scores offer a restricted insight 
into the calibration of a model. With a small number of identifiable predicted risk 
groups the estimated calibration metrics will be subject to poor accuracy when 
contrast with the original model (i.e., beta coefficients and intercept available). In 
this respect the figures shown below for those score models are of more value than 
the estimates in the tables. 
Models for SICH post rtPA were poorly calibrated in the IST-3 data. All models had 
a slope less than one suggesting that the weights associated with the risk factors per 
score were optimistically large. The HAT, SEDAN and SPAN-100 scores each had 
negative intercepts indicating a systematic over prediction of SICH risk post rtPA 
due to a higher observed rate of SICH in the development cohorts. The SITS and 
GRASPS scores had positive intercepts suggesting a systematic under prediction of 
the SICH risk.  
Models for poor functional outcome (OHS≥3) were well calibrated amongst the IST-
3 patients. The Stroke-TPI score was developed to predict a more severe functional 
outcome (mRS≥5, a common variant of OHS) so a systematic under prediction of 
mRS≥2 could be anticipated. If the outcome was fixed to OHS≥5 the intercept 
dropped to 1.22 (95% CI 1.09 to 1.34) and for an OHS of 6 the intercept dropped to 
0.37 (95% CI 0.23 to 0.51). The DRAGON, THRIVE and Kӧnig scores all had low 
calibration intercepts suggesting small systematic under prediction. Calibration 
slopes were close to one indicating that the weights associated with each risk factor 




Table 7-5 Calibration statistics of the five prediction scores for risk of SICH post rtPA and the 
risk of poor functional outcome (OHS≥3) post rtPA in the IST-3 dataset (N = 1515). 
Risk Score n/N  Intercept (95% CI)  Slope (95% CI) 
SICH models 
HAT 87/1365  -0.29 (-0.52 to -0.05)  0.39 (0.21 to 0.57) 
SEDAN 87/1365  -0.46 (-0.69 to -0.24)  0.53 (0.27 to 0.78) 
SITS 85/1357  0.98 (0.76 to 1.20)  0.76 (0.41 to 1.11) 
GRASPS 87/1365  0.28 (0.06 to 0.50)  0.62 (0.30 to 0.94) 
SPAN-100 102/1507  -1.35 (-1.55 to -1.14)  0.36 (0.11 to 0.61) 
Poor functional outcome models 
Stroke-TPI 856/1365  2.49 (2.37 to 2.62)  0.99 (0.87 to 1.11) 
DRAGON 855/1363  0.20 (0.07 to 0.33)  0.96 (0.84 to 1.08) 
THRIVE 955/1504  0.26 (0.15 to 0.37)  1.07 (0.91 to 1.23) 
























































































































































































































































Figure 7-2 Calibration graphs for risk of poor functional outcome (OHS≥3). Each plot shows the 






Previously developed models to predict SICH or poor functional outcome 
discriminated modestly between those with and those without an SICH with 
AUROCC values ranging from 0.56 to 0.65. Models for poor functional outcome 
post rtPA achieved moderate discrimination with AUROCC values ranging from 
0.66 to 0.88 (Table 7-6, Figure 7-3 and Figure 7-4). 
The AUROCCs of all models were similar (P-value ≥ 0.05) with the exception of the 
SPAN-100 score which achieved significantly lower discrimination with SICH (P-
value < 0.05) and significantly lower discrimination with poor functional outcome 






Table 7-6 Discrimination of models to predict intracranial haemorrhage and poor functional outcome after rtPA in IST-3 dataset. 
 Seven day SICH post rtPA  Six month poor functional outcome post rtPA 
 n/N AUROCC (95%CI) R2 (%)  n/N AUROCC (95%CI) R2 (%) 
SICH models       
HAT 87/1365 0.62 (0.56 to 0.68) 3.23  856/1365 0.71 (0.68 to 0.73) 19.66 
SEDAN 87/1365 0.62 (0.56 to 0.69) 3.48  856/1365 0.74 (0.71 to 0.76) 21.97 
SITS 85/1357 0.63 (0.58 to 0.69) 3.84  851/1357 0.66 (0.63 to 0.69) 8.87 
GRASPS 87/1365 0.63 (0.57 to 0.68) 2.90  856/1365 0.77 (0.74 to 0.79) 26.40 
SPAN-100 102/1507 0.56 (0.52 to 0.61) 1.26  957/1507 0.66 (0.64 to 0.68) 17.03 
Poor functional outcome models        
Stroke-TPI 87/1365 0.64 (0.58 to 0.69) 3.43  856/1365 0.80 (0.78 to 0.83) 33.95 
DRAGON 87/1363 0.65 (0.59 to 0.70) 4.25  855/1363 0.78 (0.76 to 0.81) 29.26 
THRIVE 101/1504 0.60 (0.55 to 0.66) 1.71  955/1504 0.76 (0.74 to 0.79) 20.60 
Kӧnig 102/1507 0.63 (0.58 to 0.68) 3.04  957/1507 0.80 (0.77 to 0.82) 32.33 


























ROC Curves for SICH
 



























ROC Curves for poor outcome (OHS 3-6)
 
Figure 7-4 Receiver Operating Characteristic (ROC) curves for poor functional outcome (OHS 





7.4 Model development 
The development of a novel prediction model in the IST-3 trial data is of interest as it 
is often argued that improvements in methodology could have an impact on 
performance (Royston et al., 2009). A complete case analysis is considered first with 
an exploration of missing data to follow. 
7.4.1 Predictor selection and model assumptions 
Predictor selection was defined a priori using a systematic review of risk factors 
associated with SICH post rtPA in acute ischaemic stroke patients (Whiteley et al., 
2012). This approach avoids the harmful effects of data dependent selection such as 
those associated with stepwise selection (see chapter 2 for a more detailed 
discussion). In brief, data-dependent selection methods have a tendency to over-fit 
model to data. A simple way of circumventing this is by pre-specifying a set of 
clinically important variables a priori to include regardless of their achieved 
statistical significance. Novel methods for estimating parameters in small studies, for 
example shrinkage of effect estimates using penalized maximum likelihood 
estimation exist and will be discussed later in this chapter (Steyerberg et al., 2001). 
The ratio of events per degree of freedom spent (the 10EPV rule, see Chapter 2) 
suggests that with 86 post rtPA SICH events observed, no more than nine parameters 
should be estimated under these data. This was used as an upper threshold placing a 
necessary limit on the number of parameters that could be reasonably estimated 
without compromising the model with over-fit estimates. The predictors included in 
the multivariable binary logistic regression were: age (per decade), NIHSS, glucose 
(mg/dl), prior hypertension, atrial fibrillation, prior use of anti-platelets, diabetes, 
leukoaraiosis and visible infarction on CT. These variables were selected from the 
systematic review by Whiteley et al. as variables associated with an increase in the 
risk of post rtPA SICH evidenced in multiple studies of patients treated with rtPA 
(Whiteley et al., 2012). Selection was conditional upon the availability of covariates 
recorded in the IST-3 dataset as well as the associated EPV. All continuous 
predictors entered the model in their original continuous form – categorising these 




functional form of the continuous predictors was assessed using restricted cubic 
splines (RCS), i.e., for age, NIHSS, and glucose, varying the number of knots over 3, 
4 and 5. The RCS function provides a versatile assessment of the relationship 
between outcome and predictor and was used to test how plausible a non-linear 
relationship was beyond that of the simple linear fit. The additivity assumption was 
assessed by comparing nested models with and without two-way interactions 
between the continuous variables and the binary variables: diabetes, visible infarct on 
CT, anti-platelets, leukoaraiosis, hypertension, and atrial fibrillation. This formally 
tests the hypothesis that each effect has a constant impact on the log odds of the risk 
from post rtPA SICH. Although the model χ2 was larger under the more complicated 
RCS fit (Figure 7-5), after penalizing for the additional parameters estimated this 
improvement was either removed or was more conservative (Table 7-7).  
There was insufficient evidence to support the inclusion of any two way interactions 
or any non-linear relationships with the log odds of SICH.  
The final model is provided in Table 7-8. Higher NIHS scores were associated with a 
statistically significant increase in the odds of SICH (1.06 with 95%CI: 1.03 to 1.09, 
P-value = 0.0005), as was prior anti-platelet use (2.15 with 95%CI: 1.32 to 3.50, P-
value = 0.0022). History of atrial fibrillation was associated with a significant 














Linear fit, χ2 15.01 and RCS fit, χ2 16.06

















Linear fit, χ2 0.75 and RCS fit, χ2 5.05


















Linear fit, χ2 5.48 and RCS fit, χ2 11.22








Figure 7-5 Transformations of NIHSS, age per decade and glucose in univariate analysis 





Table 7-7 Testing model assumptions for seven day SICH post rtPA model in the IST-3 dataset. 
  Seven day SICH post rtPA 
 Age (per decade) NIHSS Glucose (mg/dl) 
Additivity     
Diabetes -1.04 (0.3073) 0.40 (0.5291) 2.72 (0.0992) 
Visible infarct on CT -1.95 (0.1623) -1.42 (0.2341) 2.23 (0.1351) 
Antiplatelet 0.92 (0.3379 -1.65 (0.1996) -1.93 (0.1649) 
Leukoaraiosis -1.12 (0.2905) 1.41 (0.2351) 2.52 (0.1122) 
Hypertension -1.87 (0.1715) -1.68 (0.1954) -1.98 (0.1598) 
Atrial Fibrillation -1.29 (0.2559) -2.00 (0.1576) -0.03 (0.8522) 
Linearity    
Restricted cubic spline    
Three knots 2.68 (0.1017) -0.65 (0.4204) -0.57 (0.4488) 
Four knots 0.83 (0.6602) -2.42 (0.2976) -1.27 (0.5297) 
Five knots -1.01 (0.7990) -4.32 (0.2286) 0.33 (0.9553) 
Square term 2.06 (0.0439) -0.33 (0.1962) -1.15 (0.3570) 
NOTE: The difference in AIC units contrasting a complex fit to a simple fit is provided 
alongside the P-value for the associated LR test. Positive AIC on the chi-squared 




Table 7-8 Multivariable logistic regression model for seven day risk of SICH post rtPA based on 
complete case data (86/1361). 
Variable Coefficient (SE) Wald OR (95% CI) P-value 
Intercept -4.461 (0.929) -4.80 - <0.0001 
Age (per decade) -0.013 (0.116) -0.11 0.99 (0.79 to 1.24) 0.9102 
NIHSS 0.057 (0.017) 3.47 1.06 (1.03 to 1.09) 0.0005 
Glucose (mg/dl) 0.005 (0.002) 1.92 1.00 (1.00 to 1.01) 0.0553 
Prior Hypertension -0.121 (0.251) -0.48 0.89 (0.54 to 1.45) 0.6297 
Atrial Fibrillation -0.551 (0.267) -2.06 0.58 (0.34 to 0.97) 0.0392 
Visible infarct on CT 0.228 (0.239) 0.95 1.26 (0.79 to 2.01) 0.3404 
Anti-platelet  0.764 (0.249) 3.06 2.15 (1.32 to 3.50) 0.0022 
Diabetes 0.089 (0.352) 0.25 1.09 (0.55 to 2.18) 0.8005 




7.4.2 Missing data 
The handling of missing data in this analysis was primarily a sensitivity analysis. If 
the results of a complete-case analysis did not differ qualitatively from that of an 
analysis based on imputation then the complete-case data would be favored for its 
simplicity. Indeed under a complete-case analysis only 10% of those treated with 
rtPA were excluded (Table 7-8). For a clinical audience a complete-case model 
would be easier to accept. The extent of missingness was small amongst those risk 
factors known to be associated with post rtPA SICH which, with the exception of 
blood glucose, were either completely observed or had fewer than 1% missing (Table 
7-9). Blood glucose was not recorded for the first 283 patients entering the trial and 
can therefore be assumed to be Missing At Random (MAR). 
Of those missing variables listed in Table 7-9, 1945 (64%) patients had completely 
observed data, 403 (13%) had one missing observation, 406 (13%) had two missing 
observations, 139 (5%) had three missing observations whilst fewer had multiple 
missing values. The maximum number of missing observations per patient was eight, 
of which there was only one. A cluster plot was used to visualize joint missingness 
(Figure 7-6). Impairments caused by the initial stroke were often jointly missing and 
along with blood glucose and prior use of warfarin and/or heparin, contributed the 
majority of missingness. Ascertainment of patient data was good. The imputation 
model used all of those variables listed in Table 7-9. The Missing At Random 
(MAR) mechanism could be assessed in part using logistic regression. Indicator 
variables for missing values for each variable with missing data where used to 
establish to what extent missingness could be described by the observed values 
amongst the other predictors. Explained variation ranged from 53% for weakness in 
leg after stroke to 4% for other deficits suggesting that values were therefore at least 
partly missing at random and that a multiple imputation approach could reduce the 
risk of bias. The model based on complete-case data was compared to the model 
averaged over 50 imputations. This made little material difference to the magnitude 
or direction of the estimates (beta coefficients shown in Figure 7-7) or the variation 
explained (Nagelkerke’s R2 in MI fit 7.15%, and CC fit 6.94%). For ease of 




Table 7-9 Baseline characteristics of IST-3 patients. The median and IQR is provided for 
continuous variables and the frequency and percentage for categorical variables. 
 rtPA (N=1515)  Control (N=1520) 
Characteristic Measure Missing  Measure Missing 
Prediction model variables      
Age, years 81 (72-86) 0 (0)  81 (71-86) 0 (0) 
NIHSS 11 (6-18) 0 (0)  11 (6-17) 0 (0) 
Blood glucose (mg/dl) 126 (108-144) 142 (9)  126 (108-144) 141 (9) 
Prior hypertension 975 (64) 2 (<1)  979 (64) 6 (<1) 
Atrial Fibrillation 473 (31) 0 (0)  441 (29) 0 (0) 
Visible infarct on CT 628 (41) 0 (0)  604 (40) 0 (0) 
Taking antiplatelets 775 (51) 4 (<1)  787 (52) 7 (<1) 
Diabetes 184 (12) 2 (<1)  204 (13) 2 (<1) 
Presence of leukoaraiosis 765 (50) 8 (1)  782 (51) 10 (1) 
Additional variables      
Gender, male 733 (48) 0 (0)  732 (48) 0 (0) 
Weight (kg) 70 (62-80) 0 (0)  70 (60-80) 0 (0) 
Systolic BP (mmHg) 156 (140-170) 0 (0)  155 (140-170) 0 (0) 
Diastolic BP (mmHg) 80 (71-91) 12 (1)  80 (72-90) 7 (<1) 
Delay from randomisation (hours) 3.8 (2.9-4.8) 0 (0)  3.9 (2.9-4.8) 0 (0) 
Prior stroke or TIA 354 (23) 3 (<1)  345 (23) 2 (<1) 
Taking warfarin or heparin 50 (3) 149 (10)  44 (3) 149 (10) 
Imaging variables      
Hyperdense artery 376 (25) 8 (1)  359 (24) 10 (1) 
Deficits caused by stroke      
Weakness in face 1255 (83) 12 (1)  1267 (83) 15 (1) 
Weakness in arm 1300 (86) 4 (<1)  1322 (87) 6 (<1) 
Weakness in leg 1189 (78) 10 (1)  1208 (79) 13 (1) 
Presence of dysphasia 775 (51) 39 (3)  809 (53) 26 (2) 
Presence of hemianopia  588 (39) 226 (15)  576 (38) 251 (17) 
Visuospatial disorder 550 (36) 282 (19)  532 (35) 329 (22) 
Brainstem signs 106 (7) 105 (7)  132 (9) 117 (8) 
Other deficits 173 (11) 96 (6)  176 (12) 90 (6) 
ABBREVIATIONS: NIHSS - National Institutes of Health Stroke Scale; BP - Blood 
Pressure; mmHg - millimeter of mercury; mg/dl – milligram per deciliter; kg – 


















































































































































































































































































Complete case Multiple Imputation (m=50)
 
Figure 7-7 Comparison of two models in the IST-3 data for the prediction of post rtPA SICH: complete-case (dark grey) versus imputation across 50 imputed 




7.4.3 The added predictive value of brain imaging variables 
The use of novel brain imaging techniques may improve the prediction of SICH 
(Whiteley et al., 2012). The IST-3 protocol stipulated that prior to randomisation all 
patients must have received a brain scan so as to exclude any haemorrhagic strokes. 
Additional scans were taken between 24 and 48 hours from randomisation 
(Sandercock et al., 2011). The preference was for a computed tomography (CT) scan 
of the entire brain, though if not possible then magnetic resonance (MR) imaging 
could be used provided the radiological support was available to interpret the 
obtained scans. 
A sub-study within IST-3 was devised to evaluate novel techniques or scores for 
brain imaging. The aim was to assess how perfusion and angiographic imaging using 
CT or MRI may be used in selecting those patients most likely to benefit from 
treatment with rtPA (Wardlaw et al., 2012b). Specifically, the identification of dense 
arteries or substantial changes in white matter may help avoid treating those likely to 
suffer harm from rtPA. Cerebral perfusion describes the flow of blood throughout the 
vascular network in the brain; a CT or MRI has the potential to determine the amount 
of tissue that remains at risk (Petrella and Provenzale, 2000). The Alberta Stroke 
Program Early CT (Computed Tomography) score (ASPECTS) is a ten-point scoring 
system which aims to improve the reliability of ischaemic change in the middle 
cerebral artery (MCA) as identified through CT (Pexman et al., 2001). Here a lower 
score is associated with a worse prognosis. Previous studies have suggested an 
association with an increased risk from SICH (Puetz et al., 2009). 
The total ASPECTS score was associated with SICH post rtPA (OR 0.90 with 95% 
CI: 0.83 to 0.97 and P-value = 0.0053) at the univariate level in the IST-3 data. When 
this was adjusted for those predictors used in the multivariable model (Table 7-8) the 
association was no longer significant (OR 0.96 with 95% CI: 0.85 to 1.07 and P-
value = 0.4524). The AUROCC statistic increased only slightly by 0.003 (P-value = 
0.4343) and the Nagelkerkes R2 by 0.11%. Similar findings were made for the 
presence of hyperdense arteries with regards to: association (univariate OR 1.86 




0.83 to 2.47) with P-value = 0.2014); discrimination (difference in AUROCC of 
0.006, P-value = 0.3720); and the variation explained (difference in Nagelkerkes R2 
of 0.31%). 
Reclassification metrics were used to examine the utility of scan measurements to 
classify patients (Pencina et al., 2008). These were introduced in Chapter 2. Strata of 
risk were defined and reclassification tables produced. These were supplemented by 
the categorised NRI. Low (<3%), medium (3 to 8%), and high (>8%) risk categories 
of SICH risk were defined by surveying the thresholds reported in previous studies 
and using the means of these thresholds. Reclassification plots were produced and 
supplemented by the continuous NRI thus exploring the case where no thresholds are 
defined (Pencina et al., 2011). 
For total ASPECTS (Table 7-10), the net-reclassification amongst events (N = 86) 
was +2.33% but was not statistically different from zero (P-value = 0.6543) with 
only three patients (3/86) correctly reclassified at greater risk and one (1/86) at lower 
risk. Amongst non-events (N = 1275) the net-reclassification was -0.31% which was 
also not statistically different from zero (P-value = 0.5862), here, 25 patients 
(25/1275) incorrectly moved up to a greater risk category whilst 29 (29/1275) 
correctly moved down. The total NRI was 0.0264 (95% CI: -0.0206 to 0.0733 with 
P-value = 0.2706). 
For visible hyperdense arteries (Table 7-11), the net-reclassification amongst events 
was +1.16% which was not statistically different from zero (P-value = 0.3145) with 
three patients (3/86) correctly reclassified at greater risk and two (2/86) incorrectly 
classified as lower risk. Amongst non-events the net-reclassification was 0% since 55 
patients (55/1275) incorrectly moved up to a greater risk category whilst 55 
(55/1275) correctly moved down. The total NRI was 0.0116 (95% CI: -0.0418 to 





Table 7-10 Reclassification table for the predicted probabilities with and without the imaging 
variable, total ASPECTS. NRI was 0.0264 (95% CI: -0.0206 to 0.0733, P-value= 0.2706). 
Model without ASPECTS  Model with ASPECTS  
Frequency (Row %)  < 3 % 3 to 8 % > 8 % Total 
Participants who experience a SICH event   
< 3 %  5 (71) 2 (29) 0 (0) 7 (8) 
3 to 8 %  0 (0) 38 (97) 1 (3) 39 (45) 
> 8 %  0 (0) 1 (2) 39 (98) 40 (47) 
Total  5 (6) 41 (48) 40 (47) 86 
      
Participants who did not experience a SICH event   
< 3 %  269 (95) 15 (5) 0 (0) 284 (22) 
3 to 8 %  10 (1) 677 (97) 10 (1) 697 (55) 
> 8 %  0 (0) 19 (6) 275 (94) 294 (23) 
Total   279 (22) 711 (56) 285 (22) 1275 
Note: dark grey shaded area indicates movement in the correct direction whilst 
light shaded area indicates movement in the wrong direction 
 
Table 7-11 Reclassification table for the predicted probabilities with and without the visible 
hyperdense arteries. The NRI was 0.0116 (95% CI: -0.0418 to 0.0651, P-value= 0.6698). 
Model without hyperdense arteries  Model with hyperdense arteries  
Frequency (Row %)  < 3 % 3 to 8 % > 8 % Total 
Participants who experience a SICH event   
< 3 %  7 (100) 0 (0) 0 (0) 7 (8) 
3 to 8 %  0 (0) 36 (92) 3 (8) 39 (45) 
> 8 %  0 (0) 2 (5) 38 (95) 40 (47) 
Total  7 (8) 38 (44) 41 (48) 86 
      
Participants who did not experience a SICH event   
< 3 %  260 (92) 24 (8) 0 (0) 284 (22) 
3 to 8 %  20 (3) 646 (93) 31 (4) 697 (55) 
> 8 %  0 (0) 35 (12) 259 (12) 294 (23) 
Total   280 (22) 705 (55) 290 (23) 1275 














Risk without total ASPECTS








Continuous NRI = -0.236
w ith 95% CI -0.455 to -0.018















Risk without hyperdense arteries








Continuous NRI = 0.202
w ith 95% CI -0.016 to 0.421
and P-value = 0.0692
 




A more flexible assessment of reclassification is provided by the continuous NRI 
which does not impose any pre-specified, and potentially arbitrary, risk categories, 
but instead quantifies any upward or downward movement in risk (Pencina et al., 
2011). This is demonstrated in Figure 7-8. 
For total ASPECTS the continuous net-reclassification for SICH was -11.60% (95% 
CI: -3.28% to +9.51%) with a P-value of 0.2810 and for no SICH was -12.00% (95% 
CI: -17.50% to -6.51%) with a P-value <0.0001. For the presence of hyperdense 
arteries the continuous net-reclassification for SICH was -20.90% (95% CI: -42.07% 
to +0.21%) with a P-value of 0.0523 and for no SICH was +41.20% (95% CI: 
+35.69% to +46.67%) with a P-value <0.0001.  
A detailed discussion was provided in Chapter 2 outlining the many concerns that are 
associated with these NRI statistics. In particular the continuous NRI which 
attributes equal weight to any movement in classification. It is likely that this will 
give undue importance to small shifts amongst those at low risk resulting in a larger 
NRI value which is void of any meaningful interpretation. 
If an added predictor is not significant when assessed by a simple LR test then 
ultimately any exploration of reclassification is futile (Cook, 2007). Using the LR 
test it was found that the inclusion of total ASPECTS did not correspond to a 
significant improvement in the model chi-squared (a gain in model χ2 of 0.56 with a 
P-value of 0.4557). Similarly with the presence of hyperdense arteries there was little 





7.4.4 Shrinkage of regression coefficients 
Maximum likelihood (ML) estimation tends to overstate the evidence provided by 
small data sets producing an optimal fit that is unlikely to generalise well. By 
shrinking the estimated coefficients the model may have better application post 
development (Steyerberg et al., 2001). A heuristic estimate of shrinkage can be used 










=  (7.1) 
For the SICH model given in Table 7-8 the model χ2 was 35.97 with nine degrees of 
freedom, it is expected that 25% of this fit was noise. This model is unlikely to 
perform well in new data. The Penalised Maximum Likelihood (PML) estimation 
method implements an active shrinkage of regression coefficients during estimation 
with a dynamic penalty (Steyerberg, 2009). 
 βλβ PlPML T
2
1ˆ −=  (7.2) 
Where λ is the penalty factor, β is the vector of estimated predictor effects (which 
excludes the intercept), βT is the transpose of β and P is a non-negative penalty 
matrix which, for k estimated parameters, can be set as the diagonal matrix of the k 
variance estimates, i.e., )ˆ,,ˆ,ˆ( 222
2
1 kdiag σσσ L . It is noted that if the penalty factor is 
set equal to zero then the standard log likelihood is used. Also, since the expression 
0.5 λβT P β is non-negative, the PLM will always be less than l̂ provided that λ>0. 
Choosing an optimal value for λ is undertaken by maximising a modified version of 
the Akaike’s Information Criterion (AICc). The AICc is used because it corrects for 















Where df effective is the effective degrees of freedom and n is the size of the sample. 
The effective degrees of freedom describe the reduction in variance achieved when 
moving from standard ML estimation to PML estimation and is given by, 
 )]()([ ββ CovItrdfeffective = .  
Where I(β) is the information matrix, or Fisher’s information, calculated without 
penalty (the expected value of the second derivative of the log likelihood) and Cov(β) 
as the inverse of I(β) calculated with penalty (note: in linear algebra tr[·] denotes the 
trace of a matrix which is simply the sum of the on-diagonal values). By varying λ 
across a fine grid of values an optimal value which maximises the AICc can be 
obtained (shrinkage of the model presented in Table 7-8 yields a maximised AICc of 
20.99 with a penalty of 19.35). 
The model presented in Table 7-12 will be used as the novel model and will be 
referred to as the IST-3 model. 
 
Table 7-12 PML multivariable logistic regression model for 7 day risk of SICH post rtPA based 
on complete case data (86/1361). 
Variable Coefficient (SE) Wald OR (95% CI) P-value Penalty 
Intercept -4.203 (0.796) -5.28 - <0.0001 0.00 
Age (per decade) 0.005 (0.095) 0.05 1.00 (0.83 to 1.21) 0.9617 5.26 
NIHSS 0.045 (0.014) 3.16 1.05 (1.02 to 1.08) 0.0016 31.29 
Glucose (mg/dl) 0.004 (0.002) 1.89 1.00 (1.00 to 1.01) 0.0584 192.54 
Prior Hypertension -0.041 (0.196) -0.21 0.96 (0.65 to 1.41) 0.8337 3.11 
Atrial Fibrillation -0.304 (0.120) -1.52 0.74 (0.50 to 1.09) 0.1290 3.11 
Visible infarct on CT 0.186 (0.190) 0.98 1.20 (0.83 to 1.75) 0.3291 3.11 
Anti-platelet  0.482 (0.191) 2.52 1.62 (1.11 to 2.36) 0.0116 3.11 
Diabetes 0.064 (0.236) 0.27 1.07 (0.67 to 1.69) 0.7849 3.11 





7.4.5 Model performance: internal evaluation 
With only the IST-3 data available to evaluate performance an internal evaluation 
using repeated bootstrap sampling (150 replicates) was followed. This expressed the 
likely performance of the ML SICH post rtPA fit and the PML fit. The estimates of 
performance obtained through internal evaluation correct for the optimism expressed 
when evaluating the model in the original data (apparent performance). The 
AUROCC for the PML fit suggested moderate discrimination (Table 7-13) which 
was slightly more conservative (0.65) than the apparent performance (0.68). Note 
that as of yet there is no agreed method for obtaining confidence intervals for 
estimates obtained from internal evaluation in this way. 
 
Table 7-13 Internal evaluation of IST-3 model (Table 7-12) in 150 bootstrap replicates. 
 Apparent Training Test Optimism Optimism corrected 
Standard ML model      
Nagelkerkes R2 (%) 6.940 9.283 5.674 3.609 3.331 
AUROCC 0.688 0.712 0.670 0.042 0.646 
Slope 1.000 1.000 0.787 0.213 0.787 
Intercept 0.000 0.000 -0.511 0.511 -0.511 
PML model      
Nagelkerkes R2 (%) 5.175 6.218 5.781 0.437 4.738 
AUROCC 0.685 0.699 0.670 0.029 0.646 
Slope 1.000 1.000 1.148 -0.148 1.148 





7.5 A stratified treatment approach for rtPA 
Having assessed the performance of pre-existing models and explored the potential 
for an increase in performance where more robust methods have been used in model 
development, the remainder of this chapter will explore the hypothesis that treatment 
effect varies according to predicted risk.  
7.5.1 Recalibration using a simple updating procedure 
Predictions were made for each patient recruited to the IST-3 using the prediction 
scores and models discussed in sections 7.3.2 and 7.3.3. If a full regression model 
was available with an associated intercept term then a simple updating procedure was 
used adjusting for the difference in incidence of the outcome between the data used 
in development and the IST-3 data (Janssen et al., 2009). This form of adjustment 
relates only to the estimated risk and does not affect the ordering of the patients; 
therefore, discrimination – a rank based measure – is unaffected. As noted earlier in 
Chapter 6, a correction factor is calculated from the incidence of the outcome in the 
new data and the mean predicted risk estimated by the model using equation (6.1). 
This correction factor (cf) can be interpreted as the log odds ratio of incidence and 
estimated risk. Adding this cf to the original model constitutes as updating the old 
model to the new local setting. Recalibration was possible for three of the ten 
models: the Stroke-TPI model; the Kӧnig model and the IST-3 model (see section 
7.8 Appendix B on page 240). Two of which were pre-existing models for the 
prediction of poor functional outcome and one which was developed on the IST-3 
data for the prediction of post rtPA SICH. Each therefore required updating for the 
incidence of post rtPA SICH and/or poor functional outcome (OHS≥3) specific to the 
IST-3 patients. Low, medium and high risk strata were defined separately for the 
predicted risk of SICH and for poor functional outcome by surveying those defined 
categories used by authors of previous models. The distribution of these strata varied 





Table 7-14 Total number within each model predicted risk strata (N, %) with associated number of poor outcomes (n, %). Note: in some cases risk strata 
were left undefined as no patients were classified by these models. This was due to a limited number of estimated categories available in some score models. 












(35 to 56%) 
High 
(>56%) 
HAT 581 (33)/1246 (46) 392 (23)/626 (23) 763 (44)/863 (32)  - - 1736 (100)/2735 (100) 
SEDAN 370 (21)/956 (35) - 1366 (79)/1779 (65)  - - 1736 (100)/2735 (100) 
SITS 832 (48)/1523 (56) 815 (47)/1099 (40) 75 (4)/93 (3)  - - 1722 (100)/2715 (100) 
SPAN-100 - - 1939 (100)/3017 (100)  - - 1939 (100)/3017 (100) 
GRASPS 206 (12)/649 (24) 1131 (65)/1657 (61) 399 (23)/429 (16)  - - 1736 (100)/2735 (100) 
Stroke-TPI 703 (40)/1574 (58) 496 (29)/603 (22) 537 (31)/558 (20)  282 (22)/903 (33) 389 (30)/630 (23) 1065 (48)/1202 (44) 
THRIVE - - 1934 (100)/3009 (100)  290 (15)/809 (27) 1039 (54)/1542 (51) 605 (31)/658 (22) 
DRAGON - - 1734 (100)/2732 (100)  123 (7)/506 (19) 547 (32)/1007 (37) 1064 (61)/1219 (45) 
Kӧnig model 731 (38)/1652 (55) 561 (29)/677 (22) 647 (33)/688 (23)  269 (14)/885 (29) 437 (23)/728 (24) 1233 (64)/1404 (47) 




7.5.2 Absolute risk reduction 
For each of the risk groups per model described in Table 7-14 a two by two table 
cross-classifying patient outcome (i.e., OHS<3 vs. OHS≥3) with treatment received 
(i.e., rtPA vs. control) was produced. The absolute risk reduction (ARR) was then 
calculated as the difference in the conditional probabilities for poor outcome in the 
control and in the treatment arms. Positive ARR values denote benefit whilst negative 
values denote harm. An estimate for the variance can be obtained to provide an 
asymptotic 95% CI. 
The following two figures (Figure 7-9 and Figure 7-10) illustrate the absolute 
estimated effect of rtPA according to strata of predicted risk from SICH and from 
poor functional outcome amongst the IST-3 patients. The size of each point is related 
to the proportion of patients categorised by a given model. 
In general, the ARR of poor functional outcome with rtPA was at its greatest favoring 
the active treatment amongst those patients with high predicted risk of SICH (Figure 
7-9) or high predicted risk of poor functional outcome (Figure 7-10). Under this 
categorisation there was no indication of significant harm amongst those with a 


























No patients classified by the SEDAN score
Low risk (<3%)
Medium risk (3 to 8%)
High risk (>8%)
Risk strata by model (n/N) Absolute risk reduction (%)
-15 0 15 30
1.40 [ -4.14 , 6.94 ]
2.57 [ -3.61 , 8.74 ]
3.01 [ -1.99 , 8.01 ]
0.64 [ -6.53 , 7.80 ]
-4.65 [ -15.29 , 5.99 ]
-0.64 [ -5.55 , 4.27 ]
0.05 [ -4.74 , 4.84 ]
1.99 [ -5.58 , 9.57 ]
-2.64 [ -7.81 , 2.53 ]
2.32 [ -2.16 , 6.80 ]
0.59 [ -3.83 , 5.00 ]
7.07 [ 0.98 , 13.16 ]
3.38 [ -2.28 , 9.04 ]
3.56 [ -0.69 , 7.81 ]
1.74 [ -2.18 , 5.67 ]
9.86 [ -6.18 , 25.90 ]
4.50 [ -0.29 , 9.29 ]
7.00 [ 1.72 , 12.27 ]
5.04 [ 2.00 , 8.07 ]
6.00 [ 2.51 , 9.50 ]
Overall effect (1939/3017)
Harm Benefit
1.53 [ -1.89 , 4.95 ]
 
Figure 7-9 Effect of rtPA on six month OHS≥3 stratified by predicted SICH risk. No patients 
were classified ‘medium risk’ by the SEDAN score. Point size is relative to the size of the 





















Medium risk (35 to 56%)
High risk (>56%)
Risk strata by model (n/N) Absolute risk reduction (%)
-30 -15 0 15
-20.00 [ -55.06 , 15.06 ]
-1.01 [ -7.06 , 5.04 ]
-4.75 [ -12.21 , 2.71 ]
1.89 [ -4.72 , 8.50 ]
-2.08 [ -8.15 , 3.98 ]
-3.16 [ -9.48 , 3.15 ]
2.32 [ -5.27 , 9.91 ]
2.50 [ -3.66 , 8.66 ]
0.55 [ -4.13 , 5.23 ]
2.25 [ -4.86 , 9.37 ]
3.85 [ 0.00 , 7.92 ]
5.08 [ 1.51 , 8.64 ]
5.02 [ 1.30 , 8.73 ]
4.78 [ 0.66 , 8.89 ]
5.46 [ 2.06 , 8.86 ]
Overall effect (1939/3017)
Harm Benefit
1.53 [ -1.89 , 4.95 ]
 
Figure 7-10 Effect of rtPA on six month OHS≥3 stratified by predicted poor functional outcome 





7.5.3 Relative risk reduction 
A more sensitive test for treatment interaction was explored by modelling the 
predicted risks directly within a logistic regression (with both binary and ordinal 
outcomes). The inclusion of an interaction term was assessed via a likelihood ratio 
test comparing the two nested models: one with the treatment by predicted risk 
interaction and one without. This formally tests whether or not rtPA acts additively 
with the log odds of poor functional outcome against predicted risk. An important 
clinical question is whether or not such an interaction can be classed as qualitative or 
quantitative. A qualitative interaction occurs where one group of patients in the trial 
suffer a qualitatively different treatment effect (e.g., harm) compared to another 
group (e.g., benefit) with regression slopes going in opposing directions (-ve vs. +ve) 
across predicted risk. 
The dichotomous classification of patients six month functional outcome was defined 
as an OHS≥3. The ordinal structure of the OHS was also utilised and interpreted as a 
5-level outcome collapsing levels 4 to 6 as per the original IST-3 publication (The 
IST-3 collaborative group, 2012a). This left levels 0, 1, 2, 3 and “4 to 6” as distinct 
categories whilst still maintaining an ordinal structure. This particular interpretation 
of the scale has both a clinical and a statistical justification. The clinical justification 
relates to the qualitative definition of the extent of disability a patient experiences 
with an OHS score of 4 or 5. Any treatment associated with an improvement at this 
end of the scale, e.g., moving a patient from an OHS score of 6 to an OHS score of 5, 
would not be worthwhile. The statistical justification relates to the proportional odds 
assumption which – under this grouping – becomes more tenable. 
Some of the identified prediction models (presented as risk scores) only quantified 
predicted risk at a group level. Those models which grouped the IST-3 patients into 
three or fewer risk strata levels were included as categorical variables. For those that 
gave a continuous prediction, or approximately continuous (i.e., >3 levels), the logit 
transformation was applied and the variable was fit as continuous. The proportional 
odds assumption was assessed using plots of the score residuals (see section 7.9 




broadly flat score residuals obtained for each of the included effects. An interaction 
between a continuous variable, X1, and a binary variable, X2, on the log odds scale 
can be interpreted as a difference in the estimated slope of X1 given the presence or 
absence of X2 (see Chapter 2). The additivity assumption is formally assessed in 
Table 7-15 with the corresponding interaction plots provided in section 7.9 Appendix 
C page 244. 
Under a proportional odds logistic regression (POLR) model only two out of the 10 
presented model fits demonstrated a statistically significant improvement at the 5% 
level when including the interaction term (i.e., the Kӧnig model and the IST-3 
model). Based on the improvement in the AIC alone interactions between treatment 
and those models originally derived to predict poor functional outcome post rtPA 
typically gave a better fit (i.e.: Stroke-TPI [∆AIC 0.83]; DRAGON [∆AIC 1.53]; and 
the Kӧnig model [∆AIC 2.22]) in contrast with those models originally derived to 
predict SICH post rtPA. This may be an artefact of the grouping of predicted risks 
though which will have caused a loss in precision. Inspection of the interaction plots 
(see section 7.9 Appendix C on page 244) illustrates that in each case the slopes 
favour greater benefit (i.e., smaller common ORs<1 for those with a higher predicted 
risk) which is arguably more quantitative as there is no indication of harm for those 
at low risk (i.e., no 95%CI with a lower limit greater than one). 
Under a binary logistic regression model five out of the 10 model fits suggested a 
statistically significant interaction at the 5% level. Again this favoured those models 
originally derived to predict post rtPA poor functional outcome with ∆AIC values 
ranging from 0.20 to 11.29 (Table 7-15). With reference to the plots provided in 
Appendix C (section 7.9 on page 244) some of these interactions where qualitative, 
notably: the Stroke-TPI score (Figure 7-24), the Kӧnig model (Figure 7-25) and the 
IST-3 model (Figure 7-26). Caution is stressed in their interpretation though. The 
POLR was adopted in this analysis as a more sensitive test, however, rather counter 
intuitively, in some instances the binary logistic regression model reached statistical 
significance where the POLR did not. To understand why this is it is important to 
acknowledge the differences in each approach. The POLR relies on the proportional 




estimates suggested under the POLR model fits are plausible. In this way the effects 
are common across all potential dichotomies and in some sense can be viewed as a 
reasonable average across each split. In the case of the binary logistic regression if 
other dichotomies are considered (i.e., OHS≥2, OHS≥4 etc.) the qualitative aspect of 
the interaction effect noted in the binary logistic regression models is attenuated 
considerably (see section 7.9 Appendix C Figure 7-27, note that only the Kӧnig 
model is presented for illustrative purposes). 
The results obtained under the POLR models point toward the same position reached 
in the absolute case. Those at low risk from either post rtPA SICH or poor functional 
outcome do not appear to derive any overall harm from treatment. Those at a high 
predicted risk from either event appear to experience more benefit, with a relative 





Table 7-15 Assessing treatment additivity under binary and ordinal logistic regression fits. 
Predicted SICH is fitted as a continuous predictor with a logit transform for linearity except 
where specified (see also section 7.9 Appendix C on page 244). 
 
Binary logistic regression 
(OHS≥3) 
 
Proportional odds logistic 
regression (five levels) 
Model ∆AICa χ2 P-value  ∆AICa χ2 P-value 
HAT -0.54 1.46 0.2264  0.20 2.20 0.1384 
SEDAN -0.95 1.05 0.3065  -0.79 1.21 0.2711 
SITS -1.79 0.21 0.6493  -1.98 0.02 0.8837 
SPAN-100b 3.13 5.13 0.0235  0.28 2.28 0.1312 
GRASPS 1.81 3.81 0.0511  -0.59 1.41 0.2359 
THRIVEb,c 0.20 4.20 0.1222  -1.55 2.45 0.2933 
Stroke-TPI 6.70 8.70 0.0032  0.83 2.83 0.0928 
DRAGON 6.60 8.60 0.0034  1.53 3.53 0.0602 
Kӧnig model 11.29 13.29 0.0003  2.22 4.22 0.0399 
IST3 model 5.09 7.09 0.0078  3.50 5.50 0.0190 
a ∆AIC are the difference in AIC units between the interaction model and the additive model. 
Positive values indicate an improvement in model fit. 
b Predicted SICH risk fit as a categorical variable 





There was insufficient evidence to support a stratified approach to treating acute 
ischaemic stroke patients with rtPA according to their predicted risk from harm. 
There are a number of explanations for this. The discrimination of those with post 
rtPA SICH events and those without was modest. Theoretically, a better 
discriminating model could separate those who will suffer a post rtPA SICH from 
those that will not. As was illustrated in this chapter it would seem that this is not an 
issue which can be immediately addressed through the use of more sophisticated 
statistical methodology but will rather involve identifying stronger risk factors 
through etiological research. It is possible that variables not measured in IST-3, such 
as advanced imaging methods, genotyping, or blood biomarkers related to the 
pathophysiology of post-rtPA SICH may better predict response to treatment 
(Álvarez-Sabín et al., 2013). Based on the current evidence it is unlikely that those 
available clinical prediction models will play a role in the influence of routine 
clinical practice. 
The correlation between predicted post rtPA SICH and post rtPA poor-functional 
outcome risk is large with a spearman’s correlation coefficient of 0.76 in the IST-3 
data. The associations between outcome and predictors are similar regardless of the 
outcome (Figure 7-11). This explains why the message from Figure 7-9 and from 
Figure 7-10 was the same. 
The position taken in this chapter on the contrasting conclusions drawn from the 
binary logistic regression and the POLR model (see section 7.5.3 page 229) can be 
framed as a question of simplicity versus complexity question – first discussed in 
Chapter 2. Despite the data limitations (note that few patients had a low predicted 
risk, see section 7.9 Appendix C page 244), the binary logistic model offers the 
simplest answer to what is arguably a complex question. The POLR adds an extra 
layer of complexity by requiring the proportional odds assumption to hold, however 
it offers a halfway-house between the binary fit approach and an approach whereby a 
different effect is thought to hold for each of the potential dichotomies. The POLR 




regression does not. The conclusion drawn in this chapter was to favor the POLR 
model which indicated no excess harm in the low risk patients. This is rather post-
hoc though and further investigation within low risk patients is required before 
evidence of harm could be concluded. 
At the time of writing this thesis a collaborative individual patient data meta-analysis 
between rtPA trialists was underway. The Stroke Thrombolytic Trialists’ 
Collaborative (STTC) used data from all of the available rtPA trials to explore 
patient subgroups of interest (The Stroke Thrombolysis Trialists' Collaborative 
Group, 2013). The group published their findings in August 2014. Analysing all of 
the rtPA trial data, Emberson et al. found that the benefit of treatment with rtPA did 
not depend upon the age or the severity of the patient, concluding benefit for older 
patients as well as those with milder strokes (Emberson et al., 2014). They also 
emphasised the urgency in onset time to treatment illustrating that the effect of rtPA 
in improving the odds of a good outcome reduced the later it was given. 
The direction of the results and the conclusions drawn were not affected by adopting 
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7.7 Appendix A: Sensitivity analyses and additional 
tables 
The various sensitivity analyses conducted in this chapter are summarised in Table 
7-16 below. Additional tables summarising formal comparisons of areas under the 
ROC curve are given for post rtPA: (i) SICH (Table 7-17); parenchymal 
haemorrhage (Table 7-18); and OHS≥3 (Table 7-19). 
 
Table 7-16 Summary of sensitivity analyses. 
 Per protocol rtPA randomisation 
 Randomised to treatment 
within 4.5 hours 
 Randomised to treatment 
after 4.5 hours 
Analysis Comment  Comment  Comment 
Model development 
 




covariate effects or 
effect size, slight 
inflation in SE as 
expected 
 
A reduction of 460 
patients. No difference in 
direction of covariates, but 
slight differences in effect 
size. Large inflation of SE. 
Likely due to reduction in 
sample size 




increases patient risk of 
SICH. It is noted that when 
simply adjusting for time to 















Reduction in sample size is 
expressed in the pseudo R2 
values. Differences in 
nonparametric 
comparison of ROC curves: 
likely due to reduction in 
sample size 
 
No difference, small 
differences resulting from 
reduced sample; 
differences in 
discrimination, balanced by 
larger 95% CI intervals  
SICH As above 
 
As above 
 As above. Some large 
differences in R2 noted 
OHS≥3 As above 
 As above. Slight 
improvement in 
discrimination, but 
balanced by an increase in 
the width of the 95% CIs. 
Differences in 
nonparametric 
comparison of ROC curves: 
likely due to reduction in 
sample size 
 
As above. Differences in 
discrimination noted, likely 






Table 7-17 Assessing the prognostic value of different clinical prediction models for post rtPA SICH and poor functional outcome by nonparametric 
comparison of ROC curves computed using the IST3 data for post rtPA SICH. 
Model HAT SEDAN SITS GRASPS SPAN-100 STROKE TPI DRAGON THRIVE 
Kӧnig 
model 
HAT - - - - - - - - - 
SEDAN 0.2,.8831 - - - - - - - - 
SITS 0.6, .5513 0.5, .6353 - - - - - - - 
GRASPS 0.2, .8558 0.0, .9669 -0.5, .6426 - - - - - - 
SPAN-100 -1.6, .1051 -1.6, .1126 -2.1, .0392 -2.3, .0222 - - - - - 
STROKE TPI 0.8, .4211 0.5, .6310 -0.2, .8347 0.5, .5940 2.8, .0051 - - - - 
DRAGON 1.3, .2099 1.2, .2410 0.2, .8617 1.0, .3167 2.6, .0097 0.7, .5066 - - - 
THRIVE -0.5, .6557 -0.6, .5694 -1.0, .3034 -1.1, .2592 1.9, .0636 -1.3, .1995 -1.5, .1234 - - 
Kӧnig model 0.3, .7665 0.1, .9077 -0.4, .6976 0.1, .8873 3.4, .0007 -0.6, .5396 -0.9, .3494 1.4, .8576 - 
IST3 model 2.8, .0047 2.5, .0123 1.9, .0557 2.4, .0179 3.9, .0001 2.4, .0159 1.9, .0592 2.8, .0045 2.6, .0106 





Table 7-18 Assessing the prognostic value of different clinical prediction models for post rtPA SICH and poor functional outcome by nonparametric 
comparison of ROC curves computed using the IST3 data for post rtPA parenchymal haemorrhage. 
Model HAT SEDAN SITS GRASPS SPAN-100 STROKE TPI DRAGON THRIVE 
Kӧnig 
model 
HAT - - - - - - - - - 
SEDAN 0.0, .8506 - - - - - - - - 
SITS 0.7, .4130 0.7, .4035 - - - - - - - 
GRASPS 0.1, .7091 0.0, .8634 0.6, .4500 - - - - - - 
SPAN-100 7.4, .0066 5.7, .0174 2.6, .1071 9.1, .0026 - - - - - 
STROKE TPI 0.1, .7915 0.2, .6879 1.1, .2931 0.7, .4068 15.4, .0001 - - - - 
DRAGON 1.3, .2575 2.6, .1104 2.9, .0897 2.8, .0961 15.3, .0001 1.5, .2260 - - - 
THRIVE 0.2, .6819 0.1, .7831 0.4, .5297 0.1, .8150 10.5, .0012 0.7, .4178 2.4, .1236 - - 
Kӧnig model 0.0, .9050 0.1, .8043 1.0, .3188 0.6, .4384 22.8, <.0001 0.0, .8467 1.2, .2665 0.1, .8018 - 
IST3 model 0.7, .4038 0.8, .3824 3.6, .0590 1.2, .2814 11.5, <.0001 0.5, .4666 0.0, .9910 1.2, .2752 0.6, .4290 





Table 7-19 Assessing the prognostic value of different clinical prediction models for post rtPA SICH and poor functional outcome by nonparametric 
comparison of ROC curves computed using the IST3 data for post rtPA death or dependency. 
Model HAT SEDAN SITS GRASPS SPAN-100 STROKE TPI DRAGON THRIVE 
Kӧnig 
model 
HAT - - - - - - - - - 
SEDAN 2.8, .0048 - - - - - - - - 
SITS -2.7, .0062 -5.0, <.0001 - - - - - - - 
GRASPS 4.4, <.0001 2.3, .0233 7.5, <.0001 - - - - - - 
SPAN-100 -3.3, .0010 -5.3, <.0001 0.4, .7286 -8.6, <.0001 - - - - - 
STROKE TPI 8.7, <.0001 6.7, <.0001 10.0, <.0001 5.0, <.0001 13.5, <.0001 - - - - 
DRAGON 6.9, <.0001 6.0, <.0001 8.3, <.0001 3.4, .0663 9.9, <.0001 -2.9, .0038 - - - 
THRIVE 4.4, <.0001 2.3, .0216 7.6, <.0001 0.1, .9000 9.6, <.0001 -4.6, <.0001 -1.6, .1035 - - 
Kӧnig model 7.6, <.0001 5.4, <.0001 9.5, <.0001 4.8, <.0001 14.3, <.0001 -0.7, .5086 2.2, .0312 4.8, .0168 - 
IST3 model 0.3, .7965 -2.4, .0165 3.7, .0003 -4.4, <.0001 3.1, .00182 -8.1, <.0001 -6.4, <.0001 -4.2, <.0001 -7.5, <.0001 




7.8 Appendix B: Re-calibration in IST-3 dataset 
The calibration metrics for the Stroke-TPI score, the Konig model and the IST-3 
model are provided in Table 7-20. In each case the estimated correction factor (cf) 
represents the log odds ratio of incidence and estimated risk. Recalibration involves 
adding the cf to in each instance to the linear predictor therefore adjusting for the 
observed differences in incidence of each outcome in IST-3. The benefit of 
recalibration is illustrated by comparing the updated calibration metrics in Table 7-20 
with the original metrics presented in Table 7-5. For instance, recalibration 
considerably improved the systematic under-prediction of patients risk from post 
rtPA poor functional outcome according to the Stroke-TPI score, with a calibration 
intercept that was 2.49 reduced to 0.68. Note that Figure 7-12, Figure 7-13 and 
Figure 7-14 illustrate the impact of recalibration in each case. 
Table 7-20 Models recalibrated for IST-3 data for: (i) post rtPA SICH; and (ii) post rtPA poor 
functional outcome (OHS≥3). Note intervals provided are 95%CIs. 
Model SICH OHS≥3 
Stroke-TPI   
Correction factor (cf) -1.39 1.81 
events/Total 87/1365 856/1365 
Calibration intercept (95%CI) -0.34 (-0.57 to -0.10) 0.68 (0.55 to 0.81) 
Calibration slope (95%CI) 0.33 (0.17 to 0.48) 0.99 (0.87 to 1.11) 
Kӧnig model   
Correction factor (cf) -3.32 -0.14 
events/Total 102/1507 957/1507 
Calibration intercept (95%CI) -1.14 (-1.36 to -0.92) 0.17 (0.05 to 0.30) 
Calibration slope (95%CI) 0.27 (0.14 to 0.40) 0.84 (0.74 to 0.94) 
IST-3 model   
Correction factor (cf) - 3.26 
events/Total - 957/1507 
Calibration intercept (95%CI) - 0.11 (0.00 to 0.22) 































Original model, SICH events




























Re-calibrated model, SICH events
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Re-calibrated model, OHS ≥ 3
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Re-calibrated model, OHS ≥ 3
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Re-calibrated model, OHS ≥ 3
 





7.9 Appendix C: Interaction on relative risk scale 
A formal test for a treatment by predicted risk interaction is presented here on the 
relative risk scale. This was undertaken using the OHS outcome as a binary outcome 
(OHS≥3) as well as when maintaining the full ordinal structure of the OHS outcome 
(as defined previously). 
The proportional odds assumption is assessed visually using the residual plots 
provided below (Figure 7-16, Figure 7-17 and Figure 7-18). The largely flat residuals 
support the proportional odds assumption in each case. 
Where possible prediction models were recalibrated (i.e., Stroke-TPI (Figure 7-12) 
and the model proposed by Kӧnig et al. (Figure 7-13) see Appendix B above). This 
improves the obtained predicted risks which, after recalibration, adequately reflect 
the observed difference in the incidence of post rtPA SICH as recorded in IST-3 in 
contrast to the incidence noted in development. 
In each of the interaction plots provided below (see Figure 7-19 to Figure 7-26) the 
left hand-side shows the interaction from a binary logistic regression model whilst 
the right hand-side shows the interaction from a POLR model. See results section 








































































































































































Figure 7-15 Score residual plots for HAT, SEDAN and SITS (binary model score residuals for 
all cut-points of the ordinal outcome). Each model includes the predicted risk, the treatment 

























































































































































































Figure 7-16 Score residual plots for SPAN-100, GRASPS and Stroke-TPI (binary model score 
residuals for all cut-points of the ordinal outcome). Each model includes the predicted risk, the 




































































































































































Figure 7-17 Score residual plots for DRAGON, Kӧnig model and the IST-3 model and SITS 
(binary model score residuals for all cut-points of the ordinal outcome). Each model includes the 





























































































































Figure 7-18 Score residual plots for the THRIVE score (binary model score residuals for all cut-
points of the ordinal outcome). Predicted risk is included as categorical variable, the treatment 



















(i) Binary LR ( HAT )


























(ii) Proportional odds LR ( HAT )









Figure 7-19 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the HAT model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.2264 and 0.1384 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( SEDAN )


























(ii) Proportional odds LR ( SEDAN )









Figure 7-20 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the SEDAN model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.3065 and 0.2711 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( SITS )


























(ii) Proportional odds LR ( SITS )









Figure 7-21 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the SITS model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.6493 and 0.8837 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( GRASPS )


























(ii) Proportional odds LR ( GRASPS )









Figure 7-22 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the GRASPS model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.0511 and 0.2359 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( Stroke-TPI )


























(ii) Proportional odds LR ( Stroke-TPI )









Figure 7-23 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the Stroke-TPI model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.0032 and 0.0928 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( DRAGON )


























(ii) Proportional odds LR ( DRAGON )









Figure 7-24 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the DRAGON score: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 



















(i) Binary LR ( Konig model )


























(ii) Proportional odds LR ( Konig model )









Figure 7-25 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the Kӧnig model: (i) a poor functional 
outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with predicted SICH risk) 
gave P-values of 0.0003 and 0.0399 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the categorisation of risk used in the 



















(i) Binary LR ( IST-3 model )


























(ii) Proportional odds LR ( IST-3 model )









Figure 7-26 The effect of rtPA on six month functional outcome and patients predicted risk of post rtPA SICH by the internally developed IST-3 model: (i) a 
poor functional outcome; and (ii) disability or death across a five levelled categorisation of OHS stroke outcome. A global test of additivity (rtPA with 
predicted SICH risk) gave P-values of 0.0078 and 0.0190 for a binary LR (i) and a POLR (ii) respectively. Vertical dashed lines correspond to the 



















(i) OHS 0-1 vs. 2-6























(ii) OHS 0-2 vs. 3-6























(iii) OHS 0-3 vs. 4-6









Figure 7-27 The effect of rtPA on six month functional outcome and patients predicted risk of 
post rtPA SICH by the Kӧnig model: (i) a dichotomy set at OHS≥2; (ii) a dichotomy set at 




Chapter 8: The effect of rtPA on mortality 
Background and summary 
Treatment with rtPA as early as possible after an acute ischaemic stroke can reduce 
the severity of six month disability. The impact on long term survival is less clear. In 
this chapter a secondary analysis of the 18 month IST-3 data is undertaken to 
explore whether patient characteristics interact with treatment causing differences in 
mortality. It is concluded that patients on rtPA with a poorer prognosis achieve 
better long term survival than those with a good prognosis who may experience 
excess mortality on rtPA. 
8.1 Introduction 
Recombinant tissue plasminogen activator (rtPA) given as early as possible (< 6 
hours) after acute ischaemic stroke favours good functional outcome (mRS 0 to 2 
versus 3 to 6) with an increase in absolute benefit of 42 (95% CI 19 to 66) per 1000 
treated (Wardlaw et al., 2012a). Despite this benefit rtPA is known to increase the 
risk of early symptomatic intracranial haemorrhage (SICH) by 58 (95% CI 49 to 68) 
per 1000. This is the most likely explanation of a known increase in early mortality 
(≤7 days) with around 25 more deaths (95% CI: 11 to 39) for every thousand patients 
treated with rtPA. On excluding those deaths that could be attributed to haemorrhage 
the difference in deaths between placebo and rtPA was no longer statistically 
significant with a P-value of 0.54. The majority of studies of rtPA in acute ischaemic 
stroke used a follow-up of three months or less (11 out of 12 included studies, 
Wardlaw et al., 2012). Little remains known about the long term impact of rtPA on 
patient mortality. 
The third International Stroke Trial (IST-3) was introduced in the previous chapter 
were details of the design was provided. It was noted that the IST-3 had two follow-




ischaemic stroke patients treated within six hours of stroke onset (The IST-3 
collaborative group, 2012a). The second phase explored the impact of rtPA on long 
term survival (The IST-3 collaborative group, 2013). Details of the IST-3 
collaborative group’s analysis of the long term follow-up data are now discussed.  
Ten out of the twelve contributing countries followed all patients recruited to their 
centres for a total of 18 months after randomisation. This comprised just over 77% of 
the original sample size (2348/3035). Those contributing countries were: Austria, 
Belgium, Canada, Italy, Mexico, Poland, the United Kingdom, Australia, Norway, 
and Sweden. Eighteen month mortality rates were similar between the two treatment 
arms with 34.9% and 35.1% on rtPA and control respectively. The IST-3 
collaborative group formally compared the survival distributions under treatment and 
control using a log-rank test declaring no statistically significant difference between 
the survival rates under treatment with rtPA and control (P-value = 0.8456). 
However, the use of the log-rank test is not strictly appropriate for these data given 
the clear violation of the proportional hazards assumption (Figure 8-1) attributable to 
an early hazard of death in the rtPA treated arm. A test of the proportional hazards 
assumption on the same data, i.e., the 2348 patients, resulted in its rejection with a P-
value of 0.0061 (Grambsch and Therneau, 1994). 
It seems self-evident that for the proportion of those dead by 18 months to be 
approximately equal between treatment arms (34.9% and 35.1%) that some patients 
must experience an excess of mortality from treatment whilst others a survival 
benefit. 
There are two patient characteristics that are plausibly related with survival: (i) the 
severity of the initial stroke; and (ii) the delay between stroke onset and treatment. 
The aim of this chapter is to explore these features using data from the IST-3: one of 
the largest trials of rtPA carried out to date in acute ischaemic stroke patients with 
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Figure 8-1 Kaplan-Meier survival curves reproduced as per the data used in the eighteen month 
follow-up paper. 
8.2 Survival analysis methods 
In a standard clinical trial - cross-over trials excluded - patients are randomised to 
receive one of k possible treatments and followed for a fixed period of time recording 
the occurrence of any events of interest. Analyses which formally incorporate the 
recorded time-to-event data are termed survival analyses. The standard vernacular 
denotes events (e.g., death) as failures occurring at some observed time, or failure 
time. A subset of those recruited to IST-3 was followed for 18 months for the 
occurrence of all-cause mortality. Of course not all patients died during follow-up 
meaning that a proportion of the patients had no observed failure times: such data 
must be handled appropriately. In what follows, a brief exploration of the survival 




8.2.1 Failure times, censoring times and the survival function 
Patients who meet the trial inclusion criteria enter the trial as and when they become 
available. Various ethical and monetary constraints mean that typically the trial 
design will not be an ‘observe all till failure’ approach with instead patients being 
monitored via scheduled follow-up appointments for a fixed period of time. Those 
patients alive at the end of the 18 month follow-up in the IST-3 trial were known to 
have survived for at least 18 months. Such patients can be regarded as right-censored 
were the event time is unobserved and therefore censored by virtue of trial 
administration (e.g., Patient 4 in Figure 8-2 who in theory could fail at any point after 
18 months). Similarly, patients who drop out of the trial during follow-up can still 
provide some information since it will be known that they survived up until the point 
at which they dropped out, therefore, such patients are also right-censored (e.g., 
Patient 1 in Figure 8-2). 
The original analysis of long-term follow-up in the IST-3 was restricted to those 
patients with planned eighteen month follow-up (The IST-3 collaborative group, 
2013). The analysis presented in this chapter adopts a more dynamic censoring 
scheme which attempts to incorporate all patients. In Portugal and Switzerland, 
planned follow-up was only for six months. Therefore any patient with a returned six 
month form but no record of death was censored at 183 days. If the six month form 
was unavailable but the date last known to be alive was greater than six months then 
the patient was censored at 183 days, or if this was less than six months then the last 
known date to be alive was used. There were nine Portuguese patients with eighteen 
month forms; 18 month follow-up was not planned for these patients so they were 
censored at 183 days. For those patients randomised in: Austria, Belgium, Canada, 
Italy, Mexico, Poland, the United Kingdom, Australia, Norway, and Sweden the 
following censoring scheme was applied. If the six month form was available and the 
eighteen month form was unavailable and there was no date when they were last 
known to be alive, the patient was censored at 183 days. If the six month form was 
available or was unavailable, the eighteen month form was available and there was 
no date last known to be alive then the patient was censored at 548 days. If neither 




to be alive was less than eighteen months then the patient was censored at this date, if 
it exceeded eighteen months then the patient was censored at 548 days. One 
Portuguese patient was excluded from all analyses since neither of the forms was 
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Figure 8-2 Time profiles for four hypothetical patients observed for 18 months for the 
occurrence of morality. Solid black circles denote failure times whilst open circles denote 
censoring times. Dotted lines illustrate potential unobserved follow-up. 
At this stage two random variables can now be defined using more general 
terminology: patient survival time (TS) and patient censoring time (TC). An 
assumption of any formal statistical analysis of survival data is that these two random 
variables remain independent of one another, i.e., CS TT ⊥ , meaning that the 
underlying reason for any censoring should not depend on the outcome itself. The 
observed time is the minimum of the two, i.e., T = min (TS , TC). Each patient 
therefore provides an observed time and an event type (ti, δi) where δi is an indicator 
function equal to 1 if Si Tt ∈ or 0 if Ci Tt ∈ . A cumulative density function is defined 
such that survival can be described as the probability of surviving beyond some time 
point, t, 




where TS is as previously defined and FS (t) = P(TS < t) is the cumulative density 
function (Collett, 2003). The survival function is a non-increasing function equal to 1 
at time point 0 decreasing to 0 as time extends to infinity. A similar function can be 
described for TC the censoring function C (t) (van Houwelingen and Putter, 2012). 
8.2.2 The Kaplan-Meier estimator 
There are two ways in which the survival function can be estimated. First, it is 
possible to make some parametric assumption and fit a known distribution which is 
defined on the real numbers, e.g., an exponential, Weibull, Gamma, log-normal 
distribution and so on. A drawback of this approach is a lack of flexibility, for 
example consider the exponential distribution which is fully specified by a single 
parameter; this means that a single constant hazard must hold which is unlikely to be 
true of, or applicable to, most clinical settings. Second, a non-parametric approach 
may be adopted making no distributional assumptions. The most frequently used is 
the Kaplan-Meier (KM) estimator (Kaplan and Meier, 1958). This was used earlier 
on in this chapter without specification (Figure 8-1); some theory is now provided.  
The KM estimate provides a non-parametric estimate of the probability of failure at 
any given time point, 
for mittt ii ,,1,)1()( K=<≤ + with m event times. An estimate of the standard error can 
be obtained by first recognising that the KM estimate can be described as the product 
of a series of binomial estimates of conditional probabilities, jp̂ , with sj successes 
out of rj trials such that sj ~ Bi(rj, pj). A simple rearrangement of the asymptotic 
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This can be used to obtain (1 – α) 100% point-wise confidence intervals for the KM 
estimate at each specified time point, i.e., ( ))(ˆ)(ˆ 2/1 tSSEztS KMKM α−± , where z1- α /2 is 
obtained from the standard Normal distribution. This can sometimes produce invalid 
intervals that fall out with the 0 and 1 boundary limits. This can be handled by 
adopting a transformation of the KM estimator. Some common transformations 
include the log and the log( - log) (van Houwelingen and Putter, 2012). 
8.2.3 The hazard function and the modelling of covariates 
The hazard function describes the instantaneous rate of failure. It is the limit of the 
probability that an individual experiences the event of interest in the next small time 
period of observation (∆t) as ∆t tends to zero given that they survived up until time t, 
in this way the hazard function incorporates the ageing process (Collett, 2003). It 
should be noted that the hazard and survival functions are both related. Appealing to 
standard probability theory equation (8.4) can be expressed as follows: 
Since S (t) is the survival function as defined previously (equation (8.1)), and f (t) is 
the derivative of F (t), in the limit, as ∆t approaches zero (Collett, 2003). By 
integrating h (t) over time, t, the cumulative hazard rate H (t) is obtained for which 
the survival function can be expressed as S (t) = exp (–H (t)). This means that the 

























































The most popular method for incorporating covariates into a survival analysis is the 
proportional hazards model (Harrell, 2001). In this way it is only necessary to 
specify a regression model through the hazard function, not the probability density 
function (Collett, 2003): 
In general, the baseline hazard, denoted by h0 (t), expresses how the hazard function, 
h (t | z), varies with survival time whilst the relative hazard function, exp (βT z), 
determines how the hazard changes with z, the observed patient characteristics. Note 
that the PHM is the only model that will be considered for the analysis of survival 
data in this thesis. 
The only requirement now is to suitably handle h0 (t) which can be done by either 
adopting some parametric specification (e.g., exponential or Weibull etc.) or else by 
leaving it completely unspecified under the Cox Proportional Hazards model (Cox 
PHM). Before exploring the Cox model further it is important to discuss some 
assumptions. As stated in equation (8.5) the Proportional Hazards Model (PHM) has 
three identifiable assumptions that must hold in order that the resulting parameter 
estimates may be correctly interpreted (Harrell et al., 1988): (i) all continuous 
measurements have a particular shape with respect to the log hazard of the outcome 
(the simplest being a linear association, although a more complicated non-linear 
association may be pursued using splines (Harrell, 2001) or fractional polynomials 
(Sauerbrei and Royston, 1999)); (ii) the individual effects act additively with respect 
to the log hazard of the outcome; and (iii) the hazards are assumed to be 
proportional. The first two assumptions were covered in Chapter 2. The third 
assumption requires that the relative hazard function, exp (βT z), is constant with 
respect to time and therefore has the same effect on the hazard throughout follow-up. 
This means for instance that each predictor effect has the same relative effect no 
matter how far the patient is from the beginning or the end of the study. Consider two 
patients, one on treatment (z1) and one on control (z0). Using the PHM the 
interpretation of the effect of the treatment, β, is reduced to a single value in the 
following way, 




with dummy variables coded 1 and 0 respectively for z1 and z0 the so called hazard 
ratio (HR) is determined as exp (β). This is the relative difference between the hazard 
of the individual on treatment and the hazard of the individual off treatment. 
The Cox Proportional Hazards Model is by far the most commonly adopted method 
for regressing covariates on the hazard function  which uniquely leaves the baseline 
hazard unspecified (Cox, 1972). The appeal of this approach is that no distributional 
assumptions need be made, yet β, the vector of regression parameters associated with 
z, can still be estimated so long as the proportional hazards assumption holds 
(Hosmer Jr et al., 2011). Cox proposed the partial likelihood function, an approach to 
estimation applicable when the full likelihood function can be expressed as the 
product of two separate functions specified on distinct parameters (e.g., in equation 
(8.5) the baseline hazard and the relative hazard function) of which only one is of 
interest (i.e., the estimation of β) (Cole et al., 2014, Cox, 1975). 
8.2.4 Handling non-proportional hazards 
It was noted in the introduction of this chapter that an early hazard of excess deaths 
in rtPA treated patients caused a violation of the proportional hazards assumption, 
thus precluding the standard application of the Cox PHM. Formal tests of the 
proportional hazards assumption exist based on the linear correlation between the 
rank ordered failure times and scaled Schoenfeld’s partial residuals (Grambsch and 
Therneau, 1994). Schoenfeld’s residuals are calculated from the individual 
contribution that each observation makes to the derivative of the log partial 
likelihood (Hosmer Jr et al., 2011). It is useful to supplement such a test with a plot 
of time against the residuals (see Appendix A Figure 8-7). Three analytical 
approaches for handling non-proportional hazards are outlined below. 
8.2.4.1 First approach: difference in estimated survival 
The first and simplest approach considered stems from the idea that if you are 
interested in the difference between treatment arms then you should plot them (Senn, 




















2009, Senn et al., 1990). Empirical estimates of the differences in survival at 
specified time points can be obtained following a similar approach to that described 
by Frank E. Harrell, Jr. using his survdiffplot function – one of many useful 
functions from his library in R, rms (regression modeling strategies) which 
accompanies his book by the same name (Harrell, 2001, Harrell, 2013). There is no 
requirement for the Kaplan-Meier estimate to assume proportional hazards. It is 
therefore possible to explore the differences between the empirical estimates of 
survival probabilities on control and on rtPA at any observed time point, t. 
Let )(ˆ itD denote the difference between the Kaplan-Meier estimates of survival, 
control minus rtPA, at the ith time, ti, 
The standard error of the difference can be estimated from the individual standard 
errors for the Kaplan-Meier estimates of survival on control and on rtPA, 
where the associated Kaplan-Meier standard errors are obtained using equation (8.3). 
It logically follows that in order to test whether the absolute effect of treatment 
defined by equation (8.6) differs by some prognostic factor then the difference of the 
differences may be compared using estimates obtained in an identical manner to 
equations (8.6) and (8.7). The covariates of primary interest are: delay to 
randomisation; and patient’s predicted prognosis. The motivation is to determine 
whether or not there is any significant long term or short term harm from rtPA 
relative to control after adjusting for these identifiable baseline measurements. 
8.2.4.2 Second approach: restricted time interval Cox PH models 
Whilst the method described previously is appealing in its simplicity, it is not 
possible to make efficient adjustments for multiple patient characteristics. In addition 
all the limitations associated with the categorisation of continuous predictors are 
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From a statistical perspective the most direct way to handle the non-proportional 
hazards problem would be to include an interaction between treatment and time to 
event thus fully accounting for the fact that the effect of rtPA is non-constant. Putter 
et al give an excellent illustration as to how this can be presented (Putter et al., 2005). 
However in the presence of treatment interactions with patients baseline 
characteristics it is less clear how the findings can be easily presented to medical 
audiences. To overcome this, it is possible to split time into distinct windows or 
epochs of observation and describe the effect of treatment in the presence of 
treatment interactions with patients baseline characteristics (Harrell, 2001). It should 
be stressed though that when splitting time in this manner the estimated treatment 
effects in the later epochs are dependent on the survival of the preceding time 
periods. 
8.2.4.3 Third approach: using binary logistic regression 
The most straightforward analysis would be to ignore the available time to event data 
and instead restrict the analysis of mortality to those with planned 18 month follow 
up using a simple multivariable binary logistic regression. Tests for interactions 






The third International Stroke Trial (IST-3) recruited 3035 patients between May 
2000 and July 2011. The original findings from the long term follow-up published by 
the IST-3 Collaborative group used 2348 (77.4% of 3035) of the original sample of 
patients for which 18 month follow-up had been planned (The IST-3 collaborative 
group, 2013). The censoring scheme applied in this chapter excludes only one patient 
from the rtPA arm. At the end of the 18 month follow-up period, 34.9% (529/1514) 
of those on rtPA and 35.5% (539/1520) of those on control were dead. The baseline 
characteristics of those randomised to each arm are summarised in Table 8-1. Patient 
characteristics in the IST-3 were described in detail in the previous chapter; as 
expected good balance was achieved between the two arms due to a minimisation 
algorithm employed in randomisation. 
Two patients in the control group did not meet the inclusion criteria. This was 
highlighted in the initial publication (The IST-3 collaborative group, 2012a) with the 
following note: 
Two patients in the control group were randomly assigned at 
more than 6 h (protocol violation). One of these was recorded 
as having severe swelling on the randomisation scan, because 
the stroke had in fact occurred about 24 h earlier. 
These two patients (enrolled at 10.83 and 24 hours) were retained in the following 
analysis, although excluded in a per protocol sensitivity analysis (see Appendix B). 
Again a test of proportional hazards (Grambsch and Therneau, 1994) suggests that 
this does not hold true for treatment in IST-3 (N = 3034) with a P-value of 0.0011 
(NB this is slightly different from the test presented at the beginning of this chapter 
which was based on those 2348 patients with planned 18 month follow-up). 
Inspection of the Scaled Schoenfeld residuals (see Appendix A Figure 8-7) suggests 






Table 8-1 Baseline characteristics of IST-3 patients included in 18-month follow-up. 
Baseline variables collected before randomisation rtPA (1514) Control (1520) 
Age (Median, IQR) 81 (72 to 86) 81 (71 to 86) 
NIHSS (Median, IQR) 11 (6 to 18) 11 (6 to 17) 
Time to randomisation (Median, IQR) 3.9 (2.9 to 4.9) 3.9 (2.9 to 4.8) 
Sex, female (n, %) 781 (52) 788 (52) 
Stroke Syndrome (n, %)   
TACI 639 (42) 666 (44) 
PACI 595 (39) 551 (36) 
LACI 168 (11) 164 (11) 
POCI 110 (7) 136 (9) 
Other 2 (<1) 3 (<1) 
Country (n, %)   
Northwest Europe 792 (52) 797 (52) 
Scandinavia 251 (17) 250 (16) 
Australasia 89 (6) 90 (6) 
Southern Europe 203 (13) 204 (13) 
Eastern Europe 174 (11) 173 (11) 
Americas 5 (<1) 6 (<1) 
Expert reader’s assessment of acute ischaemic change1 (n, %)  
Scan completely normal 140 (9) 129 (9) 
Abnormal scan, no sign of acute ischaemic change 742 (49) 781 (52) 
Signs of acute ischaemic change 624 (41) 600 (40) 
Abbreviations: IQR – Inter Quartile Range; NIHSS – National Institute of Health Stroke Scale; rtPA - 
recombinant tissue plasminogen activator; LACI - lacunar circulation infarcts; PACI - partial anterior 
circulation infarcts; POCI - posterior circulation infarcts; and TACI - total anterior circulation infarcts. 




8.3.1 First approach: absolute difference in survival 
The difference of survival functions (control minus rtPA) is summarised in the plot 
below (Figure 8-3). Supposing for a moment that proportional hazards had in fact 
held (i.e., no excess mortality in the first few weeks of treatment) and that rtPA had 
no overall impact on mortality, in which case the plot of the difference in survival 
functions would simply be a random scatter about zero. However, this was not the 
case, which is immediately evident in the figure below. 



























Figure 8-3 Difference of survival functions (%) amongst all patients, control minus rtPA (i.e., 
negative values indicate excess mortality in rtPA). Grey band highlights 95% point-wise CI. 
In particular, by seven days those treated with rtPA experienced an excess of 
mortality over control of -3.46% (95% point-wise CI: -5.44 to -1.49), there was no 
excess mortality in either groups by six months (183 days) -0.10% (95% point-wise 
CI: -3.25 to 3.06) nor by 18 months (548 days) 0.63% (95% point-wise CI: -2.86 to 
4.13). See also Table 8-2. 
It is again stressed that since the clear early hazard of death was not sustained in the 




then there must be groups of patients for which there is significantly more harm and 
groups for which there is significantly more benefit. 
8.3.1.1 Absolute difference in survival by delay in enrolment 
Two categorisations of delay in enrolment were considered: <3 versus ≥3 hours; and 
<4.5 versus ≥4.5 hours. The point estimates for strata specific differences in 
mortality between control and rtPA are provided in Table 8-2 whilst a test of the size 
of these differences between strata for specific time points are provided in Table 8-3. 
Those treated less than three hours from enrolment appear to benefit from a reduction 
in long term mortality (548 days) which was significantly larger than the same 
difference amongst those treated 3 hours or later (0.09 with 95% CI: 0.01 to 0.17, P-
value = 0.0317). Moving the dichotomy to a later cut-point of time (4.5 hours) 
yielded a non-significant difference in late mortality (0.03 with 95% CI: -0.04 to 
0.10, P-value = 0.3751). A plot of the difference of the differences is provided in 
section 8.5 Appendix A on page 285, Figure 8-8 (A). 
8.3.1.2 Absolute difference in survival by predicted prognosis 
Again with reference to Table 8-2 and Table 8-3 there was an indication that those 
with a good prognosis (<50%) experienced an excess of long term mortality (548 
days) when treated with rtPA over control of 4.32% (95% point-wise CI: 8.48 to 
0.17). There was evidence that this was significantly different from the size of the 
effect experienced by those with a poor predicted prognosis (≥50%) (-0.08 with 95% 
CI: -0.14 to -0.02, P-value = 0.0091). This effect was similar for a cut-point of 40% 
(-0.08 with 95% CI: -0.14 to -0.02, P-value = 0.0090) but not for 20% (-0.02 with 
95% CI: -0.09 to 0.05, P-value = 0.5178) (see Table 8-2). A plot of the difference of 






Table 8-2 Kaplan Meier estimates of mortality with 95% Point-wise CIs post stroke, with absolute difference of control minus rtPA. 
 Control (%) rtPA (%)  Difference (control - rtPA) 
Days since enrolment Deaths (n) KM estimate (95% CI) Deaths (n) KM estimate (95% CI)  Estimate (95% CI) P-value 
All patients, (Number of patients control versus rtPA, 1520 vs. 1514) 
7 102 6.71 (5.44 to 7.96) 154 10.17 (8.64 to 11.68)  -3.46 (-5.44 to -1.49) 0.0006 
183 407 26.80 (24.54 to 29.00) 407 26.90 (24.63 to 29.10)  -0.10 (-3.25 to 3.06) 0.9510 
548 539 36.56 (34.03 to 38.99) 529 35.93 (33.41 to 38.35)  0.63 (-2.86 to 4.13) 0.7235 
        
Delay to randomisation       
Time to randomisation, < 3 hours, (395 vs. 406) 
7 35 8.86 (6.01 to 11.62) 41 10.10 (7.12 to 12.98)  -1.24 (-5.29 to -2.82) 0.5497 
183 142 35.95 (31.04 to 40.51) 130 32.02 (27.33 to 36.41)  3.93 (-2.63 to 10.49) 0.2401 
548 184 47.84 (42.55 to 52.65) 161 40.62 (35.54 to 45.30)  7.22 (0.21 to 14.23) 0.0434 
Time to randomisation, ≥ 3 hours, (1125 vs. 1108) 
7 67 5.96 (4.56 to 7.33) 113 10.20 (8.40 to 11.96)  -4.24 (-6.50 to -1.99) 0.0002 
183 265 23.59 (21.06 to 26.03) 277 25.03 (22.43 to 27.54)  -1.44 (-5.00 to 2.12) 0.4287 
548 355 32.58 (29.72 to 35.33) 368 34.20 (31.29 to 37.00)  -1.62 (-5.62 to 2.38) 0.4270 
Time to randomisation, < 4.5 hours, (994 vs. 983) 
7 74 7.44 (5.80 to 9.06) 110 11.19 (9.20 to 13.14)  -3.75 (-6.30 to -1.19) 0.0041 
183 306 30.81 (27.88 to 33.62) 297 30.22 (27.29 to 33.03)  0.59 (-3.47 to 4.65) 0.7753 
548 398 41.12 (37.91 to 44.16) 379 39.42 (36.23 to 42.45)  1.70 (-2.70 to 6.11) 0.4489 
Time to randomisation, ≥ 4.5 hours, (526 vs. 531) 
7 28 5.32 (3.39 to 7.22) 44 8.29 (5.91 to 10.60)  -2.96 (-5.99 to 0.07) 0.0552 
183 101 19.23 (15.79 to 22.53) 110 20.76 (17.23 to 24.13)  -1.53 (-6.35 to 3.30) 0.5353 
548 141 27.89 (23.84 to 31.72) 150 29.41 (25.31 to 33.28)  -1.52 (-7.12 to 4.08) 0.5941 
        
        





Table 8-2 Continued from previous page 
     
 Control (%) rtPA (%)  Difference (control - rtPA) 
Days since enrolment Deaths (n) KM estimate (95% CI) Deaths (n) KM estimate (95% CI)  Estimate (95% CI) P-value 
Subgroups of differing stroke severity      
Predicted prognosis < 50%, (538 vs. 520) 
7 8 1.49 (0.46 to 2.50) 14 2.69 (1.29 to 4.07)  -1.21 (-2.93 to 0.52) 0.1713 
183 36 6.71 (4.57 to 8.81) 45 8.67 (6.22 to 11.06)  -1.96 (-5.18 to 1.26) 0.2323 
548 55 10.71 (7.99 to 13.36) 74 15.03 (11.80 to 18.15)  -4.32 (-8.48 to -0.17) 0.0415 
Predicted prognosis ≥ 50%, (982 vs. 994) 
7 94 9.57 (7.71 to 11.39) 140 14.08 (11.89 to 16.22)  -4.51 (-7.35 to -1.67) 0.0018 
183 371 37.78 (34.67 to 40.74) 362 36.42 (33.36 to 39.35)  1.36 (-2.90 to 5.62) 0.5330 
548 484 50.60 (47.30 to 53.70) 455 46.78 (43.52 to 49.85)  3.82 (-0.67 to 8.32) 0.0956 
Predicted prognosis < 40%, (378 vs. 351) 
7 6 1.59 (0.32 to 2.84) 8 2.28 (0.71 to 3.83)  -0.69 (-2.70 to 1.31) 0.4991 
183 17 4.51 (2.39 to 6.58) 27 7.72 (4.88 to 10.47)  -3.21 (-6.70 to 0.28) 0.0715 
548 27 7.53 (4.75 to 10.23) 42 12.56 (8.92 to 16.05)  -5.03 (-9.53 to -0.53) 0.0284 
Predicted prognosis ≥ 40%, (1142 vs. 1163) 
7 96 8.41 (6.78 to 10.00) 146 12.55 (10.63 to 14.44)  -4.15 (-6.64 to -1.65) 0.0011 
183 390 34.18 (31.37 to 36.87) 380 32.68 (29.93 to 35.32)  1.50 (-2.35 to 5.35) 0.4461 
548 512 46.06 (43.02 to 48.94) 487 42.94 (39.96 to 45.77)  3.12 (-1.02 to 7.27) 0.1395 
Predicted prognosis < 20%, (99 vs. 107) 
7 0 0.00 (0.00 to 0.00) 2 1.87 (0.00 to 4.40)  -1.87 (-4.44 to 0.70) 0.1534 
183 1 1.01 (0.00 to 2.96) 3 2.80 (0.00 to 5.88)  -1.79 (-5.49 to 1.90) 0.3416 
548 3 3.33 (0.00 to 6.97) 5 4.95 (0.61 to 9.10)  -1.63 (-7.26 to 4.01) 0.5719 
Predicted prognosis ≥ 20%, (1421 vs. 1407) 
7 102 7.18 (5.83 to 8.51) 152 10.80 (9.17 to 12.41)  -3.63 (-5.73 to -1.52) 0.0007 
183 406 28.60 (26.21 to 30.92) 404 28.73 (26.33 to 31.06)  -0.13 (-3.46 to 3.21) 0.9406 




Table 8-3 Testing the difference of the differences. 
Comparing groups Estimate SE. P-value 
Delay, <3 hours vs. ≥3 hours    
7 0.0301 0.0237 0.2043 
183 0.0537 0.0381 0.1585 
548 0.0884 0.0412 0.0317 
Delay, <4.5 hours vs. ≥4.5 hours    
7 -0.0078 0.0202 0.6989 
183 0.0212 0.0322 0.5104 
548 0.0322 0.0364 0.3751 
Prognosis, <50% vs. ≥50%    
7 0.0331 0.0170 0.0511 
183 -0.0332 0.0272 0.2235 
548 -0.0814 0.0312 0.0091 
Prognosis, <40% vs. ≥40%    
7 0.0346 0.0163 0.0343 
183 -0.0471 0.0265 0.0759 
548 -0.0815 0.0312 0.0090 
Prognosis, <20% vs. ≥20%    
7 0.0176 0.0169 0.2998 
183 -0.0167 0.0254 0.5117 
548 -0.0222 0.0343 0.5178 
 
8.3.2 Second approach: Cox PHMs in distinct epochs of time 
As previously noted there are two main flaws in adopting an approach which looks at 
the difference in survival functions: first, only one interaction can be assessed at a 
time; and second, the two strictly continuous baseline measurements are handled in a 
rather inefficient way through necessary categorisation. Under this approach, such an 




earlier that the added complication of non-proportional hazards precludes the 
standard use of Cox PHMs fit with main effects (i.e., treatment, predicted prognosis 
and delay to treatment) and the two treatment interactions. In order to circumvent 
this problem whilst simultaneously incorporating the treatment interactions, the 
period of follow-up was split into epochs of time: 0 to 7 days; 7 to 90 days; 90 to 183 
days; and 183 to 548 days. Within each follow-up period the effect of: treatment; 
prognosis; delay; treatment with delay interaction; and treatment with prognosis 
interaction was assessed using four separate Cox PHMs for each of which the 
proportional hazards assumption held with global test P-values > 0.3 (see legend of 
Figure 8-4). 
Table 8-4 demonstrates the impact on the quality of the model fit for each period of 
observation assuming an increasingly larger model (i.e., adding interactions with 
treatment) as well as reducing the fit from the full model (i.e., removing interactions 
with treatment). The Likelihood Ratio (LR) test was used to assess the individual 
nested model fits. The LR test is based on the chi-squared distribution and tests 
whether there is a significant contribution from the larger model to the amount of 
information that is already known through the smaller model (note that the size of the 
model relates to the number of parameters fit, see Chapter 2 for more detail). For 
early mortality (within at most 7 days) there was no additional information gained 
via the inclusion of interactions with treatment. A safe conclusion here may then be 
that the single main effects treatment HR (i.e., M0) is the best estimate of the effect 
of rtPA on early (0 to 7 day) mortality, 1.54 (95%CI: 1.19 to 2.00). When building 
from the main effects fit in the interval 7 to 90 days there was a weak indication that 
treatment interacted with prognosis (χ2=3.02) though not significantly. In the interval 
90 to 183 days there was a strong suggestion that treatment interacted with delay 
(χ2=4.86), though in the final epoch (183 to 548 days) the importance of predicted 
prognosis far out-weighed any interaction with delay (χ2=7.37). 
Figure 8-4 illustrates how the treatment hazard ratios for M3 differ across the 




Table 8-4 Comparing Cox PHMs with and without treatment interactions. Note, n denotes the 
number of deaths, N the number at risk and df the degrees of freedom. 
Model comparison n N LR χ2 df P-value 
Time interval: 0 to 7 days 251 3034    
M1 vs M0 - - 1.40 1 0.2371 
M2 vs M0 - - 0.01 1 0.9386 
M3 vs M0 - - 1.42 2 0.4910 
M3 vs M1 - - 0.03 1 0.8743 
M3 vs M2 - - 1.14 1 0.2339 
Time interval: 7 to 90 days 437 2783    
M1 vs M0 - - 1.29 1 0.2554 
M2 vs M0 - - 3.02 1 0.0825 
M3 vs M0 - - 5.61 2 0.0604 
M3 vs M1 - - 4.32 1 0.0377 
M3 vs M2 - - 2.60 1 0.1070 
Time interval: 90 to 183 days 126 2342    
M1 vs M0 - - 4.86 1 0.0275 
M2 vs M0 - - 0.41 1 0.5247 
M3 vs M0 - - 4.86 2 0.0880 
M3 vs M1 - - 0.00 1 0.9524 
M3 vs M2 - - 4.46 1 0.0348 
Time interval: 183 to 548 days 254 2213    
M1 vs M0 - - 1.64 1 0.1994 
M2 vs M0 - - 7.37 1 0.0066 
M3 vs M0 - - 7.71 2 0.0212 
M3 vs M1 - - 6.10 1 0.0138 
M3 vs M2 - - 0.34 1 0.5622 
Model Key 
M0 β1*prognosis + β2*delay + β3*treatment 
M1 β1*prognosis + β2*delay + β3*treatment + β4*delay:treatment 
M2 β1*prognosis + β2*delay + β3*treatment + β5* prognosis:treatment 



































































Predicted poor prognosis 90%
 
Figure 8-4 Treatment interaction hazard ratios per time epoch for distinct types of patients with 
fixed prognosis (20%, 50%, 70% and 90%) and fixed hours till enrolment (2, 3, and 5 hours). 
Note an HR>1 indicates an increase in the hazard of mortality and HR<1 a decrease. Global 
tests of proportional hazards for each Cox model fit within the four time windows, ordered with 





8.3.3 Third approach: binary logistic regression analysis 
The final approach discards all time to event information focusing on any deaths that 
occurred across the 18 month follow-up period for those patients on which 18 month 
follow-up was planned. Here the IST-3 data are restricted to the same data analysed 
in the Lancet paper, (The IST-3 collaborative group, 2013). A similar analysis was 
conducted in the cited publication, although no assessment was made for treatment 
interactions. This analysis fit a logistic regression adjusting for: age, NIHSS, and 
delay (all linear) and visible infarct on baseline scan yielding a treatment effect of 
0.95 (95%CI: 0.78 to 1.16, P-value = 0.628). 
In this secondary analysis, the same model comparison process as described in the 
previous section is followed only here binary logistic regression models are fitted 
instead of Cox PHMs. An interaction between delay and treatment (χ2=0.46) was not 
as great as including an interaction between treatment and predicted prognosis 
(χ2=7.78) and even less important in the presence of the treatment-prognosis 
interaction (χ2=0.04) (Table 8-5). Figure 8-5 summarises the extent of the treatment 
effect on 18 month mortality and its interaction with patient prognosis and delay. 
Table 8-5 Comparing Binary logistic regression model fits with and without treatment 
interactions. Note, n denotes the number of deaths, N the number at risk and df the degrees of 
freedom. 
Model comparison n N LR χ2 df P-value 
18 month mortality 822 2348    
M1 vs M0 - - 0.46 1 0.4990 
M2 vs M0 - - 7.78 1 0.0053 
M3 vs M0 - - 7.81 2 0.0201 
M3 vs M1 - - 7.36 1 0.0138 
M3 vs M2 - - 0.04 1 0.8402 
Model Key 
M0 β1*prognosis + β2*delay + β3*treatment 
M1 β1*prognosis + β2*delay + β3*treatment + β4*delay:treatment 
M2 β1*prognosis + β2*delay + β3*treatment + β5* prognosis:treatment 





















(i) Onset time fixed at median























(ii) Predicted prognosis fixed at median









Figure 8-5 The effect of rtPA on 18 month mortality. (i) Treatment with rtPA OR across predicted prognosis (log odds scale) with onset time to 
randomisation fixed at median time (3.9 hours). The ORs for rtPA at the 25th, 50th and 75th percentiles are: 1.32 (95%CI 0.98 to 1.77); 1.09 (95%CI 0.88 to 
1.34); and 0.83 (95%CI 0.66 to 1.04) respectively. (ii) Treatment with rtPA OR across onset time to randomisation with predicted prognosis fixed at median 
risk (64%, log odds = 0.57) at 1, 3 and 6 hours are: 1.04 (95%CI 0.64 to 1.70); 1.07 (95%CI 0.84 to 1.38); and 1.13 (95%CI 0.76 to 1.66) respectively. A global 





This chapter has demonstrated that although rtPA does not correspond to any 
significant difference in mortality overall by 18 months, there is evidence to support 
the hypothesis that the effect of rtPA on mortality depends, to an extent, upon delay 
to randomisation and prognosis. When comparing the difference in Kaplan-Meier 
estimates of mortality between treatment arms across a binary categorisation of delay 
split at 3 hours it appeared that those treated within 3 hours experienced a beneficial 
absolute reduction in late mortality (548 days) compared to those randomised later, 
i.e., ≥3 hours (P-value = 0.0317). Those with a good predicted prognosis (risk of 
death or dependency <50%) fared better with regards to late mortality (548 days) on 
control than on rtPA when contrast to those with a poor predicted prognosis (P-value 
= 0.0091). However, in an adjusted analysis the relative improvement in the model 
fit when allowing treatment and delay to interact was not as great as when allowing 
treatment and prognosis to interact; this attenuation of the effect of delay may be 
explained by confounding. Reassuringly each of the approaches adopted to tackle the 
problem of non-proportional hazards reached a similar conclusion. In particular, that 
treatment with rtPA interacts with patient prognosis such that those with a good 
predicted prognosis may be subject to a higher risk of late mortality whilst those with 
a poor predicted prognosis experience a late survival benefit. 
A recent IPDMA of nine completed trials (including IST-3) of recombinant tissue 
plasminogen activator (rtPA) in acute ischaemic stroke explored the impact of delay 
to randomisation upon the efficacy of rtPA on 90 day mortality (Emberson et al., 
2014). The analysis presented by Emberson et al. found no evidence to support the 
hypothesis that the effect of rtPA on short term mortality interacts with delay to 
randomisation (P-value = 0.22); although they did note that a lack of statistical power 
to detect a true interaction likely played a part. 
Three specific analytical approaches were adopted in this chapter in order to handle 
the problem of non-proportional hazards in the IST-3 data. It is important to reflect 
upon the pros and cons of each method so that recommendations may be made for 




allowing inferences to be made from an easily obtained summary measure 
quantifying the differences in standard Kaplan-Meier estimates of survival for any 
given follow-up time. However, limitations include the need to categorise continuous 
variables and the inability to efficiently adjust for more than one characteristic at a 
time. In the context of the IST-3 data it is known that those randomised later where 
on average younger and had less severe strokes (Sandercock et al., 2011). Delay and 
prognosis should therefore not be interpreted separately as confounding plays an 
important role. This approach is best justified as a useful exploration tool but caution 
must be emphasised when drawing inferences. 
Fitting individual Cox PHMs within epochs of follow-up offers an interpretable way 
of describing the dependency of treatment upon time in the presence of non-
proportional hazards. This is akin to the explicit inclusion of an interaction between 
treatment and follow-up time, i.e. a time-dependent effect; however, to also explore 
whether treatment – which already varies with time –varies with delay to 
randomisation and prognosis adds an extra layer of complexity which is difficult to 
express in a simple and clear way. Splitting follow-up time has a detrimental impact 
on the statistical power to detect true effects and is a penalty that must be weighed up 
with the appeal of this simpler summary. 
Finally, a simple binary logistic regression model using only the data corresponding 
to those countries which followed patients up for 18 months was implemented. This 
is perhaps an oversimplification of the problem especially when a biological 
explanation for the early hazard of mortality is most likely attributed to an early risk 
of SICH (Figure 8-6). Nevertheless the logistic regression fit does reach the same 
conclusion that was drawn from a Cox PHM fit within the later time epoch (183 to 
548 days) that predicted prognosis has an important interaction with the effect of 
rtPA on late mortality whilst delay to randomisation has little impact (see Figure 8-4 
and Figure 8-5). 
The conclusion of the previous chapter was that current prediction models for SICH 
post rtPA are similar to those for poor functional outcome. In general, they both 




gain the largest absolute benefit from rtPA in reducing six month poor functional 
outcome. Therefore whilst early mortality is likely attributable to the increase in risk 
from SICH, it is not yet possible to reliably identify those that will likely suffer an 
SICH from those that will not as current predictions largely correlate with the 
predicted risk of poor functional outcome.  
The direction of the results and the conclusions drawn were not affected by adopting 
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Figure 8-6 Cumulative mortality plots of rtPA-treated versus control patients split by record of 


























Figure 8-7 Scaled Schoenfeld residuals plotted against log time provide a visual assessment of 






A: Randomisation delay 
























Time split at 4.5 hours
























Time split at 3 hours
 
B (i): Predicted prognosis 


























Prognosis split at 50%


























Prognosis split at 40%
 
B (ii): Predicted prognosis 


























Prognosis split at 20%
 
Figure 8-8 Plot of differences by various categorisations of: (A) randomisation time; and (B(i) 




8.6 Appendix B: per protocol sensitivity analysis 
It is possible that the intention to treat analysis presented in this chapter could be 
different from a per protocol analysis. This was therefore conducted as a sensitivity 
analysis reducing the sample from 3034 patients to 2714. Here the analysis of the 
difference in mortality estimates based on the Kaplan-Meier estimates are repeated 
(Table 8-6 and Table 8-7). This did not lead to any qualitatively different conclusions 
with slight differences in estimates as would be expected. 
Similarly, the process of comparing Cox PHMs fit to time epochs was replicated in 
these data (Table 8-8). Again, there was no qualitative difference in conclusions. 
It appears safe to conclude that the findings presented in this chapter are robust 







Table 8-6 Per protocol analysis: Kaplan Meier estimates of mortality with 95% Point-wise CIs post stroke, with absolute difference of control minus rtPA. 
 Control (%) rtPA (%)  Difference (control - rtPA) 
Days since enrolment Deaths (n) KM estimate (95% CI) Deaths (n) KM estimate (95% CI)  Estimate (95% CI) P-value 
All patients, (Number of patients control versus rtPA, 1368 vs. 1346) 
7 84 6.14 (4.86 to 7.40) 125 9.29 (7.72 to 10.82)  -3.15 (-5.15 to -1.14) 0.0021 
183 359 26.27 (23.90 to 28.57) 354 26.32 (23.93 to 28.64)  -0.05 (-3.37 to 3.26) 0.9762 
548 479 36.23 (33.56 to 38.79) 464 35.47 (32.80 to 38.03)  0.76 (-2.93 to 4.45) 0.6868 
        
Delay to randomisation       
Time to randomisation, < 3 hours, (364 vs. 358) 
7 33 9.07 (6.07 to 11.97) 32 8.94 (5.93 to 11.85)  0.13 (-4.05 to 4.30) 0.9523 
183 131 35.99 (30.86 to 40.73) 113 31.56 (26.58 to 36.21)  4.42 (-2.47 to 11.32) 0.2082 
548 170 48.04 (42.50 to 53.04) 137 39.17 (33.79 to 44.10)  8.87 (1.51 to 16.23) 0.0182 
Time to randomisation, ≥ 3 hours, (1004 vs. 988) 
7 51 5.08 (3.71 to 6.43) 93 9.41 (7.57 to 11.22)  -4.33 (-6.60 to -2.06) 0.0002 
183 228 22.75 (20.11 to 25.30) 241 24.42 (21.69 to 27.06)  -1.68 (-5.41 to 2.05) 0.3785 
548 309 31.93 (28.90 to 34.82) 327 34.12 (31.03 to 37.07)  -2.19 (-6.42 to 2.03) 0.3093 
Time to randomisation, < 4.5 hours, (894 vs. 873) 
7 62 6.94 (5.25 to 8.59) 91 10.42 (8.37 to 12.43)  -3.49 (-6.11 to -0.87) 0.0091 
183 274 30.68 (27.59 to 33.64) 257 29.44 (26.35 to 32.40)  1.23 (-3.04 to 5.51) 0.5721 
548 356 40.98 (37.59 to 44.19) 329 38.53 (35.16 to 41.73)  2.45 (-2.20 to 7.10) 0.3023 
Time to randomisation, ≥ 4.5 hours, (474 vs. 473) 
7 22 4.64 (2.73 to 6.52) 34 7.19 (4.83 to  9.49)  -2.55 (-5.55 to 0.45) 0.0962 
183 85 17.96 (14.43 to 21.35) 97 20.55 (16.82 to 24.12)  -2.59 (-7.62 to 2.43) 0.3120 
548 123 27.21 (22.95 to 31.23) 135 29.77 (25.40 to 33.89)  -2.57 (-8.49 to 3.36) 0.3955 
        
        





Table 8-6 Continued from previous page 
     
 Control (%) rtPA (%)  Difference (control - rtPA) 
Days since enrolment Deaths (n) KM estimate (95% CI) Deaths (n) KM estimate (95% CI)  Estimate (95% CI) P-value 
Subgroups of differing stroke severity      
Predicted prognosis < 50%, (486 vs. 466) 
7 6 1.23 (0.25 to 2.21) 13 2.79 (1.28 to 4.27)  -1.56 (-3.34 to 0.23) 0.0884 
183 31 6.40 (4.20 to 8.56) 42 9.03 (6.39 to 11.60)  -2.63 (-6.03 to 0.76) 0.1287 
548 48 10.41 (7.57 to 13.16) 68 15.42 (11.96 to 18.74)  -5.01 (-9.41 to -0.62) 0.0253 
Predicted prognosis ≥ 50%, (882 vs. 880) 
7 78 8.84 (6.95 to 10.7) 112 12.73 (10.50 to 14.90)  -3.88 (-6.78 to -0.99) 0.0085 
183 328 37.19 (33.92 to 40.3) 312 35.46 (32.22 to 38.55)  1.73 (-2.76 to 6.22) 0.4512 
548 431 50.33 (46.82 to 53.6) 396 45.99 (42.53 to 49.24)  4.34 (-0.43 to 9.10) 0.0744 
Predicted prognosis < 40%, (345 vs. 317) 
7 5 1.45 (0.18 to 2.70) 8 2.52 (0.78 to 4.24)  -1.07 (-3.21 to 1.06) 0.3247 
183 16 4.65 (2.40 to 6.84) 26 8.23 (5.15 to 11.21)  -3.58 (-7.34 to 0.18) 0.0617 
548 26 8.00 (4.99 to 10.91) 41 13.57 (9.60 to 17.36)  -5.57 (-10.45 to -0.7) 0.0252 
Predicted prognosis ≥ 40%, (1023 vs. 1163) 
7 79 7.72 (6.07 to 9.34) 117 11.37 (9.41 to 13.29)  -3.65 (-6.19 to -1.11) 0.0048 
183 343 33.56 (30.60 to 36.39) 328 31.88 (28.97 to 34.67)  1.68 (-2.38 to 5.74) 0.4184 
548 453 45.64 (42.42 to 48.68) 423 42.18 (39.02 to 45.18)  3.46 (-0.93 to 7.85) 0.122 
Predicted prognosis < 20%, (96 vs. 100) 
7 0 0.00 (0.00 to 0.00) 2 2.00 (0.00 to 4.71)  -2.00 (-4.74 to 0.74) 0.1531 
183 1 1.04 (0.00 to 3.05) 3 3.00 (0.00 to 6.29)  -1.96 (-5.87 to 1.95) 0.3265 
548 3 3.44 (0.00 to 7.20) 5 5.30 (0.65 to 9.72)  -1.86 (-7.79 to 4.08) 0.5403 
Predicted prognosis ≥ 20%, (1272 vs. 1246) 
7 84 6.60 (5.23 to 7.96) 123 9.87 (8.20 to 11.51)  -3.27 (-5.41 to -1.12) 0.0028 
183 358 28.18 (25.66 to 30.61) 351 28.19 (25.65 to 30.65)  -0.01 (-3.53 to 3.51) 0.9961 




Table 8-7 Per protocol analysis: testing the difference of the differences 
Comparing groups Estimate SE. P-value 
Delay, <3 hours vs. ≥3 hours    
7 0.0446 0.0243 0.0659 
183 0.0610 0.0400 0.1270 
548 0.1107 0.0433 0.0106 
Delay, <4.5 hours vs. ≥4.5 hours    
7 -0.0094 0.0203 0.6433 
183 0.0383 0.0337 0.2559 
548 0.0502 0.0384 0.1917 
Prognosis, <50% vs. ≥50%    
7 0.0233 0.0173 0.1795 
183 -0.0436 0.0287 0.1292 
548 -0.0935 0.0331 0.0047 
Prognosis, <40% vs. ≥40%    
7 0.0257 0.0169 0.1285 
183 -0.0526 0.0282 0.0624 
548 -0.0903 0.0335 0.0070 
Prognosis, <20% vs. ≥20%    
7 0.0127 0.0178 0.4756 
183 -0.0195 0.0268 0.4676 




Table 8-8 Per protocol analysis: comparing Cox PHMs with and without treatment interactions. 
Note, n denotes the number of deaths, N the number at risk and df the degrees of freedom. 
Model comparison n N LR χ2 df P-value 
Time interval: 0 to 7 days 204 2714    
M1 vs M0 - - 0.79 1 0.3729 
M2 vs M0 - - 0.13 1 0.7155 
M3 vs M0 - - 1.12 2 0.5705 
M3 vs M1 - - 0.33 1 0.5666 
M3 vs M2 - - 0.99 1 0.3198 
Time interval: 7 to 90 days 395 2510    
M1 vs M0 - - 1.14 1 0.2858 
M2 vs M0 - - 4.91 1 0.0267 
M3 vs M0 - - 7.70 2 0.0213 
M3 vs M1 - - 6.56 1 0.0104 
M3 vs M2 - - 2.79 1 0.0949 
Time interval: 90 to 183 days 114 2111    
M1 vs M0 - - 6.01 1 0.0143 
M2 vs M0 - - 1.10 1 0.3024 
M3 vs M0 - - 6.16 2 0.0460 
M3 vs M1 - - 0.15 1 0.6987 
M3 vs M2 - - 5.10 1 0.0240 
Time interval: 183 to 548 days 230 1994    
M1 vs M0 - - 2.69 1 0.1012 
M2 vs M0 - - 6.61 1 0.0102 
M3 vs M0 - - 7.57 2 0.0227 
M3 vs M1 - - 4.88 1 0.0272 
M3 vs M2 - - 0.96 1 0.3270 
Model Key 
M0 β1*prognosis + β2*delay + β3*treatment 
M1 β1*prognosis + β2*delay + β3*treatment + β4*delay:treatment 
M2 β1*prognosis + β2*delay + β3*treatment + β5* prognosis:treatment 




Chapter 9: The impact of major haemorrhagic 
and arterial thrombotic events on mortality 
Background and summary 
Following an acute ischaemic stroke, patients may suffer an additional adverse event 
which can further complicate their recovery. In this chapter a large registry of stroke 
trial data is analysed assessing the impact that such events have upon patient 
mortality rate. Prediction models were developed in a competing risk framework for 
the separate prediction of major haemorrhage and arterial thrombosis over a 90-day 
follow-up period. Mortality rates could then be explored within defined strata of 
predicted risk. 
9.1 Introduction 
The risk of early mortality after ischaemic stroke is largely determined by the 
severity of the initial stroke in addition to the general health of the patient prior to the 
stroke. It has been shown that in the case of acute coronary syndrome thrombotic and 
haemorrhagic complications during recovery have a significant impact on patient 
mortality rate (Pocock et al., 2010). It is likely that intervening events which occur 
during recovery from a stroke (e.g., major bleeds and/or thromboses) will also impact 
the rate of mortality. The influence of acute medical complications and pneumonia in 
stroke has been investigated though there has been little focus on the separate impact 
of thrombotic and haemorrhagic events (Grube et al., 2013, Hong et al., 2008). 
Previous analyses have treated such events as fixed and therefore ignored the natural 
evolution of these events with time. If it were possible to identify those most likely to 
suffer a serious complication during recovery then this could be used to help manage 
the treatment or counselling of stroke patients. 
The aims of this chapter are: (i) to explore the impact that early complications have 




be predicted accurately; and (iii) to illustrate a stratified framework for understanding 
patient mortality according to grouped predicted risk strata. 
9.2 The Virtual International Stroke Trial Archive 
The Virtual International Stroke Trial Archive (VISTA) collaborative is run by a 
group of clinical stroke specialists who are experienced in undertaking clinical trials 
in stroke. The group has collected and collated datasets of completed stroke trials at 
the patient-level for the purpose of secondary investigation and analyses. It is 
envisaged that methodological lessons may be learnt through such analyses which 
could consequently improve the conduct and analysis of future trials (Ali et al., 2007, 
VISTA Collaborative, 2012). The VISTA-Acute collaboration was established in 
2001 offering researchers’ access to the patient level data from its repository of 
stroke trial data. This included a record of patients: medical history; demographic 
characteristics; laboratory measurements; treatment history; and any endpoints (i.e., 
primary, secondary and adverse events) recorded during the trial. At the time of 
writing this thesis, VISTA-Acute was one of six distinct subsections. It is part of 
strict VISTA policy that no reanalysis of the original randomised trial treatment be 
allowed. The obtained data extract is therefore stripped of any identifiable treatment 
codes. There is also no information made available regarding the original trial 
design. This makes it impossible to identify plausible sources of methodological or 
clinical heterogeneity. It is therefore important to recognise that any clinical findings 
made using VISTA data will normally require validation in new or pre-existing 
datasets which have been reported in detail. 
The data are provided by VISTA in a stacked format. Where a unique trial identifier 
has been supplied it is expected that the investigators will explore heterogeneity. In 
Chapter 6 a specific form of meta-analysis (type A) was introduced: that is an 
Individual Patient Data Meta-Analysis (IPD-MA) were the original patient level data 
are available for secondary analysis (Ahmed et al., 2014, Debray et al., 2013). The 
obtained VISTA extract has the same structure as any other IPD-MA only after the 
necessary data collection stage. This is an important difference to highlight though 




VISTA data: The typical format of an IPD-MA will see the investigators search the 
literature for all studies which meet their inclusion criteria. They will then contact all 
of the original investigators of these studies inviting them to contribute their raw 
patient level data. It is implicit that during this process the: patient population; the 
study design; the original mode of data collection and so on will be known in some 
detail for each of the individually included studies. Without this information it is not 
possible to ascribe any a priori notions about how sensible it is to pool the data. This 
is the case with the VISTA IPD-MA interpretation: without being able to identify the 
likely sources of clinical and methodological heterogeneity, any detected statistical 
heterogeneity that exceeds chance cannot be explained. It is very likely that the 
individual studies included in the VISTA extract will indeed differ from one another. 
This is the main drawback of using these data for testing clinical hypotheses, which, 
for the most part, will be ignored in the analysis that follows. 
The VISTA extract made available for analysis in this thesis was updated at various 
dates. The data were initially obtained on the 8th of October 2009; there were two 
additional extractions made on the 26th of March 2014 and the 16th of June 2014. 
9.2.1 Outcome definitions 
The initial extract included a detailed record of adverse events recorded during 
follow-up with a unique patient ID matching those with adverse events to their 
baseline data and associated trial endpoints (i.e., mortality and functional outcome). 
A clinician (Dr. William Whiteley) categorised each of these events into the 
following broad levels which comprised any: ischaemic strokes (IS); myocardial 
infarctions (MI); pulmonary embolisms (PE); deep-venous thromboses (DVT); 
unstable anginas (UA); transient ischaemic attacks (TIA); other thrombotic events; 
major intracranial haemorrhages (ICH); gastrointestinal haemorrhages (GI); other 
extra-cranial haemorrhages (ECH); or minor haemorrhages (MH). 
More data were requested from VISTA (26/03/2014) who provided an extract with 
far more detail denoting any adverse events as recorded by each trial. This comprised 
a total of 33,982 records. First this was restricted to those entries that had been coded 




adverse event levels categorised as one of the events identified above were mapped 
onto the new extract, leaving 4,810 rows to search. Of these entries there were 1,527 
unique levels. Finally, a text search was carried out so as to limit the length of time 
spent searching by hand for those important events that remained. A series of word 
fragments were screened against the adverse event list. The word fragments 
comprised of a number of key terms most likely to capture those serious adverse 
events. By fixing all event data text as upper-case the search undertaken was not case 
sensitive. The word fragment comprised the following key terms: haem; hemo; hem; 
bleed; blood; ICH; infarct; cereb; throm; isch; stroke; myocard; TIA; venous; recur; 
deep; PE; embolus; and angina. This reduced the set of events levels to be 
considered to a total of 383. 
For the purpose of this chapter two composite binary events were defined (i) a major 
haemorrhagic event (i.e., ICH, GI and ECH) and (ii) an arterial thrombotic event 
(i.e., IS, MI, UA and other thrombotic events). The number of recurrent events was 
not sufficient to warrant the modelling of multiple thrombotic and/or haemorrhagic 
events. Following categorisation, all analyses of intermediate adverse events (defined 
as above) were restricted to the first record only. 
Any records of an adverse event denoting a progression of the initial stroke were 
excluded. 
9.2.1.1 Censoring scheme for outcomes 
Time to event information was available through a record of the number of days 
from study start to the observed event. The patients in the VISTA extract had a 
minimum follow-up of 90 days. The primary endpoints were functional outcome 
measured on the modified Rankin Scale (mRS) at 90 days. It was assumed that those 
with as observed mRS had been followed for at least 90 days giving a strict 
definition of the end of follow-up. Any events beyond this point were right censored. 
Of those who suffered an adverse event 28 occurred on the day the study began (i.e., 
day zero), similarly 30 deaths occurred. To accommodate for these events the 




random value added to their observed time chosen from a Uniform (0, 0.5) 
distribution. Similarly, for those dead on day zero a random value was chosen from a 
Uniform (0.5, 1) and added to the observed death time. This meant that a patient 
suffering an adverse event on the day that the study began was randomly chosen a 
time over the first 12 hours of that day. Likewise, for those patients who died on the 
day the study began a time across the latter 12 hours of the day was randomly 
chosen. By setting the parameters of the two uniform distributions in this way the 
possibility that a patient who suffered an adverse event on the day the study began 
could also suffer mortality later that same day was allowed. 
9.2.2 Baseline characteristics 
A record of all the baseline characteristics made available within the obtained 
VISTA extract is provided in Table 9-1. 
Smoking status was recorded in detail with the following unique levels: ex-smoker; 
habitual smoker; occasional smoker; answered yes; never and no. For the purpose of 
this chapter levels associated with being a current or previous smoker were collapsed 
and a binary indicator denoting any smoking versus no smoking was defined. In the 
case of patient record of ECG scan abnormal and borderline were combined creating 
a binary variable. 
Detailed records of non-randomised medications were retrieved following a second 
update of the original extract (16/06/2014). This included the Anatomical 
Therapeutic Chemical (ATC) Classification System which had been hand coded by a 
VISTA student directly from each entry recorded in the original clinical report forms 
per patient. These have been checked and verified by various clinicians and whilst 
supported by the VISTA group cannot be guaranteed. The ATC codes were used in 
this chapter to identify previous and current: antiplatelets (including: aspirin 
[B01AC06]; clopidogrel [B01AC04]; dipyridamole [B01AC07]; and ticlopidine 
[B01AC05]) and anticoagulants (including: heparin [B01AB01]; warfarin 
[B01AA03]; and dicoumarol [B01AA01]). Each medication was coded as a binary 
yes/no variable. A record of the start time and stop time measured in days from the 




prior anticoagulant, any of the treatment records characterised by a positive entry on 
the prior medication variable or else those with a negative start time (used to denote 
pre-origin) were selected using the aforementioned ATC codes for various 
antiplatelets and anticoagulants. Current treatments were recorded throughout trial 
follow-up and are therefore strictly speaking “time-varying covariates”. To avoid 
introducing any further complexity to the prediction models though, these were 
treated as fixed and restricted to only those administered within the first week (i.e., 7 





Table 9-1 Baseline characteristics and outcome event information for VISTA data extract. 
Variable Description 
Patient characteristics and medical history 
Trial Anonymous trial ID (categorical variable, 1 to 7) 
Age Measured in years at baseline 
Male Male=1/female=0 
Weight Measured at baseline in kgs 
Systolic BP Measured at baseline in mmHg 
Diastolic BP Measured at baseline in mmHg 
Smoker* Detailed record, coded as current or 
previous=1/none=0 
History of hypertension Present=1/Absent=0 
History of previous stroke Present=1/Absent=0 
History of TIA Present=1/Absent=0 
History of diabetes mellitus Present=1/Absent=0 
History of MI Present=1/Absent=0 
History of CHF Present=1/Absent=0 
History of atrial fibrillation Present=1/Absent=0 
Detail of stroke on admission 
NIHSS Measured at baseline 
Type or stroke Ischaemic=2/haemorrhagic=1/unknown=0 
Hemisphere Stroke in right hemisphere=1/ left=0 
ECG results Recorded as Abnormal=2/Borderline=1/Normal=0 
Cause of initial stroke Recorded as large vessel/cardioembolic/lacunar/other 
Medication 
Prior antiplatelets* Present=1/Absent=0 
Prior anticoagulants* Present=1/Absent=0 
Current antiplatelets* Present=1/Absent=0 
Current anticoagulants* Present=1/Absent=0 
rtPA administered Present=1/Absent=0 
Outcome 
Major haemorrhage* Intracranial, gastrointestinal or other extra-cranial (1/0) 
Time of above Recorded in days 
Minor haemorrhage* Any minor bleeds (1/0) 
Time of above Recorded in days 
Arterial thrombosis* Ischaemic stroke, myocardial infarction, unstable 
angina, or other thrombosis (1/0) 
Time of above Recorded in days 
Venous thrombosis* Pulmonary embolism or deep venous thrombosis (1/0) 
Time of above Recorded in days 
mRS Recorded at 90 days (ordinal measure ranging from 0 
to 6) 
Mortality Present=1/Absent=0 
Time of above Recorded in days 
Note: (*) defined for this thesis. Abbreviations: CHF – Coronary Heart Failure; TIA – Transient 
Ischaemic Attack; NIHSS – National Institute of Health Stroke Score; mRS – modified Rankin Score; 





9.3 Methods: Time-varying Cox PH Model 
The impact made on the rate of mortality by an adverse event that occurs during 
follow-up can be measured by introducing the variable as a time-varying covariate 
within a Cox Proportional Hazards (PH) modelling framework. This is a simple 
extension of the fixed-covariate Cox PH model which was defined in Chapter 7. The 
terms “fixed” and “varying” are introduced here so as to distinguish the two 
covariate types, with fixed-covariate Cox PH models denoting the standard Cox 
model. The time-varying Cox PH model accommodates for the inclusion of 
covariates which can change value over time. This is achieved by allowing multiple 
entries per patient conditional on the time-varying covariates change (Hosmer Jr et 
al., 2011). All time-varying covariates considered in this chapter are categorical: 
each indicating the presence or absence of an associated complication i.e., an arterial 
thrombosis and/or a major haemorrhage. A general vector of patient characteristics, 
z(t), is specified such that each of the included elements can be defined as a function 
of time which includes fixed-covariates as a special case, 
Parameter estimates are obtained in exactly the same way as the fixed-covariate Cox 
PH model by maximising the partial log-likelihood. Coding a time-varying covariate 
for a Cox PH model requires some caution as a degree of manipulation is required so 
as to format the data correctly. Imagine using a stopwatch to record the track times 
for a series of runners competing in the 400m sprint. Suppose that if a runner 
stumbles during the course of their run, a split will be used thus marking their 
stumble-time in addition to their track-time. This is precisely what is required in the 
case of a time-varying covariate. If an adverse event occurs during follow-up: the 
time is split at the stumble-time creating two entries for that patient; otherwise only 
one entry is required. The interpretation of the effect estimates differ from the fixed-
covariate fit (Altman and De Stavola, 1994). Under the fixed-covariate Cox PH 
model each effect estimate is made with respect to a covariate measured at time zero. 
For the time-dependent Cox PH model the effect estimates are obtained on entry or 
at any other time during follow-up, under the PH assumption.




9.4 Methods: Modelling Competing Events 
As was noted in section 9.2.1, patient recovery is complex and subject to many 
additional adverse events. Composite events were created in the VISTA data so as to 
simplify the problem as well as increase the power through the number of events per 
variable (Steyerberg, 2009). Restricting to the two adverse composite events and 
mortality observed over follow-up, a standard competing event set-up is described. 
Patient recovery is assumed to follow a particular pathway as seen in Figure 9-1. All 
patients enter the study alive (the initial state) then, over the course of follow-up, one 
of four events are observed: (1) arterial thrombosis; (2) major haemorrhage; (3) 









Figure 9-1 The competing event set up with endpoints: arterial thrombosis; major 
haemorrhage; and death. 
It is noted that more complex multi-state processes can be envisaged with patients 
passing through states (e.g., initial → arterial thrombosis → major haemorrhage) 




competing event framework described in Figure 9-1 will be considered. All analysis 
is restricted to first event data only. 
Outcomes of this form require an appropriate method of analysis. One such approach 
works by extending the standard methods used in survival analysis to incorporate 
such complex outcome structures. In general, patient outcome information is fully 
described by a record of time to event, T, and a record of the type of event, D, which 
takes on any real valued number between 0 and k (Note that 0 typically denotes a 
censored event). Therefore the observed time, T, is the minimum time till one of the 
events 0, 1, 2,…, k occur. The specific set up described in Figure 9-1 implies that k 
takes on the real values 1, 2 and 3 representing: arterial thrombosis; major 
haemorrhage; and death respectively. 
9.4.1 A competing event 
Concepts unique to survival analysis were introduced in Chapter 8: Patients are 
followed for a fixed period of time during which any events of interest are recorded 
(e.g., recurrent stroke or death). The idea of censoring was discussed as not every 
patient will have an observed time-to-event over follow-up; this means that a 
proportion will either be censored during follow-up or else censored at the end of 
follow-up (i.e., right censored). They will however have censoring times. This 
introduces one of the essential assumptions in survival analysis: that the event 
distribution and the censoring distribution are independent of one another. In the case 
of competing events though an additional reason for censoring is introduced. The 
following analogy is offered as a way to illustrate this. 
A game of outdoor tennis is to be played between two opponents. Match day comes 
but immediately before the two adversaries take to the court there is a freak thunder 
storm calling halt to the contest before it can even begin. The match score was the 
event of interest however this was precluded by the occurrence of a separate and 
exclusive competing event: the thunder storm. When studying the elderly or frail who 
are subject to a far greater number of multiple morbidities there is an abundance of 
competing events which can occur. Despite this the analyses traditionally adopted by 




censoring on the competing event and thus obtaining incorrect predicted risks (Koller 
et al., 2012, Wolbers et al., 2009). The key issue is that by assumption when 
censoring a patient it is argued that the patient could go on to develop the event of 
interest in the future. However, when the reason for censoring precludes the event of 
interest then this assumption no-longer holds and the error of making it will 
introduce a bias into prediction (Putter et al., 2007). 
Throughout this chapter the events of primary interest are major haemorrhages and 
arterial thromboses; with death playing the role of the freak thunderstorm calling 
time on the occurrence of either of these adverse events. 
9.4.2 Analysing competing risk data 
9.4.2.1 Cause specific hazards 
The hazard function is fundamental in the analysis of survival data; however, the 
hazard function as defined in Chapter 8 does not incorporate competing events. An 
adaptation of this function is defined which describes the hazard of suffering the 
event of interest (e.g., arterial thrombosis) in the presence of some competing event. 
This is the cause-specific hazard function (Putter et al., 2007): 
Here D denotes the possibly censored outcome, e.g., arterial thrombosis (k = 1, with 
h1 (t)) and death (k = 2, with h2 (t)). It follows that by integrating over time the 
cumulative cause specific hazard is obtained and similarly the marginal survival 
function can be obtained as exp (-Hk (t)). 
When working with competing events the cumulative incidence function provides a 
non-parametric estimate of the probability of failure from any cause: 
In the absence of censoring, the cumulative incidence function for the kth event can 


















in the sample (Wolbers et al., 2014). Adjustments must be made when censoring has 
occurred (Putter et al., 2007). An estimate for equation (9.3) is given by: 
The cumulative incidence function describes the joint probability of failing from the 
kth cause having survived up until some given time point, tj-1 as estimated by the 
Kaplan-Meier estimator (van Houwelingen and Putter, 2012). An estimate for the 
cause specific hazard is given by, 
which, for discrete time, is simply the ratio of the number of observed events at time 
t over the number that remain within the risk set. 
9.4.2.2 Regression models for competing risk 
The two most commonly adopted methods for adjusting for multiple covariates in a 
competing risk analysis are: (i) cause-specific Cox PH models and (ii) the cumulative 
incidence Fine and Gray (FG) modelling approach. Each method is characterised by 
the way the event causes are handled and the necessary definition of the risk set, i.e., 
those that remain at risk from the event of interest (Lau et al., 2009). 
With two exclusive endpoints, i.e., an event of interest and the competing event, two 
Cox PH models are fit modelling the cause specific hazards for: (i) the event of 
interest, which censors on the competing event as well as any other right censored 
observations; and similarly (ii) a model for the competing event itself, this time 
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The cause-specific hazard approach therefore involves modelling the specific hazard 
from each failure using standard Cox PH models. Subjects who suffer any observed 
events (i.e., the competing event or the event of interest) are removed from the risk 
set used to estimate the respective hazard (Lau et al., 2009). In order to produce 
absolute risk estimates the following expression must be used which combines each 
of the cause-specific hazard models obtained for each mode of failure, 
This avoids introducing the bias associated with a standard application of the Cox PH 
model (Wolbers et al., 2009).  
Fine and Gray suggested a different approach which involves direct regression on the 
cumulative incidence via the subdistribution hazard (Fine and Gray, 1999). The 
subdistribution hazard is based on the complement to the incidence function for the 
kth event, i.e., the absolute estimate of a subject surviving without suffering the event. 
This is analogous to the survival function which can be transformed as the hazard, or 
in the case of competing risks, the subdistribution hazard, 
with Ik (t) as defined in equation (9.3). Putter et al. note that the subdistribution 
hazard is uniquely different from the cause-specific hazard in how the risk set is 
defined (Putter et al., 2007). In the case of the cause-specific hazards, failure from 
any event will result in a removal from the corresponding risk set. For the 
subdistribution hazard though, any failures from the competing event are retained 
within the risk set (Lau et al., 2009). 
Fine and Gray suggested direct regression on the subdistribution hazard through a 
model which assumes proportional subdistribution hazards, 















All aspects of model development outlined in Chapter 2 apply in the development of 
a prediction model in the presence of competing events. The Fine and Gray approach 
has been highlighted as appealing from the perspective of prediction, whilst 
modelling the cause-specific hazards is deemed more suitable for etiological research 
(Wolbers et al., 2009, Lau et al., 2009). 
9.4.2.3 Model development – assessing non-linearity 
Restricted cubic splines (RCS) have been used throughout this thesis to explore the 
plausible existence of non-linear relationships between continuous predictors and 
outcomes. This process is complicated when multiple imputation methods have been 
used to account for missing data. Typically the placement of the knots will be at 
specific values which correspond to the percentiles of the observed sample 
distribution, for example with four knots, the 5th, 35th, 65th and 95th percentiles would 
be used (Harrell, 2001). Alternatively, their exact placement can be specified, though 
this will usually require some clinical justification. Nevertheless, imputing missing 
values multiple times generates several complete and conditionally plausible 
datasets, each of which will have slightly different covariates distributions and thus 
slightly different knot positions specified by the percentiles of the distribution. A 
more explicit and practical approach was demonstrated by Vergouwe et al., with the 
adoption of a majority multiple fractional polynomial selection process (Vergouwe et 
al., 2010) whereby the most frequently selected transformation out of the m imputed 
datasets is chosen for the final pooled model fit. 
Fractional polynomials (FP) offer an alternative method for the modelling of non-
linear predictor outcome associations (Royston and Altman, 1994). Here a reduced 
set of powers are specified, e.g., Ρ = [-2, -1, -0.5, 0, 0.5, 1, 2, 3] where 0 denotes the 
natural logarithm, ln (X), which necessarily restricts the predictor to be positive and 
therefore enforces the required scaling, x* = x + δ, for the random variable x with 
some constant δ such that x* is positive (Sauerbrei and Royston, 1999). For a first 
degree fractional polynomial a single transformation is chosen from this small set of 




exponents outlined in P. Selection involves iterating though a table of deviance 
statistics which at each stage contrast the proposed transformation (i.e., p ≠ 1) with 
the simple linear fit (i.e., p = 1). More flexible fits can be allowed by adding a larger 
number of transformations of x from the same set of exponents, P. Note that if a first-
degree fractional polynomial is of the form β0 + β1xp1, then a two-degree fractional 
polynomial is of the form β0 + β1xp1+ β2xp2. In practice, a two-degree fractional 
polynomial is adequate to capture most transformations (Royston et al., 1999). The 
general expression for the mth degree FP is given by, 
where, 
Routines for selecting a fractional polynomial transformation for continuous 
predictors in an FG model are not currently available. However, in practice the two 
approaches (i.e., cause-specific Cox PH models and FG models) give similar results 
(Wolbers et al., 2009) therefore in this chapter non-linear transformations were 
selected under separate cause-specific hazard models for arterial thrombosis and 
major haemorrhage before being applied within the Fine and Gray subdistribution 
hazard framework. 
9.4.2.4 Model development – variable selection 
The variables to include in each of the multivariable clinical prediction models are 
restricted by the availability of patient variables provided in the original VISTA 
extract. Issues with overfitting were discussed in Chapter 2. However, with few 
variables to choose from no further selection was deemed necessary. In each case a 
full prediction model was fit with no screening of significance. 
































9.4.2.5 Model performance – competing event models 
For prediction models, discrimination summarises how well a given model or score 
separates observed events in follow-up based on a weighted sum of characteristics 
measured at baseline. A standard statistic in this context is the c-index: the 
probability of correctly ordering a given pair of patients, one with an event and one 
without. The patient with the event should be assigned a greater score or predicted 
risk than the patient without. With competing events it is necessary to make an 
alteration to the definition of possible pairs. One such definition is that which was 
proposed by Wolbers et al. who suggest that a relevant pairing can be made between 
those who suffer the event of interest at some given time point and those patient still 
at risk (Wolbers et al., 2009). This requires that any competing events are retained 
within the risk set whilst those who suffer either the event of interest or else those 
censored (whichever occurs first) are removed at the corresponding time during 
follow-up. This definition closely corresponds to the risk set implicitly used during 
Fine and Gray regression on the subdistribution hazard. 
Absolute estimates of patients’ predicted risk can be obtained using a Fine and Gray 
model. Typically, a non-parametric estimate of the observed absolute risk for a given 
grouping of predicted risk made through a Cox PH model (e.g., predicted categorised 
into equally sized deciles) is obtained using the Kaplan-Meier estimator (van 
Houwelingen, 2000). With competing events the cumulative-incidence function is 
used in place of the Kaplan-Meier estimator (Wolbers et al., 2009).  
9.4.3 Between trial heterogeneity 
The trial level data made available for analysis within the obtained VISTA extract 
comprised data from seven individual trials. The predictor-outcome associations 
could differ between trials; therefore between trial heterogeneity was explored. 
Formal tests for heterogeneity are presented in an attempt to assess departures from a 
single common effect (Debray et al., 2013). 
9.4.4 Missing data 
A multiple imputation method is used to account for any observed missingness in the 




the impact of the biases associated with complete-case analyses should the data be 
missing at random (Vergouwe et al., 2010). 
The structure of the dataset plays an important role in how missingness should be 
explored. It is implicit that if between-trial heterogeneity is of interest then Trial 
itself must be incorporated within the imputation process. Resche-Rigon et al. 
discuss an across studies approach for dealing with systematically missing values in 
the context of IPD-MAs (Resche-Rigon et al., 2013). Often entire covariates will be 
missing from certain studies, however; the information between trials may be 
utilised. Treating Trial as random in this multi-level approach would be one way of 
doing a one-step imputation with stacked datasets. The approach taken in this chapter 
though is to regard the process as one which might be encountered in practice with 
Trial being treated as a stratification factor and separately implementing multiple 
imputation within each of the identifiable datasets. First prediction models will be 
developed in a single trial where missing data is handled using multiple imputation. 
Second the developed models will be evaluated within the remaining Trial cohorts, 
where again for each of the identifiable datasets, missing data will be handled, 
generating multiple imputed datasets. 
It is recommended that when imputing missing data for survival analysis instead of 
using the raw time variable during imputation, a cumulative hazard estimate (e.g., the 
Nelson–Aalen estimate) should be used in its place (White and Royston, 2009). The 
cause specific cumulative hazards for death, arterial thrombosis and major 
haemorrhage were therefore used during imputation. 
9.4.5 Sensitivity Analyses 
Concomitant treatment with rtPA was reported in two out of seven trials. It is not 
clear whether this is a misreporting or true absence of treatment with rtPA. This was 






Of the 10574 patients made available for analysis 10003 had an ischaemic or 
unknown stroke on entry. There was evidence to suggest that 190 of these patients 
experienced a progressive stroke and where therefore removed – leaving a total of 
9834 patients for analysis. Over the course of a 90-day follow-up period 465 (5%) 
and 404 (4%) of these patients developed an arterial thrombosis and a major 
haemorrhage respectively. 
9.5.1 Baseline characteristics and outcomes 
Patient summary characteristics split by trial are provided below (see Table 9-2 and 
Table 9-3). The median patient age varied between trials, ranging from as young as 
67 to as old as 74. Similarly, median stroke severity, as measured using the NIHS 
Score, ranged from as low as 11 to as high as 17. From these tables it is evident that 
patient characteristics differed from trial to trial according to both the prevalence of 
various risk factors measured at baseline in addition to the incidence of outcomes 
recorded in follow-up. 
A non-parametric estimate of the hazard functions for arterial thrombosis, major 
haemorrhage and death is provided in Figure 9-2 using the muhaz library in R 
(Kenneth and Gentleman, 2010). There is a notable positive skew in each distribution 
suggesting that patients are at greatest risk immediately following their initial stroke. 
The hazard rate for major haemorrhage is larger than that of arterial thrombosis but 
declines rapidly over the first week whilst the hazard rate of arterial thrombosis has a 
steadier decline over the first 20-days or so after which point the two rates are about 
the same. 
9.5.2 Missing data 
The proportion and frequency of observed missingness for each variable is 
summarised in Table 9-2 and Table 9-3. Of the seven trials, Trial 1 was both the 
largest and the most complete. For a number of trials some variables were missing 
entirely – either because they were never recorded or else never provided to the 
VISTA collaborative. For Trials 2, 4, 5, 6 and 7 there was no record of patients 




(CHF). There was no record of: prior Transient Ischaemic Attack (TIA) for Trials 4 
and 5; of prior stroke for Trials 6 and 7; and finally of electrocardiogram (ECG) or of 
any arterial thrombotic outcomes in follow-up for Trial 3. 
Joint missingness was explored for each of the seven obtained trials using cluster 
plots (see section 9.7 Appendix A on page 332). In what follows those completely 
missing variables are excluded from interpretation: Of those recruited to Trial 1, 
4640 (94%) had completely observed baseline data, 286 had one missing value (6%) 
and 17 (<1%) had two or more missing values. For Trials 2 to 6 the median 
proportion of completely observed baseline data was 86% (with Inter Quartile Range 
[IQR] 81% to 89%). More detail regarding the frequency of NAs per observation is 
provided in Appendix A. 
A multiple imputation model was implemented within each of the trial datasets, 
conditioning in each case on the dependency specific to the corresponding trial. This 
was implemented in R using the mice library (van Buuren and Groothuis-
Oudshoorn, 2011). The adopted model included: all of the variables listed in Table 
9-2 and Table 9-3; indicator variables for the events of interest in follow-up; and the 
estimated hazard function for 90 day arterial thrombosis, major haemorrhage and 
mortality. A new variable was defined so as to account for those instances of missing 
variables for vascular events. Therefore, any record of: previous stroke, TIA; and MI 
were merged into one newly defined composite variable denoting any vascular event. 
Predictive mean matching was used for continuous variables, binary logistic 
regression for binary categorical variables and proportional odds models for ordinal 
categorical variables. Missing data were imputed multiple times generating ten 
complete datasets per trial. 
For the most part, Trial 3 is excluded from the analysis conducted in this chapter due 
to the complete lack of any arterial thrombotic adverse events in follow-up. Explicit 










































B: piecewise exponential estimate (bin-width=4-days)
 
Figure 9-2 Estimates of the instantaneous rate of failure: (A) smoothed kernel estimate with bandwidth set at 4-days; and (B) piecewise exponential estimate 





Table 9-2 Patient characteristics for trials 1 through to 4. (Note: acronyms are as denoted in Table 9-1). For continuous measurements the median and inter-
quartile range is quoted; for categorical measurements the frequency and % is provided (continued in Table 9-3). 
 Trial 1 (N = 4943) Trial 2 (N = 574) Trial 3 (N = 825) Trial 4 (N = 1289) 
Characteristic Measure Missing Measure Missing Measure Missing Measure Missing 
Age, years 71 (60-78) - 74 (66-81) - 73 (63-79) 1 (<1) 72 (62-78) - 
Gender, male 2713 (55) - 274 (48) - 428 (52) 1 (<1) 683 (53) - 
Weight, kg 75 (65-85) 2 (<1) 73 (62-84) 1 (<1) 75 (66-85) 79 (10) 75 (65-86) 10 (1) 
SBP (mmHg) 154 (138-172) 14 (<1) 151 (135-172) 16 (3) 155 (140-172) 54 (7) 152 (135-170) 1 (<1) 
DBP (mmHg) 82 (72-94) 15 (<1) 80 (69-91) 16 (3) 80 (72-90) 55 (7) 80 (70-90) 2 (<1) 
Smoker, yes 2167 (44) 10 (<1) 303 (53) - 769 (93) 47 (6) 322 (25) 119 (9) 
Atrial Fibrillation 1270 (26) - 152 (26) - 216 (26) 47 (6) 319 (25) 119 (9) 
Hypertension 3663 (74) - 428 (75) - 548 (66) 47 (6) 873 (68) 119 (9) 
Previous stroke 978 (20) - 125 (22) - 83 (10) 47 (6) 624 (48) 75 (6) 
TIA 409 (8) 279 (6) 109 (19) - 50 (6) 47 (6) 0 (0) 1289 (100) 
Diabetes 1135 (23) - 139 (24) - 180 (22) 47 (6) 315 (24) 119 (9) 
Myocardial Infarction 641 (13) - 87 (15) - 103 (12) 47 (6) 288 (22) 119 (9) 
CHF 467 (9) - 0 (0) 574 (100) 38 (5) 47 (6) 0 (0) 1289 (100) 
NIHSS 12 (8-17) - 17 (13-20) - 15 (11-18) 48 (6) 11 (7-17) - 
Hemisphere 2625 (53) 1 (<1) 264 (46) 5 (1) 376 (46) 50 (6) 655 (51) 1 (<1) 
ECG 3206 (65) - 395 (69) 91 (16) 0 (0) 825 (100) 703 (55) 19 (1) 
Prior antiplatelet 1606 (32) - 92 (16) - 305 (37) - 535 (42) - 
Current antiplatelet 3163 (64) - 146 (25) - 509 (62) - 0 (0) - 
Prior anticoagulant 332 (7) - 49 (9) - 70 (8) - 207 (16) - 
Current anticoagulant 1307 (26) - 183 (32) - 279 (34) - 0 (0) - 
rtPA 1915 (39) - 0 (0) - 483 (59) 47 (6) 316 (25) - 
Outcomes by 90 days         
Arterial thrombosis 311 (6) - 16 (3) - 0 (0) - 53 (4) - 
Major haemorrhage 236 (5) - 23 (4) - 12 (1) - 49 (4) - 






Table 9-3 Patient characteristics for trials 5 through to 7 as well as an overall trials summary. (Note: acronyms are as denoted in Table 9-1). For continuous 
measurements the median and inter-quartile range is quoted; for categorical measurements the frequency and % is provided. 
 Trial 5 (N = 1419) Trial 6 (N = 383) Trial 7 (N = 401)  Total (N = 9834) 
Characteristic Measure Missing Measure Missing Measure Missing  Measure Missing 
Age, years 72 (63-79) 1 (<1) 67 (59-73) - 68 (61-75) -  71 (61-78) 2 (<1) 
Gender, male 803 (57) 1 (<1) 245 (64) - 227 (57) -  5373 (55) 2 (<1) 
Weight, kg 72 (63-80) 71 (5) 73 (65-82) - 74 (65-84) -  75 (65-85) 163 (2) 
SBP (mmHg) 160 (140-180) 2 (<1) 150 (140-170) - 154 (140-169) -  154 (138-171) 87 (1) 
DBP (mmHg) 86 (79-97) 2 (<1) 90 (80-100) 1 (<1) 85 (77-90) -  82 (72-93) 91 (1) 
Smoker, yes 307 (22) 191 (13) 1 (<1) - 233 (58) 2 (<1)  4102 (42) 369 (4) 
Atrial Fibrillation 414 (29) 191 (13) 66 (17) - 28 (7) 152 (38)  2465 (25) 509 (5) 
Hypertension 772 (54) 191 (13) 133 (35) - 98 (24) 152 (38)  6515 (66) 509 (5) 
Previous stroke 628 (44) 133 (9) 0 (0) 383 (100) 0 (0) 401 (100)  2438 (25) 1039 (11) 
TIA 0 (0) 1419 (100) 31 (8) - 2 (<1) 152 (38)  601 (6) 3186 (32) 
Diabetes 259 (18) 191 (13) 63 (16) - 23 (6) 1 (<1)  2114 (21) 358 (4) 
Myocardial Infarction 200 (14) 191 (13) 18 (5) - 3 (1) 152 (38)  1340 (14) 509 (5) 
CHF 0 (0) 1419 (100) 0 (0) 383 (100) 0 (0) 401 (100)  505 (5) 4113 (42) 
NIHSS 12 (8-18) 4 (<1) 13 (7-18) 15 (4) 12 (8-16) -  12 (8-18) 67 (1) 
Hemisphere 711 (50) 7 (<1) 185 (48) 15 (4) 193 (48) 23 (6)  5009 (51) 102 (1) 
ECG 814 (57) 37 (3) 215 (56) 9 (2) 146 (36) 3 (1)  5479 (56) 984 (10) 
Prior antiplatelet 415 (29) - 76 (20) - 31 (8) -  3060 (31) - 
Current antiplatelet 0 (0) - 99 (26) - 196 (49) -  4113 (42) - 
Prior anticoagulant 42 (3) - 6 (2) - 2 (<1) -  708 (7) - 
Current anticoagulant 0 (0) - 120 (31) - 174 (43) -  2063 (21) - 
rtPA 0 (0) - 0 (0) - 0 (0) -  2714 (28) 2824 (29) 
Outcomes by 90 days          
Arterial thrombosis 55 (4) - 16 (4) - 14 (3) -  465 (5) - 
Major haemorrhage 43 (3) - 29 (8) - 12 (3) -  404 (4) - 




9.5.3 Measuring the impact of adverse events on mortality 
The median time to an arterial thrombotic event across all trials (excluding Trial 3) 
was 11 days (IQR: 4 to 32) and 3 days (IQR: 1 to 15) for a major haemorrhagic 
event. Of those who suffered a major haemorrhage during follow-up 44% were dead 
by the end of the 90 day follow-up, similarly of those who suffered an arterial 
thrombotic event, 51% died, whilst 15% of those without a major haemorrhage and 
15% of those without an arterial thrombosis died by the end of the 90-day follow-up. 
Note that in setting up the time-varying covariates it was noted that on occasion a 
death and an adverse event were recorded as having occurred on the same day. An 
approach implemented by Frank Harrell in the ie.setup function in his rms 
library is to subtract some random number chosen from a Uniform (0, 1) which thus 
breaks such ties (Harrell, 2013). The approach used here therefore stipulates that 
death can follow an adverse event but cannot occur exactly at once. 
The risk of 90-day all-cause mortality was assessed with an adjusted time varying 
covariate Cox proportional hazards model. The risk of mortality was predicted for 
each of the patients using a simple pre-existing prediction model based on patient age 
and stroke severity (baseline NIHS Score) previously developed and evaluated 
within the VISTA data to predict the risk of three month mortality amongst stroke 
patients with acute cerebral ischemia (König et al., 2008, Weimar et al., 2004). The 
obtained linear predictor (i.e., on the log odds scale) was entered into the time 
updated Cox PH model along with the two time-varying binary covariates: arterial 
thrombosis and major haemorrhage. The possibility of a non-linear association 
between outcome and the log odds of mortality was allowed through a restricted 
cubic spline with five knots. Finally, the model was stratified by Trial therefore 
incorporating a different baseline hazard for each level of Trial whilst assuming 
common effects for all other covariates across the unique Trial levels. 
Table 9-4 below summarises the constant relative effect upon the 90 day hazard of 
mortality and the proportional hazard assumption. The occurrence of any major 
haemorrhagic events or any arterial thrombotic events during recovery was 




underlying predicted risk of mortality. The quoted hazard ratios suggest an increase 
in the rate of mortality, however when inspecting the Schoenfeld residual plots 
(Figure 9-3) a more complex association is apparent: an interaction with time. A test 
for the correlation between rank ordered time and the scaled Schoenfeld residuals 
gave P-values <0.0001 and 0.0065 for major haemorrhage and arterial thrombosis 
respectively. The visible departure from the constant effect estimate assumed by the 
time-independent Cox PH model implies that the effect of an early adverse event has 
a larger relative effect on mortality than a late adverse event. The impact of a major 
haemorrhage and arterial thrombosis on the risk of mortality within 90-days of acute 
ischaemic stroke cannot therefore be summarised by two constant relative hazards. 
It could be argued that this dependency on time holds some biological plausibility 
when it is considered that those who suffer a serious adverse event not long after 
their initial stroke have had less time to recover and thus the impact on mortality is at 
its greatest – though this is speculation (Figure 9-3). 
 
Table 9-4 Impact of intervening events on mortality rate, fit as time varying covariates with 
adjustment for the underlying risk of mortality in a stratified Cox PH model (see text for 
details). 
Intervening event Number dead Adjusted HR 95%CI P-value 
Arterial thrombosis     
Absent 1248 1.00 -  
Present 235 12.94 11.18 to 14.99 <0.0001 
Major Haemorrhage     
Absent 1312 1.00 -  
Present 171 5.60 4.73 to 6.62 <0.0001 


















































Figure 9-3 Spline fit through Schoenfeld residuals for the time-varying covariates: arterial thrombosis and major haemorrhage. The broken red horizontal 




9.5.4 Prediction of early complications 
9.5.4.1 Univariable associations for adverse events 
Not all of the baseline patient characteristics were observed for each of the trials 
(Table 9-2 and Table 9-3). An estimated predictor-outcome association cannot be 
obtained in each of the available trials. Exploring heterogeneity on the univariable 
level therefore necessarily depends upon the associated number of individual trial 
estimates made. Recall that no covariate effects on the risk of arterial thrombosis 
could be obtained for Trial 3 as there were no records of any such events. Each of the 
univariable associations were obtained under the Fine and Gray model with death 
and the opposing adverse event regarded as competing events in the case of arterial 
thrombosis and major haemorrhage respectively per trial. All continuous covariates 
were fit as simple linear terms. Each estimate was pooled over the 10 imputed 
datasets using Rubin’s rules; these individual trial estimates were then pooled across 
the available trials using both fixed effect and random effects meta-analysis. A 
formal assessment of heterogeneity was made using the Q-statistic. Between trial 
heterogeneity was regarded as statistically significant with a P-value <0.05. 
None of the covariate associations with arterial thrombosis had a statistically 
significant level of between trial heterogeneity (Table 9-5); although there was 
statistically significant between trial heterogeneity present in the estimates of the 
impact of NIHSS on major haemorrhage (Table 9-6). 
The pooled estimates for the risk of arterial thrombosis were similar whether pooled 
using a fixed effect or a random effects meta-analytic approach. There was evidence 
to suggest that those patients who were: older; with worse index strokes (i.e., larger 
NIHS Scores); with a history of atrial fibrillation; hypertension; any previous 
vascular events; diabetic; with an abnormal ECG scan; and who were on prior 
antiplatelets or anticoagulants were at an increased risk from suffering an arterial 
thrombotic event. Similarly being male and having a smaller weight was associated 
with a decreased risk from arterial thrombosis. 
The pooled estimates for the risk of major haemorrhage were similar irrespective of 




patients who were: older; with worse index strokes; a history of atrial fibrillation; had 
an abnormal ECG scan; and who were on prior antiplatelets or anticoagulants were at 
an increased risk from suffering a major haemorrhage. Similarly, a history of having 
smoked in the past or of being a current smoker and currently receiving 






Table 9-5 Univariable Fine and Gray models fits for arterial thrombotic events within 90 days (competing events: death and major haemorrhage), pooled 
over 10 MI data sets, and over possible trials. 
 Fixed effect meta-analysis  Random effects meta-analysis  Heterogeneity 
Measure sHR 95%CI P-value  sHR 95%CI P-value  Q df P-value 
Age, per year 1.02 1.01-1.03 <0.0001  1.02 1.01-1.03 <0.0001  2.76 5 0.7375 
Male 0.84 0.70-1.00 0.0558  0.83 0.65-1.08 0.1659  6.34 5 0.2745 
Weight (kg) 0.99 0.98-1.00 0.0009  0.99 0.98-1.00 0.0285  7.8 5 0.1677 
SBP (mmHg) 1.00 1.00-1.00 0.6573  1.00 1.00-1.00 0.6573  1.61 5 0.9005 
DBP (mmHg) 1.00 0.99-1.00 0.4306  1.00 0.99-1.00 0.4306  1.64 5 0.8962 
Atrial Fibrillation 1.55 1.28-1.89 <0.0001  1.55 1.28-1.89 <0.0001  2.54 5 0.7705 
Hypertension 1.27 1.02-1.59 0.0325  1.27 1.02-1.59 0.0325  1.01 5 0.9618 
Any vascular event 1.39 1.14-1.69 0.0012  1.39 1.14-1.69 0.0012  0.45 3 0.9304 
Diabetes Mellitus 1.52 1.24-1.86 0.0001  1.52 1.19-1.94 0.0008  5.45 5 0.3637 
Baseline NIHSS 1.02 1.00-1.04 0.0151  1.02 1.00-1.05 0.0736  7.84 5 0.1652 
Abnormal hemisphere 1.12 0.93-1.35 0.2274  1.11 0.91-1.36 0.2891  5.17 5 0.3956 
Abnormal ECG 1.97 1.59-2.45 <0.0001  1.97 1.59-2.45 <0.0001  3.87 5 0.5677 
Antiplatelets            
Prior 1.57 1.30-1.90 <0.0001  1.57 1.30-1.90 <0.0001  2.52 4 0.6412 
Current 0.97 0.78-1.21 0.8061  0.86 0.56-1.31 0.4732  3.77 3 0.2878 
Anticoagulants            
Prior 1.60 1.17-2.17 0.0029  1.60 1.17-2.17 0.0029  0.97 2 0.6145 
Current 1.16 0.93-1.46 0.1925  1.16 0.93-1.46 0.1925  2.68 3 0.4433 





Table 9-6 Univariable Fine and Gray models fits for major haemorrhagic events within 90 days (competing events: death and arterial thromboses), pooled 
over 10 MI data sets, and over possible trials. 
 Fixed effect meta-analysis  Random effects meta-analysis  Heterogeneity 
Measure sHR 95%CI P-value  sHR 95%CI P-value  Q df P-value 
Age, per year 1.02 1.02-1.03 <0.0001  1.02 1.02-1.03 <0.0001  3.65 6 0.7241 
Male 1.10 0.91-1.34 0.3295  1.08 0.87-1.35 0.4852  6.50 6 0.3691 
Weight (kg) 1.00 0.99-1.00 0.1392  1.00 0.99-1.00 0.1392  5.26 6 0.5105 
SBP (mmHg) 1.00 1.00-1.00 0.6385  1.00 1.00-1.01 0.1871  10.12 6 0.1196 
DBP (mmHg) 0.99 0.99-1.00 0.0574  1.00 0.99-1.01 0.7618  9.13 6 0.1663 
Atrial Fibrillation 1.82 1.48-2.24 <0.0001  1.87 1.48-2.37 <0.0001  6.58 6 0.3610 
Hypertension 1.16 0.92-1.47 0.2106  1.16 0.92-1.47 0.2155  6.05 6 0.4177 
Any vascular event 1.06 0.86-1.31 0.5801  1.07 0.78-1.46 0.6715  7.48 5 0.1873 
Diabetes Mellitus 1.15 0.92-1.44 0.2308  1.15 0.92-1.44 0.2308  3.76 5 0.5849 
Baseline NIHSS 1.07 1.06-1.09 <0.0001  1.07 1.04-1.09 <0.0001  12.90 6 0.0447 
Abnormal hemisphere 1.02 0.84-1.24 0.8248  1.02 0.84-1.24 0.8248  1.20 6 0.9771 
Abnormal ECG 1.52 1.22-1.91 0.0002  1.52 1.22-1.91 0.0001  1.10 5 0.9544 
Antiplatelets            
Prior 1.37 1.12-1.68 0.0026  1.37 1.12-1.68 0.0026  2.58 6 0.8597 
Current 0.46 0.36-0.58 <0.0001  0.46 0.36-0.58 <0.0001  2.58 4 0.6311 
Anticoagulants            
Prior 1.90 1.39-2.59 0.0001  2.05 1.31-3.21 0.0017  6.09 4 0.1924 
Current 0.96 0.75-1.23 0.7449  1.00 0.66-1.50 0.9918  5.91 4 0.2060 




9.5.4.2 Multivariable prediction models for adverse events 
Multivariable FG models were developed using data from Trial 1 in the VISTA 
extract. This was the largest of the seven trials and the most complete (see Table 9-2 
and Table 9-3). The remaining trials were used for testing model performance. 
Multiple Fractional Polynomials’ (MFP) were fit for all continuous measurements 
which included: patient age; weight; systolic BP; and NIHSS. The stability of the 
imputations for the continuous variables in Trial 1 is illustrated in Figure 9-4 with 
each of the 10 obtained imputed sample distributions overlain in the same plot. There 
was no discernible variability in the covariate distributions across the ten imputed 
datasets. The majority MFP approach supported the same transformation for each of 
the 10 imputed datasets. Only one non-linear transformation was chosen for the 
major haemorrhage FG model which was a natural log transformation for NIHSS. 
This was chosen consistently across each of the imputed sets – all other continuous 
variables entered the FG competing risk models as linear. The NIHS Score ranges 
from 0 to 42 increasing in unit increments. Since a natural zero exists within the 
NIHSS range it was necessary to shift all values up by a single unit. After selection, 
these transformations were all fit within the FG model framework using a single 
imputed dataset. The final multivariable FG models are presented in Table 9-7. 
Under the 10EPV rule of thumb there were a total of 31 candidate degrees of 
freedom for the arterial thrombosis model and 24 candidate degrees of freedom for 
the major haemorrhage model. The assumption of proportionality was assessed by 
visually inspecting residual plots. There was no indication from these plots that the 
covariate-outcome effects depended on time (see section 9.8 Appendix B on page 
340). Risk of arterial thrombotic events was associated with: increasing age (per 10 
years); being a current or previous smoker; having an abnormal ECG; diabetic; a 
prior history of taking antiplatelets; a prior history of taking anticoagulants; and a 
concurrent record of antiplatelets. Similarly, increasing age (per 10 years); increasing 
NIHSS; being male; and concurrent antiplatelets were all associated with an 

























































Table 9-7 Fine and Gray regression models for the prediction of: (i) arterial thrombosis and (ii) major haemorrhage. 
 Arterial thrombosis competing risk model  Major haemorrhage competing risk model 
Variable Coefficient (SE) sHR (95% CI) P-value  Coefficient (SE) sHR (95% CI) P-value 
Age, per 10 yearsa 0.133 (0.056) 1.14 (1.02-1.27) 0.0173  0.159 (0.064) 1.17 (1.03-1.33) 0.0125 
SBP, per 10mmHga -0.006 (0.021) 0.99 (0.96-1.04) 0.7883  -0.031 (0.024) 0.97 (0.92-1.02) 0.1913 
Weight, per 10kga -0.073 (0.045) 0.93 (0.85-1.02) 0.1043  -0.008 (0.046) 0.99 (0.91-1.09) 0.8567 
NIHSSa        
Linear -0.005 (0.011) 1.00 (0.97-1.02) 0.6634  - - - 
Log (x + 1) - - -  1.330 (0.185) 3.78 (2.63-5.43) <0.0001 
Gender, male -0.143 (0.130) 0.87 (0.67-1.12) 0.2687  0.412 (0.144) 1.51 (1.14-2.00) 0.0042 
Current or previous smoker 0.258 (0.124) 1.29 (1.02-1.65) 0.0372  -0.155 (0.151) 0.86 (0.64-1.15) 0.3031 
ECG, abnormal scan 0.484 (0.150) 1.62 (1.21-2.18) 0.0012  -0.011 (0.169) 0.99 (0.71-1.38) 0.9488 
Hemisphere, right vs. left side 0.164 (0.117) 1.18 (0.94-1.48) 0.1601  0.216 (0.134) 1.24 (0.95-1.61) 0.1068 
History of diabetes 0.396 (0.130) 1.49 (1.15-1.92) 0.0024  0.037 (0.160) 1.04 (0.76-1.42) 0.8176 
History of hypertension 0.021 (0.145) 1.02 (0.77-1.36) 0.8876  0.077 (0.162) 1.08 (0.79-1.48) 0.6353 
History of atrial fibrillation 0.207 (0.135) 1.23 (0.94-1.60) 0.1252  0.025 (0.166) 1.03 (0.74-1.42) 0.8816 
History of any vascular eventb 0.042 (0.124) 1.04 (0.82-1.33) 0.7306  -0.143 (0.142) 0.87 (0.66-1.15) 0.3159 
Prior medication        
Any antiplateletc 0.368 (0.124) 1.44 (1.13-1.84) 0.0031  0.136 (0.144) 1.15 (0.86-1.52) 0.3453 
Any anticoagulantd 0.437 (0.194) 1.55 (1.06-2.26) 0.0239  0.294 (0.232) 1.34 (0.85-2.12) 0.2063 
Concurrent medication        
Any antiplateletc 0.296 (0.123) 1.35 (1.06-1.71) 0.0156  -0.641 (0.147) 0.53 (0.39-0.70) <0.0001 
Any anticoagulantd 0.137 (0.128) 1.15 (0.89-1.47) 0.2849  -0.161 (0.152) 0.85 (0.63-1.15) 0.2901 
a Functional form of continuous variables selected using a multiple fractional polynomial routine chosen at P-value <0.157 
b Any previous strokes, TIAs or MIs 
c Any used of aspirin, clopidogrel, dipyridamole or ticlopidine 




9.5.4.3 Model performance 
Model performance was evaluated in six of the seven available trials, five of which 
offered an assessment of the external validity of the Fine and Gray competing event 
model fits. For each of the trials missing data were imputed using multiple 
imputation methods generating 10 completed datasets, therefore each of the 
performance measures provided per trial in Table 9-8 (i.e., the c-statistic and 
calibration slope) corresponds to a pooled estimate over 10 imputed datasets using 
Rubin’s rules (Vergouwe et al., 2010). Across the five external trial datasets, the 
prediction model for arterial thrombosis achieved c-statistics which ranged from as 
low as 0.50 to as high as 0.67, suggesting no discrimination to moderate 
discrimination depending on which trial was considered. The corresponding pooled 
random effects estimate of those evaluation c-statistics was 0.59 (95%CI 0.52 to 
0.66) with a 95%PI of 0.37 to 0.81. Similarly, for major haemorrhage the c-statistics 
ranged from as low as 0.57 to as high as 0.74, suggesting poor to good discrimination 
depending on which trial was considered. The pooled random effects estimate was 
0.64 (95%CI 0.58 to 0.70) with a 95%PI of 0.46 to 0.82. 
Calibration was not consistent across trials indicating that in addition to potential 
over-fitting within the development dataset there were real differences in the risk 
profiles of patients across the individual trials. The incidence of adverse events 
differed from trial to trial and in all but one of the five external datasets the Fine and 
Gray models over-predicted the observed 90 day risk from both events (Table 9-8). 
The calibration slope gives an indication as to how well the linear predictor 
generalises from the development cohort to the evaluation cohort and thus 
summarises whether the relative risks were well specified by the proposed fit (van 
Houwelingen, 2000). In some trials the models were a good fit but in others they 
were very poor. The 95% prediction intervals illustrate the extent of this suggesting 
that based on these data 95% of any estimates obtained for future trials the effect 
sizes amongst these models will could range from too large right through to too small 
without updating (Steyerberg, 2009). More detail regarding calibration appears in the 





Table 9-8 Model performance of Fine and Gray regression models within six trial datasets pooled over 10 imputed datasets. 
  Discrimination  Predicted 90-day riskc  Calibrationb 
Trial Model c-index 95% CIa 95% PI  Estimated Observed  Slope 95% CI 95% PI 
1 (Development-set) Thrombosis 0.64 0.61 to 0.67 -  6.29% 6.29%  1.00 0.79 to 1.21 - 
 Haemorrhage 0.71 0.67 to 0.74 -  4.76% 4.77%  1.00 0.82 to 1.16 - 
2 Thrombosis 0.50 0.37 to 0.64 -  6.24% 2.79%  0.00 -0.80 to 0.80 - 
 Haemorrhage 0.74 0.63 to 0.85 -  7.56% 4.01%  1.47 0.44 to 2.51 - 
4 Thrombosis 0.67 0.60 to 0.73 -  5.24% 4.11%  1.16 0.67 to 1.66 - 
 Haemorrhage 0.61 0.53 to 0.69 -  6.95% 3.80%  0.53 0.11 to 0.96 - 
5 Thrombosis 0.65 0.58 to 0.72 -  4.75% 3.88%  1.02 0.43 to 1.61 - 
 Haemorrhage 0.57 0.49 to 0.65 -  6.86% 3.03%  0.34 -0.04 to 0.71 - 
6 Thrombosis 0.50 0.37 to 0.64 -  4.07% 4.18%  -0.06 -0.96 to 0.84 - 
 Haemorrhage 0.62 0.52 to 0.72 -  6.16% 7.57%  0.40 0.02 to 0.78 - 
7 Thrombosis 0.53 0.38 to 0.68 -  4.17% 3.49%  0.38 -0.82 to 1.58 - 
 Haemorrhage 0.73 0.56 to 0.89 -  4.40% 2.99%  1.39 0.25 to 2.52 - 
            
Pooled RE model estimated Thrombosis 0.59 0.52 to 0.66 0.37 to 0.81  - -  0.59 0.06 to 1.13 -1.12 to 2.31 
 Haemorrhage 0.64 0.58 to 0.70 0.46 to 0.82  - -  0.57 0.25 to 0.88 -0.29 to 1.42 
a Boot strap 95% CIs are provided for each of the individual estimates per trial (over 1000 replications). Estimated SEs were used to obtain the pooled estimates 
b Estimated risk obtained from the mean predicted risk from the FG models. Observed risk obtained from cumulative incidence function 
c Calibration slope estimated via a Fine and Gray model with the linear predictor produced for the corresponding trial as the only variate 




9.5.5 Mortality rate stratified by predicted risk 
The predicted risk from arterial thrombosis and major haemorrhage can be obtained 
using the two multivariable FG models presented in Table 9-7 at any time-point 
within the 90 day follow-up period. Predicted risks were evaluated using the 
predict.crr function in the cmprsk R library which combines a Breslow-type 
estimate of the underlying hazard with the linear predictor for each patient across the 
period of follow-up (Gray, 2013).  
Each patient is given a predicted 90 day cumulative risk of major haemorrhage and 
predicted 90 day cumulative risk of arterial thrombosis (Figure 9-5). Excluding the 
development set, all those patients with intermediate events in follow-up are plotted 
irrespective of trial. When restricting attention to the margins in the left-hand side 
plot, it is seen that those with observed major haemorrhages and those with observed 
arterial thromboses in follow-up have similarly distributed predicted risks with little 
distinction between the two. The right-hand side plot shows a simple random sample 
(SRS) of 800 patients who were either dead or alive and event free for illustrative 
purposes. Again, looking at the marginal distributions (calculated on all patients who 
were either alive and event free or dead) for predicted 90 day cumulative risk of 
arterial thrombosis risk and of major haemorrhage it can be seen that the predicted 90 
day cumulative risk of major haemorrhage is far better at separating those who are 
dead from those who are alive and event free than the arterial thrombosis model. 
Finally, it is noted that there was no indication that particular adverse event types 
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Figure 9-5 Predicted risk of arterial thrombosis vs. predicted risk of major haemorrhage. The left hand plot shows all recorded major haemorrhagic and 
arterial thrombotic events, whilst the right hand side displays a SRS of 800 patients who were either alive or dead. Marginal box plots are based on summary 




Using the median predicted 7-day risk estimated within the development dataset 
(Trial 1) it is possible to specify a categorisation of predicted adverse event risk 
creating four distinct strata of low versus high risk of major haemorrhage and arterial 
thrombosis, i.e.: (i) low risk of major haemorrhage and low risk of arterial 
thrombosis; (ii) low risk of major haemorrhage and high risk of arterial thrombosis; 
(iii) high risk of major haemorrhage and low risk of arterial thrombosis; and finally 
(iv) high risk of major haemorrhage and high risk of arterial thrombosis. Within each 
of the identifiable risk stratum the cumulative risk of mortality can be estimated 
across the five evaluation trial datasets which could then be pooled. 
In Figure 9-6 each grey box represents the random effects point estimate with the 
corresponding 95%CI and assessment of trial heterogeneity (i.e., Q-statistic, degrees 
of freedom (df) and I-squared value). The black diamond shows the overall pooled 
estimate. Contrasting the low and high risk strata for one event type whilst holding 
the other event type constant is a useful way of exploring which of the predicted risk 
groups has the largest impact on the rate of mortality. There was a considerable 
increase in the rate of mortality when moving from low to high risk from a major 
haemorrhage whilst holding the risk of arterial thrombosis constant (low or high)  
The individually obtained estimates had a large degree of between trial heterogeneity 
with large I-squared values as high as 77% in some strata. However, this was 
anticipated since the incidence of the individual outcomes split by trial (see Table 
9-2and Table 9-3) ranged between 6% and 18%. It is noted that in another meta-
analysis which combined the cumulative risks obtained from various studies over 
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Patient survival following an acute ischaemic stroke is heterogeneous. This 
variability is explained at least in part by various measurable characteristics 
regarding: the severity of the stroke; patient’s age; as well as their underlying 
medical history (Weimar et al., 2004). Intervening events that occur over the course 
of recovery also impact the rate of mortality; although attributing a single constant 
hazard ratio to each adverse event type may not be plausible, indeed, the impact on 
mortality may interact with time. This interaction may though be biologically 
plausible as those who suffer an adverse event late in follow-up will have had longer 
to recover and therefore be in a better position to overcome an adverse event. 
Whereas those that suffer an adverse event early on in follow-up will be in a poorer 
condition and therefore the impact could indeed cause a greater increase in the 
hazard of mortality. 
Clinical prediction models developed for predicting patient risk from major 
haemorrhage and arterial thrombosis over a 90-day follow-up period performed 
moderately well in evaluation. However, this was highly dependent upon the dataset 
used. The prediction model developed to predict major haemorrhage after acute 
ischaemic stroke achieved good discrimination for the most part though was poorly 
calibrated in different trials. It is important to recognise that calibration is a joint 
property of both model and data (Vickers and Cronin, 2010), though it was not 
possible to investigate whether poor calibration could be attributed to particular trial 
level characteristics and therefore these models require further assessment in data 
were aspects of design etc. is known. 
The data analysed in this chapter are made up of a highly selected sample of stroke 
patients who are unlikely to represent patients typically seen during standard clinical 
practice. These results should therefore be interpreted with caution. They could, 
however, play a role in the recruitment of patients to future randomised trials for the 
purpose of enriching the cohort of patients. 
One of the strengths of this analysis is that it illustrates the application of novel 




models in the presence of competing events. However, further work is warranted. For 
instance, whilst a competing risk framework enables the modelling of covariates for 
the risk of the primary event of interest in the presence of a competing event, a more 
complex multistate system is more plausible in practice. Under such a system, 
patients can either: suffer a single adverse event type after which they will either 
survive or die; alternatively they may suffer multiple event types again following 
which they will either survive or die. By modelling each of the cause-specific hazard 
pathways it would be possible to explore how patient risk profiles differ according to 
common adverse events during recovery. A very large registry of routinely collected 
data would be needed to ensure a sufficient number of event types moving from one 






9.7 Appendix A: Missing data 
Missing data were explored per trial using hierarchical cluster plots each presented 
alongside a simple dot-plot summarising the number of missing variables per 
observation (see Figure 9-7 to Figure 9-13 below). The most common jointly missing 
variables were blood pressure (systolic and diastolic), in Trials 4 and 5 the same 
variables were jointly missing: previous stroke; myocardial infarction; diabetes 
mellitus; hypertension; any (previous or current) smoking status; and atrial 
fibrillation. Similarly, in Trial 7 those variables that were commonly jointly missing 
were: myocardial infarction; hypertension; atrial fibrillation; and previous TIA. 
The proportion of joint missingness was smallest amongst Trials 1, 2 and 6. From 
Trials 1 through to 7, the proportion of missingness varied with: 6%, 17%, 11%, 
11%, 20%, 10% and 42% missing respectively (note that those completely missing 
variables are excluded from this assessment). The trial with the fewest complete data 
was therefore Trial 7 with only 58% of patients with no missing values and 38% of 
those in this trial with 4 missing values or more.  
It is noted that Trial 3 had the greatest number variables with jointly missing entries, 
which included all but the following variables: previous or current treatment with 











































































































































































TRIAL 1 (N=4943) Number of Missing Variables Per Observation
Frequency
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TRIAL 2 (N=574) Number of Missing Variables Per Observation
Frequency







































































































































































TRIAL 3 (N=825) Number of Missing Variables Per Observation
Frequency

































































































































































TRIAL 4 (N=1289) Number of Missing Variables Per Observation
Frequency
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TRIAL 5 (N=1419) Number of Missing Variables Per Observation
Frequency
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TRIAL 6 (N=383) Number of Missing Variables Per Observation
Frequency


























































































































































TRIAL 7 (N=401) Number of Missing Variables Per Observation
Frequency













9.8 Appendix B: residual plots for Fine and Gray 
models 
The plots below are used to assess whether or not the required proportionality 
assumption holds in the case of the two developed Fine and Gray models. The 
corresponding Schoenfeld type residuals were obtained from the crr function 
implemented in R (Gray, 2013). Under the proportionality assumption a plot of the 
residuals against the unique failure times should illustrate a random scatter of points 
with no discernable shape, i.e., no significant trends against time. A non-parametric 
smoothing function can be used to help guide the eye. In the residual plots that 
follow a lowess smoother was used to highlight the general trend of the scatter of 
points. 
Figure 9-14 and Figure 9-15 show the residual plots for the covariate effects in the 
arterial thrombosis model. With no strong departures from a random scatter, the 
proportionality assumption looks as if it holds for these data. Similarly Figure 9-16 
and Figure 9-17 show the residual plots for the covariate effects in the major 
haemorrhage model. Again there is no strong departure from a random scatter in any 















































































































































































































































































































































































































































































































































































































9.9 Appendix C: Calibration of models 
Calibration plots are provided for each of the trial datasets within which individual 
patient predictions could be made for 90 day arterial thrombotic risk and 90 day 
major haemorrhage risk (see Figure 9-18 to Figure 9-23 below). For each trial a 
single imputed complete dataset was used to illustrate the general direction of model 
calibration in these data, whilst the values provided in Table 9-8 are pooled over the 
10 imputed datasets. 
Since Trial 1 was used in the development of the two competing risk regressions it 
should be anticipated that the predicted risk matches the observed risk accurately. In 
this regard the calibration plots for Trial 1 offer no real value in the assessment of 
model performance and are provided for completeness only. 
For Trials 2, 5 and 7, the prediction model for major haemorrhage consistently 
overestimated the risk of haemorrhage. In the case of Trial 4 there was an indication 
that the major haemorrhage model underestimated those at low risk and 
overestimated those at high risk, whereas with Trial 6, the same model consistently 
underestimated the risk of haemorrhage. 
The prediction model for arterial thrombosis was poorly calibrated within Trials 2, 6 
and 7. This model was well calibrated in Trials 4 and 5, although there is an 
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Trial number 5 (N=1419)

















































Trial number 6 (N=383)

















































Trial number 7 (N=401)



























9.10 Appendix D: Sensitivity analyses 
There was a record of treatment with recombinant tissue plasminogen activator 
(rtPA) amongst those randomised in Trials 1 and 3. This comprised some 29% of the 
patients that made up the VISTA extract. It is not clear whether the other trials (i.e., 
Trials 2, and 4 through to 7) suffer from a misreporting of a concomitant treatment 
with rtPA or else a true record of no rtPA. An assessment is now made as to what 
impact this makes to the Fine and Gray models. Additionally, an exclusion analysis 
is considered with all patients on rtPA removed from analysis. As Trial 1 was one of 
the few trials with a record of concomitant rtPA treatment it is straightforward to 
make the required adjustment within the multivariable Fine and Gray models (see 
Table 9-7). 
The effect of rtPA on arterial thrombosis was not significant with an adjusted sHR 
of 0.97 (95%CI 0.76 to 1.23) and a P-value of 0.8007. There were small differences 
in the magnitude of the other effects after including rtPA, though they were not 
substantial enough to change any conclusions previously drawn (see Figure 9-24). 
The effect of rtPA on major haemorrhage was significant at the 5% level with an 
adjusted sHR of 1.52 (95%CI 1.16 to 2.00) and a P-value of 0.0023. There was no 
qualitative difference in the magnitude of the other effects though the effect of 
increasing NIHSS was slightly less in the model which included rtPA. Additionally, 
the effect of prior use of any anticoagulants was slightly larger though remained non-
significant (Figure 9-25). 
Excluding those who received rtPA from the Fine and Gray models reduced the 
sample size from 4943 to 3028. This inflated the SEs which therefore widened the 
95%CIs (see Figure 9-24 and Figure 9-25). For arterial thrombosis, the effect 
estimates for those characteristics related to medical history were further from the 
null effect whilst estimates for treatments were closer to the null. A similar inflation 
in the effect sizes was seen in the case of major haemorrhage. Diabetes was 
associated with a considerably larger increase in the hazard of haemorrhage as was 
NIHSS whilst current antiplatelets no longer increased the hazard of major 



































































































































As before Including rtPA Excluding rtPA
Fine and Gray models for arterial thrombosis
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Chapter 10: Discussion and Recommendations 
Background and summary 
This thesis has explored the use of clinical prediction models in stroke medicine. This 
work serves as an example as to how trial datasets can be better analysed to 
investigate more individualised estimates of a given treatment effect. 
10.1 An overview of the thesis 
This thesis has explored the possibility of a stratified framework for the treatment of 
ischaemic stroke patients based on their predicted risks of treatment harm and 
benefit. A critique of the methods of prediction was made contrasting formal with 
informal prediction to determine whether expert clinical gestalt differs from the 
predictions made by an objective clinical prediction model. 
10.1.1 Methods of prediction in stroke 
Recurrent events that follow a stroke in the short, medium and long term are 
important. Reliable predictions about prognosis would be useful in the management 
and treatment of patients. It was found that the clinical prediction models which are 
currently available for the prediction of recurrent stroke or MI (Chapter 3) suffered 
from the same methodological and reporting issues which persist in other medical 
conditions (Bouwmeester et al., 2012). Continuous predictors were frequently 
categorised thus discarding a considerable amount of predictive information. Authors 
favoured data-dependent variable selection techniques which were often applied to 
small samples of data with too few events to reliably estimate parameters. The 
quality of data was also poor with retrospective studies used and missing data poorly 
handled. A common theme was poor reporting: the consumers of research need to be 
informed about any decisions made by the researchers over the course of model 




these weaknesses, a number of published evaluation studies suggested that some of 
these models achieved a moderate level of discriminative ability. 
Expert opinion is the clear alternative to statistical prediction. A direct comparison of 
the two methods is a crucial – though rarely adopted – step in the process of model 
evaluation. Models identified in Chapter 3 were compared with clinicians’ 
predictions in a prospective single centre observational study (Chapter 4). It was 
found that there was no real difference between them with regards discrimination 
suggesting that formal and informal methods of prediction not only discriminated 
between events and non-events moderately well but also did so similarly. 
Models for the prediction of functional outcome (Chapter 5) were identified via a 
pre-existing systematic review – again these were compared to the predictions made 
by clinicians within the same observational cohort used in Chapter 4 (Veerbeek et al., 
2011). Similar levels of ordinal discrimination were achieved suggesting that models 
and clinicians did as well as each other. 
10.1.2 Application of clinical prediction models in RCTs 
Exploring treatment interactions through one-at-a-time subgroup analyses is an 
inefficient method for investigating whether treatments benefit some patients but 
harm others. Multivariable risk prediction is a superior way of understanding patient 
heterogeneity and the consequent heterogeneity of the treatment effect (Kent et al., 
2010, Pocock et al., 2014). 
Three of the largest trials of aspirin in acute ischaemic stroke (i.e., IST-1, CAST and 
MAST-I) were re-analysed to explore the hypothesis that targeting treatment with 
aspirin to those patients at a high predicted risk of thrombosis (arterial or venous), a 
low predicted risk of haemorrhage, or a higher predicted risk of poor functional 
outcome would lead to overall benefit (Chapter 6). It was concluded that based on 
these datasets and the common simple clinical variables between them that there was 
no support for the stratified treatment of patients. It is likely that new prognostic 




A secondary analysis of the IST-3 dataset was presented in Chapter 7 exploring the 
stratified treatment of acute ischaemic stroke patients with rtPA according to their 
risk of treatment related harms (i.e., post rtPA SICH or poor functional outcome). 
Those at a high predicted risk of poor functional outcome were more likely to 
experience benefit with an indication that the beneficial relative effect of rtPA was 
greater with increasing risk. Paradoxically, those with a greater risk of post rtPA 
SICH also derived a larger treatment benefit. This is explained by the tendency for 
the two groups (i.e., high risk SICH and high risk poor outcome) to share similar 
attributes. Therefore, based on those existing clinical prediction models it appears 
that the stratification of treatment based on post rtPA SICH risk is not possible. 
In Chapter 8 an exploratory analysis of the IST-3 dataset was presented. Here the 
impact of rtPA on mortality was investigated across an 18 month follow-up period 
whilst allowing for the possibility that treatment may interact with predicted 
prognosis at baseline and the delay in receiving treatment. These findings support the 
need for early administration of rtPA amongst those eligible and also support the 
treatment of those with a poor predicted prognosis at baseline. Although this analysis 
indicated that there is the potential for harm (increased risk of mortality) amongst 
those with a good prognosis (i.e., mild strokes) an emphasis should be placed on 
further randomised study of these patients before any firm conclusion can be drawn. 
Finally, Chapter 9 explored the impact that secondary events (i.e., arterial thrombosis 
and major haemorrhage) have on mortality after an acute ischaemic stroke using data 
from the VISTA repository. A central aspect to this chapter was the illustration of a 
methodologically sophisticated approach to the handling of competing events. Again 
it was concluded that the predicted risks of thrombosis and haemorrhage based on 
simple clinical variables were too strongly correlated with the risk of other events 





10.2 Clinical Implications 
The hypothesis that overall treatment benefit varies according to a patient’s risk from 
treatment related harms is a biologically plausible one. Should there be any empirical 
evidence to support this hypothesis then a stratified approach would surely be 
advocated and adopted into clinical practice. In this thesis the use of pre-existing or 
newly developed clinical prediction models in randomised trial datasets failed to 
support such qualitative interactions under treatment with aspirin or treatment with 
rtPA in acute ischaemic stroke. However, if the current alternative is to base 
contraindications to treatment on single risk factors, each implicitly weighted by the 
treating clinician; then the lack of an interaction based on multivariable prediction 
techniques – a more formalised approach to combining the totality of clinical 
evidence – highlights concerns over the possible under-treatment of patients. 
Thrombolysis with rtPA is one of the most effective treatments for acute ischaemic 
stroke; though the current licences held in Europe and the US are restricted. The 
Stroke Thrombolysis Trialists’ Collaborative (STTC) group addressed these concerns 
in their IPD-MA (Emberson et al., 2014).They found that regardless of patient age, 
NIHSS score, and the heightened risk of SICH, rtPA significantly improved the 
chance of a good outcome when administered within a four and a half hour window 
from stroke onset. It is hoped that the work by the STTC group will now galvanise 
support for an extension in the current rtPA licences (Hill and Coutts, 2014). The 
STTC’s conclusions corroborate the findings made in Chapter 7: the elderly and 
those that suffer more severe strokes are precisely those that stand to gain the largest 
benefit from rtPA. 
Aspirin administered within 48 hours of acute ischaemic stroke onset is associated 
with a small but beneficial reduction in the risk of death or dependency. It was 
argued that the perceived risk of haemorrhage is best understood by considering the 
risk profile of a patient and that such a risk profile is multifaceted. Although the IPD-
MA presented in Chapter 6 failed to identify those most likely to experience overall 
benefit or overall harm; the conclusion drawn is one of generalisability. This point 




difference as an important finding stressing that this could indicate that treatment is 
more generalisable than previously thought (Rothwell, 2007b). The analysis in 
Chapter 6 supports the wide-spread use of aspirin immediately following an acute 
ischaemic stroke placing more emphasis on the benefits of early treatment with 
aspirin despite the risk of harm which could not be predicted using simple clinical 
variables. Aspirin remains an important treatment for improving the outcomes of 
acute ischaemic stroke patients especially amongst those who are currently ineligible 
for treatment with rtPA. 
This thesis has drawn focus on the limitations of current prediction models, 
especially where simple clinical risk factors have been used. What role should 
prediction then play in stroke medicine? It will be argued here that the findings made 
in this thesis should be interpreted not as reason against using clinical prediction 
models in stroke but instead as a motivation to do better. For instance, it is evident 
that the prediction of poor functional outcome after an acute ischaemic stroke can be 
achieved using simple clinical risk factors producing models which perform 
exceptionally well in external evaluation. This was not the case though when 
predicting intermediate events, e.g., thromboses or haemorrhages. Here 
improvements in prediction may require novel predictors enabling better separation 
of the intermediate events from those with poor functional outcome. Such variables 
were not recorded reflecting the pragmatism adopted in the running of these large 
trials (recall that together IST-1 and CAST randomised around 40,000 patients). For 
example there was no record of: previous gastrointestinal ulceration; prior DVT; 
cancer; cerebral microbleeds; more advanced brain imaging findings; or 
physiological or genetic markers of aspirin metabolism. These variables may be 
available in newer trials of antiplatelet agents for the treatment of acute stroke. 
Similar points apply to the prediction of post rtPA SICH and those models adopted in 
Chapter 7. All of these used simple baseline clinical and imaging variables, however 
variables not measured, e.g., advanced imaging methods, genotyping or blood 
biomarkers related to the pathophysiology of post-rtPA SICH may better predict 




Many prediction models in stroke have yet to find a role in the clinic. For instance, it 
was concluded in Chapter 5 that clinical prediction models make predictions of poor 
functional outcome that are at least as good as informal predictions made by doctors. 
Given this good performance it is plausible that any one of these models could be 
implemented in the screening of stroke patients on admission to the clinic. This has 
the potential to streamline the running of a stroke clinic, making more efficient use of 
the specialists’ time as well as more focussed targeting of resources. Trained hospital 
staff (e.g., nurses or junior medics) could enter patient information into a simple 
application run on a computer tablet or a smart phone which acts as an interface for 
the mathematical equation pre-specified by a prediction model. This would utilise the 
ability of the prediction model in making reproducible and objective predictions. The 
following observations are now made. A dichotomisation of the predicted risk is 
required – one which is tuned to achieve high sensitivity or specificity at some 
threshold in a given dataset. The selection of this threshold will require long and 
careful consideration and should be closely and continuously monitored to establish 
the impact on patient outcomes. It is unlikely that the same threshold would be 
effective in different centres and as a consequence a centre-by-centre specification 
may be required. Periodic evaluations of the prediction model and regular re-
calibration could be scheduled using within-centre data. This process could be 
automated with updates automatically compiled and reported to the clinical team 
using the markdown package in R calling upon a pre-prepared R script applied to a 
securely structured dataset ultimately generating an HTML document with imbedded 
results (Allaire et al., 2014). A dedicated and password protected webpage on an 
institution’s intranet could be created precisely for reporting this information back to 
the clinical team. The Six Simple Variables model would be an ideal candidate for 
this as it is well established and has strong ‘face-validity’ (Counsell et al., 2002). 
Additionally, a previous study has already illustrated that the SSV model could serve 
a purpose in hospital audits: adjusting for case differences so as to give a fair 





10.3 Methodological Implications 
The work presented in this thesis adds to the growing number of published secondary 
analyses which take a fresh look at existing trial datasets by adopting an analysis 
strategy that recognises the heterogeneity present in any given patient population. A 
patient’s risk-profile is individual and unique. Distributed across a population, it 
provides a continuous description of the rate at which bad outcomes are likely to 
occur in the absence of treatment. This understanding has received considerable 
interest over the last 10 years or so, particularly amongst vascular medicine groups. 
10.3.1 Related work 
For example, Pocock et al. illustrated the harmful impact that early ischaemic events 
(MI) and haemorrhagic complications have on the rate of mortality amongst those 
with Acute Coronary Syndrome (ACS) (Pocock et al., 2010). A risk-based decision 
strategy for selecting treatment was presented using new multivariable logistic 
regression models developed within the Acute Catheterization and Urgent 
Intervention Triage Strategy (ACUITY) trial. The ACUITY trial was a trial of 
patients with ACS randomised to receive either: heparin plus a glycoprotein IIb/IIIa 
inhibitor; bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. 
Pocock et al. found that the predictors for MI and haemorrhage were, for the most 
part, distinct, thus enabling individual predictions to be made which supported the 
selective treatment of patients, whereby a balance could be struck between the 
predicted chance of benefit and the predicted risk of harm. 
Salisbury et al. have also described a risk-stratified framework for the treatment of 
Acute Coronary Syndrome (ACS) patients for the prevention of ischaemic 
complications but instead treated with clopidogrel or prasugrel (Salisbury et al., 
2013). The authors re-analysed the Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in 
Myocardial Infarction 38 (TRITON-TIMI 38). They obtained individual estimates of 
the risk of major/minor bleeding events and major ischaemia by developing new 
multivariable prediction models which adjusted for a number of pre-identified 




considerable variation in the predicted response to treatment (harms and benefits) 
concluding that it was indeed possible to maximise the beneficial payoff from 
treatment whilst minimising the potential for harm. 
Dorresteijn et al. re-analysed the Justification for the Use of Statins in Prevention 
(JUPTER) trial of 20mg rouvastatin versus placebo for the primary prevention of 
cardiovascular disease (i.e., MI, stroke etc.) (Dorresteijn et al., 2011b). They 
demonstrated that the use of either existing models or a newly developed model 
applied to the original trial data provided more net benefit in contrast to the two 
alternative treatment strategies, i.e., treat no-one; or treat everyone. In a separate, but 
similar analysis, Dorresteijn et al. re-analysed data from the Women’s Health Study 
(WHS) trial for the primary reduction in the rate of vascular events (i.e., non-fatal MI 
or stroke, or a cardiovascular death) with 100mg aspirin (Dorresteijn et al., 2011a). 
Again, using either existing models or a newly developed model they illustrated the 
merits of selective treatment based on individualised risks. Note that in both of these 
publications Dorresteijn et al. used the net-benefit approach described by Vickers et 
al. which works by varying the threshold for deciding whether or not to treat 
(Dorresteijn et al., 2011a, Dorresteijn et al., 2011b, Vickers and Elkin, 2006). The 
following stances are then contrast with one another for the assessment of net 
benefit: (i) treat all; (ii) treat none; or (iii) treat some according to risk prediction. 
A review by van der Leeuw et al. highlighted that one of the issues associated with 
weighting benefits and harms using individualised predicted risks is that frequently 
harmful effects will occur at a much lower prevalence requiring larger samples of 
patients to enable the accurate modelling of patient risk from harm (van der Leeuw et 
al., 2014). This is hardly surprising though, after all: a treatment with as great a risk 
of harm as the chance of benefit would be unlikely to reach approval from the FDA 
or a similar drug authority let alone garner enough interest to reach evaluation within 
a phase III trial (Note though that this entirely depends upon factors such as severity 
and chronicity of the disease). Additionally, van der Leeuw et al. point out that often 
the predicted risk of harm is intrinsically related to the predicted chance of benefit, 
i.e., those at a high predicted risk of treatment harm are the same that will derive the 




thesis, which as discussed earlier in this chapter suggests that the targeted treatment 
of stroke patients by their predicted risk is currently not a viable option. This is 
arguably the main barrier in succeeding with the risk-stratified approach in the 
treatment of acute stroke patients. Similar findings have been made elsewhere, for 
example, an IPD-MA which re-analysed five heparin RCTs in acute ischaemic stroke 
found that there was no evidence to suggest targeting the treatment of patients 
according to their predicted risks of treatment harm or benefit (Whiteley et al., 2013). 
Since Kent et al. originally published their proposal in 2010 there has been a 
considerable amount of interest in this area with many researchers implementing the 
use of multivariable regression techniques to explore the heterogeneity of treatment 
effects in old datasets (Kent et al., 2010). More recently, an article by Pocock et al. 
again stressed the benefits of this approach calling on more trialists to include such 
methods in their publications (Pocock et al., 2014). This method has the potential to 
replace the inefficient one-at-a-time subgroup analysis approach; however, it is 
entirely dependent upon the availability of existing background information with 
regards to patient prognosis – though in most medical conditions some prior 
knowledge will be available. The work presented not only in this thesis but also 
across the various publications summarised above have provided extensive insight 
into the processes of harms and benefits associated with randomised treatments. It 
seems possible that such post-hoc analyses could be used to encourage trialists to 
design their next RCT to suitably test for a plausible treatment interaction with the 
predicted risk of harm. Of course to ensure suitable statistical power for the 
interaction test it is inevitable that the sample size must be inflated by some factor 
(Brookes et al., 2004). A direction for future research could explore the required 
increase in sample size when conditioning on the predictive accuracy of a given 
clinical prediction model. This could for instance be investigated using a simulation 
approach. If it were to be found that the factor of inflation was too great then this 
could be used to encourage more international collaboration and the sharing of 
existing datasets. 
An ongoing question is how the results from such an analysis can most effectively be 




one medication over another (Pocock et al., 2014). Graphical presentation of risk is 
essential but given the inherent subjectivity involved in interpretation it is important 
that the most appropriate methods are used (Spiegelhalter, 2008, Spiegelhalter et al., 
2011). 
10.3.2 Simplicity versus complexity 
A variety of clinical prediction models have been identified during this research. The 
methods applied in development ranged from those which used no statistical analysis 
(e.g., the SPAN-100 score derived using the unweighted sum of patient’s age and 
NIHSS score arbitrarily categorised at 100 declaring any patients above that 
threshold as ‘SPAN positive’) to the development of new prediction models adopting 
more sophisticated methodology (e.g., the FG models developed in Chapter 9). This 
raises some interesting points regarding simplicity and complexity (see Chapter 2). 
The large majority of pre-existing models evaluated in Chapter 7 were presented as 
point risk scores: a simplification of the regression equation achieved by finding a 
common denominator and rounding the estimated effects (Steyerberg, 2009). It 
might be anticipated that as a result of a loss in accuracy that is associated with the 
point risk score approach a regression equation would achieve better performance. In 
the IST-3 data the DRAGON score (an 11 point risk score) achieved an AUROCC of 
0.78 whilst the Kӧnig et al. model (a logistic regression model) achieved an 
AUROCC of 0.80. Therefore, despite the associated loss in accuracy, the two models 
performed just as well as one another at separating events from non-events. The 
calibration slopes of the two models were also good, suggesting that the weights 
adopted for each of the predictors were on average smaller in these data though still 
good (≈1). Calibration-in-the-large suggested that on average the DRAGON score 
overpredicted patients risk (intercept of 0.20) whilst the Kӧnig model was a near 
perfect match on average (intercept of 0.03). 
Here it is argued that there are considerable drawbacks associated with model 
developers not sharing the unique regression equation with original coefficients. 
First, this approach can preclude others from making accurate assessments of model 




calibration); an approach which brings an existing model in-line with new data 
(Steyerberg, 2009). Model updating can range from subtle changes which correct the 
systematic component of the model (i.e., the intercept or baseline hazard which 
anchors the linear predictor) to completely re-estimating the weights attributed to 
each of the included predictors. In any case, model updating makes better use of the 
existing scientific knowledge (i.e., the prediction model already available) and the 
new knowledge acquired (i.e., the new data). This should be favoured over simply 
developing a new model whenever an existing model does not yield a good fit 
(Moons et al., 2012b). 
If authors cannot be persuaded to present this information in the body of their 
publication then they should be encouraged to provide it as an online supplement. By 
sharing these data authors are allowing more efficient use of their work. Explicitly 
reporting the baseline hazard in the case of proportional hazards models derived from 
time-to-event data (e.g., the Cox PHM) is slightly more complicated and requires 
more information to be reported. This is discussed in detail by Royston and Altman, 
who note that whilst a complete expression for the baseline hazard cannot be 
provided, a smoothed estimate can be obtained using spline functions or Fractional 
Polynomials (Royston and Altman, 2013). In this form the baseline hazard can then 
be explicitly written down. One drawback of this is that expert statistical input is 
required, but it might be argued that this should nevertheless be essential, and 
mandating such practice might improve the quality of the published literature. 
In any case, with the volume of published prediction models increasing and 
methodologists highlighting new methods for aggregating multiple models, the 
developers of new prediction models must be as explicit as possible when reporting 
their models to enable better assessment of the possible biases involved as well as 






A general comment is made here which holds true of all of the analyses presented in 
this thesis. It is invariably impossible that a common consensus in science is reached 
and it is therefore very likely that some will disagree with approaches taken both 
with the analysis and with the handling of these datasets. The stance taken 
throughout this thesis has been one of inclusivity. The analyses that were favoured 
and therefore presented as primary were based on the majority of patients. It is 
inevitable then that the opinions of the reader and the author may, on occasion, be 
split. However, sensitivity analyses have been utilised throughout in an attempt to 
shed some light on areas of disagreement. It is the author’s opinion that it is 
preferable to let the data ‘speak’ and allow the reader to make up his or her own 
mind as to whether they agree or disagree with the inferences that have been drawn. 
Some issues regarding the quality of the analysed datasets are now considered. 
Across its life span – pre and post publication – the IST-3 trial has attracted a 
considerable amount of interest (Lyden, 2012). Following the publication of the 
primary results in 2012 various critics voiced their concerns about the findings, citing 
in particular issues with design and analysis (Hoffman and Cooper, 2012, Fatovich, 
2012, Fatovich et al., 2012). There are indeed a number of acknowledged limitations 
associated with the IST-3 (Lyden, 2012). Firstly (apart from an initially blinded pilot 
phase) it was an un-blinded trial, i.e.: the patient; any proxies; and the treating staff 
knew whether or not rtPA had been administered. The investigators attempted to 
mitigate this problem by blinding the assessment of six month functional outcome 
from treatment allocation. However, this may have had an influence on the patient’s 
(or proxy’s) responses to the interviewer. Secondly, the use of the ‘uncertainty 
principle’ meant that no distinct inclusion or exclusion criteria were enforced. If the 
treating physician was certain that the patient should receive rtPA then they should 
be treated accordingly and not randomised, likewise if the physician thought that the 
patient should not receive rtPA then, again, the patient should be treated accordingly 
and not randomised. Only if the physician was suitably uncertain then the patient 




statistically significant treatment difference in the primary outcome (OHS 0-2 vs. 3-
6). However, the key secondary outcome, which adopted the more statistically 
efficient POLR approach in the analysis of ordinal outcomes, did demonstrate a 
favourable shift in disability scores at both 6 and 18 months. 
It is wrong to simply discard the IST-3 out of hand because of its limitations; 
especially when one considers the efforts made by the trialists and the patients. The 
harshest critic could not deny that even at its worst IST-3 is an exceptional survey of 
similar patients in receipt of rtPA or standard care – there may be some bias 
associated with the effect of rtPA but the data are still of great value. At its best 
though the IST-3 is a fully randomised clinical trial offering fascinating insights into 
the effects of rtPA in patient groups previously untested. The IST-3 has undoubtedly 
made considerable additions to the evidence base for thrombolytics in acute 
ischaemic stroke. 
One possible concern with the aspirin IPD-MA presented in Chapter 6 is the age of 
the trials with some of the patients recruited as long ago as January 1991. However, 
this raises an arguably more general question which should be considered first: when 
do data become no-longer relevant (e.g., through a secular shift in clinical practice) 
and become historical artefacts? A formal investigation of this might adopt a meta-
regression analysis assessing whether a trend could be attributed to the date of 
publication (or perhaps date of recruitment start/end). Specifically though in the case 
of the aspirin trials, it is noted from the most recent Cochrane review of antiplatelets 
in acute ischaemic stroke that only eight trials were pooled with no new trials added 
since the previous review was undertaken in 2008 (Sandercock et al., 2014, 
Sandercock et al., 2008). In fact in the 2014 review the authors state that 98% of the 
total available data are made up by just two of the included trials (notably IST-1 and 
CAST). In short, even if there was concern that the data are somehow no longer 
relevant, it remains the case that there is an insufficient amount of trial-level data to 
properly test this hypothesis. 
The issue of ‘trial age’ also placed an inherent restriction on the availability of 




more common in modern trials, however, in IST-1, CAST and MAST-I only single 
binary deficit measures were available. This limits comparisons to other more 
modern stroke trials; for the purpose of the analysis presented though it is likely that 
the same conclusions would have been drawn had for example the NIHSS been 
recorded. In any case, measures of stroke deficits are strongly related with one 
another and the single deficits used in these aspirin trials likely captured most of the 
prognostic information (Goldie et al., 2014). 
Additionally, aspects of trial design differed between the aspirin datasets (e.g.: 
duration of early follow-up and consequently the assessment of endpoints; the dosage 
of aspirin administered and the dosage time etc.). In particular, these were large 
pragmatic trials where the primary endpoint was ‘poor functional outcome’ at six 
months. It is very likely that there is an under ascertainment of early secondary 
events which is therefore a potential source of bias. All of these issues may have 
diluted the effect of aspirin. However, considering each trial on its own, none were 
adequately powered to detect a treatment by benefit/harm interaction if it exists. The 
pooling of these datasets was therefore necessary increasing the sample size and the 
statistical power. Indeed this handling of the datasets matched the Cochrane 
antiplatelet review. 
More generally, model development and application is entirely dependent upon the 
availability of patient information, i.e., the model inputs. It was often the case in this 
thesis that either existing models could not be assessed in the available data (i.e., 
Chapters 4 and 5) or else variable selection in model development was limited by the 
record of clinical risk factors (i.e., Chapters 6, 7, 8 and 9). 
Finally, one of the main limitations of the analyses presented in Chapters 6, 7, 8 and 
9 is that they were all post-hoc and unplanned. None of these trials were designed to 
test the hypotheses explored in this thesis and therefore caution is advised when 






10.5 Future work 
This thesis provides a strong argument for exploring the formal impact that any one 
of the prediction models presented in Chapter 5 would have in clinical practice. A so 
called ‘model impact study’ could be designed to assess whether the explicit use of a 
prediction model for the risk of poor functional outcome after stroke yields benefits 
for patients (e.g., improved recovery or quality of life outcomes) and/or savings for 
the health care providers (e.g., better use of resources be that economic or time) 
(Moons et al., 2012a). One candidate for this would be the SSV model, a few reasons 
are given: first, the external performance of the SSV model has already been 
illustrated; second, there is evidence to suggest that it discriminates just as well as a 
clinician (i.e., from Chapter 5 and the work by Counsell et al.); and finally it has 
good face validity (Counsell et al., 2004). 
It was consistently demonstrated in Chapters 6, 7 and 9 that the predicted risk of 
intermediate events is strongly related to longer term outcomes like patient disability 
or mortality. The identification of new risk factors through etiological research to 
uniquely characterise those at high risk from haemorrhage but low risk from 
thrombosis must be identified before the stratified treatment of stroke patients can 
progress. 
In Chapter 9 competing events were explored. A more sophisticated methodological 
approach using multi-state modelling could help elucidate whether risk factors and 
the qualitative or quantitative strength of the predictor-outcome associates differ in 
distinguishing those who suffer either a haemorrhagic event or a thrombotic event 
and then either survive or die in follow-up. The incidence of these intermediate 
events is small placing some restrictions on the availability of sufficient statistical 
power to obtain reliable parameter estimates especially under a multi-state 
framework. Therefore, access to data obtained under a large stroke registry or 
perhaps through multiple stroke centres, is required. Recent collaborative efforts of 
the like conducted by the Farr Institute of Health Informatics Research could allow 
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